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Abstract
The Panel on Food Additives and Flavourings added to Food (FAF) provided a scientiﬁc opinion
re-evaluating the safety of phosphates (E 338–341, E 343, E 450–452) as food additives. The
Panel considered that adequate exposure and toxicity data were available. Phosphates are authorised food
additives in the EU in accordance with Annex II and III to Regulation (EC) No 1333/2008. Exposure to
phosphates from the whole diet was estimated using mainly analytical data. The values ranged from
251 mg P/person per day in infants to 1,625 mg P/person per day for adults, and the high exposure (95th
percentile) from 331 mg P/person per day in infants to 2,728 mg P/person per day for adults. Phosphate is
essential for all living organisms, is absorbed at 80–90% as free orthophosphate excreted via the kidney.
The Panel considered phosphates to be of low acute oral toxicity and there is no concern with respect to
genotoxicity and carcinogenicity. No effects were reported in developmental toxicity studies. The
Panel derived a group acceptable daily intake (ADI) for phosphates expressed as phosphorus of 40 mg/kg
body weight (bw) per day and concluded that this ADI is protective for the human population. The
Panel noted that in the estimated exposure scenario based on analytical data exposure estimates exceeded
the proposed ADI for infants, toddlers and other children at the mean level, and for infants, toddlers,
children and adolescents at the 95th percentile. The Panel also noted that phosphates exposure by food
supplements exceeds the proposed ADI. The Panel concluded that the available data did not give rise to
safety concerns in infants below 16 weeks of age consuming formula and food for medical purposes.
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Summary
The present opinion document deals with the re-evaluation of phosphoric acid–phosphates – di-,
tri- and polyphosphates (E 338–341, E 343, E 450–452) when used as a food additive.
Phosphates are authorised food additives in the European Union (EU) in accordance with Annex II
and III to Regulation (EC) No 1333/2008 on food additives and speciﬁc purity criteria have been
deﬁned in the Commission Regulation (EU) No 231/2012. E 338, E 339, E 340 and E 341 are also
authorised in food category 13.1 foods for infants and young children.
Phosphates have been previously evaluated by the EU Scientiﬁc Committee on Food (SCF, 1978,
1991, 1994, 1997) and by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 1974,
1982a,b, 2002). JECFA concluded that the allocation of an acceptable daily intake (ADI) was not
appropriate for phosphates ‘as phosphorus is an essential nutrient and unavoidable constituent of food’
and it was decided, therefore, to assign a ‘maximum tolerable daily intake’ (MTDI) rather than an ADI.
The MTDI allocated was 70 mg/kg body weight (bw) per day (expressed as phosphorus) for the sum
of phosphates and polyphosphates, both naturally present in food and ingested as food additives
(JECFA, 1982a). The SCF subsequently agreed with the JECFA MTDI estimate for phosphates and
assigned the cations an ADI ‘not speciﬁed’ as they are natural constituents of man, animals and plants
(SCF, 1991).
The Expert Group on Vitamins and Minerals (EVM) further concluded that a total intake of
2,400 mg/day (considering 2,110 mg/day inorganic phosphorus from food including food additives and
water and 250 mg/day from supplemental phosphorus) does not result in any adverse effects (Expert
Group on Vitamins and Minerals, 2003).
In the EFSA NDA Opinion on Tolerable Upper Intake level of phosphorus, the upper level for
phosphorus was not established because available data were not sufﬁcient and indicate that normal
healthy adults can tolerate phosphorus (phosphates) intake up to at least 3,000 mg/day without
adverse systemic effects (EFSA NDA Panel, 2005).
The Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientiﬁc
Committee for Food Safety (VKM) published an assessment of dietary intake of phosphorus in relation
to tolerable upper intake levels suggesting 3,000 mg/day as provisional upper level (UL) for total
phosphorus intake in adults and 750 mg/day as UL for supplements (VKM, 2017).
Phosphate is essential for all living organisms. Inorganic phosphate used as food additives assessed
in this opinion is assumed to dissociate in the gastrointestinal tract. The inorganic phosphorus deriving
from food additives is mainly absorbed in the amount of approximately 80–90% as free
orthophosphate. Excretion is via the kidney through glomerular ﬁltration and tubular handling.
The Panel considered phosphates to be of low acute oral toxicity and there is no concern with
respect to genotoxicity and carcinogenicity.
In standard short-term, subchronic and chronic toxicity studies, the only signiﬁcant adverse effect
of phosphates is calciﬁcation of the kidney and tubular nephropathy. In the chronic rat study with
sodium triphosphate, the no-observable-adverse-effect level (NOAEL) was 76 mg/kg bw per day
phosphorus (Hodge, 1960). Adding the background dietary phosphorus of 91 mg/kg bw per day to the
NOAEL of 76 mg P/kg bw per day gives a total value of 167 mg P/kg bw per day.
In studies performed in mice, rats, rabbits or hamsters, there are no signs of reproductive or
developmental toxicity at any dose tested. The Panel thus concluded that exposure to phosphates do
not present any risk for reproductive or developmental toxicity.
The epidemiological studies reviewed did not ﬁnd consistent associations between dietary
phosphorous intake and cardiovascular-related outcomes and do not provide sufﬁcient and reliable
data to assess the role of phosphate on bone health.
Clinical interventional trials in which the doses were given on top of the normal diet were
performed over several months. No impairment of the renal function was reported with daily doses up
to 2,000 mg phosphorus (28.6 mg/kg per day), whereas doses of 4,800 mg/day (68.6 mg/kg per day)
elicited renal impairment. Histopathological examinations of human kidney specimens from exposed
patients showed similar ﬁndings as seen in animals. In several of the studies using phosphorus doses
up to 2,000 mg/day, the subjects had soft stools or diarrhoea which is not to be seen as adverse but
is classiﬁed as discomfort. However, when higher doses are given, such as the doses for bowel
cleansing in preparation for colonoscopy (e.g. 11,600 mg/kg or 165.7 mg/kg bw) these doses acted as
a cathartic agent and this effect has to be clearly seen as adverse.
Several case reports indicate that a high acute single dose of phosphate (160 mg/kg bw and more)
can induce renal impairment.
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The evidence from epidemiological and human interventional studies is not suited to derive an ADI.
The Panel therefore selected the 167 mg P/kg bw per day NOAEL identiﬁed by Hodge (1960) as the
basis to derive the ADI. The chemical-speciﬁc adjustment factor for phosphate accounting for
interspecies and interindividual differences in toxicokinetics (TK) and toxicodynamics (TD) is 2 9 2 = 4.
To this value, the phosphorus-speciﬁc uncertainty factor of 4 is to be applied resulting in an ADI value
of 42 mg/kg bw per day, rounded to 40 mg/kg bw per day.
Currently, phosphates (E 338–341, E 343, E 450–452) are authorised food additives in the EU with
maximum permitted levels (MPLs) ranging from 500 to 20,000 mg/kg in 104 authorised uses and at
quantum satis (QS) in four.
To assess the dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses as
food additives, the exposure was calculated based on two different sets of concentration data: (1)
MPLs as set down in the EU legislation (deﬁned as the regulatory maximum level exposure assessment
scenario); and (2) reported use levels (deﬁned as the reﬁned exposure assessment scenario).
While analytical data were used to consider the exposure to phosphorus from all dietary sources.
In the context of this opinion, the Panel was in the special situation to assess the safety of food
additives, phosphate salts, which are also nutrients. The Panel based its assessment on the toxicity of
phosphorus (phosphate moiety). Since the ADI encompasses the phosphorus intake from natural
sources and from food additives sources, the usual exposure assessment using the reported use levels
of the food additives was not appropriate to characterise the risk linked to the exposure to phosphorus
and the exposure assessment was based on analytical data of the total phosphorus content of foods.
In this scenario, the exposure exceeds the ADI of 40 mg/kg bw per day in infants from 12 weeks to
11 months, toddlers and children both at the mean and high level. In adolescents, the high level is
also exceeding the ADI of 40 mg/kg bw per day.
Based on the reported use levels, the Panel calculated two reﬁned exposure estimates: a brand-
loyal consumer scenario and a non-brand-loyal scenario. The Panel considered that the reﬁned
exposure assessment approach resulted in more realistic long-term exposure estimates and that the
reﬁned non-brand loyal scenario is the most relevant exposure scenario for the safety evaluation of
phosphates. In the non-brand-loyal exposure assessment scenario, estimated exposure to phosphates
ranged between 1 and 48 mg P/kg bw per day at the mean and between 3 and 62 mg P/kg bw per
day at the 95th percentile for all population groups.
The derived ADI 40 mg P/kg bw per day results in a exposure to phosphorus of 2,800 mg/person
per day for an adult of 70 kg which is within the safety level of exposure of 3,000 mg/person per day
set by the EFSA NDA Panel (2005).
The Panel concluded that the group ADI of 40 mg/kg bw per day, expressed as phosphorus, is
protective for healthy adults because it is below the doses at which clinically relevant adverse effects
were reported in short-term and long-term studies in humans. However, this ADI does not apply to
humans with moderate to severe reduction in renal function. Ten per cent of general population might
have chronic kidney disease with reduced renal function and they may not tolerate the amount of P
per day which is at the level of ADI.
The Panel noted that in the exposure estimates based on analytical data exceeded the proposed
ADI for infants, toddlers and children at the mean level and for infants, toddlers, children and
adolescents at the 95th percentile. The Panel also noted that P exposure from food supplements
exceeds the proposed ADI.
The Panel concluded that the available data did not give rise to safety concerns in infants below
16 weeks of age consuming formula and food for medical purposes. When receiving data on the
content of contaminants in formula, the Panel noted that the high aluminium content may exceed the
tolerable weekly intake (TWI).
The Panel recommends that:
• The EC considers setting numerical Maximum Permitted Level for phosphates as food additives
in food supplements.
• The European Commission considers revising the current limits for toxic elements (Pb, Cd, As
and Hg) in the EU speciﬁcations for phosphates (E 338–341, E 343, E 450–452) in order to
ensure that phosphates (E 338–341, E 343, E 450–452) as a food additive will not be a
signiﬁcant source of exposure to those toxic elements in food.
• The European Commission considers revising the current limit for aluminium in the EU
speciﬁcations for the use of calcium phosphate (E 341).
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• The European Commission to consider revising the current EU speciﬁcations for calcium
dihydrogen phosphate (E 341(i)), calcium hydrogen phosphate (E 341(ii)), tricalcium phosphate
(E 341(iii)), dimagnesium phosphate (E 343(ii)) and calcium dihydrogen diphosphate
(E 450(vii)) to include characterisation of particle size distribution using appropriate statistical
descriptors (e.g. range, median, quartiles) as well as the percentage (in number and by mass) of
particles in the nanoscale (with at least one dimension < 100 nm) present in calcium dihydrogen
phosphate (E 341(i)), calcium hydrogen phosphate (E 341(ii)), tricalcium phosphate (E 341(iii)),
dimagnesium phosphate (E 343(ii)) and calcium dihydrogen diphosphate (E 450(vii)) used as a
food additive. The measuring methodology applied should comply with the EFSA Guidance
document (EFSA Scientiﬁc Committee, 2018).
• The development of analytical methods for the determination of phosphate additives in the
range of foods and beverages permitted to contain them should be considered.
• The EFSA Scientiﬁc Committee reviews current approaches to the setting of health-based
guidance values for regulated substances which are also nutrients to assess if a coherent
harmonised strategy for such risk assessments should be devised.
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1. Introduction
The present opinion deals with the re-evaluation of the following food additives: phosphoric acid
(E 338), monocalcium phosphate (E 341(i)), dicalcium phosphate (E 341(ii)), tricalcium phosphate (E 341
(iii)), monomagnesium phosphate (E 343(i)), dimagnesium phosphate (E 343(ii)) monosodium phosphate
(E 339(i)), disodium phosphate (E 339(ii)), trisodium phosphate (E 339(iii)), monopotassium phosphate
(E 340(i)), dipotassium phosphate (E 340(ii)), tripotassium phosphate (E 340(iii)), disodium diphosphate
(E 450(i)), trisodium diphosphate (E 450(ii)), tetrasodium diphosphate (E 450(iii)), tetrapotassium
diphosphate (E 450(v)), dicalcium diphosphate (E 450(vi)), calcium dihydrogen diphosphate (E 450(vii)),
magnesium dihydrogen diphosphate (E 450(ix)), pentasodium triphosphate (E 451(i)), pentapotassium
triphosphate (E 451(ii)), sodium polyphosphate (E 452(i)), potassium polyphosphate (E 452(ii)), sodium
calcium polyphosphate (E 452(iii)) and calcium polyphosphate (E 452(iv)). For brevity, these food
additives will be referred to as phosphates in this document (listed overview of the substances considered
in this opinion is available in Appendix A).
As usual in the re-evaluation of food additives, this opinion addresses the safety of phosphorus
intake from the use of the above listed food additives in the general population.
During the drafting of the opinion, a request for extension of use has been received and is included
in this opinion. The terms of reference are reported below.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background to the re-evaluation of phosphoric acid–phosphates – di-, tri-
and polyphosphates (E 338–341, E 343, E 450–452) as food additives
Regulation (EC) No 1333/20081 of the European Parliament and of the Council on food additives
requires that food additives are subject to a safety evaluation by the European Food Safety Authority
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food
additives must be kept under continuous observation and must be re-evaluated by EFSA.
For this purpose, a programme for the re-evaluation of food additives that were already permitted in
the European Union before 20 January 2009 has been set up under the Regulation (EU) No 257/20102.
This Regulation also foresees that food additives are re-evaluated whenever necessary in the light of
changing conditions of use and new scientiﬁc information. For efﬁciency and practical purposes, the re-
evaluation should, as far as possible, be conducted by group of food additives according to the main
functional class to which they belong.
The order of priorities for the re-evaluation of the currently approved food additives should be set on
the basis of the following criteria: the time since the last evaluation of a food additive by the Scientiﬁc
Committee on Food (SCF) or by EFSA, the availability of new scientiﬁc evidence, the extent of use of a
food additive in food and the human exposure to the food additive taking also into account the outcome
of the Report from the Commission on Dietary Food Additive Intake in the EU3 of 2001. The report ‘Food
additives in Europe 20004’ submitted by the Nordic Council of Ministers to the Commission, provides
additional information for the prioritisation of additives for re-evaluation. As colours were among the ﬁrst
additives to be evaluated, these food additives should be re-evaluated with a highest priority.
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised
food additives. However, as a result of adoption of Regulation (EU) 257/2010 the 2003 Terms of
References are replaced by those below.
1.1.1.1. Terms of Reference
The Commission asks the European Food Safety Authority to re-evaluate the safety of food
additives already permitted in the Union before 2009 and to issue scientiﬁc opinions on these
additives, taking especially into account the priorities, procedures and deadlines that are enshrined in
1 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16–33.
2 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
3 COM(2001) 542 ﬁnal.
4 Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic Council of
Ministers, TemaNord 2002, 560.
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the Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of
approved food additives in accordance with the Regulation (EC) No 1333/2008 of the European
Parliament and of the Council on food additives.
1.1.2. Background to the request for the extension of use of phosphoric acid–
phosphates – di-, tri- and polyphosphates (E 338–341, E 343, E 450–452)
as food additives
The Directorate-General for Health and Food Safety received a request for the extension of use of
phosphoric acid–phosphates – di-, tri- and polyphosphates (E 338–341, E 343, E 450–452) by
removing the restriction ‘only sugar confectionary’ in the relevant provision in the food category 05.2
‘Other confectionary including breath refreshing microsweets’.
1.1.2.1. Terms of Reference
The European Commission requested EFSA to provide a scientiﬁc opinion on the safety of the
proposed extension of use in accordance with Regulation (EC) No 1331/2008 establishing a common
authorisation procedure for food additives, food enzymes and food ﬂavourings and proposed that EFSA
incorporates in that risk assessment the assessment of the safety of the proposed extension of use.
1.1.3. Interpretation of Terms of Reference
The former ANS Panel described its risk assessment paradigm in its Guidance for submission for
food additive evaluations in 2012 (EFSA ANS Panel, 2012). This Guidance states, that in carrying out
its risk assessments, the Panel sought to deﬁne a health-based guidance value (HBGV), e.g. an
acceptable daily intake (ADI) (IPCS, 2004) applicable to the general population. ADI is deﬁned as ‘an
estimate of the amount of a substance in food or drinking water that can be consumed over a lifetime
without presenting an appreciable risk to health. It is usually expressed as milligrams of the substance
per kilogram of body weight and applies to chemical substances such as food additives, pesticide
residues and veterinary drugs’. (EFSA Glossary).
Phosphates are normal constituents in the body and are regular components of the diet. According
to the EFSA NDA Panel the available data are not sufﬁcient to establish an upper level (UL) for
phosphorus (EFSA NDA Panel, 2005). The EFSA NDA Panel stated in this opinion that ‘The available
data indicate that normal healthy individuals can tolerate phosphorus (phosphate) intakes up to at
least 3,000 mg/day without adverse systemic effects’. In 2015, the NDA Panel set adequate intakes
(AIs) values for various age groups.
Inorganic phosphates authorised as a food additive are efﬁciently absorbed and used systemically.
It is noteworthy that although phosphorus is an essential constituent of the human body and other life
forms, the element itself always occurs systemically in the oxidation state (V) as free or combined
phosphate. It is absorbed and involved in many structural and functional roles as phosphate (HPO24)
(see Section 3.5.1). However, dietary and environmental exposure to phosphorus may come from
other forms of phosphorus (V). Whereas the systemic physiologically active moiety is phosphate it has
become conventional in nutritional and risk assessment as well as regulatory contexts to use inorganic
phosphorus as generic the term (Pi). For the purposes of this opinion, phosphorus will be expressed as
P. This is particularly necessary in the context of establishing a group ADI which encompasses
phosphorus from all sources including all classes of phosphates as food additives (E 338–341, E 343, E
450–452). The mass conversion factors between phosphate and P2O5 or P are summarised in
Appendix B.
The Panel considered that sodium, potassium, calcium and magnesium salts of phosphate and
condensed phosphates are expected to dissociate in the gastrointestinal tract into phosphate and their
corresponding cations. The resulting sodium, potassium, calcium and magnesium cations will enter
their normal physiological processes. The kinetics of the corresponding cations are not assessed in the
opinion.
Data were not always available for all the authorised phosphates for all endpoints but for the
reason described above the Panel considered that it is possible to perform read-across between
different phosphate additives.
The opinion will also conclude on the proposed extensions of use received during the course of the
drafting opinion.
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1.2. Information on existing authorisations and evaluations
Phosphates are authorised food additives in the EU in accordance with Annex II and III to
Regulation (EC) No 1333/20085. E 338, E 339, E 340, E 341 are also authorised in food category 13.1
foods for infants and young children. Commission Delegated Regulation (EU) 2016/127 and
Commission Delegated Regulation (EU) 2016/128, as well as Commission Directive 2006/141/EC and
Commission Directive 1999/21/EC, deﬁne minimum and maximum levels for phosphorus as well as for
the cations of the various phosphate salts (i.e. calcium, potassium and sodium) in the ﬁnal formula.
These statutory requirements are based on the scientiﬁc advice by the Scientiﬁc Committee on Food
(SCF, 1996, 1997, 1998) and EFSA (EFSA NDA Panel, 2013). The minimum and maximum levels of
phosphorus for infant formula are set at 25 mg/100 kcal and 90 mg/100 kcal, in the case of infant
formula based on soy the maximum level is 100 mg/100 kcal. The minimum and maximum levels for
infant formula for special medical purposes are set at 25 mg/100 kcal and 100 mg/100 kcal. In Europe,
the phosphates that are permitted as additives in infant formula (category 13.1.1) and foods for infants
for special medical purposes (13.1.5.1) are speciﬁed in Regulation (EC) No 1333/2008. The permitted
level of phosphates used as a food additive, either alone or in combination, is set at a maximum
concentration of 1,000 mg/L reconstituted formula. The maximum level is expressed as P2O5.
In addition, tricalcium phosphate is authorised, according to Annex III to Regulation (EC) No 1333/2008,
for use as food additives in nutrients in infant formula. Themaximum carry-over of tricalcium phosphate from
nutrients is set at 150 mg/kg as P2O5 and within the limit for calcium, phosphorus and calcium:phosphorus
ratio as speciﬁed in Commission Directive 2006/141/EC. In addition to their use as food additives, calcium,
magnesium, potassium and sodium salts of orthophosphoric acid are included in the list of mineral
substances which may be used in the manufacture of food supplements reported in the Annex II of Directive
2002/46/EC6 and in the list of mineral substances which may be added to foods reported in the Annex II of
Regulation (EC) No 1925/20067.
Calcium, magnesium, potassium and sodium salts of orthophosphoric acid are included in the Union
list set out in the Annex to Regulation (EU) No 609/20138 as permitted for use in: infant formula and
follow-on formula, food for special medical purposes and total diet replacement for weight control.
Calcium and magnesium sodium salts of orthophosphoric acid are also permitted for use in processed
cereal-based food and baby food.
According to the CODEX STAN 72-1981 on Infant Formula and Formulas for Special Medical
Purposes (FSMP) intended for infants, sodium phosphates (339(i), (ii), (iii)) and potassium phosphates
(340(i), (ii), (iii)) may be used as additives in infant formula and infant FSMP. The maximum level is
speciﬁed at 450 mg/L as phosphorus in the ready-to-use product, singly or in combination and within
the limits for sodium, potassium and phosphorus (SNE, 2018).
Phosphates have been previously evaluated by the EU SCF (1978, 1991, 1994, 1997) and by the Joint
FAO/WHO Expert Committee on Food Additives (JECFA) latest in 1973 and 1982 (JECFA, 1974, 1982a,b).
The toxicology and safety of diphosphates, triphosphates and polyphosphates when used as food
additives has previously been evaluated by the Joint FAO/WHO Expert Committee on Food Additives
(JECFA) as part of a larger group of phosphate compounds (JECFA, 1964, 1974, 1982a,b, 1986, 2002).
At its 26th meeting, JECFA concluded that the allocation of an ADI was not appropriate for phosphates
‘as phosphorus is an essential nutrient and unavoidable constituent of food’ (JECFA, 1982a). It was
decided, therefore, to assign a ‘maximum tolerable daily intake’ (MTDI) rather than an ADI. The MTDI
allocated was 70 mg/kg bw per day (expressed as phosphorus) for the sum of phosphates and
polyphosphates, both naturally present in food and ingested as food additives. ‘The lowest level of
phosphate that produced nephrocalcinosis in rat (1% P in the diet) is used as the basis for the
evaluation and, by extrapolation based on the daily food intake of 2,800 calories, gives a dose level of
5 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008.
6 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57.
7 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins
and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38.
8 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181,
29.6.2013, p. 35–56.
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6,600 mg P per day as the best estimate of the lowest level that might conceivably cause
nephrocalcinosis in man’. The use of a safety factor was not considered suitable by JECFA with the
justiﬁcation that phosphorous is also a nutrient.
The SCF agreed with the JECFA MTDI estimate for phosphates and assigned the cations an ADI
‘not speciﬁed’ as they are natural constituents of man, animals and plants (SCF, 1991).
In 2012, JECFA evaluated magnesium dihydrogen diphosphate (E 450(ix)) for use as food additive
(JECFA, 2012a). In its 76th report, JECFA stated the following: ‘The information submitted to the
Committee and in the scientiﬁc literature did not indicate that the MTDI of 70 mg/kg bw for phosphate
salts, expressed as phosphorus, is insufﬁciently health protective. On the contrary, because the basis
for its derivation might not be relevant to humans, it could be overly conservative. Therefore, there is
a need to review the toxicological basis of the MTDI for phosphate salts expressed as phosphorus
(JECFA, 2012b).
The Expert Group on Vitamins and Minerals (EVM) used as a starting point 750 mg/day; this is the
dose that, after oral administration of phosphorus as various phosphate salts, gives osmotic diarrhoea
and mild gastrointestinal symptoms in humans. The EVM applied an uncertainty factor of 3 (to allow
interindividual variations) to the 750 mg/day and concluded that a supplemental intake of 250 mg/day
(3.6 mg/kg bw per day) would not be expected to induce adverse effects (Expert Group on Vitamins
and Minerals, 2003). The EVM further concluded that a total intake of 2,400 mg/day (considering
2,110 mg/day inorganic phosphorus from food including food additives and water and 250 mg/day
from supplemental phosphorus) does not result in any adverse effects. The exposure calculation in
food has been based on a survey from 1986/7 (NDNS 1986/7) which does not include speciﬁc
estimation of phosphates content in food from food additives.
In the EFSA NDA Opinion on Tolerable Upper Intake level of phosphorus (EFSA NDA Panel, 2005),
the upper level for phosphorus was not established because available data were not sufﬁcient,
although some adverse gastrointestinal effects have been reported at doses of phosphorus-containing
supplements exceeding 750 mg/day. EFSA reported that the mean dietary and supplemental intake of
phosphorus in European countries is approximately 1,000–1,500 mg/day and indicate that normal
healthy adults can tolerate phosphorus (phosphates) intake up to at least 3,000 mg/day without
adverse systemic effects.
In 2015, EFSA published a Scientiﬁc Opinion on Reference Values for phosphorus setting adequate
intakes (AIs) for all population groups. The AI recommended is 160 mg/day for infants aged
7–11 months, between 250 and 640 mg/day for children and 550 mg/day for adults. The AI for
phosphorus has been derived based on the Dietary Reference Values (DRVs) for calcium by using a
molar calcium to phosphorus ratio of 1.4:1 (EFSA NDA Panel, 2015).
In 2006, the National Health and Medical Research Council of Australia and the New Zealand
Ministry of Health published AIs for infants between 0 and 6 months (Australian Government, NHMRC).
The AI of 100 mg/day was calculated by multiplying the average intake of breast milk (0.78 L/day) by
the average concentration of phosphorus in breast milk (124 mg/L) from 10 studies reviewed by
Atkinson et al. (1995).
The Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientiﬁc
Committee for Food Safety (VKM) published an assessment of dietary intake of phosphorus in relation
to tolerable upper intake levels suggesting 3,000 mg/day as provisional UL for total phosphorus intake
in adults and 750 mg/day as UL for supplements (Norwegian Scientiﬁc Committee for Food Safety
(VKM, 2017)).
2. Data and methodologies
2.1. Data
The Panel on Food Additives and Flavourings (FAF) and its predecessor, the Panel on Food Additives
and Nutrient Sources, were not provided with a newly submitted dossier. EFSA, therefore, launched a
public call for data9 and a public consultation.10 A technical report has been issued by EFSA collecting
9 Call for technical and toxicological data on phosphates authorised as food additives in the EU. Published: 14 July 2017.
Available online: https://www.efsa.europa.eu/en/data/call/170615
10 Questions for health professionals in the ﬁelds of nephrology, mineral metabolism, cardiovascular and nutrition medicine on
phosphates food additives re-evaluation. Published: 1 June 2018. Available online: https://www.efsa.europa.eu/en/c
onsultations/call/180601
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the answers received in response to the public consultation. All answers received were considered in
the development of this opinion.
For the re-evaluation, the Panel based its assessment on information submitted to EFSA following the
public calls for data, the public consultation, information from previous evaluations and additional available
literature up to 18 March 2019. Attempts were made at retrieving relevant original study reports on which
previous evaluations or reviews were based however these were not always available to the Panel.
Following the request for additional data on particle size sent by EFSA on 18 September 2018, one
of the Interested Parties requested a clariﬁcation teleconference, which was held on 4 October 2018.
An applicant has submitted a dossier in support of the application for the extension of use of
phosphoric acid–phosphates – di-, tri- and polyphosphates (E 338–341, E 343, E 450–452) as a food
additive which is also addressed in this opinion (Documentation provided to EFSA n. 1).
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database11) was
used to estimate the dietary exposure.
The Mintel’s Global New Products Database (GNPD) is an online resource listing food products and
compulsory ingredient information that are included in labelling. This database was used to verify the
use of food additive (E 338, E 341(i), E 341(ii), E 341(iii), E 343(i), E 343(ii) E 339(i)), (E 339(ii),
E 339(iii), E 340(i), E 340(ii), E 340(iii), E 450(i), E 450(ii), E 450(iii), E 450(v), E 450(vi), E 450(vii),
E 450(ix), E 451(i), E 451(ii), E 452(i), E 452(ii), E 452(iii) and E 452(iv) in food products.
2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientiﬁc aspects of risk assessment (EFSA Scientiﬁc Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientiﬁc Committee.
The FAF Panel assessed the safety of phosphates as food additives in line with the principles laid
down in Regulation (EU) 257/2010 and in the relevant guidance documents: Guidance on submission
for food additive evaluations by the SCF (2001) and taking into consideration the Guidance for
submission for food additive evaluations in 2012 (EFSA ANS Panel, 2012).
On 31 May 2017, EFSA published a guidance document on the risk assessment of substances
present in food intended for infants below 16 weeks of age thus enabling EFSA to assess the safety of
food additives uses in food for infants below 12 weeks of age (EFSA Scientiﬁc Committee, 2017).
Therefore, the current evaluation also addresses the safety of use of food additives for all age groups,
including the infants below 12 or 16 weeks of age following the principles outlined in that guidance.
When the test substance was administered in the feed or in the drinking water, but doses were not
explicitly reported by the authors as mg/kg bw per day based on actual feed or water consumption,
the daily intake was calculated by the Panel using the relevant default values as indicated in the EFSA
Scientiﬁc Committee Guidance document (EFSA Scientiﬁc Committee, 2012a) for studies in rodents or,
in the case of other animal species, by JECFA (2000). In these cases, the daily intake is expressed as
equivalent. When in human studies in adults (aged above 18 years) the dose of the test substance
administered was reported in mg/person per day, the dose in mg/kg bw per day was calculated by the
Panel using a body weight of 70 kg as default for the adult population as described in the EFSA
Scientiﬁc Committee Guidance document (EFSA, 2012a).
Dietary exposure to phosphates from their use as food additives was estimated combining food
consumption data available within the EFSA Comprehensive European Food Consumption Database with
the maximum levels according to Annex II to Regulation (EC) No 1333/200812. Reported use levels and
analytical data submitted to EFSA following a call for data were used to assess exposure under different
scenarios(see Section 3.3.1). Uncertainties on the exposure assessment were identiﬁed and discussed.
Dietary exposure for infants (0–16 weeks) from infant formula and from foods for special medical
purposes (FSMP) was calculated based on the minimum and maximum content as deﬁned in the
Commission Delegated Regulation (EU) 2016/127 and Commission Delegated Regulation (EU) 2016/128,
as well as Commission Directive 2006/141/EC and Commission Directive 1999/21/EC and the
reference values on the energy requirements of infants in the ﬁrst months of life (EFSA NDA Panel,
2013, 2014).
For the assessment of epidemiological studies, a systematic approach has been taken and the
protocol is provided in the Appendixes C and D. In addition, the answers received in response to the
11 Available online: http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
12 Commission Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food
additives. OJ L 354, 31.12.2008, p. 16.
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Public Consultation have been considered for the interpretation of the epidemiology studies. It should
be noted that because this opinion is dealing with general population, studies focussing on
subpopulations with speciﬁc health conditions (e.g. patients with moderate to severe decreased renal
function) were not considered.
3. Assessment
3.1. Technical data
3.1.1. Chemistry of phosphates
All phosphorus oxoacids and anions have POH groups in which the hydrogen atom is ionisable
(Cotton and Wilkinson, 1972). The principal acid is orthophosphoric acid and its various anions. The
phosphate ion carries a 3 formal charge and is the conjugate base of the hydrogen phosphate ion,
HPO4
2, which is the conjugate base of H2PO4
, the dihydrogen phosphate ion, which in turn is the
conjugate base of H3PO4, phosphoric acid. Linear polyphosphates are salts of the anions of general
formula [PnO3n+1]
(n+2). Examples are MI4P2O7, (where M represents the associated cation)
diphosphate (also named pyrophosphate), and MI5P3O10, a tripolyphosphate. Cyclic phosphates are
salts of anions of general formula [PnO3n+1]
n. Examples are M3P3O9, a trimetaphosphate, and
M4P4O12, a tetrametaphosphate.
The sodium, potassium and ammonium orthophosphates are all water-soluble. Most other
phosphates (including magnesium and calcium) are only slightly soluble or are insoluble in water. As a
rule, the hydrogen and dihydrogen phosphates are slightly more soluble than the corresponding non-
hydrogenated phosphates. The pyrophosphates are mostly water-soluble. Aqueous phosphate exists in
four forms: in strongly basic conditions, the phosphate ion (PO4
3) predominates. Phosphoric acid is
tribasic: at 25°C, pK1 = 2.15, pK2 = 7.1 and pK3 ﬃ 12.4. In weakly basic conditions, the hydrogen
phosphate ion (HPO4
2) is prevalent. In weakly acidic conditions, the dihydrogen phosphate ion
(H2PO
4) is most common. In strongly acidic conditions, trihydrogen phosphate (H3PO
4) is the main
form. H3PO4, HPO4
2 and H2PO
4 behave as separate weak acids because the successive pK values
differ by more than 4. The region in which the acid is in equilibrium with its conjugate base is deﬁned
by pH  pK  2. Thus, the three pH regions are approximately 0–4, 5–9 and 10–14.
A general structural formula of basic structure of ortho and condensed phosphates is given in
Figure 1.
Annex 1 of EU 1333/2008 describes the range of additive functional classes which have been
summarised in Appendix A for phosphates as described in JECFA Monographs (JECFA, 2018).
Organic phosphates in different forms are also present in the diet and differ considerably in the
physico-chemical and physiological properties from inorganic phosphates.
Figure 1: Example of basic structure of ortho- and condensed phosphates taken from Weiner et al.
(2001)
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3.1.2. Speciﬁcations
The identity of substances description and speciﬁcations for phosphates as deﬁned in the
Commission Regulation (EU) No 231/2012 and by JECFA are listed in Appendix E.
The Panel noted that, according to the EU speciﬁcations for phosphates impurities of elements
arsenic, cadmium, lead and mercury are each permitted up to a concentration of 1 mg/kg.
Contamination of phosphate additives at such levels could have a signiﬁcant impact on the exposure to
these metals, for which the exposure already are close to the HBGVs or benchmark doses (lower
conﬁdence limits) established by EFSA (EFSA CONTAM Panel, 2009a,b, 2010, 2012a,b,c, 2014).
The Panel noted that in EU speciﬁcations for E 343(i) the chemical name monomagnesium
dihydrogen monophosphate has to be corrected.
When considering the information submitted by the industry on the actual aluminium content in
infant formula (ﬁnal food), the Panel noted that the amount of aluminium may result in an exceedance
of the respective tolerable weekly intake (TWI) (Documentation provided to EFSA n. 2,3,4,5).
The Panel noted that the use of calcium phosphate (E 341), for which maximum limits for
aluminium have been set in the EU speciﬁcations, can contribute to the total aluminium content in
infant formula.
3.1.3. Particle size
Industry (Documentation provided to EFSA n. 6) provided information on the particle size
distribution (volume-based (Dv) values) of calcium dihydrogen phosphate (E 341(i)) (n = 3), calcium
hydrogen phosphate (E 341(ii)) (n = 6), tricalcium phosphate (E 341(iii)) (n = 7), dimagnesium
phosphate (E 343(ii)) (n = 2) and calcium dihydrogen diphosphate (E 450(vii)) (n = 2) analysed by
ﬁve laboratories using dynamic light scattering (DLS). One of the laboratories indicated that the
sample feeding took place by vibrating plate. The lower Dv50 values were reported for six out of the
seven samples of E 341(iii) (around 5 lm) while for the other sample the Dv50 value range from 33 to
92 lm (STD = 22). The major difference in the Dv50 value was observed between the two analysed
samples for (E 343(ii)), for one was around 7 lm (STD = 0689) and for the other ranged from 152 to
196 lm (STD = 18).
Additional information of the analysis of other samples of calcium dihydrogen phosphate (E 341(i))
(n = 3), calcium hydrogen phosphate (E 341(ii)) (n = 5), tricalcium phosphate (E 341(iii)) (n = 6),
dimagnesium phosphate (E 343(ii)) (n = 3) and calcium dihydrogen diphosphate (E 450(vii)) (n = 3)
by transmission electron microscopy (TEM), scanning electron microscopy (SEM) and DLS was
submitted (Documentation provided to EFSA n. 7). Median minimum Feret diameter values were
reported among other parameters for SEM and TEM.
The lower median minimum Feret diameter values were reported for E 341(iii) (ranged from 2 to
7 lm) using SEM. A big variability on the median minimum Feret diameter values was observed
between the analysed samples of E 341(i) (ranged from 3 to 150 lm) using SEM. Similar observations
were noted for the results reported by TEM. Before the microscopic analyses, the samples were
applied at the adhesive carbon tape by gently tapping of the SEM stub with the applied adhesive tape
on top of the appropriate sample. According to the authors, this approach allowed them to observe
the particles and their aggregates/agglomerates in the native form.
SEM imagines were post-processed considering a uniform rectangular grid (49–196 nodal points)
and only the particles or particles aggregates/agglomerates in the nodal-points were analysed. The
Panel noted that the point counting methodology tends to give biased results since large particles have
more chance to be selected for measurement than the small. In addition, for some samples
magniﬁcation should be higher to allow precise measurement.
As indicated in the report, in the TEM images only the particles with well detectable boundaries
were analysed. The Panel noted that the magniﬁcation used did not allow to identify if there are or not
smaller particles.
The same samples were analysed by DLS and number-based (Dn) values were reported
(Documentation provided to EFSA n. 6). Dn10 values for some of the samples of E 341(ii), E 341(iii),
E 343(ii) and E 450(vii) were around 140 nm.
Based on the available information, the Panel cannot exclude that particles in the nanorange can be
present in phosphates when used as a food additive.
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3.1.4. Manufacturing process
Information was submitted by CEFIC – Phosphoric Acid and Phosphates Producers Association
(PAPA) in response to the public call for data.
Phosphoric acid and salts
Phosphoric acid is produced commercially by two main methods, either a wet process or an
electrothermal process. In the wet process, phosphate rock is digested with a mineral acid (usually
sulfuric acid, but nitric or hydrochloric acids may also be used). A ﬁltration step then separates the
‘wet’ phosphoric acid from the insoluble calcium sulfate slurry. As variable amounts of inorganic
impurities may be present depending on the origin of the phosphate rock the phosphoric acid is
puriﬁed through a solvent extraction puriﬁcation process to produce the food-grade additive. In the
electrothermal process, the phosphate rock, coke and silica are ﬁrst heated in an electric resistance
furnace to more than 1,100°C to extract elemental phosphorus from the ore. The elemental
phosphorus is then oxidised to P4O10 (phosphorus pentoxide) and subsequently hydrated and the mist
is collected. This process produces a high-purity orthophosphoric acid due to the use of pure
phosphorous for combustion and only the impurity arsenic needs to be removed in an additional
puriﬁcation step involving treatment with excess hydrogen sulﬁde and ﬁltration of the precipitate
(Documentation provided to EFSA n. 8).
Calcium and magnesium phosphates are produced commercially from phosphoric acid and either
calcium oxide or calcium hydroxide, and either magnesium oxide or magnesium hydroxide,
respectively. The raw materials are mixed together and the product is separated via centrifugation or
ﬁltration. The product is a solid that undergoes further physical treatment (drying, milling, sieving)
before being passed through a metal detector and then packaged (Documentation provided to EFSA n.
9,10). No further information on purity requirements for the Ca and Mg containing starting materials
were provided.
Both mono- and disodium phosphates are prepared commercially by neutralisation of phosphoric
acid using sodium carbonate or sodium hydroxide. Crystals of a speciﬁc hydrate can then be obtained
by evaporation of the resultant solution within the temperature range over which the hydrate is stable.
For the preparation of trisodium phosphate, sodium hydroxide must be used to reach the high pH
because carbon dioxide cannot be stripped readily from the solution above a pH approaching 8.
Similarly, the potassium phosphates are produced by successive replacement of the protons (H+) of
phosphoric acid with potassium ions.
Diphosphates
The three sodium diphosphates are produced commercially by the neutralisation of phosphoric acid
with sodium hydroxide. Solutions of the two reagents are mixed in the required proportions for the
speciﬁc product (1:1 sodium hydroxide:phosphoric acid for E 450(i); 3:2 for E 450(ii); and 2:1 for
E 450(iii)). After reaction, the solution is ﬁltered to remove insoluble impurities. The solution is spray-
dried or passed through a rotary kiln or drum dryer. Temperatures greater than 200°C are used; as
well as evaporating the water, this temperature promotes a condensation reaction between phosphate
groups to produce the diphosphate. The solid material produced is milled, sieved or ground, passed
through a metal detector and packaged. Information on manufacturing of tetrasodium diphosphate
(E 450(iv)) is missing.
Tetrapotassium diphosphate is manufactured in a similar way, using potassium hydroxide and
phosphoric acid. A higher temperature of 350–400°C is used to dry the product and promote the
condensation of phosphate groups. The solid product is processed in the same way as described
above.
Dicalcium diphosphate is produced from anhydrous dicalcium phosphate (calcium hydrogen
phosphate, CaHPO4). The dicalcium phosphate is calcined in a drum drier, rotary kiln or kneader drier
at 350–400°C, under which conditions a condensation reaction occurs between phosphate groups. The
coarse granules formed are milled, sieved, passed through a metal detector and bagged.
Calcium dihydrogen diphosphate is made in a similar way to the above, but the starting material is
monocalcium phosphate (Ca(H2PO4)). This is calcined in a drum drier, rotary kiln or kneader drier at
270–350°C, where condensation between phosphate groups occurs. The solid product is treated in the
same way as described in the above paragraphs.
Magnesium dihydrogen diphosphate (E 450(ix)) is manufactured by adding an aqueous dispersion
of magnesium hydroxide slowly to phosphoric acid, until a molar ratio of approximately 1:2 (Mg:P) is
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achieved. The temperature is held at 60C during the reaction. Approximately 0.1% hydrogen peroxide
is added and the resulting slurry is heated and milled (Documentation provided to EFSA n. 7).
Triphosphates
Pentasodium triphosphate and pentapotassium triphosphate are produced commercially by the
neutralisation of phosphoric acid with sodium or potassium hydroxide, respectively. The neutralised
mixture is dried via spray-drying or by being passed through a drum dryer or rotary kiln at
temperatures above 250°C. The phosphate produced (di-, tri- etc) depends on the degree of
neutralisation and the temperature and residence time in the dryer or kiln. The coarse granules formed
are usually milled, sieved, passed through a metal detector and then bagged.
Polyphosphates
The thermal dehydration of monosodium phosphate can give a number of condensed polyphosphates.
The particular products formed depend on the conditions used – temperature, water vapour and
tempering. Heating NaH2PO4 to above 620°C and quenching rapidly gives Graham’s salt, a water-soluble
polyphosphate glass with a composition of (NaPO3)x (where x = 4–1.1). The glass consists of around 90%
high molecular weight polyphosphates, with the rest being made up of various cyclic metaphosphates. In
contrast, the dehydration of NaH2PO4 at 260–300°C produces the low temperature form of Maddrell’s salt,
(NaPO3)n – III, insoluble metaphosphate III. Further heat treatment of this at 360–430°C produces a
second form of Maddrell’s salt, insoluble metaphosphate II (also (NaPO3)n). The potassium compound,
Kurrol’s salt, is similarly obtained by thermal dehydration of KH2PO4. No information on manufacturing of
E 452(iii) sodium calcium polyphosphate and E 452(iv) calcium polyphosphate.
3.1.5. Methods of analysis in food
Introduction
A variety of analytical methods have been used for the determination of phosphate additives in
foods and beverages. So-called ‘classical’ methods are generally only useful for total phosphate but
have been modernised for current applications in some areas. Modern methods such as ion
chromatography (IC), capillary zone electrophoresis (CZE) and nuclear magnetic resonance
spectroscopy (NMR) can separate, identify and quantify different phosphate types but are not be able
to differentiate between added and naturally occurring phosphates. Moreover, most methods suffer
from lack of information on natural variation of phosphate levels where only a few useful but limited
reviews are available.
Plasma spectrometry is a useful tool for the estimation of the total phosphorus content. Upon
comparing IC with direct current plasma spectrometry (DCP), IC can only provide information on ionic
phosphates while DCP can allow the determination of all forms of phosphorus. However, a combination
of the two techniques can provide a powerful tool for separating, identifying and measuring all forms
of phosphorus (Urasa and Ferede, 1986).
The measurement of added phosphates in food products is not straightforward due to the presence
of several types of phosphate additives (i.e. poly, tri-, pyro-, orthophosphates). The quantiﬁcation of
phosphate alone cannot be used to verify the presence of added phosphates due to the presence of
naturally occurring phosphates and other phosphorus-containing components such as phospholipids
and phosphoproteins. For example, there is ca. 0.1–4.8% naturally occurring phosphates in seafood
(Campden, 2012); hence, there is a need to distinguish between natural phosphates, which are not
well deﬁned, and added phosphates. In addition, there is the issue of stability since polyphosphates
are readily hydrolysed to pyrophosphates and (eventually) to orthophosphates due to phosphatase
activity (temperature-dependent), processing conditions and during analysis (Scharpf and Kichline,
1967; Das et al., 2011; Campden 2012).
Extraction procedures for phosphates are sample-speciﬁc and therefore vary across foods and
beverages permitted to contain phosphate additives. Certain extraction conditions (e.g. acids) can also
promote the degradation of polyphosphates to orthophosphates.
Indirect methods
Indirect methods for estimation phosphate content are essentially restricted to moisture content
and protein content. The ratios of moisture:protein and phosphate:protein can provide useful
information on added phosphates. However, the moisture contents of foodstuffs vary greatly and
protein measurement relies on the use of interim nitrogen factors following Kjeldahl analysis. While
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these methods can show when phosphates and/or water have been added, their accuracy is
questionable due to natural variation in phosphate content of foodstuffs (Campden, 2012).
Direct methods
Phosphate may be determined in meat samples using digestion with a mixture of hydrochloric and
nitric acids, followed by ﬁltration and treatment with quimociac reagent to form precipitates of
quinolinium phosphomolybdate, which are then ﬁltered, washed, dried and quantiﬁed gravimetrically
(USDA, 2009).
Spectrophotometric methods
Direct analysis of phosphate in foodstuffs is commonly carried out using spectrophotometric
(colorimetric) methods, e.g. by measuring the intensity of colour resulting from the interaction of
orthophosphates with reagents such as molybdenum blue, yellow vanamolybdate complex and
malachite green (Þorarinsdottir et al. (2010); Campden, 2012). Colorimetric analysis requires the
decomposition of poly-, tri- and other forms to orthophosphates achieved through the use of strong
acids such as trichloroacetic acid (TCA) and sulfuric acid (H2SO4). The total phosphate content is
usually expressed as P2O5 and therefore does not distinguish between different classes of phosphate
additive. A spectrophotometric method has been developed that is able to distinguish between
phosphorus due to water-soluble (i.e. inorganic) from organic phosphorus sources such as
phospholipid and phosphoprotein (Cupisti et al., 2012). An adaptation of this method can be used to
distinguish between orthophosphate and condensed polyphosphates (Þorarinsdottir et al., 2010). The
condensed forms react much more slowly, so measurements are made at 15 and 90 min and the
difference between the results is the amount of the condensed forms. The method described above
cannot distinguish between the di-, tri- and polyphosphates.
Modern spectrophotometric methods have good sensitivity and precision, which is important
because of the natural variation in total phosphates content in foodstuffs. McKie and McCleary (2016)
developed and validated a novel and rapid method for the determination of total phosphorus and
phytic acid in foods and animal feeds. The method involves the extraction of phytic acid followed by
dephosphorylation with phytase and alkaline phosphatase, and measured colorimetrically using a
modiﬁed molybdenum blue assay. Such methods are used for determining the phosphate content of
fertilisers and for assessing the purity of phosphate food additives (JECFA, 2018; EU, 231/2012). The
Association of Ofﬁcial Analytical Chemists (AOAC) method describes a standard colorimetric method for
the determination of orthophosphate in water (AOAC, 1997). Method details are summarised in
Table 1.
Chromatographic methods
Thin-layer chromatography (TLC) methods for determining phosphates are relatively simple and
cheap and can separate poly-, tri-, pyro- and orthophosphates. Quantitative estimates of phosphates
content can be achieved by comparing colour intensities of spots with standard phosphate solutions.
The main disadvantage of TLC is the hydrolysis in situ of phosphates during sample extraction and
analysis (Campden, 2012). Without additional analysis, TLC is essentially a qualitative technique and it
has been shown that false-negative results can arise. For example, where polyphosphates have
completely hydrolysed to orthophosphates and are no longer detectable as a distinct species, while
similar observations during the TLC analysis of white shrimp, where the limit of detection was
estimated at 0.08% (w/w) sodium triphosphate (Campden 2012).
High-performance liquid chromatography (HPLC), or more accurately IC, has been shown to be a
useful method for the determination of individual polyphosphates and other phosphate species. IC can
separate and quantify poly-, tri-, pyro- and orthophosphates. Post-column colorimetric and conductivity
detection can be used to provide sensitive and selective performance with good linear range. IC
methods can be used for the simultaneous determination of condensed phosphates including
orthophosphates (P1), diphosphates (P2) and polyphosphates (P3 and greater).
Examples of the application of IC in ﬁsh, shellﬁsh and crustacea may be found in Campden (2012).
A similar methodology has been used IC has been used to determine phosphate species in sausage
(Dionex 2010) and for the determination of polyphosphates in ﬁsh, shrimp and cuttleﬁsh, and on
commercial products of cooked ham, wurstel, corned beef, processed cheese and ﬁsh (Iammarino and
Di Taranto, 2012). IC has been used recently for the rapid and automated determination of
orthophosphate in carbonated soft drinks (De Borba and Rohrer, 2018). Method details are
summarised in Table 1.
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Electrophoretic methods
Capillary electrophoresis (CE) is a family of related techniques used to separate charged particles
based on their size to charge ratio when an electric current is applied (Campden, 2012). The most
commonly used technique is capillary zone electrophoresis (CZE), where separation is based on
differences in solute size and charge at a given pH. In capillary isotachophoresis (cITP), samples are
loaded into a capillary set between two electrolytes (leading and terminating), whereupon the analytes
are separated into discrete zones between the electrolytes according to their electrophoretic mobility.
Both techniques, either alone or in combination, have been used to detect added phosphates in
foodstuffs. Detection techniques include conductivity, ﬂuorescence or ultraviolet (UV). CZE/cITP with
conductivity detection has been used to determine phosphate in meat, canned meat products, ham,
smoked ham, sausages, pate, prawns, squid and mixed seafood (Jastrzezbska, 2009, 2011; Campden
2012). Method details are summarised in Table 1. The clear advantages of using CZE/cITP methods is
that they can determine different phosphate species (ortho, di- and tri-) simultaneously and rapidly,
requiring a relatively small amount of sample. While results have been reported to be sensitive,
accurate and precise the importance of robust sample preparation is requisite. Sample inhomogeneity
and the presence of protein and fat can decrease method precision.
Nuclear magnetic resonance (NMR)
31P NMR has been used generally as a research tool rather than as a routine analytical procedure but
this technique is becoming more widely available and affordable. 31P NMR can differentiate
simultaneously between different phosphate types and is quantiﬁable. It has been applied to ﬁsh and
meat products with adequate sensitivity (Campden, 2012). Method details are summarised in Table 1.
The results obtained by 31P NMR are reported to more accurate and precise compared to those obtained
using the molybdovanadate yellow spectrophotometric method (Szłyk and Hrynczyszyn, 2011).
The issue of polyphosphate degradation notwithstanding, non-destructive, simultaneous
observation of different phosphate species is clearly an analytical advantage. Moreover, 31P NMR it has
been used to measure total phosphates or polyphosphates but cannot be used to distinguish between
natural and added compounds.
Ion chromatography
Upon comparing IC with DCP, IC can only provide information on ionic phosphates while DCP can allow
the determination of all forms of phosphorus. However, a combination of the two techniques can provide a
powerful tool for separating, identifying and measuring all forms of phosphorus (Urasa and Ferede, 1986).
Other methods
Much less widely used techniques for phosphate determination include thermal differential
photometry and microwave dielectric spectroscopy, which are essentially research tools that are not
readily applicable to routine analysis of foodstuffs. X-ray ﬂuorescence has also been used
(Documentation provided to EFSA n. 7) although is not a widespread technique.
Standard methods and norms
There are few validated ofﬁcial methods available. Those identiﬁed to date are summarised with
standard methods listed by BVL (2018) in Table 1. The scope of these methods covers ortho-,
condensed and polyphosphate analytes, and most foodstuffs and beverages apart from those for
infants (e.g. infant formula). Analytical techniques are essentially limited to TLC and/or
spectrophotometry, except for IC which is speciﬁed for the analysis of soft drinks. Data provided by
CEFIC-PAPA provide evidence for the accuracy and precision requirements of standard methods for
phosphate determination. For example, the total phosphorus is calculated as g/100 g reported to two
signiﬁcant ﬁgures (Documentation provided to EFSA n. 11).
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The scope of methods for the determination of phosphates in foodstuffs must cover the complete
range of foods and beverages permitted to contain phosphate additives and must be readily applicable
in laboratories, i.e. not unnecessarily complex or costly.
While quantitative spectrophotometric methods provide sufﬁcient sensitivity and ease of use, they
are limited in scope to the detection and measurement of phosphates in the ortho form, i.e. di-, tri-
and polyphosphates must be hydrolysed ﬁrst to orthophosphates. Hydrolysis may be achieved
chemically and/or enzymatically but it will not be possible to discriminate between phosphates present
naturally and phosphate additives (however, the latter are likely to be present at a much higher
concentration relative to natural phosphates). Published spectrophotometric methods therefore require
Table 1: Reference methods listed by BVL (2018) and available standard methods
E number(s)
Method number,
name, origin
Analyte(s) Analytical technique Matrices
BVL methods
450–452 L 06.00-15
L 07.00-20
L 08.00-22
Condensed
phosphates
Thin-layer
chromatography
Meat, meat products, processed
meats, bakery wares
450–452 L 06.00-9 Di-, Tri-, Poly-
Phosphate
Spectrophotometry Foodstuff, e.g. meat products,
ﬁsh products, dairy, bakery
products, grain-based foods
450(i–vii) L 06.00-15
ISO-Norm 5553
Diphosphate Thin-layer
chromatography
Dairy, meat products, ﬁsh
products
451(i, ii) L 06.00-15
ISO-Norm 5553
Triphosphate Thin-layer
chromatography
Dairy, meat products, ﬁsh
products
452(i–iv) L 06.00-15 mod. Iso-
Norm 5553
(qualitative)
L 06.00-09 mod.
(quantitative)
Di-, Tri-, Poly-
Phosphate
Thin-layer
chromatography
Spectrophotometry
Meat products, dairy (cheese,
processed cheese), ﬁsh products
338–341,
343,450–452
Photometric
determination of
phosphate after acid
digestion in drinks
Total
phosphate as
PO4
Spectrophotometry Soft drinks
338–341,
343,450–452
L 06.00-9 Total
phosphate as
P2O5
Spectrophotometry Meat, meat products, cheese,
dairy
338–343, 450,
451
Condensed phosphates
L 06.00-15
Condensed
phosphates
Qualitative
chromatography
Meat and meat products
338–343, 450,
451
Total phosphorus
content
L 06.00-9
P2O5 Spectrophotometry Meat and meat products
338–343, 450,
451
Total phosphorus
content
L 03.00-17
Phosphorous Spectrophotometry Cheese, processed cheese,
processed cheese preparations
339(i–iii) L 06.00-15 mod Triphosphate Thin-layer
chromatography
Fish products
340(i–iii) Not speciﬁed Phosphoric
acid
Ion chromatography Soft drinks
338 L 31.00-6 Phosphate Spectrophotometry
without ashing
Soft drinks
Other standard methods/norms
BSI 4401-15:1981/ISO 5553;1981. Methods of test for meat and meat products. Detection of polyphosphates
(by spectrophotometry)
PD ISO/TS 18083:2013. Processed cheese products. Calculation of content of added phosphate calculated as
phosphorus (by spectrophotometry)
AOAC, 1997. Standard colorimetric method for the determination of orthophosphate in water (by
spectrophotometry)
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further development to encompass all foodstuffs within the required scope, especially with respect to
extraction and isolation techniques.
Since spectrophotometric methods cannot be used qualitatively to identify different phosphate
additive species, the use of more sophisticated techniques that can separate, identify and quantify
different phosphate species is required. Of the available methods, IC is the most widely used but to
date, has not been applied to the full range of foodstuffs permitted to contain phosphate additives. For
the simultaneous determination of condensed phosphates using IC, systems employing a mobile phase
comprising KOH (or NaOH) and macroporous divinyl benzene/ethylvinyl benzene stationary phase run
under gradient elution conditions with suppressed conductivity detection, are the most widely
reported. In order to reduce the reporting of false positive and/or false negative results, it is
recommended that sample preparation times should be as short as possible and should include steps
to deactivate phosphatase enzymes.
Appropriate analytical methods must be developed and validated to recognised international
protocols so that they are ﬁt for purpose with respect to expected phosphate concentration ranges
(i.e. ranging from ca. 500 to 50,000 mg/kg, as well as quantum satis). Some foodstuffs have ‘no limit
deﬁned’. There should also be clear distinction between methods for total phosphate and methods for
identifying and quantifying separate phosphate types, i.e. methods must be robust, and the units used
for reporting phosphate content should be standardised.
There is a clear inconsistency in the reporting of levels of phosphates in food products (as well as
in serum and urine), due largely to the form in which the results are expressed. Historically,
phosphorus content has been expressed in terms of mg P2O5/100 g, which is usually applied to
determination of total phosphorus and phytic acid in fertilisers, which allows for normalisation of P
content across a range of products comprising different mixtures of phosphates. It is also applied to
some foods and animal feeds. Other (particularly clinical) studies report phosphorus levels as mg P/kg.
Modern analytical methods tend to report P content as mg/kg total phosphate or where possible as
mg/kg individual ortho-, pyro- or polyphosphates.
In order to fulﬁl the requirements of EU regulation EU 1333/2008 with regard to the presence and
maximum levels of phosphates, it is recommended that analytical results are expressed as either total
phosphates (P3O4
3 irrespective of counter ion), or in terms of the individual phosphate species, as mg/kg.
Literature sources show that spectrophotometry has been established as a reliable technique for
the determination of total phosphate in foodstuffs. Similarly, IC has been applied successfully to a
limited range of foodstuffs for the simultaneous determination of different phosphate additive species.
The Panel noted the need for development of analytical methods since those currently available for
total phosphate and phosphate speciation do not cover the entire range of foodstuffs permitted to
contain phosphate additives.
3.1.6. Stability of the substance and fate in food
No information was identiﬁed in the literature on the reaction and fate of phosphoric acid or its
calcium and magnesium salts in food. Phosphoric acid is soluble in water and is expected to dissociate
in beverages and fresh food to phosphate and H+ ions. No information was identiﬁed in the literature
on the reaction and fate of sodium and potassium phosphates in food. Since sodium and potassium
phosphates are freely soluble in water they are expected to be dissolved in beverages and fresh food
to phosphate and the respective cations.
Phosphoric acid and its sodium and potassium salts dissociate readily after being added to foods
and beverages, thereby affecting its technological function as an acidity regulator (Documentation
provided to EFSA n. 8), whereas calcium and magnesium phosphates require solubilisation under acidic
conditions (Documentation provided to EFSA n. 9,10).
The effects of phosphates in general on the colour and quality of salted ﬁsh are summarised by
Þorarinsdottir et al. (2010). Yellowing of the ﬁsh due to oxidation reduces the commercial quality.
Positive effects of phosphates on colour and the commercial quality of the ﬁsh (by maintaining the
natural colour of the ﬁsh) are thought to be due to reduced oxidation, which is brought about by the
sequestering action of the phosphates on metals present in the salt used.
The addition of sodium phosphates to meat has been shown to have antioxidant effects that
decrease the rate of oxidation of lipids in meat (Miller, 2010). Di-, tri- and higher phosphates are
susceptible to the action of phosphatase enzymes, in particular during extraction from food or
biological samples when they can be converted into monophosphates. Das et al. (2011) used Zn(II)
and Cd(II)-based complexes to bind with tetrasodium diphosphate in order to investigate the activity
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of alkaline phosphatase in physiological conditions. Allen and Cornforth (2009) describe the iron-
binding activity of sodium tripolyphosphate in a lipid-free model system. At concentrations of 1 and
0.05 mg/mL, 88% and 21%, respectively, of the added iron was bound. This activity was considered
to be the basis for the antioxidant effect of sodium tripolyphosphate. Weilmeier and Regenstein (2004)
added sodium polyphosphate to mackerel samples and observed an antioxidant effect, although this
was not as strong as the effect with propyl gallate, ascorbic acid or erythorbic acid. Jin et al. (2011)
puriﬁed and characterised the tripolyphosphatase responsible for the hydrolysis of tripolyphosphates in
rabbit psoas major muscle tissue.
Polyphosphates
All polyphosphates (also referred to as condensed phosphates) are subject to hydrolytic
decomposition (reversion) when in solution. The rate of decomposition is affected by:
• Temperature
• pH (generally < 7 or > 11)
• Multivalent metal ions, e.g. Ca2+, Fe2+
• Concentration at mg/L level, since as the concentration increases, the reversion rate decreases
• Phosphatase enzymes
• Phosphate species.
It is generally accepted that pyrophosphate is the most stable, followed by tripolyphosphates.
During hydrolysis of the longer chain phosphates, shorter chains as well as orthophosphates are
formed. Among the shorter chains formed are pyrophosphates. Research suggests that when the
pyrophosphate concentration increases, due to hydrolysis of higher polyphosphates, the rates of
reversion diminish. It may be that an equilibrium is established between the higher condensed
phosphates and their hydrolysis products.
Scharpf and Kichline (1967) showed that following the addition of long-chain sodium polyphosphate
to cheese extracts in which the natural alkaline phosphatase activity was high, the concentration and
distribution of phosphate species remained unchanged after storage at 3–7°C for 4 weeks. After
4 weeks storage at 20°C, the concentration of the long-chain species decreased from 89% to 64%,
whereas the concentration of the orthophosphate species increased from 4% to 27%.
In a conservative review of polyphosphate breakdown and stability (Campden, 2012) it was
reported that:
• Most polyphosphates added to food are broken down to orthophosphate units in the stomach
and may be signiﬁcantly hydrolysed to orthophosphates during storage and cooking.
• After 2 weeks of frozen storage, only 12% of the total phosphorus in uncooked shrimp muscle
corresponded to the tripolyphosphate added. After ten weeks, the phosphorus levels
corresponded to 45% orthophosphate. This was considered to be due to natural rather than
heat-induced hydrolysis.
• At elevated temperatures, such as in steam cooking, sodium tripolyphosphate will hydrolyse
rapidly to orthophosphates.
• Samples of three different commercially available cooked shrimp products treated with
tripolyphosphate and stored frozen for 11 months, showed that the total polyphosphate was
87%, 89% and 103% of the original levels, indicating that very little hydrolysis occurred.
The stability of polyphosphates in ﬁsh and shrimps under various treatment and storage regimen was
reported by Campden (2012). Samples were either untreated or treated and analysed after 0, 1, 2 and
3 days storage. The relative level of polyphosphate (expressed as P2O5) in raw shrimps was reduced from
1,500 mg/kg to 0 mg/kg after 4 days due to phosphatase activity. Conversely, no polyphosphate
degradation was observed in cooked shrimp treated with polyphosphate (at 2,600 mg/kg) after cooking,
indicating heat-induced phosphatase deactivation during cooking.
The addition of sodium phosphates to meat has been shown to have antioxidant effects that
decrease the rate of oxidation of lipids in meat (Miller, 2010). Di-, tri- and higher phosphates are
susceptible to the action of phosphatase enzymes, in particular during extraction from food or
biological samples when they can be converted into monophosphates. Campden (2012) report that
ﬂash heat treatment with a microwave oven can be used to avoid this.
The impact of high temperature treatments of on the composition of polyphosphates with regard to
phosphate chain length in aqueous solutions in the presence and absence of calcium ions has been
reported by Rulliere et al. (2012). Treatment at 120°C for 10 min led to the hydrolytic degradation of
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long-chain polyphosphates into orthophosphate and trimetaphosphate, whereas heating the salts to
100°C in aqueous solutions had little effect on composition. The presence of calcium ions increased the
rate of hydrolysis of long-chain phosphates leading to increased amounts of trimetaphosphate and
pyrophosphate end products. The evolution of emulsifying salts composition under heat treatment was
reported to lead to modiﬁcation of their chelating properties since short-chain phosphates are less
efﬁcient at chelating calcium than long-chain phosphates.
3.2. Authorised uses and use levels
Maximum levels of phosphates (E 338–341, E 343, E 450–452) have been deﬁned in Annex II to
Regulation (EC) No 1333/200813 on food additives, as amended. In this document, these levels are
named maximum permitted levels (MPLs).
Currently, phosphates (E 338–341, E 343, E 450–452) are authorised food additives in the EU with
MPLs ranging from 500 to 20,000 mg/kg expressed as P2O5 in 104 authorised uses and at quantum
satis (QS) in four. The 108 different uses and use levels are corresponding to 65 different food
categories. Table for converting phosphates into P2O5 and P is in Appendix B.
Table 2 summarises the food categories with their restrictions/exceptions that are permitted to
contain added phosphates (E 338–341, E 343, E 450–452) and the corresponding MPLs as set by
Annex II to Regulation (EC) No 1333/2008.
13 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16.
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Table 2: MPLs of phosphates (E 338–341, E 343, E 450–452) in foods according to the Annex II to Regulation (EC) No 1333/2008
Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
0 Food additives permitted in all
categories of foods
Only foods in dried powdered form (i.e.
foods dried during the production
process, and mixtures thereof),
excluding foods listed in table 1 of Part A
of this Annex
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
10,000 (1),(4),(57)
01.1 Unﬂavoured pasteurised and
sterilised (including UHT) milk
Only sterilised and UHT milk E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
01.4 Flavoured fermented milk
products including heat-treated
products
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
3,000 (1),(4)
01.5 Dehydrated milk as deﬁned by
Directive 2001/114/EC
Only partly dehydrated milk with less
than 28% solids
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
01.5 Dehydrated milk as deﬁned by
Directive 2001/114/EC
Only partly dehydrated milk with more
than 28% solids
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,500 (1),(4)
01.5 Dehydrated milk as deﬁned by
Directive 2001/114/EC
Only dried milk and dried skimmed milk E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,500 (1),(4)
01.6.3 Other creams Only sterilised, pasteurised, UHT cream
and whipped cream
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
01.7.1 Unripened cheese excluding
products falling in category 16
Except mozzarella E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,000 (1),(4)
01.7.5 Processed cheese E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
01.7.6 Cheese products (excluding
products falling in category 16)
Only unripened products E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,000 (1),(4)
01.8 Dairy analogues, including
beverage whiteners
Only whipped cream analogues E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
01.8 Dairy analogues, including
beverage whiteners
Only processed cheese analogues E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
01.8 Dairy analogues, including
beverage whiteners
Only beverage whiteners E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
30,000 (1),(4)
01.8 Dairy analogues, including
beverage whiteners
Only beverage whiteners for vending
machines
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
50,000 (1),(4)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
02.2.1 Butter and concentrated butter
and butter oil and anhydrous
milkfat
Only soured cream butter E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,000 (1),(4)
02.2.2 Other fat and oil emulsions
including spreads as deﬁned by
Council Regulation (EC) No
1234/2007 and liquid emulsions
Only spreadable fats E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
02.3 Vegetable oil pan spray Only water-based emulsion sprays for
coating baking tins
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
30,000 (1),(4)
03 Edible ices E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
04.2.4.1 Fruit and vegetable
preparations excluding compote
Only fruit preparations E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
800 (1),(4)
04.2.4.1 Fruit and vegetable
preparations excluding compote
Only seaweed based ﬁsh roe analogues E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
04.2.4.1 Fruit and vegetable
preparations excluding compote
Only glazings for vegetable products E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
4,000 (1),(4)
04.2.5.4 Nut butters and nut spreads Only spreadable fats excluding butter E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
04.2.6 Processed potato products Including prefried frozen en deep frozen
potatoes
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
05.2 Other confectionery including
breath refreshening
microsweets
Only candied fruit E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
800 (1),(4)
05.2 Other confectionery including
breath refreshening
microsweets
Only sugar confectionery, except candied
fruit
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
05.3 Chewing gum E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
Quantum satis (1),(4)
05.4 Decorations, coatings and
ﬁllings, except fruit based
ﬁllings covered by category
4.2.4
Only toppings (syrups for pancakes,
ﬂavoured syrups for milkshakes and ice
cream; similar products)
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
3,000 (1),(4)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
05.4 Decorations, coatings and
ﬁllings, except fruit based
ﬁllings covered by category
4.2.4
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
06.2.1 Flours E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,500 (1),(4)
06.2.1 Flours Only self-raising ﬂour E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
06.2.1 Flours Only self-raising ﬂour E 450(ix) Magnesium dihydrogen
diphosphate
15,000 (4),(81)
06.3 Breakfast cereals E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
06.5 Noodles E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,000 (1),(4)
06.5 Noodles E 450(ix) Magnesium dihydrogen
diphosphate
2,000 (4),(81)
06.6 Batters E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
12,000 (1),(4)
06.6 Batters E 450(ix) Magnesium dihydrogen
diphosphate
12,000 (4),(81)
07.1 Bread and rolls Only soda bread E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
07.1 Bread and rolls Only refrigerated, prepacked yeast based
doughs used as basis for pizzas, quiches,
tarts and similar products
E 450 Diphosphates 12,000 (4)
07.1 Bread and rolls Only pizza dough (frozen or chilled) and
‘tortilla’
E 450(ix) Magnesium dihydrogen
diphosphate
15,000 (4),(81)
07.2 Fine bakery wares E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
07.2 Fine bakery wares E 450(ix) Magnesium dihydrogen
diphosphate
15,000 (4),(81)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
08.2 Meat preparations as deﬁned by
Regulation (EC) No 853/2004
Only breakfast sausages: in this product,
the meat is minced in such a way so that
the muscle and fat tissue are completely
dispersed, so that ﬁbre makes an
emulsion with the fat, giving the product
its typical appearance; Finnish grey-
salted Christmas ham, burger meat with
a minimum vegetable and/or cereal
content of 4% mixed within the meat,
Kasseler, Br€ate, Surﬂeisch, toorvorst,
sasl~okk, ahjupraad, Bıla klobasa, Vinna
klobasa, Svatecnı klobasa, Syrova
klobasa and frozen vertical rotating meat
spits made of sheep, lamb, veal and/or
beef treated with liquid seasoning or
from poultry meat treated with or
without liquid seasoning used alone and/
or combined as well as sliced and/or
minced and designed to be roasted by a
food business operator and then
consumed by the ﬁnal consumer
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
08.3.1 Non-heat-treated meat
products
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
08.3.2 Heat–treated meat products Except foie gras, foie gras entier, blocs
de foie gras, Libamaj, libamaj egeszben,
libamaj t€ombben
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
08.3.3 Casings and coatings and
decorations for meat
Only glazings for meat E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
4,000 (1),(4)
09.1.1 Unprocessed ﬁsh Only frozen and deep-frozen ﬁsh ﬁllets E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
09.1.2 Unprocessed molluscs and
crustaceans
Only frozen and deep-frozen molluscs
and crustaceans
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
09.2 Processed ﬁsh and ﬁshery
products including molluscs and
crustaceans
Only canned crustaceans products;
surimi and similar products
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
09.2 Processed ﬁsh and ﬁshery
products including molluscs and
crustaceans
Only ﬁsh and crustacean paste and in
processed frozen and deep-frozen
molluscs and crustaceans
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
09.2 Processed ﬁsh and ﬁshery
products including molluscs and
crustaceans
Only salted ﬁsh of the Gadidae family
that have been pre-salted by injecting
and/or brine salting with an at least 18%
salt solution and often followed by dry
salting
E 450 Diphosphates 5,000 (1),(79)
09.2 Processed ﬁsh and ﬁshery
products including molluscs and
crustaceans
Only salted ﬁsh of the Gadidae family
that have been pre-salted by injecting
and/or brine salting with an at least 18%
salt solution and often followed by dry
salting
E 451 Triphosphates 5,000 (1),(79)
09.2 Processed ﬁsh and ﬁshery
products including molluscs and
crustaceans
Only salted ﬁsh of the Gadidae family
that have been pre-salted by injecting
and/or brine salting with an at least 18%
salt solution and often followed by dry
salting
E 452 Polyphosphates 5,000 (1),(79)
10.2 Processed eggs and egg
products
Only liquid egg (white, yolk or whole
egg)
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
10,000 (1),(4)
11.1 Sugars and syrups as deﬁned
by Directive 2001/111/EC
Only dried powdered foods E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
10,000 (4)
11.4.2 Table-top sweeteners in powder
form
E 341 Calcium phosphates Quantum satis
12.1.1 Salt E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
10,000 (1),(4)
12.1.2 Salt substitutes E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
10,000 (1),(4)
12.5 Soups and broths E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
3,000 (1),(4)
12.6 Sauces E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
12.9 Protein products, excluding
products covered in category
1.8
Only vegetable protein drinks E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
13.1.1 Infant formulae as deﬁned by
Directive 2006/141/EC
E 338 Phosphoric acid 1,000* (4),(44)
13.1.1 Infant formulae as deﬁned by
Directive 2006/141/EC
E 339 Sodium phosphates 1,000* (4),(15)
13.1.1 Infant formulae as deﬁned by
Directive 2006/141/EC
E 340 Potassium phosphates (4),(15)
13.1.2 Follow-on formulae as deﬁned
by Directive 2006/141/EC
E 338 Phosphoric acid (4),(44)
13.1.2 Follow-on formulae as deﬁned
by Directive 2006/141/EC
E 339 Sodium phosphates 1,000* (4),(15)
13.1.2 Follow-on formulae as deﬁned
by Directive 2006/141/EC
E 340 Potassium phosphates (4),(15)
13.1.3 Processed cereal-based foods
and baby foods for infants and
young children as deﬁned by
Directive 2006/125/EC
Only processed cereal based foods and
baby foods, only for pH adjustment
E 338 Phosphoric acid 1,000* (4)
13.1.3 Processed cereal-based foods
and baby foods for infants and
young children as deﬁned by
Directive 2006/125/EC
Only cereals E 339 Sodium phosphates 1,000* (4),(20)
13.1.3 Processed cereal-based foods
and baby foods for infants and
young children as deﬁned by
Directive 2006/125/EC
Only cereals E 340 Potassium phosphates 1,000* (4),(20)
13.1.3 Processed cereal-based foods
and baby foods for infants and
young children as deﬁned by
Directive 2006/125/EC
Only cereals E 341 Calcium phosphates 1,000* (4),(20)
13.1.3 Processed cereal-based foods
and baby foods for infants and
young children as deﬁned by
Directive 2006/125/EC
Only in fruit-based desserts E 341 Calcium phosphates 1,000* (4)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
13.1.3 Processed cereal-based foods
and baby foods for infants and
young children as deﬁned by
Directive 2006/125/EC
Only biscuits and rusks E 450 Diphosphates 5,000* (4),(42)
13.1.4 Other foods for young children E 338 Phosphoric acid (1),(4),(44)
13.1.4 Other foods for young children E 339 Sodium phosphates 1,000* (1),(4),(15)
13.1.4 Other foods for young children E 340 Potassium phosphates 1,000* (1),(4),(15)
13.1.5.1 Dietary foods for infants for
special medical purposes and
special formulae for infants
Only for pH adjustment E 338 Phosphoric acid 1,000* (1),(4)
13.1.5.1 Dietary foods for infants for
special medical purposes and
special formulae for infants
E 339 Sodium phosphates 1,000* (1),(4),(20)
13.1.5.1 Dietary foods for infants for
special medical purposes and
special formulae for infants
E 340 Potassium phosphates 1,000* (1),(4),(20)
13.1.5.1 Dietary foods for infants for
special medical purposes and
special formulae for infants
E 341 Calcium phosphates 1,000* (1),(4),(20)
13.1.5.2 Dietary foods for babies and
young children for special
medical purposed as deﬁned in
Directive 1999/21/EC
E 338 Phosphoric acid 1,000* (4),(44)
13.1.5.2 Dietary foods for babies and
young children for special
medical purposed as deﬁned in
Directive 1999/21/EC
E 339 Sodium phosphates 1,000* (4),(15)
13.1.5.2 Dietary foods for babies and
young children for special
medical purposed as deﬁned in
Directive 1999/21/EC
E 340 Potassium phosphates 1,000* (4),(15)
13.1.5.2 Dietary foods for babies and
young children for special
medical purposed as deﬁned in
Directive 1999/21/EC
E 341 Calcium phosphates 1,000* (4),(20)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
13.1.5.2 Dietary foods for babies and
young children for special
medical purposed as deﬁned in
Directive 1999/21/EC
Only biscuits and rusks E 450 Diphosphates 5,000* (4),(42)
13.2 Dietary foods for special
medical purposes deﬁned in
Directive 1999/21/EC (excluding
products from food category
13.1.5)
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
13.3 Dietary foods for weight control
diets intended to replace total
daily food intake or an
individual meal (the whole or
part of the total daily diet)
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
13.4 Foods suitable for people
intolerant to gluten as deﬁned
by Regulation (EC) No 41/2009
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
14.1.1 Water, including natural mineral
water as deﬁned in Directive
2009/54/EC and spring water
and all other bottled or packed
waters
Only prepared table waters E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
500 (1),(4)
14.1.4 Flavoured drinks E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
700 (1),(4)
14.1.4 Flavoured drinks Only sport drinks E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
500 (1),(4)
14.1.4 Flavoured drinks Only chocolate and malt dairy-based
drinks
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,000 (1),(4)
14.1.4 Flavoured drinks Only whey protein containing sport
drinks
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
4,000 (1),(4)
14.1.4 Flavoured drinks Only vegetable protein drinks E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
20,000 (1),(4)
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
14.1.5.2 Other Only coffee-based drinks for vending
machines; Instant tea and instant herbal
infusions
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
2,000 (1),(4)
14.2.3 Cider and perry E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.4 Fruit wine and made wine E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.5 Mead E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.6 Spirit drinks as deﬁned in
Regulation (EC) No 110/2008
Except: whisky, whiskey E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.7.1 Aromatised wines E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.7.2 Aromatised wine-based drinks E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.7.3 Aromatised wine-product
cocktails
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
14.2.8 Other alcoholic drinks including
mixtures of alcoholic drinks with
non-alcoholic drinks and spirits
with less than 15% of alcohol
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
1,000 (1),(4)
15.1 Potato-, cereal-, ﬂour- or
starch-based snacks
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
15.2 Processed nuts E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
5,000 (1),(4)
16 Desserts excluding products
covered in category 1, 3 and 4
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
3,000 (1),(4)
16 Desserts excluding products
covered in category 1, 3 and 4
Only dry powdered dessert mixes E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
7,000 (1),(4)
17.1 Food supplements supplied in a
solid form, excluding food
supplements for infants and
young children
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
Quantum satis
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Food
category
code
Food category name Restrictions/exceptions E-number Name
MPL (mg/L or
mg/kg as
appropriate)
Footnotes (as in
Reg (EC)
No 1333/2008
17.2 Food supplements supplied in a
liquid form, excluding food
supplements for infants and
young children
E 338–452 Phosphoric acid–phosphates –
di-, tri- and polyphosphates
Quantum satis
MPL: maximum permitted level; UHT: Ultra High Temperature.
(1): The additives may be added individually or in combination.
(4): The maximum level is expressed as P2O5.
(15): E 339 and E 340 are authorised individually or in combination and in conformity with the limits set in Directives 2006/141/EC, 2006/125/EC, 1999/21/EC.
(20): E 339, E 340 and E 341 are authorised individually or in combination.
(44): In conformity with the limits set in Directives 2006/141/EC, 2006/125/EC, 1999/21/EC.
(57): The maximum level shall apply unless a different maximum level is speciﬁed in points 01 to 18 of this Annex in relation to individual foods or categories of foods.
(79): The maximum level applies to the sum of E 450, E 451 and E 452 used individually or in a combination.
(81): The total amount of phosphates shall not exceed the maximum level for E 338–452.
*: The maximum levels of use indicated refer to foods ready for consumption prepared following manufacturer’s’ instructions, for all subcategories under 13.1 Foods for infants and young children.
The Panel noted that for three food categories, no number for the maximum level is provided for certain provisions (see above for FC 13.1.1 for food
additive E 340, FC 13.1.2 for food additive E 338 and E 340 and for FC 13.1.4 for food additive E 338). However, the footnotes associated with the
provisions refer to the limits set in Directives 2006/141/EC, 2006/125/EC and 1999/21/EC which shall be respected. In addition, for E 340 in FC 13.1.1 and
13.1.2 the use level is set up individually or in combination with E 339 by the footnote (15).
The directives considered in the footnotes (15) or (44) prescribe that the maximum level of 1,000 mg/kg in the FC 13.1.1 for instance are applicable to
all the phosphates additives authorised in the same food category. In the MPL scenario, the Panel agreed to use a MPL of 1,000 mg/kg for the food
categories that for which MPLs were not provided (FCs 13.1.1, 13.1.2 and 13.1.4).
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According to Annex III, Part 1 of Regulation (EC) No 1333/2008, calcium phosphates (E 341) is
authorised as a carrier in all food additives at QS.
According to Annex III, Part 2 of Regulation (EC) No 1333/2008, E 338, E 339, E 340, E 343,
E 450, E 451 are also authorised as food additive in preparations of the colour E 163 anthocyanins
with a maximum level in the preparations of 40,000 mg/kg singly or in combination (expressed as
P2O5). E 341 is also authorised, according to Part 2, as food additive:
– in colour and emulsiﬁer preparations with a maximum level in the preparations of 40,000 mg/kg
(expressed as P2O5);
– in polyol preparations and E 412 guar gum preparations with a maximum level in the
preparation of 10,000 mg/kg (expressed as P2O5).
According to Annex III, Part 3 of Regulation (EC) No 1333/2008, phosphoric acid (E 338) is also
authorised as a food additive in food enzymes with a maximum level in the enzymes preparation of
10,000 mg/kg (expressed as P2O5) and at QS in the ﬁnal products (food or beverages).
According to Annex III, Part 3 of Regulation (EC) No 1333/2008, E 339, E 340, E 341, E 343 are
also authorised as a food additive in food enzymes with a maximum level in the enzymes preparation
of 50,000 mg/kg (expressed as P2O5) and at QS in the ﬁnal products (food or beverages). These food
additives are also authorised to be used as carriers.
According to Annex III, Part 3 of Regulation (EC) No 1333/2008, E 450, E 451, E 452 are also
authorised as a food additive in food enzymes with a maximum level in the enzymes preparation of
50,000 mg/kg (expressed as P2O5) and at QS in the ﬁnal products (food or beverages).These food
additives are not authorised to be used as carriers.
According to Annex III, Part 4, phosphates (E 338–341, E 343, E 450–452) are authorised at the
maximum level of 40,000 mg/kg (singly or in combination expressed as P2O5) in all ﬂavourings.
In addition, according to Annex III, Part 5, Section A of Regulation (EC) No 1333/2008, phosphates
(E 338–341, E 343, E 450–452) are also authorised at the maximum level of 40,000 mg/kg expressed
as P2O5 in the nutrient preparation, in all nutrients.
According to Annex III, Part 5, Section B of Regulation (EC) No 1333/2008, tricalcium phosphate
(E 341(iii) is also authorised at the maximum carry-over of 150 mg/kg as P2O5 and within the limit for
calcium, phosphorus and calcium:phosphorus ratio as set in Directive 2006/141/EC in all nutrients in
infant formulae and follow-on formulae as deﬁned by Directive 2006/141/EC; and at the maximum
level of 1,000 mg/kg expressed as P2O5 from all uses in ﬁnal food mentioned in point 13.1.3 of Part E
of Annex II is respected in all nutrients in processed cereal based foods and baby foods for infants and
young children as deﬁned by Directive 2006/141/EC.
3.2.1. Proposed extension of use
One request for extension of use was also considered in the exposure estimates. The request
referred to the removal of the restriction ‘only sugar confectionary’ in the food category 05.2 ‘Other
confectionary including breath refreshing microsweets’. This request would change the Regulation (EC)
No 1333/2008 as reported in Table 3.
Re-evaluation of the safety of phosphates (E 338–341, E 343, E 450–452)
www.efsa.europa.eu/efsajournal 33 EFSA Journal 2019;17(6):5674
Table 3: Proposed uses and maximum use levels for phosphates (E 338–341, E 343, E 450–452) in food category 05.2 following the requested extension
of use
Food
category
code
Food category name
Restrictions/
exceptions
E-number Name
MPL (mg/L or mg/kg
as appropriate)
Footnotes (as
in Reg (EC) No
1333/2008)
05.2 Other confectionery including breath
refreshening microsweets
Only candied fruit E 338–452 Phosphoric acid–phosphates – di-,
tri- and polyphosphates
800 (1),(4)
05.2 Other confectionery including breath
refreshening microsweets
Except candied fruit E 338–452 Phosphoric acid–phosphates – di-,
tri- and polyphosphates
5,000 (1),(4)
MPL: maximum permitted level.
(1): The additives may be added individually or in combination.
(4): The maximum level is expressed as P2O5.
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3.3. Exposure data
3.3.1. Reported use levels or data on analytical levels of phosphates (E 338–341,
E 343, E 450–452)
Most food additives in the EU are authorised at a speciﬁc MPL. However, a food additive may be
used at a lower level than the MPL. Therefore, information on actual use levels is required for
performing a more realistic exposure assessment, especially for those food additives for which no MPL
is set and which are authorised according to QS. In the case of phosphates additives, only chewing-
gum and food supplements were authorised at QS.
In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued a
public call14 for occurrence data (usage level and/or concentration data) on phosphates (E 338–341,
E 343, E 450–452). In response to this call, both types of data on phosphates (E 338–341, E 343,
E 450–452) were submitted to EFSA by industry and Member States, respectively.
Summarised data on reported use levels in foods provided by industry
Industry provided EFSA with data on use levels (n = 1,298) of phosphates (E 338–341, E 343,
E 450–452) in foods for 89 out of the 108 authorised uses in which phosphates (E 338–341, E 343,
E 450–452) are authorised.
Updated information on the actual use levels of phosphates (E 338–341, E 343, E 450–452) in
foods was made available to EFSA by the Association des Entreprises Produits Alimentaires Elabores
(ADEPALE), Association of the European Self-Medication Industry (AESGP), Comite Europeen des
Fabricants de Sucre (CEFS), Dr Loges Naturheilkunde neu entdecken, European Chemical Industry
Council (CEFIC), European Dairy Association (EDA), European Fish Processors and Traders Association
& European Federation of National Organisations of Importers and Exporters of Fish (AIPCE-CEP),
European Potato Processors’ Association (EUPPA), Food Drink Europe (FDE), Food Supplement Europe
(FSE), IMACE, International Chewing Gum Association (ICGA), Intersnack, L’ALLIANCE 7, Nathura,
Specialised Nutrition Europe (SNE).
The Panel noted that a data provider (namely CEFIC) is not a food industry using phosphates in its
food products but is an association representing food additive producers/chemical suppliers and not
directly using these substances as additives in foods. Usage levels reported by food additive producers are
not considered at the same level as those provided by food industry. Food additive producers may
recommend usage levels to the food industry but the ﬁnal levels might, ultimately, be different. Therefore,
unless food additive producers conﬁrm that the recommended levels are used by food industry, they are
not considered in the reﬁned exposure scenario. In this opinion, data coming from CEFIC were not
considered in the reﬁned assessment. These data are nevertheless presented in the Appendix F.
Data provided by Nathura (n = 3) were also discarded from the current exposure estimates. These
data were initially checked with the provider but the levels submitted were found not to be correct as
these levels would results in a phosphates content which is higher than 100%.
The Panel noted that 325 usage levels referred to niche products. When other usage levels were
available for the same authorised uses, the Panel decided to exclude them from further analysis.
Levels from niche products were used for unﬂavoured pasteurised and sterilised (including UHT) milk
(FC 01.1), chewing-gum (FC 05.3) and processed cereal-based foods and baby foods for infants and
young children (FC 13.1.3) in the absence of other levels.
The Panel also noted that levels provided for the use of phosphates as nutrient sources (e.g.
phosphates in formulae) and not as food additives. These levels were not taken into account for
estimating exposure of phosphates (E 338–341, E 343, E 450–452) as food additives.
Some data (n = 190) were provided as phosphates (‘E 338–452’) or as mixture of different
E-numbers.
Most of the data submitted to EFSA were expressed directly in P2O5, the other in the food additive
added. In the latter, thanks to the availability of the speciﬁc E-number, the use levels were converted into
P2O5, based on the conversion factors (see Appendix B). However, some data providers are using
phosphates in a subcomponent of their ﬁnal product. In these instances, the E number subcategories
(i, ii, iii) were not speciﬁed. Thus, the levels could not be expressed as P2O5, which is the case for all data
on snacks (n = 7) and 73 levels on food supplements. Food supplements and snacks use levels not
14 http://www.efsa.europa.eu/sites/default/ﬁles/consultation/170223.pdf
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expressed as P2O5, were converted using the converting factors reported in Appendix B. In case the salt
is not speciﬁed, the factor used to convert this level in P2O5 is the one of the anhydrous form and this
could lead to an overestimation. The use levels not expressed as P2O5 are indicated in Appendix F.
Some levels were submitted for food categories not listed in Table 1. However, phosphates could be
used in those as these foods are in dried powdered form and can contain phosphates. This is the case for:
– icing sugar (belonging to FC 11.2)
– pasta (FC 06.4.2) with seasonings.
Some levels were also submitted for FC 07.1 Bread and rolls. Foods belonging to this category can
contain phosphates from their authorisation and uses in their ingredients [e.g. ﬂour (FC 06.2.1),
decorations, coatings and ﬁllings (FC 05.4)]. After considering all the data, the Panel agreed that for
FC 07.1 maximum uses reported by industry were used in the regulatory maximum exposure
assessment scenario.
Appendix F provides data on the use levels of phosphates (E 338–341, E 343, E 450–452) in foods
as reported by industry.
Summarised data on analytical results in food submitted by Member States
In total, 2,418 analytical results were reported to EFSA by 10 countries: Belgium (n = 379), the
Czech Republic (n = 674), Germany (n = 310), Hungary (n = 302), Ireland (n = 42), Italy (n = 18),
Lithuania (n = 66), Portugal (n = 6), Spain (n = 325) and the UK (n = 296). Substances analysed were
expressed either as phosphorus (P), phosphoric acid or sum of phosphates expressed as P2O5. For this
evaluation all results were converted to P.
Some of the analytical results were left-censored (LC): either not quantiﬁed (< LOQ) in 824 samples
or not detected (< LOD) in 14 samples. To consider left-censored analytical data (i.e. analytical results
< LOD or < LOQ), the substitution method as recommended in the ‘Principles and Methods for the Risk
Assessment of Chemicals in Food’ (WHO, 2009) and the EFSA scientiﬁc report ‘Management of left-
censored data in dietary exposure assessment of chemical substances’ (EFSA, 2010) was used. In the
present opinion, analytical data below LOD or LOQ were assigned half of LOD or LOQ, respectively.
Therefore, it should be noted that the use of middle-bound (MB) LOD/LOQ values (half of LOD or
LOQ) in the exposure assessment, may have resulted in either an overestimation, where phosphates
were not present, or underestimation, where the concentration was between the MB and LOQ/LOD
value, but the analytical method was not able to detect or quantify it. The higher percentage of left-
censored data was observed for the food categories confectionary (FC 05.2, 96.7% of LC data), water
(FC 14.1.1, 81.8% LC data), ﬂavoured drinks (FC 14.1.4, 72.6% of LC data). Some left-censored
samples were identiﬁed with a very high LOQ. While checking LOQ with the data provider, it appears
that there was an error in the reporting of the LOQ. Therefore, these samples were discarded.
Complete information on the methods of analysis (e.g. validation) was not made available to EFSA, but
all samples were analysed by accredited laboratories. Data were sampled between 2009 and 2016 and
analysed between 2009 and 2017. The Panel noted that the methods of analysis applied are generally not
able to differentiate between phosphates added as food additives and naturally present in foods.
The majority of the data (n = 2,252) were expressed as lg/kg and were converted to mg/kg as
were levels expressed in percent (n = 66) whereas the levels expressed in kcal (n = 1) or per 100 kcal
(n = 99) were discarded since no information on the food energy content was available.
The food categories with the most data were FC 15.1 snacks (n = 507), FC 14.1.4 ﬂavoured drinks
(n = 500), confectionery FC 05.2 (n = 212), unprocessed fruits and vegetables FC 04.1 (n = 159).
Almost all food categories according to the food additives nomenclature (Part D to Regulation
No 1333/2008) are covered by the analytical data available. Data on chewing-gums, processed eggs,
some sugars and syrups, salts, FSMP for infants and young children, some alcoholic beverages and
food supplements were not available.
Overall, 2,271 analytical results reported for phosphates in foods were used by the Panel in the
exposure assessment.
Appendix G shows the analytical results of phosphates in foods as reported by Member States.
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of more than 1,000,000 food and beverage products
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that are or have been available on the European food market. Mintel started covering EU’s food
markets in 1996, currently having 20 out of its 28 member countries and Norway presented in the
Mintel’s GNPD.15
For the purpose of this Scientiﬁc Opinion, the Mintel’s GNPD16 was used for checking the labelling of
food and beverages products and food supplements for phosphates (E 338–341, E 343, E 450–452)
within the EU’s food market as the database contains the compulsory ingredient information on the label.
According to the Mintel’s GNPD, phosphates (E 338–341, E 343, E 450–452) was labelled on many
products (n = 44178) between January 2014 and March 2019 (more than 84,000 since 1996).
Appendix H lists the percentage of the food products labelled with phosphates (E 338–341, E 343,
E 450–452) out of the total number of food products per food subcategories according to the Mintel’s
GNPD food classiﬁcation. The percentages ranged from less than 0.1% in many food subcategories to
73% for evaporated milk (up to 100% in the Mintel’s GNPD food subcategory ‘Growing Up Milk
(4+ years)’ but this category contains only 3 products). Infants and toddlers formulae contain quite
largely phosphates in their ingredients (more than 50% of products). Bread and bread products as
well as ﬁne bakery wares are also labelled with phosphates for more than 10% of the products on the
European market.
The average percentage of foods labelled to contain phosphates (E 338–341, E 343, E 450–452)
was 9.6%.
No data were provided to EFSA for certain products labelled as containing phosphates in which
phosphates are authorised. These include:
– alcoholic beverages,
– white milk: the few milks found in Mintel are mainly enriched with calcium, or white milk other
than from cow, e.g. goat, sheep. Levels of phosphates were provided for goat milk only, while
phosphates (E 338–341, E 343, E 450–452) are authorised in all sterilised and UHT milk.
– eggs & egg products,
– nuts,
– hard cheese & semi-hard cheese: it is not clear whether these food items are part of FC
01.7.5 Processed cheeses or contain phosphates because are seasoned cheeses or cheese
with other ingredients (such as chorizo),
– vegetables.
Phosphates (E 338–341, E 343, E 450–452) were found to be labelled in Mintel food categories of
nectar and juices. FCs 14.1.2 and 14.1.3 are not authorised to contain phosphates. However, it is not
clear whether nectars and juices as coded in the Mintel GNPD completely match with fruit juices and
fruit nectars as deﬁned in the legislation.
In most of these subcategories, the percentage of foods labelled with phosphates was low.
Approximately one-third of the products are labelled as containing diphosphates (E 450).
3.3.3. Food consumption data used for exposure assessment
EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data on food consumption at a detailed level. Competent
authorities in the European countries provide EFSA with data on the level of food consumption by the
individual consumer from the most recent national dietary survey in their country (cf. Guidance of
EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a). Consumption surveys added in the Comprehensive database in 2015 were
also taken into account in this assessment.17
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food category
and the level of detail used for exposure calculations, uncertainties could be introduced owing to possible
subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless, the EFSA
Comprehensive Database includes the currently best available food consumption data across Europe.
15 Missing Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Luxembourg, Malta and Slovenia.
16 http://www.gnpd.com/sinatra/home/ accessed on 18/3/2019.
17 Available online: http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm
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Food consumption data from the following population groups were used for the exposure
assessment: infants, toddlers, children, adolescents, adults and the elderly. For the present assessment,
food consumption data were available from 33 different dietary surveys carried out in 19 European
countries (Table 4).
Consumption records were codiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
Nomenclature from the FoodEx classiﬁcation system has been linked to the food categorisation system
(FCS) as presented in Annex II of Regulation (EC) No 1333/2008, part D, to perform exposure
estimates. In practice, the FoodEx food codes were matched to the FCS food categories.
Food categories considered for the exposure assessment of phosphates (E 338–341,
E 343, E 450–452)
The food categories in which the use of phosphates (E 338–341, E 343, E 450–452) is authorised
were selected from the nomenclature of the EFSA Comprehensive Database (FoodEx classiﬁcation
system), at the most detailed level possible (up to FoodEx Level 4) (EFSA, 2011b).
Some food categories or their restrictions/exceptions are not referenced in the EFSA
Comprehensive Database and could therefore not be taken into account in the present estimate. This
was the case for 15 authorised uses (Appendix I) and may have resulted in an underestimation of the
exposure. The authorised uses which were not taken into account are described below (in ascending
order of the FCS codes):
• 01.7.6 Cheese products (excluding products falling in category 16), only unripened products
• 02.3 Vegetable oil pan spray, only water-based emulsion sprays for coating baking tins
• 04.2.4.1 Fruit and vegetable preparations excluding compote, only seaweed based ﬁsh roe
analogues
• 04.2.4.1 Fruit and vegetable preparations excluding compote, only glazing for vegetable
products
• 06.2.1 Flours, only self-raising ﬂour. Self-raising ﬂour is not a food item available in the FoodEx
nomenclature and only ﬂour (with no restrictions) was used at the MPL of 2,500 mg/kg.
• 06.6 Batters
Table 4: Population groups considered for the exposure estimates of phosphates (E 338–341,
E 343, E 450–452)
Population Age range
Countries with food consumption surveys covering
more than 1 day
Infants
< 16 weeks
From birth up to and including
16 weeks of age
Not applicable(c)
Infants From more than 12 weeks up to
and including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, UK
Toddlers(a) From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, UK
Children(b) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark,
Finland, France, Germany, Greece, Italy, Latvia, Netherlands,
Spain, Sweden, UK
Adolescents From 10 years up to and including
17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Netherlands, Spain, Sweden,
UK
Adults From 18 years up to and including
64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands,
Romania, Spain, Sweden, UK
The elderly(b) From 65 years of age and older Austria, Belgium, Denmark, Finland, France, Germany,
Hungary, Ireland, Italy, Romania, Netherlands, Sweden, UK
(a): The term ‘toddlers’ in the EFSA Comprehensive Database corresponds to ‘young children’ in Regulations (EC) No 1333/2008
and (EU) No 609/2013.
(b): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
(c): Recommended values of 200 and 260 mL/kg bw per day as conservative mean and high level consumption values were
used (EFSA Scientiﬁc Committee, 2017).
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• 07.1 Bread and rolls, only soda bread
• 08.2 Meat preparations as deﬁned by Regulations (EC) No 853/2004, only breakfast sausages:
in this product, the meat is minced in such a way so that the muscle and fat tissue are
completely dispersed, so that ﬁbre makes an emulsion with the fat, giving the product its
typical appearance; Finnish grey salted Christmas ham, burger meat with a minimum vegetable
and/or cereal content of 4% mixed within the meat, Kasseler, Br€ate, Surﬂeisch, toorvorst,
sasl~okk, ahjupraad, Bıla klobasa, Vinna klobasa, Svatecnı klobasa, Syrova klobasa and frozen
vertical rotating meat spits made of sheep, lamb, veal and/or beef treated with liquid
seasoning or from poultry meat treated with or without liquid seasoning used alone and/or
combined as well as sliced and/or minced and designed to be roasted by a food business
operator and then consumed by the ﬁnal consumer.
• 08.3.3 Casings and coatings and decorations for meat, only glazings for meat
• 10.2 Processed eggs and egg products, only liquid egg (white, yolk or whole egg)
• 12.1.2 Salt substitutes
• 14.1.1 Water, including natural mineral water as deﬁned in Directive 2009/54/EC and spring
water and all other bottled or packed waters, only prepared table waters
• 14.1.4 Flavoured drinks, the restriction only whey protein containing sport drinks cannot be
differentiated from the sport drinks, therefore all sport drinks were taken into account at MPL
of 500 mg/kg, while MPL for whey protein containing sport drinks equals 20,000 mg/kg.
• 14.2.4 Fruit wine and made wine
• 14.2.5 Mead
For the following authorised uses, the restrictions/exceptions which apply to the use of phosphates
(E 338–341, E 343, E 450–452) could not be taken into account, and therefore, the whole food
category was considered in the exposure assessment. This applies to seven food categories
(Appendix I) and may have resulted in an overestimation of the exposure:
• 01.5 Dehydrated milk as deﬁned by Directive 2001/114/EC, the two restrictions (only partly
dehydrated milk with less than 28% solids/only partly dehydrated milk with more than 28%
solids) cannot be differentiated. Foods from the FC 01.5 were divided into two subcategories:
dehydrated milk at the MPL of 1,500 mg/kg and dried milk at the MPL of 2,500 mg/kg.
• 01.8 Dairy analogues, including beverage whiteners, only beverage whiteners for vending
machines. All beverages whiteners (for vending machines or not) were taken into account at
the same MPL of 30,000 mg/kg.
• 05.4 Decorations, coatings and ﬁllings, except fruit based ﬁllings covered by category 4.2.4,
the restriction ‘only toppings (syrups for pancakes, ﬂavoured syrups for milkshakes and ice
cream; similar products’ cannot be differentiated from the whole food category. Therefore the
whole FC 05.4 was taken into account at the MPL of 5,000 mg/kg.
• 08.3.2 Heat–treated meat products, except foie gras, foie gras entier, blocs de foie gras,
Libamaj, libamaj egeszben, libamaj t€ombben.
• 09.2 Processed ﬁsh and ﬁshery products including molluscs and crustaceans, only salted ﬁsh of
the Gadidae family that have been pre-salted by injecting and/or brine salting with an at least
18% salt solution and often followed by dry salting: ﬁshes from the Gadidae family (i.e. cod
and whiting) were taken into account as the restriction cannot be applied.
• 14.1.5.2 Other, only coffee-based drinks for vending machines
• 16 Desserts, only dry powdered mixes.
The FCs 17.1/17.2 Food supplements, in solid, liquid form, the form cannot be differentiated and
the same use level was applied to the whole FC 17. This would lead to an overestimate if use levels of
food supplements supplied in solid form are higher than use levels of food supplements supplied in
liquid form.
Phosphates (E 338–341, E 343, E 450–452) are authorised in the sterilised and UHT milk of the FC
01.1 unﬂavoured pasteurised and sterilised milk. Use levels were reported from food industry only on
goat milk. Considering that information retrieved from Mintel shows few cow milks (mainly enriched
ones), goat or sheet milk labelled with phosphates (E 338–341, E 343, E 450–452), only goat milk
available in the FoodEx nomenclature were considered.
Phosphates (E 338–341, E 343, E 450–452) are also allowed in FC 13.2, 13.3 and 13.4. Food items
under food categories 13.2, 13.3 and 13.4 consumed by population groups – children, adolescents,
adults and the elderly – may be very diverse and, in addition, there is very limited information on their
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consumption. Therefore, eating occasions belonging to the food categories 13.2, 13.3 and 13.4 were
reclassiﬁed under food categories in accordance to their main component.
The use levels available for food categories 13.2, 13.3 and 13.4 were not considered for the
exposure assessment.
3.4. Exposure estimates
3.4.1. Exposure to phosphates (E 338–341, E 343, E 450–452) from its use as
food additives
The Panel estimated the chronic dietary exposure to phosphates (E 338–341, E 343, E 450–452) for
the following population groups: infants, toddlers, children, adolescents, adults and the elderly. Dietary
exposure to phosphates (E 338–341, E 343, E 450–452) was calculated by multiplying concentrations
of phosphates (E 338–341, E 343, E 450–452) expressed as P2O5 per food category (Appendix I) with
their respective consumption amount per kilogram body weight for each individual in the
Comprehensive Database. The exposure per food category was subsequently added to derive an
individual total exposure per day. These exposure estimates were averaged over the number of survey
days, resulting in an individual average exposure per day for the survey period. Dietary surveys with
only 1 day per subject were excluded as they are considered as not adequate to assess repeated
exposure.
This was carried out for all individuals per survey and per population group, resulting in
distributions of individual exposure per survey and population group (Table 4). On the basis of these
distributions, the mean and 95th percentile of exposure were calculated per survey and per population
group. The 95th percentile of exposure was only calculated for those population groups with a
sufﬁciently large sample size (EFSA, 2011a). Therefore, in the present assessment, the 95th percentile
of exposure for infants from Italy and for toddlers from Belgium, Italy and Spain were not estimated.
Reported use levels from industry give information on the amount of the food additive added to
food.
Exposure assessment to phosphates (E 338–341, E 343, E 450–452) was carried out by the FAF
Panel based on two different sets of concentration data: (1) MPLs as set down in the EU legislation
(deﬁned as the regulatory maximum level exposure assessment scenario); and (2) reported use levels
(deﬁned as the reﬁned exposure assessment scenario). These two scenarios are discussed in detail below.
These scenarios do not consider the consumption of food supplements and FSMP. These exposure
sources are covered in two additional scenarios detailed below (foods for special medical purposes
consumer only scenario and food supplements consumers only scenario).
A possible additional exposure from the use of phosphates (E 338–341, E 343, E 450–452) as food
additives as carriers in food additives, in food colours, food enzymes, food ﬂavourings and in nutrients
in accordance with Annex III to Regulation (EC) No 1333/2008 (Parts 1, 2, 3, 4, 5 Sections A and B)
was not considered in exposure assessment scenarios.
Regulatory maximum level exposure assessment scenario
The regulatory maximum level exposure assessment scenario is based on the MPLs as set in
Annex II to Regulation (EC) No 1333/2008 and listed in Table 2. For the four uses authorised
according to QS, the maximum of the reported use levels was used (Appendix I).
The Panel considers the exposure estimates derived following this scenario as the most
conservative since it is assumed that that the population will be exposed to the food additives present
in food at the MPL/maximum reported use levels over a lifetime.
Reﬁned exposure assessment scenario
The reﬁned exposure assessment scenario is based on use levels reported by food industry. This
exposure scenario can consider only authorised uses for which these data were available to the Panel.
Appendix I summarises the concentration levels of phosphates (E 338–341, E 343, E 450–452)
used in the reﬁned exposure assessment scenario. Based on the available data set, the
Panel calculated two reﬁned exposure estimates based on two model populations:
• The brand-loyal consumer scenario: It was assumed that a consumer is exposed long-term to
phosphates (E 338–341, E 343, E 450–452) present at the maximum reported use level for
one food category. This exposure estimate is calculated as follows:
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– Combining food consumption with the maximum of the reported use levels for the main
contributing food category at the individual level.
– Using the mean of the typical reported use levels for the remaining authorised uses.
• The non-brand-loyal consumer scenario: It was assumed that a consumer is exposed long-
term to phosphates (E 338–341, E 343, E 450–452) present at the mean reported use levels in
food. This exposure estimate is calculated using the mean of the typical reported use levels for
all authorised uses.
Exposure assessment for speciﬁc population groups
• Infants below 16 weeks:
Exposure to phosphates (E 338–341, E 343, E 450–452) from their uses as food additives for
infants below 16 weeks was also estimated. This scenario is based on the recommended consumption
levels from Scientiﬁc Committee Guidance (EFSA Scientiﬁc Committee, 2017). This guidance
‘recommends values of 200 and 260 mL/kg bw per day as conservative mean and high level
consumption values to be used for performing the risk assessments of substances which do not
accumulate in the body present in food intended for infants below 16 weeks of age’. These
recommended consumption levels correspond to 14- to 27-day-old infants consumption. For regulatory
maximum level exposure assessment scenario, MPL for infant formulae of 1,000 mg/kg was used and
for the reﬁned scenario, reported use levels (typical and maximum) were considered.
Exposure on a body weight basis is the metric used to compare exposure with the ADI value but
exposure per person is also provided in the Tables for ease of reference. A body weight of 4 kg (EFSA
NDA Panel, 2018) was used for this speciﬁc assessment of infants below 16 weeks of age. This body
weight is the median weight of 4 weeks girl infants according to the report from Van Buuren et al.
(2012).
Some carers use bottled water rather than tap water to reconstitute formulae powder and make it
ready to feed. Phosphates are permitted to be added to bottled waters (Table 2, food category 14.1.1)
but only for ‘prepared table waters’. Inspection of the Mintel database revealed no incidences of still
(uncarbonated) bottled water containing phosphate additives being recorded. There were a few entries
(n = 14) covered by this general food code but they were for ﬂavoured water beverages. The scenario
of using bottled water containing phosphate additives to reconstitute formulae power was therefore
not used.
• ‘Food supplement consumers only’:
Phosphates (E 338–341, E 343, E 450–452) are authorised in the food category 17 Food
supplements as deﬁned in Directive 2002/46/EC excluding food supplements for infants and young
children. As exposure via food supplements may deviate largely from the one via food, and that the
number of food supplement consumers may be low depending on populations and surveys, an
additional estimate was calculated in order to reﬂect additional exposure to food additives from food
supplements compared to exposure to food additives excluding these sources. This will be estimated
as follow:
– Consumers only of food supplements will be assumed to be exposed to phosphates (E 338–
341, E 343, E 450–452) present at the maximum reported use levels on a daily basis via
consumption of food supplements.
– For the remaining authorised uses, the mean of the typical reported use levels is used.
As food category 17 do not consider food supplements for infants and toddlers as deﬁned in the
legislation, exposure to phosphates (E 338–341, E 343, E 450–452) from food supplements are not
estimated for these two population groups.
This exposure assessment included all authorised uses for general population and food supplements
(Appendix I).
• FSMP consumers only:
As phosphates (E 338–341, E 343, E 450–452) are also authorised in the food categories 13.1.5.1
and 13.1.5.2, an additional exposure assessment taking into account these two food categories was
performed to estimate the exposure of infants and toddlers who may eat and drink these FSMP.
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The consumption of these foods is not reported in the EFSA Comprehensive database. To consider
potential exposure to phosphates (E 338–341, E 343, E 450–452) via these foods, the Panel assumes
that the amount consumed of FSMP in infants and toddlers resembles that of comparable foods in
infants and toddlers from the general population. Thus, the consumption of FSMP categorised as food
category 13.1.5 is assumed to equal that of formulae and food products categorised as food
categories 13.1.1, 13.1.2, 13.1.3 and 13.1.4.
Phosphates (E 338–341, E 343, E 450–452) are also allowed in FSMP consumed in other population
groups (FC 13.2, 13.3 and 13.4). Food items under food categories 13.2, 13.3 and 13.4 consumed by
population groups – children, adolescents, adults and the elderly – may be very diverse and, in
addition, there is very limited information on their consumption. Therefore, eating occasions belonging
to the food categories 13.2, 13.3 and 13.4 were reclassiﬁed under food categories in accordance to
their main component. The use levels available for food categories 13.2, 13.3 and 13.4 were not
considered for the exposure assessment and no exposure estimates were calculated for these
population groups.
This exposure assessment was estimated as follows:
– Consumers only of FSMP were assumed to be exposed to phosphates (E 338–341, E 343,
E 450–452) present at the maximum reported use level on a daily basis via consumption of
food categories 13.1.5.1 and 13.1.5.2 (infant formulae, follow-on formulas and processed
cereal-based foods and baby foods for infants and young children as deﬁned by Commission
Directive 2006/125/EC).
– For the remaining authorised uses, the mean of the typical reported use levels was used.
This estimate included 50 authorised uses (Appendix I).
Dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses as food
additives
Tables 5a,b summarise the estimated exposure to phosphates (E 338–341, E 343, E 450–452) from
their uses as food additives in seven population groups (Table 4) according to the different exposure
scenarios. Results are presented in mg phosphorus (P) per person and per day and in mg P/kg bw per
day. Results expressed mg P2O5 per person and per day and mg P2O5/kg bw per day are available in
the appendixes to the opinion (Appendix J). Detailed results per population group and survey (in mg
P2O5/kg bw per day) are also presented in Appendix K.
Table 5a: Summary of dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their
uses as food additives in the regulatory maximum level exposure assessment scenario
and in the reﬁned exposure assessment scenarios, in seven population groups (minimum
–maximum across the dietary surveys in mg P/person per day)
Infants
below
16 weeks
Infants
(12 weeks–
11 months)
Toddlers
(12–35
months)
Children
(3–9 years)
Adolescents
(10–17 years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
Regulatory maximum level exposure assessment scenario
• Mean 349 198–998 446–1,554 725–1,751 857–1,945 850–1,867 890–1,848
• 95th
percentile
454 419–1,714 753–2,052 1,070–2,959 1,461–3,462 1,530–3,638 1,510–3,551
Reﬁned estimated exposure assessment scenario
Brand-loyal scenario
• Mean 213 96–309 101–372 108–620 130–733 319–722 337–747
• 95th
percentile
278 222–570 203–745 215–1,291 287–1,603 658–1,600 683–1,559
Non-brand-loyal scenario
• Mean 192 81–141 78–152 69–237 74–298 126–278 121–241
• 95th
percentile
250 191–253 153–266 135–613 155–749 253–636 212–480
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In the regulatory maximum level exposure assessment scenario, the mean exposure to phosphates
(E 338–341, E 343, E 450–452) from their uses as food additives ranged from 198 mg P/person per day in
infants (> 12 weeks) to 1,945 mg P/person per day in adolescents. The high (95th percentile) exposure
ranged from 419 mg/person per day in infants (> 12 weeks) to 3,638 mg/person per day in adults.
In the brand-loyal reﬁned estimated exposure scenario, the mean exposure to phosphates (E 338–341,
E 343, E 450–452) from their uses as food additives ranged from 96 mg P/person per day in infants
(> 12 weeks) to 747 mg P/person per day for the elderly, and the high exposure (95th percentile) from
203 mg P/person per day in toddlers to 1,600 mg P/person per day for adolescents, adults and the elderly.
In the non-brand-loyal scenario, mean exposure ranged from 69 mg P/person per day in children to
298 mg P/person per day in adolescents, and the high exposure from 135 mg P/person per day in children
to 749 mg P/person per day in adolescents.
Exposure estimated for infants below 16 weeks of age was between 349 mg P/person per day at
the mean and 454 mg P/person per day at the high level (95th percentile) when using the MPLs
(regulatory maximum level exposure assessment scenario). In the reﬁned estimated exposure
scenario, the mean exposure to phosphates (E 338–341, E 343, E 450–452) from their uses as food
additives was estimated at 213 mg P/person per day at the mean and 278 mg P/person per day at the
high level for the brand-loyal scenario while for the non-brand-loyal scenario, the estimates were
192 mg P/person per day at the mean and 250 mg P/person per day at the high level.
In the reﬁned estimated exposure scenario taking into account the foods for special medical
purposes (FSMP) for infants and toddlers, mean exposure to phosphates (E 338–341, E 343, E 450–452)
from their uses as food additives ranged for infants between 111 and 209 mg P/person per day and
between 66 and 157 mg P/person per day for toddlers. The 95th percentile of exposure to phosphates
(E 338–341, E 343, E 450–452) ranged for infants between 199 and 463 mg/person per day and for
toddlers between 201 and 217 mg/person per day. Results of infants and toddlers exposure expressed
per kg bw are presented in the table below (Table 6).
Table 5b: Summary of dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their
uses as food additives in the regulatory maximum level exposure assessment scenario
and in the reﬁned exposure assessment scenarios, in seven population groups (minimum
–maximum across the dietary surveys in mg P/kg bw per day)
Infants
below
16 weeks
Infants
(12 weeks–
11 months)
Toddlers
(12–35
months)
Children
(3–9 years)
Adolescents
(10–17 years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
Regulatory maximum level exposure assessment scenario
• Mean 87 25–113 45–113 39–82 16–40 12–27 12–24
• 95th
percentile
113 53–196 73–145 61–148 29–84 22–58 21–48
Reﬁned estimated exposure assessment scenario
Brand-loyal scenario
• Mean 53 12.0–35.0 10.1–27.2 5.9–25.6 2.4–16.6 4.4–10.6 4.7–9.9
• 95th
percentile
69 27.4–65.7 20.6–53.6 11.4–55.9 5.1–37.0 9.1–25.2 9.4–20.2
Non-brand-loyal scenario
• Mean 48 10.2–15.8 5.5–11.1 3.7–9.9 1.4–6.8 1.8–3.7 1.7–3.2
• 95th
percentile
62 21.5–38.9 12.6–21.2 7.3–26.5 3.0–17.1 3.6–8.2 3.1–7.1
bw: body weight.
Table 6: Summary of dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses
as food additives for FSMP consumers only, in infants and toddlers (minimum–maximum
across the dietary surveys in mg P/kg bw per day)
Infants (< 16 weeks) Infants (12 weeks–11 months) Toddlers (12–35 months)
• Mean 87 13–29 4–14
• 95th percentile 113 26–76 17–20
bw: body weight.
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For the food supplements consumers only, mean exposure to phosphates (E 338–341, E 343,
E 450–452) from their uses as food additives ranged from 275 mg P/person per day for children to
1,541 mg P/person per day for the elderly. The 95th percentile of exposure to phosphates (E 338–341,
E 343, E 450–452) ranged from 753 mg P/person per day for adolescents to 7,292 mg P/person per
day for adults. The Panel noted the high levels for food supplements compared to therapeutic use (see
Section 3.8.1). According to data providers, in a number of cases, the phosphates are added
principally as nutrient substance and not as additives. However, in other cases, the addition of
phosphates (e.g. higher reported use levels) is due to their technical requirements as food additives
rather than an intended use as nutrient sources. The Panel noted the high intakes resulting from such
levels and the potential risk for people who might consume food supplements regularly.
Results of children, adolescents, adults and the elderly exposure expressed per kg bw are
presented in the table below (Table 7).
Main food categories contributing to exposure to phosphates (E 338–341, E 343,
E 450–452)
The main food categories contributing to the total exposure to phosphates (E 338–341, E 343,
E 450–452) as food additives presented below are extracted from the results expressed in mg P2O5/kg
bw per day (Appendix L).
Main food categories contributing to exposure to phosphates (E 338–341, E 343,
E 450–452) using the regulatory maximum level exposure assessment scenario
In the regulatory maximum level exposure assessment scenario, the main contributing food
categories to the total mean exposure estimates for infants were infant formulae and processed
cereal-based foods and baby foods. For toddlers, ﬁne bakery wares are the main contributing food
category, while for children, ﬁne bakery wares and Unﬂavoured pasteurised and sterilised (including
UHT) milk are the main contributing food categories. For all other populations, the main contributing
food categories are bread and rolls and ﬁne bakery wares.
Main food categories contributing to exposure to phosphates (E 338–341, E 343,
E 450–452) using the reﬁned exposure assessment scenario
In the brand-loyal reﬁned estimated exposure scenario, the main contributing food categories to
the total mean exposure estimates for infants were infant formulae and processed cereal-based foods
and baby foods. For the other populations – toddlers, children, adolescents, adults, the elderly – the
main contributing food categories are bread and rolls and ﬁne bakery wares. Meat products are the
third contributing food categories for adults and the elderly.
In the non-brand-loyal reﬁned estimated exposure scenario, the main contributing food categories
to the total mean exposure estimates for infants were infant formulae and processed cereal-based
foods and baby foods. As for the brand-loyal scenario, for the other populations – toddlers, children,
adolescents, adults, the elderly – the main contributing food categories are bread and rolls and ﬁne
bakery wares. Added to these, processed cheese is also an important food contributing category for
toddlers; and for children, adults and the elderly, meat products and sugars and syrups (as deﬁned by
Directive 2001/111/EC) are also important food contributing categories.
Table 7: Summary of dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses
as food additives for food supplements consumers only, in children, adolescents, adults and
the elderly (minimum–maximum across the dietary surveys in mg P/kg bw per day)
Children
(3–9 years)
Adolescents
(10–17 years)
Adults
(18–64 years)
The elderly
(≥ 65 years)
• Mean 15–89 8–23 6–22 10–24
• 95th percentile 38–112 21–26 20–99 24–83
bw: body weight.
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Dietary exposure to phosphates (E 338–341, E 343, E 450–452) considering the proposed
extension of use
Tables 8a,b summarises the estimated exposure to phosphates (E 338–341, E 343, E 450–452)
from their uses as food additives in six population groups (Table 4) taken into account the proposed
extension of use on the FC 05.2 ‘Other confectionary including breath refreshing microsweets’
according to the different exposure scenarios. Results are presented in mg phosphorus (P)/person and
per day and mg P/kg bw per day. Results in mg P2O5/person and per day and mg P2O5/kg bw per day
are available in the appendixes to the opinion (Appendix M.1). Detailed results per population group
and survey are also presented in Appendix M.2.
While for the current authorisation, confectionery with added sugar were included, the proposed
extension of use was considered by including the FC 05.2 confectionery without added sugar. The latter
Table 8a: Summary of dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses
as food additives in the regulatory maximum level exposure assessment scenario and in the
reﬁned exposure assessment scenarios, in six population groups (minimum–maximum
across the dietary surveys in mg P/person per day) considering the proposed extension
of use
Infants
(12 weeks–
11 months)
Toddlers
(12–35 months)
Children
(3–9 years)
Adolescents
(10–17 years)
Adults
(18–64 years)
The elderly
(≥ 65 years)
Regulatory maximum level exposure assessment scenario considering the extension of use in FC
05.2 only
• Mean 198–998 446–1,555 725–1,751 857–1,945 850–1,867 890–1,848
• 95th percentile 419–1,714 754–2,052 1,070–2,959 1,461–3,462 1,530–3,638 1,510–3,551
Reﬁned estimated exposure assessment scenario considering extension of use in FC 05.2
Brand-loyal scenario
• Mean 96–309 101–372 108–620 130–733 319–722 337–747
• 95th percentile 222–570 203–745 215–1,291 287–1,603 658–1,600 683–1,559
Non-brand-loyal scenario
• Mean 81–141 78–152 69–237 74–298 126–278 121–241
• 95th percentile 191–253 153–266 135–613 155–749 253–636 212–480
Table 8b: Summary of dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses
as food additives in the regulatory maximum level exposure assessment scenario and in the
reﬁned exposure assessment scenarios, in six population groups (minimum–maximum
across the dietary surveys inmg P/kg bw per day) considering the proposed extension of
use
Infants
(12 weeks–
11 months)
Toddlers
(12–35 months)
Children
(3–9 years)
Adolescents
(10–17 years)
Adults
(18–64 years)
The elderly
(≥ 65 years)
Regulatory maximum level exposure assessment scenario considering the extension of use in FC
05.2 only
• Mean 25–113 45–113 39–82 16–40 12–27 12–24
• 95th percentile 53–196 73–145 61–148 29–84 22–58 21–48
Reﬁned estimated exposure assessment scenario considering extension of use in FC 05.2
Brand-loyal scenario
• Mean 12.0–35.0 10.1–27.2 5.9–25.6 2.4–16.6 4.4–10.6 4.7–9.9
• 95th percentile 27.4–65.7 20.6–53.6 11.4–55.9 5.1–37.0 9.1–25.2 9.4–20.2
Non-brand-loyal scenario
• Mean 10.2–15.8 5.5–11.1 3.7–9.9 1.4–6.8 1.8–3.7 1.7–3.2
• 95th percentile 21.5–38.9 12.6–21.2 7.3–26.5 3.0–17.1 3.6–8.2 3.1–7.1
bw: body weight.
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category represents a small consumption level. Added to the low use level for the food category 05.2 of
confectionary and the high number of authorised uses taken into account in the assessment, it should
explain the fact that no difference is noticed in the exposure estimates with the proposed extension of use.
Uncertainty analysis
Uncertainties in the exposure assessment of phosphates (E 338–341, E 343, E 450–452) have been
discussed above. In accordance with the guidance provided in the EFSA opinion related to
uncertainties in dietary exposure assessment (EFSA, 2007), the following sources of uncertainties have
been considered and summarised in Table 9.
Phosphates (E 338–341, E 343, E 450–452) are authorised for 108 uses. The Panel calculated that
out of the foods authorised to contain phosphates (E 338–341, E 343, E 450–452) according to
Annex II to Regulation (EC) No 1333/2008, 30% (for children) to 93% (for infants) of the amount of
food consumed (by weight) per population group was reported to potentially contain phosphates
(E 338–341, E 343, E 450–452) as a food additive.
Data were received on most of the food categories in which the food additives are authorised to be
added (no data for unprocessed ﬁsh, molluscs and crustaceans, alcoholic beverages, breakfast cereals,
butter, salts).
The Panel noted that information from the Mintel GNPD (Appendix H) indicated that phosphates
(E 338–341, E 343, E 450–452) were labelled on 134 food subcategories, categorised according to the
Table 9: Qualitative evaluation of inﬂuence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data: different methodologies/representativeness/underreporting/misreporting / no
portion size standard
+/
Methodology used to estimate high percentiles (95th) long-term (chronic) exposure based on
data from food consumption surveys covering only a few days
+
Correspondence of reported use levels to the food items in the EFSA Comprehensive Food
Consumption Database: uncertainties to which types of food the levels refer to
+/
Uncertainty in possible national differences in use levels of authorised uses +/
Reported use levels:
– reported use levels converted in P2O5 based on anhydrous form in food categories 15.1
and 17, for which the form was not speciﬁed
– use levels considered applicable to all foods within the entire food category, whereas on
average 9.6% of the foods, belonging to food categories with foods labelled with additive,
was labelled with the additive
+
+
The 57 authorised uses which were taken into account in the reﬁned exposure assessment
scenarios out of all authorised uses (N = 108), corresponded to 30% to 93% of the amount (g
of foods by body weight) of food consumption documented in the EFSA Consumption Database

Foods selected for the exposure assessment: exclusion of authorised uses due to missing
FoodEx linkage (n = 15/total number of authorised uses)

Foods selected for the exposure assessment: inclusion of authorised uses without considering
the restriction/exception (n = 7/total number of authorised uses)
+
Foods included in the exposure assessment: no data for certain authorised uses which were
therefore not considered in the reﬁned exposure estimates (n = 11/total number of authorised
uses)

Foods which may contain the food additive according to Annex III to Regulation (EC)
No 1333/2008 not taken into account

Regulatory maximum level exposure assessment scenario:
– exposure calculations based on the MPL according to Annex II to Regulation (EC)
No 1333/2008
+
Reﬁned exposure assessment scenarios:
– exposure calculations based on the maximum (in the brand-loyal scenario only) or mean
levels (reported use from industries, in both brand-loyal and non-brand loyal scenario)
+/
(a): +, uncertainty with potential to cause overestimation of exposure; , uncertainty with potential to cause underestimation of
exposure.
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Mintel GNPD nomenclature. Most of these food subcategories were included in the current exposure
assessment, as only approximately 1.5% of the foods (from 10 different food subcategories) labelled
with phosphates from Mintel were not taken into account in the assessment.
The percentage of foods per Mintel subcategory labelled to contain phosphates (E 338–341, E 343,
E 450–452) was on average of 9.6%. For eight subcategories, the percentage of foods labelled with
phosphates (E 338–341, E 343, E 450–452) was above 45%. In the assessment, it was assumed that
100% of the foods belonging to an authorised food category contained the additive. The Panel noted
that the information from the Mintel GNPD indicated that phosphates (E 338–341, E 343, E 450–452)
are used in a large range of foods. Therefore, an exposure assessment based on the premise that all
of the foods contain phosphates would probably lead to an overestimation of the dietary exposure
which represents the largest uncertainty.
The Panel noted that foods which may contain phosphates (E 338–341, E 343, E 450–452) due to
carry-over (Annex III, Parts 1, 2, 3, 4, 5) were not considered in the current exposure assessment.
Overall, the Panel considered that the uncertainties identiﬁed would, in general, result in an
overestimation of the exposure to phosphates (E 338–341, E 343, E 450–452) from their use as food
additives according to Annex II in European countries considered in the EFSA European database for
the regulatory maximum level exposure scenario. For the reﬁned estimated exposure scenario,
uncertainties would also lead to an overestimation of exposure to phosphates (E 338–341, E 343,
E 450–452).
3.4.2. Exposure to total phosphorus via the diet
Exposure to total phosphorus from the diet was estimated using analytical data. This exposure
estimate is calculated using the mean/median, whichever is higher, of analytical levels for all food
categories. This scenario was chosen to be representative of wider range of samples taken from the
market as well as the long-term intake. This calculation covers all dietary intake of phosphorus
including that emanating from other food additives containing phosphorus, as well as the use of
phosphates (E 338–341, E 343, E 450–452) according to Annex III of Regulation No 1333/2008 (carry-
over).
Analytical levels provided by the Member States reﬂect the levels of phosphorus in foods whatever
the origin (from natural and other dietary sources). Therefore, the exposure estimated with analytical
data should reﬂect more closely what is ingested through the diet including phosphorus-containing
food additives added for other technological reasons. While these limited analytical data covered most
of food categories from the diet, they were provided only by 10 Member States. Nonetheless the
Panel assumed that these estimates were indicative of dietary exposure to phosphorus in European
countries considered in the EFSA European database via the whole diet (from natural and other dietary
sources).
For some food categories for which no analytical data were available, reported use levels were used
in order to cover in a more exhaustive way foods in which phosphates can be present. This is the case
for chewing gum (FC 05.3) and sugars and syrups as deﬁned by Directive 2001/11/EC (FC 11.1).
Tables 10a,b summarise the estimated exposure to phosphates from the diet in seven population
groups (Table 4). Results are presented in mg phosphorus (P)/person and per day and in mg P/kg bw
per day. Detailed results per population group and survey (in mg P/kg bw per day and mg P/person
per day) are also presented in Appendixes N.1 and N.2.
Table 10a: Summary of dietary exposure to phosphorus from the diet,* in seven population groups
(minimum–maximum across the dietary surveys in mg P/person per day)
Infants
(< 16
weeks)
Infants
(12 weeks–
11 months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥ 65 years)
• Mean 254 251–577 693–1,032 798–1,363 986–1,573 1,204–1,625 1,185–1,561
• 95th percentile 331 451–964 1,069–1,388 1,169–2,008 1,505–2,427 1,829–2,728 1,743–2,619
*: Using analytical data except for chewing-gum (FC 05.3) and sugars and syrups (FC 11.1).
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In the estimated exposure scenario based on analytical data, the mean exposure to phosphates
ranged from 16 mg P/kg bw per day for adults and the elderly to 85 mg P/kg bw per day for infants,
and the high exposure (95th percentile) from 24 mg P/kg bw per day for the elderly to 123 mg P/kg
bw per day for toddlers (Table 10b). For infants below 16 weeks of age exposure was estimated to be
64 mg P/kg bw per day at the mean and 83 mg P/kg bw per day at the high level (95th percentile).
Main food categories contributing to exposure to phosphates using analytical data
In this scenario, the main contributing food categories to the total mean exposure estimates for
infants were unﬂavoured pasteurised and sterilised (including UHT) milk, infant and follow-on
formulae. For the other populations – toddlers, children, adolescents, adults, the elderly – the main
contributing food categories are unﬂavoured pasteurised and sterilised (including UHT) milk, bread and
rolls and meat products (Appendix O).
Speciﬁc scenarios
The speciﬁc scenarios on food supplements and FSMP were also performed. As no analytical data
for food supplements and foods for special medical purposes for infants and toddlers (FCs 13.1.5.1
and 13.1.5.2) were available, maximum levels for these food categories were taken from the reported
use levels from industry for estimating exposure of FSMP consumers only and food supplements
consumers only.
For the FSMP food categories (i.e. FCs 13.1.5.1 and 13.1.5.2), reported use levels were submitted
by industry when phosphates are added as food additives but also as nutrients. For the FSMP scenario
performed with the reported use levels only (Section 3.4.1), only the levels provided for the need of
phosphates as food additives were used. In the current FSMP scenario, also the use levels reported for
the addition of phosphates as nutrients were considered.
Estimates for the infants and toddlers consumers only of foods for special medical purposes ranged
at the mean from 35 mg P/kg bw per day for infants (12 weeks–11 months) to 154 mg P/kg bw per
day for infants below 16 weeks (Table 11). At the high level, exposure ranged from 65 mg P/kg bw
per day for toddlers to 200 mg P/kg bw per day for the infants below 16 weeks. As mentioned above,
this scenario is related to the infants and toddlers consumers only of FSMP, eating foods at mean
concentration of phosphorus except for the FCs 13.1.5.1 and 13.1.5.2 for which the maximum
reported use levels were used instead.
Table 10b: Summary of dietary exposure to phosphorus from the diet,* in seven population groups
(minimum–maximum across the dietary surveys in mg P/kg bw per day)
Infants
(< 16
weeks)
Infants
(12 weeks–
11 months)
Toddlers
(12–35
months)
Children
(3–9
years)
Adolescents
(10–17
years)
Adults
(18–64
years)
The elderly
(≥ 65
years)
• Mean 64 32–85 55–74 33–62 18–33 16–22 16–20
• 95th percentile 83 56–106 85–123 55–92 31–56 25–36 24–35
bw: body weight.
*: Using analytical data except for chewing-gum (FC 05.3) and sugars and syrups (FC 11.1).
Table 11: Summary of dietary exposure to phosphorus for FSMP consumers only from the diet,* in
infants and toddlers (minimum–maximum across the dietary surveys in mg P/kg bw per day)
Infants (< 16 weeks) Infants (12 weeks–11 months) Toddlers (12–35 months)
• Mean 154 35–75 55–78
• 95th percentile 200 65–133 81–112
bw: body weight.
*: Phosphorus is also present in other sources (e.g. milk).
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This scenario focused on the speciﬁc population of food supplement consumers only. Estimates
ranged from 1,280 mg P/person per day for children to 2,839 mg P/person per day for elderly, at the
mean; and from 1,958 mg P/person per day for the children to 8,923 mg P/person per day for adults,
at the high level. The mean concentration of phosphorus from the diet was considered background.
Dietary exposure is estimated from food supplements intake, assuming all food supplements contain
phosphates, at the maximum reported use level combined with the background. Uncertainty linked to
the lack of knowledge on the form of calcium phosphates as mentioned in the food supplements’
consumers only scenario (page 35) also apply to the above estimates. For these reasons, this scenario
reﬂects a conservative exposure estimate to phosphorus.
Uncertainty analysis for the general analytical data
Exposure intakes of phosphorus through the whole diet are subject to the same uncertainties
concerning the food consumption data than the exposure estimates of phosphates (E 338–341, E 343,
E 450–452) as food additives (as mentioned in Table 9). Uncertainties to which types of food the
analytical levels refer to is another uncertainty which applies to intakes of phosphorus through the
whole diet. Apart for the methodology used to estimate high percentiles (95th) long-term (chronic)
exposure based on data from food consumption surveys covering only a few days which should result
in an overestimation of the exposure intakes, the other uncertainties linked to consumption data could
results in both under or overestimation of the true exposure to phosphates though the whole diet.
Finally, some food categories were not taken into account as no data were available (processed
eggs, salts and some alcoholic beverages). This would lead to an underestimate of the total intake;
however, considering the food categories missing, the underestimation in that case of the general
population should be low.
3.4.3. Exposure via other sources
Phosphates are also used in cosmetic products and in medications as an active pharmaceutical
ingredient, or as a counter-ion for drugs or mostly as an excipient. Quantiﬁcation of exposure via all
these sources is not precisely known and could therefore not be taken into account in this opinion.
3.5. Biological and toxicological data
Phosphorus only occurs in the body as its pentavalent form bound to oxygen as phosphate. As such it
occurs in organic and inorganic forms. Phosphate is essential for all living organisms. The intracellular
activity of phosphate ions participates in acid base balance. Phosphate is intrinsically involved with
regulation of metabolic processes via phosphorylation of proteins and supplying energy by means of
nucleotides triphosphates (e.g. ATP, GTP, CTP and UTP) which serve as energy depots supporting protein
and polysaccharide synthesis, ion pumps, cell signalling, muscle contractility. Phosphate is also
component of second messengers such as cyclic adenosine monophosphate (cAMP), inositol
polyphosphates (IP3) and cyclic guanine monophosphate (cGMP). Phosphate is fundamental for the
structure and function of DNA and ribonucleic acid (RNA). Phospholipids are part of cell membrane
structure where they affect the membrane ﬂuidity and function. In erythrocytes, 2–3 diphosphoglycerate
modulates the release of oxygen from haemoglobin in tissues (Frausto da Silva and Williams, 2001).
The whole human body P content is 500–700 g; it varies with skeletal mass which is higher in men.
Fifteen percent of the phosphate in the body is involved in the above-mentioned metabolic function
and control, whereas the largest pool of phosphates (approximately 85%) is found together with
calcium in the skeleton.
Free phosphate is found in both intracellular and extracellular ﬂuid (ECF). Approximately 85% of P in
the ECF is present as HPO4
2 and H2PO4
 (4:1 ratio). These anions are important for acid-base
Table 12: Summary of dietary exposure to phosphorus for food supplements consumers only from
the diet, in children, adolescents, adults and the elderly (minimum–maximum across the
dietary surveys in mg P/kg bw per day)
Children
(3–9 years)
Adolescents
(10–17 years)
Adults
(18–64 years)
The elderly
(≥ 65 years)
• Mean 53–138 31–48 25–40 25–42
• 95th percentile 84–153 58–62 44–121 41–97
bw: body weight.
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regulation and their relative amounts and association with cations are pH dependent. The ratio between
the two ionised phosphate forms is integral to the control of P and of Ca absorption, distribution,
excretion and bone deposition. In some instances, inappropriate mineralisation can occur in soft tissues
such as the kidneys and cardiovascular structures. This pathological process is called biomineralisation.
Biomineralisation is sensitive to the saturation of ECF (plasma and interstitial ﬂuid) with
hydroxyapatite (Ca5(PO4)3OH) and its precipitation at foci for crystallisation, however the process and its
regulation are not fully understood (Tavafoghi and Cerruti, 2016). Hydroxyapatite is the predominant
salt in the ECF at physiological pH and pCO2 and the activity product (Ca X P) of ionised calcium
(1.1–1.3 mmol/L) and P (0.9–1.4 mmol/L) approximates to 1.3 mmol2/L2. It has been suggested that
when this value exceeds by approximately twofold the solubility constant of hydroxyapatite, the salt
precipitates at crystallisation foci. This may occur when serum phosphate exceeds 2.4–2.5 mmol/L. The
higher serum levels of P and Ca in early life compared with those of adulthood are seen to be consistent
with the concept that they support physiological skeletal mineralisation (Heaney, 2012). It has been
proposed that carbonated hydroxyapatite is the form involved in mineralisation and that charged amino
acids in non-collagen proteins, via binding of Ca2 and PO4
3, and possibly localised supersaturation of
hydroxyapatite, induce nucleation and crystal precipitation, leading to tissue mineralisation (Tavafoghi
and Cerruti, 2016). High phosphorus intake (3,000 mg phosphorus per person per day on top of the diet)
may disrupt the hormonal regulation of phosphorus, calcium and vitamin D (Calvo and Uribarri, 2013).
This imbalance may contribute to bone loss and consequently the increased risk of osteoporosis and
bone fractures (Calvo and Lamberg-Allardt, 2017). Further discussion on interaction between phosphorus
and other minerals can be found in EFSA 2013.
Phosphates which occur naturally in food are absorbed throughout the duodenum and jejunum, but
principally in the duodenum and jejunum with an efﬁciency of between 55 and 90% of the amount and
source of dietary phosphate and vitamin D status (Sabbagh et al., 2011). In the intestinal lumen, inorganic
phosphate is released from the food by phosphatases at a rate that depends on the chemical complexity of
the organic phosphates. Phosphate from phytates (myoinositol esaphosphate) is poorly released. The
formation of complexes between dietary phytates, calcium, magnesium and some amino acids mutually
reduce their availability for intestinal uptake (Cheryan, 1980). The bioavailability of phosphate from
phytates is poor (20–30%) due to the lack of the enzyme phytase in humans. Generally, the availability for
net phosphate absorption might be limited by the calcium content of the diet (Heaney and Nordin, 2002;
Sabbagh et al., 2011; Heaney, 2012; O’Brien et al., 2014; Scanni et al., 2014). Other factors including
epidermal growth factor, glucocorticoids, oestrogens, acid base balance and phosphatonins potentially
inﬂuence the absorption of phosphates either directly or indirectly (Penido and Alon, 2012).
It has been proposed that since dietary phosphates arising from food additives are in an inorganic
forms they do not require release by luminal phosphatases and could be taken up and absorbed more
efﬁciently than organic phosphate from animal or plant foods (Kalantar-Zadeh et al., 2010). The major
determinant of systemic phosphate homeostasis is renal handling of phosphate, namely the amount of
phosphate ultraﬁltered by the glomerulus and the amount that is reabsorbed at tubular level. Urinary
loss of phosphate is the major route of phosphate excretion and under normal physiologic conditions
the renal phosphate transporter threshold is the main determinant of phosphate plasma levels.
Factors inﬂuencing renal loss of phosphate are parathyroid hormone (PTH), Klotho and ﬁbroblast
growth factor-23 (FGF-23) while calcitriol is the major factor regulating intestinal phosphate absorption.
Under normal conditions, serum phosphate levels show the highest values in the ﬁrst months of
age (2.38  0.54 mmol/L corresponding to 7.4  1.7 mg/dL at 1 month, 2.21  0.43 mmol/L
corresponding to 6.9  1.3 mg/dL at 3 month of age) while it signiﬁcantly decreased at 6 month
(1.80  0.41 mmol/L corresponding to 5.6  1.3 mg/dL) (Bistarakis, 1986). Subsequently, serum
levels progressively decrease during childhood to achieve the average adult reference values of
approximately 1.0 mmol/L (corresponding to 3.2 mg/dL) by the age of 16 years (Alon, 1994). This
pattern has been attributed to higher renal tubular phosphate reabsorption in infants and children
occurring to maintain the rapid body growth and calciﬁcation of the skeleton.
3.5.1. Absorption, distribution, metabolism and excretion
Human studies
Absorption
Inorganic phosphate used as food additives assessed in this opinion is assumed to dissociate in the
gastrointestinal lumen. The released phosphate is well absorbed mainly as free orthophosphate in the
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small intestine with amounts ranging between 55 and 90% of the dose (Sabbagh et al., 2011; Heaney,
2012; O’Brien et al., 2014; Scanni et al., 2014). Several factors regulate the phosphate absorption among
them calcitriol, PTH epidermal growth factor, glucocorticoids, oestrogens, metabolic acidosis,
phosphatonins and secreted frizzled-related protein 4 (sFRP-4) (Penido and Alon, 2012). Intestinal
phosphate absorption occurs by passive diffusion (McHardy and Parsons, 1956) and sodium-dependent
active transport (Walton and Gray, 1979; Eto et al., 2006). There are different sodium transporters in the
body [NaPi-IIa (SLC34A1), NaPi-IIb (SLC34A2 or NPT2b) and NaPi-IIc (SLC34A3)]. NaPi-IIb is predominant
in the intestine (Penido and Alon, 2012; Biber et al., 2013) and its activity is modulated by active vitamin D
and by a low phosphorus diet (Segawa et al., 2005; Forster et al., 2011; Sabbagh et al., 2011).
Phosphorus availability for intestinal absorption may be limited by the calcium content of the diet
(Sabbagh et al., 2011; Heaney, 2012; O’Brien et al., 2014; Scanni et al., 2014).
Atkinson et al. (1995) reviewed data on the P content of human breast milk and reported this to be
between 160 mg/L at 14 days, 140 mg/L at 30 and 90 days and 120 mg/L at 180 days post-partum.
Neonatal absorption of phosphorus is between 86% and 97% irrespective of calcium or phosphorus
intakes (Loughead and Tsang, 1998; Kovacs, 2015).
Distribution
Phosphorus is distributed throughout the body with the largest pool (approximately 85% of body
content) together with calcium in the skeleton as hydroxyapatite.
Excretion
About 200 mmol of P is ﬁltered daily by the glomerulus of which 80% or more is reabsorbed in
proximal tubules. The tubular uptake of P is mediated via sodium phosphate co-transporters, in particular
NaPi-IIa, characterised by a threshold known as the tubular maximum for P (TmP) (Tenenhouse, 2005).
PTH and FGF-23 with Klotho inﬂuence the re-absorption rate of the ultraﬁltrated P. In steady-state
conditions, the amount of phosphorus excreted in the urine equals or is close to the amount of dietary
phosphorus absorbed by gut (Berndt and Kumar, 2009; Scanni et al., 2014). However, in the real
practice, a single urinary P measurement is not believed as a validated marker of dietary exposures in
free living populations (Cupisti and Gallieni, 2018; Stremke et al., 2018). Osgood and Ivey reported that
the concentration of P32 in plasma after intravenous injection had a mean half-life of 8.5 days in patients
with leukaemia (Osgood et al., 1950). Faecal losses of P result from non-absorbed dietary phosphorus,
mostly represented by phytate (Greger et al., 1978; Anderson, 2005; Delgado-Andrade et al., 2011), and
from digestive secretions (0.9–4 mg/kg bw per day) (O’Brien et al., 2014).
In summary, the inorganic phosphorus deriving from food additives is mainly absorbed as free
orthophosphate. The amount of orthophosphate absorbed is about 80–90%. Excretion is via the
kidney through glomerular ﬁltration and tubular handling. Data are available on the kinetics of
disodium diphosphate, trisodium diphosphate, tetrasodium diphosphate and tetrapotassium
diphosphate but not on dicalcium diphosphate and calcium dihydrogen diphosphate.
Animal studies
The absorption of P32-radiolabelled tetrasodium diphosphate, sodium tripolyphosphate, sodium
polyphosphate and sodium hexametaphosphate was investigated in rats by measuring the blood, liver,
stomach, brain, intestine and bones concentration of P32 by radiochromatography (Schreier and Noller,
1955). The lower molar mass compounds were absorbed more rapidly than those with a higher molar
mass. At 18 h, more than 60% of the sodium hexametaphosphate was still found in the intestinal
tract. Radioactive orthophosphate and a small amount of diphosphate were present in the blood. The
authors stated that high polymeric phosphates do not penetrate the intestinal wall readily; however,
the diphosphate is hydrolysed into orthophosphate at neutral pH.
Tetrasodium diphosphate absorption was measured in the rats after 3 weeks continuous treatment
via diet. Food consumption was determined and the faeces and urine collected in the 5% tetrasodium
diphosphate group over a 6-day period from ﬁve male animals (Datta et al., 1962). In another study
part, faeces and urine were collected over a 3-day period from ﬁve male animals having treated for
8 weeks with 5% tetrasodium diphosphate and from ﬁve male animals having treated for 8 weeks
with 5% sodium orthophosphate in the diet. Food, urine and faeces were analysed for calcium and
diphosphate. Diphosphate was not detected in rat faeces or urine; however, orthophosphate was
found in the urine so that it can be concluded that diphosphate was almost completely hydrolysed to
orthophosphate in the rat gut and the resulting orthophosphate was well absorbed (approximately
85%) from the gastrointestinal tract.
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There are no data on the toxicokinetics (TK) of dicalcium diphosphate and calcium dihydrogen
diphosphate.
3.5.2. Measurements of intake and exposure in humans
Markers of exposure in humans need to be evaluated in the context of the risk assessment of
phosphates. There are several indicators used to characterise the exposure in epidemiological studies
all of which have considerable limitations.
Dietary intake
Different dietary assessment methods have been used in the epidemiological studies to measure
phosphorus intake from diet. Three studies (Alonso et al., 2010; Yamamoto et al., 2013; Kwak et al.,
2014) have used food frequency questionnaires (FFQ) to measure the phosphorous intake while one
study also used 3 days food record (Itkonen et al., 2013).
All the dietary assessment methods rely on food composition tables to give the amount of
phosphorus in each food item. The food composition tables give most often one value for each food
item, and thereby do not distinguish between naturally occurring phosphorus and that from food
additives. There can be large variation in the phosphorus level in the same type of food (Benini et al.,
2011; Trautvetter et al., 2018). Total phosphorus concentrations have been shown to be up to twofold
higher in food items with phosphorus additives, compared with additive free products (Karalis and
Murphy-Gutekunst, 2006; Benini et al., 2011).
Dietary records and 24-h dietary recalls are open-ended dietary assessment methods and single 24-h
dietary recalls are not sufﬁcient to estimate chronic phosphate intake reliably (Cupisti and Gallieni, 2018;
Stremke et al., 2018). More than one 24-h dietary recall is needed to assess exposure (EFSA, 2014).
FFQ are closed methods. To be able to capture phosphorus rich foods, the questionnaires have to
be design considering this speciﬁc goal. Only one of the studies using FFQ gives an energy-adjusted
correlation coefﬁcient of 0.51 for phosphorus compared with several 24-h recalls (Kwak et al., 2014).
Both methods used the same food composition table.
Serum/plasma phosphorus concentration
The reference range for serum phosphorus is 0.8–1.5 mmol/L (2.7–4.5 mg/dL) in adults and
1.3–2.3 mmol/L (4.0–7.0 mg/dL) in children (more details in introduction to Section 3.5).
In the NHANES III study (1988–1994) dietary intake of phosphorus, encompassing 15,513
participants, was assessed by 24-h dietary recall and in addition a questionnaire for 1-month food
frequency was used (NHANES III, 1988–1994). The data were used by de Boer et al. (2009) to
investigate the relationship between dietary phosphorus intake and single measurement of serum
phosphorus concentration. A statistically signiﬁcant relationship was found between the two
parameters, with each 500-mg/day increment in phosphorus intake being associated with an increase
of 0.03 mg/dL in serum phosphorus (p < 0.001), after adjustment for age, sex, race, time of
measurement and fasting status. A further study with fewer participants (N = 3,421) did not ﬁnd any
relationship between phosphorus intake and serum phosphorus concentration (Mataix et al., 2006).
Serial measurements throughout the day and subsequent averaging the values would result in a better
estimate of phosphorus exposure (Portale et al., 1987; Calvo and Heat, 1988; Kemi et al., 2006).
Moore et al. (2015) conducted a cross-sectional study using data from the NHANES to investigate
the association between food sources rich in organic phosphorus and foods rich in inorganic phosphate
from additives and serum phosphorus levels. A total of 7,895 subjects, aged 20–85 years (mean 46.7,
SD = 0.5 years), not pregnant and with no missing data on laboratory values for serum phosphorus,
urine creatinine and albuminuria as well as dietary data were included in the study. Demographic,
clinical and dietary data (24-h food recall) was obtained for all participants. Population mean age and
the mean serum phosphorus was 46.7 years (SD = 0.5) and 3.81 mg /dL (SD = 0.01), respectively.
Phosphorus content of foods was categorised as organic and inorganic. High serum phosphorus was
associated with high consumption of dairy foods categorised as containing inorganic phosphates
(p = 0.0097) after controlling for estimated glomerular ﬁltration rate (eGFR), body mass index (BMI; in
kg/m2) and albumin-to-creatinine ratio. High serum phosphate was also observed in high consumers of
dairy food categorised as not containing inorganic phosphate.
Trautvetter et al. (2016) investigated the association between serum phosphate and dietary
phosphorous and calcium in a double-blind, placebo-controlled study of 32 women and 30 men.
Participants received dietary phosphorous (1,000 mg/day) with different amounts calcium (0, 500,
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1,000 mg/day) for 8 weeks. The study did not show any association between dietary phosphate intake
and fasting serum phosphorous. A high intake of phosphorous without adequate calcium did affect
plasma FGF-23, although with a large interindividual variability which makes it unsuitable as a
surrogate marker of intake.
Karp et al. (2013) investigated the effect of dietary phosphorous on calcium phosphorous metabolism
in an acute (24-h), placebo-controlled cross-over study on 14 women (mean age 23 years). Participants
received 1,500 mg/day phosphorous as monophosphate or polyphosphate. The results showed an acute
increase in serum and urinary phosphorous following the ingestion of the phosphorous supplement,
although serum phosphorous concentration returned to baseline concentrations after 24 h.
Kemi et al. (2006) investigated the acute effect of high dietary phosphorous and bone metabolism
in 14 women (mean age 24 years). In a randomised, placebo-controlled cross-over study, participants
received either 0, 250, 750 or 1,500 mg phosphorous, and concentrations of serum phosphate, ionised
calcium and PTH were measured for 24 h. The results suggest a dose–response relationship between
phosphorous intake and serum phosphorous concentration and PTH, and an inverse relationship with
ionised calcium concentration. These results conﬁrm ﬁndings from other studies that serum
phosphorous concentration can be affected in the short-term by dietary intake, but do not provide
information on the association with chronic or habitual intake.
At dietary phosphate intake below 20 mmol/day (619 mg/day), there is a correlation between dietary
intakes and serum or plasma phosphate concentrations. However, at intakes above this, corresponding
to customary intakes, the relationship is much weaker and is not indicative of intakes (Heaney, 1997).
All the studies on the association between measurements of phosphate intake by dietary
assessment and serum P showed only a weak correlation in subjects with normal renal functions.
The poor relationship between phosphate intake and serum/plasma level might be partially
explained by the different bioavailability of phosphate from different sources. For example, the poor
release of phosphate from phytates, as well as the interaction between phytates and inorganic
phosphorous (see Section 3.5.1), reduce the bioavailability of dietary phosphorous from plant foods
(Schlemmer et al., 2009). Vegetarian diets with the same phosphorous content as animal-based diets
therefore appear to result in a lower absorption of phosphorous and subsequently a lower serum P
and urinary excretion (Moe et al., 2011). The relationship between dietary and serum phosphorous is
therefore confounded not only by homoeostatic regulation of serum phosphorous, but also the dietary
source and form of phosphorous.
Another factor could be underestimation of phosphate content in food due to insufﬁcient
information in food composition tables and limitations of the methods of some dietary intake
measurements (EFSA, 2014).
The EFSA NDA Panel considered that single serum phosphorus concentration measurements cannot
serve as surrogate for phosphorus intake (EFSA NDA Panel, 2015). The FAF Panel agreed with this
position.
Urinary phosphorus excretion
The main route of phosphorus elimination is excretion in the urine the mechanisms being
glomerular ﬁltration and tubular reabsorption in the kidney. Hence, urinary phosphorus excretion is a
surrogate for phosphorus intake. A 24-h collection of the urine will give a more precise estimate than
measuring the concentration in a spot urine even if normalised by urine creatinine.
Urinary excretion of phosphorous has been considered to be a surrogate marker of phosphorous
intake (Morimoto et al., 2014), although this is based on the assumption of a uniform and constant
absorption of dietary phosphorous and its complete renal excretion (Hruska et al., 2008). However,
Brixen et al. (1992) has shown that urinary phosphorous is affected by short-term changes in dietary
phosphorous intake, and both Morimoto et al. (2014) and Trautvetter et al. (2018) show only weak
associations between dietary phosphorous and urinary phosphorous. The study reviewed here did not
show an association between urinary phosphorous excretion and increased risk of cardiovascular
diseases (CVDs), but this might only reﬂect short-term phosphorous intake and is therefore not
suitable to assess the risks associated with habitual phosphorous intake.
According to Sun et al. (2017) who evaluated the variability of a variety of urinary makers in three
major surveys, it is necessary to have three times within 1 year 24-h collection of urine to provide a
reasonably strong correlation with the true long-term average urinary excretion of phosphate.
The Panel considered that single spot urinary phosphorus excretion, and single 24-h urinary
excretion are not valid markers for long-term dietary exposure which is in agreement with the
conclusion from the NDA Panel in 2015.
Re-evaluation of the safety of phosphates (E 338–341, E 343, E 450–452)
www.efsa.europa.eu/efsajournal 53 EFSA Journal 2019;17(6):5674
FGF-23 – Marker of exposure and effect
FGF-23 is a hormone produced by osteocytes which regulates phosphate excretion by inﬂuencing
the phosphate reabsorption in the kidney mediated via alpha-Klotho as a cofactor.
Some publications showed that dietary intake of phosphorus was related to the FGF-23 plasma
concentration (Antoniucci et al., 2006). However, others did not ﬁnd this association (Larsson et al., 2003).
FGF-23 is elevated in relation to the decline of kidney function in patients with chronic kidney
disease (CKD; Larsson et al., 2003; Faul et al., 2011). Elevated FGF-23 was linked predominantly to
left ventricular dysfunction and consequently to related morbidity and mortality; it likely occurs nearly
exclusively in subjects with CKD in whom the FGF-23 system is strongly stimulated (reviewed in St€ohr
et al., 2018). Only few studies investigated the association in subjects without renal disease and
mostly in elderly patient which raises the question of the generalisability of the ﬁndings (Arnl€ov et al.,
2013; Brandenburg et al., 2014).
Whereas the group of Faul et al. (2011) interpreted their results obtained in patients with CKD as
demonstrating that elevated FGF-23 activity/levels caused left ventricular hypertrophy (Grabner et al.,
2015; Leifheit-Nestler et al., 2016) novel ﬁndings challenges this interpretation. Recent data allow the
interpretation that FGF-23 is locally produced and released by myocytes in the event of (acute)
myocardial damage.
When considering whether FGF-23 could be used as a marker to determine the safe level of
phosphate intake it has to be considered that the role of FGF-23 for negative inﬂuences on cardiac
function is not yet established as in a recent review (St€ohr et al., 2018) the authors concluded: ‘Prior
to any therapeutic intervention with the aim to minimize potentially negative FGF-23 effects upon
cardiac structure and function, research needs to focus on and clarify relevant unsolved issues. Just to
name a few, the community needs to prove how cardiac disease induces (rather than follows) FGF-23
secretion, to what degree cardiomyocytes may themselves produce FGF-23 in health and disease,
whether such locally produced FGF-23 has a physiological role in (acute) myocardial damage; and
whether or not (systemic) FGF-23 excess itself directly drives the development of myocardial damage’.
Furthermore, a clear dose–response relationship between phosphate intake and plasma
concentration of FGF-23 has not been established. This does not allow to estimate the phosphate
intake when FGF-23 levels were measured in clinical studies with cardiac endpoints.
Hence, the Panel decided that FGF-23 levels could not be used as an endpoint to assess the
adverse health effects of phosphate.
3.5.3. Toxicology
There are numerous toxicology studies available with most of the phosphates used as food
additives. However, the studies are generally quite old and not performed according to current
guidelines. Furthermore, cations of the phosphates are constituents of human tissues that occur
naturally in food stuffs, and intake of them does not cause adverse human health effects, providing
that the intake isn’t so high as to disturb the homeostatic mechanisms controlling the electrolyte
balance of the body. Therefore, the toxicity of the cations is not discussed in this opinion.
Furthermore, in all animal studies, the phosphates were added in addition to any phosphate present
in the diet. In order to calculate the doses administered over time (mg/kg bw per day) relevant
conversion factors from the EFSA guidance on selected default values were used (EFSA, 2012).
The Panel recognise that where the purity details of the test material(s) used in the studies below
are not stated, there will be an uncertainty associated with the true amount of phosphate used in test
dosages. The exact amount of phosphate was unknown because in some toxicological studies it was
not stated whether the test material used was in the anhydrous form or one of the several hydrated
forms. The EU (and JECFA) additive speciﬁcations for phosphates (Appendix E) prescribe a range for
the purity assay expressed as P2O5, which provides an indication of the purity limits. Moreover, the
speciﬁcations for certain phosphates reveal several synonyms for the materials, which appear to be
historically interchangeable through these and other studies. In the light of this, dosage levels have
been recalculated on an anhydrous basis.
3.5.4. Acute toxicity
There are acute oral toxicity studies with all phosphates under evaluation. Available data are
summarised below.
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Phosphoric acid
Phosphoric acid was administered to Sprague–Dawley rats at doses between 2,510 and 6,310 mg/kg.
The LD50 value was estimated to be more than 3,500 mg/kg (Randall and Robinson, 1990).
Magnesium phosphates
In an unpublished report from Food and Drug Research Laboratories (1973), cited in (JECFA,
1982b), a LD50 value of 4,600 mg/kg was reported when monocalcium phosphate was administered
orally to mice and 2,170 mg/kg when administered to rats.
When tricalcium phosphate was tested for acute oral toxicity in female Wistar rats the LD50 value
was estimated to be greater than 2,000 mg/kg bw (Harlan-Laboratories-Ltd, 2010a)
Sodium and potassium phosphates
A LD50 value of 3,700 mg/kg bw was reported when monosodium phosphate was administered
orally to mice, and 4,100 mg/kg bw when administered orally to rats (unpublished report from Food
and Drug Research Laboratories (1975), cited in (JECFA, 1982b).
A LD50 value for the guinea pig was reported to be 2,000 mg/kg bw when monosodium phosphate
was administered orally (Eichler, 1950), cited in (JECFA, 1982b).
A LD50 value of 3,200 mg/kg bw was reported when monopotassium phosphate was administered
orally to mice and 2,820 mg/kg bw when administered to rats (unpublished report from Food and
Drug Research Laboratories (1975), cited in (JECFA, 1982b).
Diphosphates
In an acute oral toxicity study where disodium diphosphate was administered to fasted adult male
Swiss Webster mice and adult male Sprague–Dawley rats LD50 values of 2,300 mg/kg bw in mice and
1,800 mg/kg were reported (Newell et al., 1974).
In another acute oral toxicity study, Sprague–Dawley rats were administered tetrasodium
diphosphate at a dose of 2,000 mg/kg bw (Seo et al., 2011). No deaths or clinical signs of toxicity
were observed up to 14 days after dosing. Thus, the LD50 for tetrasodium diphosphate was greater
than 2,000 mg/kg bw in this study.
Triphosphates
The JECFA evaluation of 1982 reports the following oral LD50 values for sodium triphosphate;
2,380 mg/kg bw in mouse, 1,700 mg/kg bw in rat and 2,500 mg/kg bw in rabbit, referencing Food
and Drug Research Lab (1973); however, the original report which was available for review does not
include the information reported by JECFA (1982b). No further detail is available for review.
Sodium triphosphate is reported to have an oral LD50 value of 3,210 mg/kg in mouse (Zipf, 1957).
The report is a summary, with no further detail available.
Polyphosphates
The JECFA monograph (unpublished report from Food and Drug Research Laboratories 1974 cited
in JECFA, 1982) reported an acute oral LD50 value for sodium hexametaphosphate in mice of
3,700 mg/kg bw and in rat of 2,400 mg/kg bw.
An acute oral LD50 of 7,250 mg/kg bw in mice has been reported for sodium hexametaphosphate
(Zipf, 1957).
According to the REACH registrant, in an unpublished acute oral toxicity study, sodium
metaphosphate (OECD, 2001) and sodium hexametaphosphate were administered to female Wistar
rats at dose of 2,000 mg/kg bw by oral gavage. There were no deaths and no adverse ﬁndings. The
LD50 value was concluded to be greater than 2,000 mg/kg bw.
Overall the acute oral toxicity of all evaluated phosphates is very low with LD50 values generally
exceeding 2,000 mg/kg bw.
3.5.5. Short-term and subchronic toxicity
There are short-term and subchronic toxicology studies with most of the phosphates under
evaluation. Most of the studies are quite old and of variable quality and not performed according to
current guidelines.
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Calcium and magnesium phosphates
A study investigated nephrocalcinosis in weanling female Wistar rats fed diets varying in
concentrations of Ca and P supplied as inorganic salts (Hitchman et al., 1979). Higher phosphate and
calcium percentages were obtained by adding: calcium carbonate and calcium dihydrogen phosphate
or a mixture of calcium dihydrogen phosphate and monosodium phosphate to the semisynthetic diet
for periods of 4–6 weeks. Treated groups were compared with control rats fed laboratory chow for the
same period of time. Nephrocalcinosis was produced by semisynthetic diets with inorganic phosphate
concentrations as low as 0.5% (equivalent to 600 mg/kg bw per day) on a weight basis; in contrast,
rats fed regular laboratory chow showed no evidence of nephrocalcinosis. The severity of the
nephrocalcinosis was proportional to dietary phosphate concentrations from 0.5 to 1.0% but other
dietary constituents also altered the severity of the lesion. With a lower dietary phosphate content of
0.5%, increasing dietary Ca from 0.5 to 1.0% resulted in a decrease in the severity of the renal
calciﬁcation. Decreasing protein concentrations from 25 to 15% casein increased the severity of the
renal lesions (p < 0.01). Other dietary factors also seemed to modify the phosphate-induced
nephrocalcinosis since no lesions occurred in rats on laboratory chow. The authors suggested that the
availability of dietary phosphate may be a factor. The phosphate in the semisynthetic diets was totally
inorganic while the natural foods of laboratory chow contain, at least in part, organic phosphate
(Hitchman et al., 1979).
Sodium and potassium phosphate
Rat
Sprague–Dawley rats (weight: 60–150 g) were placed on a chow diet containing 10% disodium
phosphate (equivalent to 12,000 mg/kg bw per day) for periods of 24–72 h (Craig, 1957). Some
animals were killed at the end of the feeding period while other animals were placed on a control diet
for 2–7 days. Animals on the experimental diet did not lose weight but developed polydipsia and high
urine volume which persisted after returning to a normal diet. Kidneys were enlarged with the degree
of enlargement correlated intake of food containing phosphate. Histological changes were found in the
inner cortex, outer medulla and less frequently in the outer cortex of the kidneys. Histochemical
changes in the form of marked deposition of minerals in the kidneys of rats kept on the diet containing
an excess of inorganic phosphate were observed.
In a study by Dymsza et al. (1959), three groups with 12 male Wistar rats in each group were fed
diets containing added dipotassium phosphate so that the calcium and phosphorus concentrations in
the experimental diets were as detailed below.
Diet Calcium % (mg/kg bw per day) Phosphorus % (mg/kg bw per day)
Control 0.56 (504) 0.42 (378)
‘Normal orthophosphate’ 0.47 (423) 0.43 (387)
‘High orthophosphate’ 0.50 (450) 1.30 (1170)
bw: body weight.
The study was conducted in three stages, with experimental observations after animals had
consumed the test diets for 50, 60 or 150 days. No adverse physiological effects were observed
clinically at autopsy or on histological examination, including absence of nephrocalcinosis in the group
of rats receiving ‘high orthophosphate’ within a period of 150 days, even though the weight of the
kidneys was increased in this group.
Groups of 26-day old female albino rats were fed either a basal diet (control) or diets containing
phosphoric acid, monosodium phosphate, disodium phosphate or trisodium phosphate at doses between
2,556 and 7,836 mg/kg bw (Mackay and Oliver, 1934). The rats were killed 44 days later. Addition of
inorganic phosphate in any form led to increase of the kidney weights and gross examination revealed
that kidneys were enlarged and ﬁrm with a pebbled surface produced by numerous scars in all dosed
groups. Renal lesions in the form of cells necrosis of the convoluted tubules, regeneration of atypical
epithelium and calciﬁcation of the necrotic debris were found in rats from all groups that had received
phosphate in the diet while the kidneys from control animals were normal.
Female Wistar rats were fed a basal diet or a basal diet containing various concentrations of
calcium, magnesium and phosphorus in the form of calcium oxide, magnesium oxide and monosodium
phosphate (Chow et al., 1980). The experiments lasted for either 7 or 11 weeks. The concentrations of
calcium and phosphorus were 0.4, 0.5, 0.8, 1.0, 1.5 and 2% of the diet dry matter (equivalent to 360,
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450, 720, 900, 1,350 and 1,800 mg/kg bw per day) while the concentrations of magnesium were
0.2%, 0.4%, 0.8% and 1% of diet dry matter (equivalent to 180, 360, 720 and 900 mg/kg bw per
day). The low levels of the minerals met or exceeded the requirements for rats. Magnesium phosphate
uroliths developed in the renal pelvis, bladder and/or ureter of rats fed diets containing 1%
magnesium (900 mg/kg bw per day) with either 1.0% or 0.5% phosphorus (900 or 720 mg/kg bw per
day). Calcium phosphate uroliths formed in the renal tubules of the corticomedullary junction of rats
fed a diet containing phosphorus ≥ 0.8% (720 mg/kg bw per day) and magnesium ≤ 0.8% of diet dry
matter (≤ 720 mg/kg bw per day). The incidence and severity of the uroliths were reduced by
increasing the magnesium content from 0.2 (180 mg/kg bw per day) to 0.8% (720 mg/kg bw per day)
and by increasing the calcium to phosphorus ratio to > 1. The results indicated that interactions
among the dietary content of calcium, magnesium and phosphorus affects incidence, severity and type
of uroliths in rats.
Three-week-old female (RIV:TOX) rats were allowed to acclimate for 13 days on a diet containing
0.4% phosphorus and 0.04% Mg (Mars et al., 1988). Phosphorus was added in the form of
monosodium phosphate dihydrate. The rats were transferred to four groups (6 animals per group) and
fed diets varying in phosphorus and magnesium content only. These diets consisted of either 0.2% or
0.6% P and 0.02% or 0.04% Mg; another four groups were fed 0.4% or 0.8% P and 0.02% or 0.04%
magnesium (the 0.2, 0.4, 0.6 and 0.8% P doses were calculated to 240, 480, 720 or 960 mg/kg bw
per day, respectively (EFSA, 2012). The study lasted for 28 days. Groups fed a diet containing 0.4%,
0.6% and 0.8% P showed a statistically signiﬁcant decrease in urinary calcium levels but faecal
excretion was not systematically affected. Dietary content of 0.4%, 0.6% and 0.8% P increased faecal
excretion of Mg (p < 0.01) and decreased urinary excretion of Mg (p < 0.01). Increased dietary P
intake was positively correlated with urinary excretion of P (r = 0.99). Kidney weights were statistically
signiﬁcantly increased by dietary P (p < 0.01) and so were kidney levels of Ca (p < 0.01) and P
(p < 0.01). Calciﬁcation was only investigated in the groups fed on a diet of 0.2% and 0.6% P.
Calciﬁcation of the kidney was only found in the group receiving 0.6% (720 mg/kg bw per day) P and
all the animals showed some degree of nephrocalcinosis in that group.
Ritskes-Hoitinga et al. (1989) studied the effects of a control diet containing 0.4% phosphorus
(1.51 g monosodium phosphate dihydrate/100 g diet) and a diet containing 0.6% phosphorus (2.52 g
monosodium phosphate dihydrate/100 g diet) (equivalent to approximately 480 and 720 mg/kg P bw
per day) fed to female SPF-derived outbred Wistar rats for 28 days. The treatment with 0.6%
phosphorus resulted in statistically signiﬁcant increase in marked kidney calciﬁcation. In rats fed the
0.6% phosphorus diet, phosphorus retention and urinary excretion were greater compared with rats
fed the 0.4% phosphorus diet. The following indicators of kidney function were examined: urinary
volume, urine and plasma osmolality, urine and plasma creatinine, urine and plasma urea, urea and
creatinine clearance and urinary albumin excretion. Of these indicators, only urinary albumin excretion
was signiﬁcantly increased in rats fed the diet containing 0.6% phosphorus. Urinary pH was also
decreased in the group fed the high phosphorus diet. A statistically signiﬁcant increase in calcium,
phosphorus and magnesium content in the kidney was observed (p < 0.01, for all).
Body weight and feed intake was not affected. No no-observable-adverse-effect level (NOAEL)
could be derived from this study.
Female Wistar rats were fed a diet of monopotassium phosphate in levels corresponding to either a
normal phosphorus diet or high phosphorus diet (Matsuzaki et al., 2001). The content of
monopotassium phosphate in normal phosphorus diet was 6,848 g/kg and 46,361 g/kg (corresponding
to 822 and 5,563 mg/kg bw per day) in the high phosphorus diet. The experiment was ended after
21 days. A statistically signiﬁcant increase in phosphorus intake was observed in animals in on the high
phosphorus diet as well as a decrease in magnesium intake. Calcium, magnesium and phosphorus
concentrations in the kidney were signiﬁcantly increased and kidney dry weight was also increased in
the group fed the high phosphorus diet compared with the group fed the normal phosphorus diet.
Nephrocalcinosis was observed in all the rats fed on the high phosphorus diet and was not observed in
the kidneys of the animals fed the normal phosphors diet. Serum urea nitrogen concentration as well
as creatinine, albumin, N-acetyl-b-D-glucosaminidase activity and b2-microglobulin in urine were not
affected. Calcium and magnesium concentration in urine showed a statistically signiﬁcant decrease in
the rats fed high phosphorus compared with rats fed normal phosphorus diet. The phosphorus content
in urine was statistically signiﬁcantly increased in the rats fed high phosphorus. Calcium absorption was
unaffected whereas magnesium absorption was decreased and phosphorus absorption was increased
in the high phosphorus group. The NOAEL of this study was 187 mg P/kg bw per day.
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Dog
Male Beagle dogs were given equimolar amounts of dipotassium phosphate (trihydrate) or disodium
phosphate (dihydrate) daily by gavage; the control group was given the vehicle (water) (Schneider
et al., 1981. In the ﬁrst week, the doses were 2,080 mg/kg bw per day dipotassium phosphate and
1,625 mg/kg bw per day disodium phosphate and the animals were dosed prior to their food. Because
vomiting occurred the doses were halved, and food was given prior to the test solutions. In weeks 2–9,
the animals received 1,040 mg/kg bw per day dipotassium phosphate and 812.5 mg/kg bw per day per
day disodium phosphate. The doses in weeks 10–22 were as in the ﬁrst week, i.e. 2,080 mg/kg bw per
day dipotassium phosphate and 1,625 mg/kg bw per day disodium phosphate. At the end of the 9th
week, two animals from each group were killed and the remaining animals were killed at the end of the
22nd week. The kidneys from all the animals were examined by light microscopy and kidneys from 2
animals in each group were examined by electron microscopy. Nephrocalcinosis with disseminated
atrophy of the proximal tubule was found in animals treated with dipotassium phosphate or disodium
phosphate and the changes were more marked after 22 weeks than after 9 weeks.
Diphosphate
Rat
Sprague–Dawley rats were administered tetrasodium diphosphate by oral gavage for 90 days
(5 doses per week) according to OECD test guideline 408 (OECD, 1998) at doses of 250, 500 and
1,000 mg/kg bw per day (Seo et al., 2011). Control animals received ﬁltered tap water only. There
were no treatment-related deaths in any of the groups. The only clinical ﬁnding was hair loss in female
rats at 500- and 1,000-mg/kg bw per day groups. Body weight gains were lower in males of the
1,000-mg/kg bw per day group compared with controls. Urinalysis results were normal for all groups.
Total white blood cell counts were statistically signiﬁcantly increased compared with controls in males
and females of the highest dose group. In the 1,000-mg/kg bw per day group, neutrophil counts were
statistically increased in females and lymphocyte counts statistically signiﬁcantly decreased. Total red
blood cell, haemoglobin, haematocrit, prothrombin time and activated partial thromboplastin time were
statistically signiﬁcantly reduced in males of the 1,000-mg/kg bw per day group compared with
controls. Prothrombin time was also statistically signiﬁcantly reduced in males of the 500-mg/kg bw
per day group. Numerous changes to serum chemistry where also detected in treated animals. Serum
total protein was statistically signiﬁcantly reduced in males and females in the 500- and 1,000-mg/kg
bw per day groups. Albumin was statistically signiﬁcantly decreased in males of the 500- and 1,000-
mg/kg bw per day groups. This reduction in albumin was also observed in females of the 1,000-mg/kg
bw per day group. The albumin/globulin ratio was statistically signiﬁcantly increased in the 500- and
1,000-mg/kg bw per day females, and the 1,000 mg/kg bw per day males. Serum aspartate
aminotransferase (AST) was statistically signiﬁcantly increased in high-dose males, and alanine
aminotransferase (ALT) was statistically signiﬁcantly decreased in high-dose females. Serum calcium
(males and females p < 0.01), phosphorus (males p < 0.01; females p < 0.05), sodium (females only
p < 0.01), potassium (males only p < 0.05) and chloride (males only p < 0.05) were statistically
signiﬁcantly reduced in the high-dose groups. Serum phosphate and sodium were also statistically
signiﬁcantly reduced in the 500-mg/kg bw per day males and females. In comparison to control
values, relative (not absolute) liver weights in males of the 500- and 1,000-mg/kg bw per day groups
were statistically signiﬁcantly increased (p < 0.05). The absolute and relative liver weights of the
1,000-mg/kg bw per day females, and the relative liver weights of the 500- and 1,000-mg/kg bw per
day females were statistically signiﬁcantly increased (all p < 0.01). There were no gross pathological
ﬁndings. The only histopathological ﬁndings were kidney lesions; cortical tubular basophilia of the renal
tubule was more evident in males of the 1000-mg/kg bw per day group. Mineralisation of the kidney
was also observed in females of the 1000-mg/kg bw per day group.
The authors of the study considered the ﬁndings regarding haematological parameters most likely
not be toxicologically relevant and they concluded that the NOAEL for this study is 500 mg/kg bw per
day tetrasodium diphosphate (corresponding to 116 mg/kg P bw per day).
The Panel agrees with this NOAEL for calciﬁcation and lesions of the kidney.
Tetrasodium diphosphate was administered to rats (10 animals/sex per group) via their diet at
concentrations of 1.0%, 2.5% and 5% (approximately 900, 2,250 and 4,500 mg/kg bw per day) for
16 weeks (Datta et al., 1962) A control group received untreated diet only. After the end of treatment
liver and kidney function tests as well as haematology, organ weights, macroscopic and microscopic
examinations were conducted. There was no effect on liver function or haematology. However, the
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kidney function (measured by speciﬁc gravity of urine between 8 and 24 h of water deprivation) of
males in the 2.5% and 5% groups and females of the 5% group was impaired. Animals of the 5%
group had statistically signiﬁcant increases in relative weights of the heart, stomach (p < 0.01),
intestines (females only; p < 0.01), kidneys (male: p < 0.05; females: p < 0.01) and testes (p < 0.05).
The relative kidney weights were also statistically signiﬁcantly increased (p < 0.01) in females of the
2.5% group. Macroscopic examinations revealed pale, pitted kidneys, calciﬁcation of kidneys, and
hypertrophy and haemorrhages of the cardiac/pyloric border of stomach in male and female animals of
the 5% group and females of the 2.5% group. The kidney was the only organ/tissue to show
microscopic changes. At all doses, there was 95–100% of the group affected by microscopic changes,
which were primarily in the cortex for the 1.0% and 2.5% groups. The main observations in the cortex
were cortical atrophy and cortical hyaline degeneration, whereas the medullary zone was more
affected in the rats treated with 5% tetrasodium diphosphate. The main ﬁndings in the medullary zone
were medullary calciﬁcation and medullary necrosis. Tubular casts and chronic inﬂammatory changes
were also observed in the 2.5 and 5% groups. Haemorrhages and exudates were observed in all
groups in a dose-dependent manner. The Panel concluded that the NOAEL for this study was less than
1.0% (the lowest dose tested; approximately 900 mg/kg bw per day tetrasodium diphosphate). This
corresponds to 209 mg/kg bw per day P assuming that the anhydrous form has been used.
Triphosphates
Rat
Rats (14 males/group) were administered 0.2%, 2% and 10% (equivalent to 180, 1,800 and
9,000 mg/kg bw per day) of sodium triphosphate (corresponding to pentasodium triphosphate) in diet
for 28 days (Hodge, 1956). A control group receiving 9,000 mg/kg sodium chloride was also included.
Three rats were sacriﬁced from each dose level on the 3rd, 7th and 14th day of the experiment and
the remaining 5 rats on day 28. Early kidney changes compatible with phosphate nephritis were
evident on the 3rd day in rats receiving 9,000 mg/kg bw per day sodium triphosphate, including
nuclear pyknosis, coagulative necrosis and early breakdown of cells of the broad limb of Henle. These
changes had become more pronounced by day 7, with tubular necrosis having spread from its origin
near the junction of the outer zone of the medulla to the inner cortex. By day 14, the 9,000 mg/kg
group had further severe changes in the tubules, including tubular necrosis with dilatation of the
proximal convoluted tubules and subcapsular spaces of glomeruli. Clinical signs included growth
retardation and increased kidney weight at the 9,000 mg/kg bw per day. Sodium chloride at
9,000 mg/kg bw per day also resulted in an increase in average kidney weight with dilated tubules and
acute pyelitis. The rats that received 1,800 mg/kg triphosphate in diet had inﬂammatory changes in
the kidney which were not characteristic of tubular necrosis as such but were likely to be due to the
phosphate in the diet (as stated by the study authors). The animals administered 180 mg/kg bw per
day had no test material-related kidney abnormalities. The Panel therefore concluded 180 mg/kg bw
per day (corresponding to 45 mg/kg P bw per day) to be the NOAEL in this study.
Dog
Dogs (4 animals) were administered 100 mg/kg bw per day of sodium triphosphate (corresponding
to pentasodium triphosphate) in diet for 28 days (Hodge, 1956). The tissues of the dogs receiving
100 mg/kg bw per day were normal, with no apparent histological changes. A second group of dogs
(4 animals) were fed sodium triphosphate on a program of increasing dose, starting at 1,000 mg/kg
and ending at 4,000 mg/kg 5 months later as follows: 1,000 mg/kg bw per day for 2 weeks,
1,500 mg/kg for 3.5 weeks, 2,000 mg/kg bw per day for 2.5 weeks, 2,500 mg/kg bw per day for
6.5 weeks, 3,000 mg/kg bw per day for 1 week, 3,500 mg/kg bw per day for 2 weeks and
4,000 mg/kg bw per day for 4 weeks. One dog began to lose weight on the 2,500 mg/kg bw per day
dose, whereas the three other dogs only lost weight once on the 4,000 mg/kg bw per day diet. Blood
samples were taken at the beginning and the end of the studies, which gave normal haematological
values. Organ weights were normal. At necropsy, hypertrophy of the left ventricle and tubular damage
in the kidney was evident in dogs receiving the high dose. The kidneys showed focal areas of
granulomatous response with associated multinucleated giant cells. A NOAEL for this study is difﬁcult
to determine due to the varying dose that was administered, and necropsy was only performed at the
end of the dosing period with the highest dose.
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Polyphosphates
Rat
Rats (14 males/group) were administered 0.2%, 2% and 10% of sodium hexametaphosphate
(corresponding to soluble sodium polyphosphate) in their diet for 28 days equivalent to 180, 1,800 and
9,000 mg/kg bw per day sodium hexametaphosphate, respectively (Hodge, 1956). Sodium
triphosphate (corresponding to pentasodium triphosphate) was also tested in this study (see above
under triphosphate). Since the results with sodium hexametaphosphate are identical with those found
with sodium triphosphate with a NOAEL of 180 mg/kg bw per day (corresponding to 55 mg/kg P bw
per day), no review of the results with hexametaphosphate is made here.
In a limited 28-day study, male weanling rats (5 animals/group) were given a diet supplemented
with sodium hexametaphosphate at a concentration of 0.2%, 2%, 5% or 10% equivalent to 180,
1,800, 4,500 and 9,000 mg/kg bw per day sodium hexametaphosphate, respectively (Franklin Institute
Research Laboratories, 1973). At sacriﬁce on days 3, 7, 15 and 28 relative splenomegaly was
observed. The kidneys were pale and swollen and renal tubular necrosis was ‘remarkable’ (no
information on the time points at which these observations were made). Following administration of a
diet containing 2% sodium hexametaphosphate, acute pelvic inﬂammation was observed on day 28.
There were no adverse effects following administration of a diet containing 0.2%, equivalent to
180 mg/kg bw per day sodium hexametaphosphate (corresponding to 55 mg/kg bw per day P) which
was thus derived as the NOAEL.
Groups of Wistar rats (12 animals/group) were given a diet containing sodium hexametaphosphate
at 0.93% and 3.5% for 50, 60 or 150 days equivalent to 837 and 3,150 mg/kg bw per day sodium
hexametaphosphate, respectively (Dymsza et al., 1959). There were no adverse physiological effects
observed in clinical tests (determination of haemoglobin and blood serum calcium and phosphorus
content after 60 days, and red blood cell counts, haemoglobin, and blood serum calcium and
phosphorus after 150 days), necropsies (organ weights after 60 days) or microscopic examinations
(heart and kidney after 150 days) at either dose. The Panel concludes that due to the limited nature of
this study it is difﬁcult to derive a NOAEL.
Summary
In summary, results of multiple studies in rats and dogs ranging from 28 to 150 days have
demonstrated that kidney is a target organ to phosphates at high doses. At high phosphate loads,
excess phosphate causes increased bone demineralisation and release of calcium. This mechanism is
part of a physiological regulatory mechanism leading to calciﬁcation of the kidney and tubular
nephropathy.
The Panel noted that the highest reliable NOAEL for kidney effects, 500 mg/kg bw per day
corresponding to 116 mg/kg bw per day phosphorus, was identiﬁed in a 90-day rat study with
tetrasodium diphosphates performed according to OECD guidelines (Seo et al., 2011). In the same
study, a dose of 1,000 mg/kg bw per day corresponding 233 mg/kg bw per day phosphorus was
demonstrated to induce effects in the kidney.
3.5.6. Genotoxicity
Phosphoric acid, phosphates, diphosphates, triphosphates and polyphosphates have been tested for
genotoxicity in a variety of in vitro and in vivo assays. In neither in vitro nor in vivo assays did any of
the tested phosphates produce a positive response.
In vitro tests included Salmonella Typhimurium mutagenicity assay (unpublished report from Litton-
Litton Bionetics cited in JECFA 1982b, Haworth et al., 1983; Cipollaro et al., 1986; Newell et al., 1974;
Ishidate et al., 1984; Kim et al., 2010; Fujita and Sasaki, 1990), Saccharomyces cerevisiae
mutagenicity assay (unpublished report from Litton Bionetics cited in JECFA 1982b), Escherichia coli
mutagenicity assays (Demerec et al., 1951; Olivier and Marzin, 1987), chromosomal aberration test in
Chinese hamster ﬁbroblasts (Ishidate et al., 1984) and in human embryonic lung cells (unpublished
report from Litton Bionetics cited in JECFA 1982b).
In vivo tests included chromosomal aberration test in rats (unpublished report from Litton Bionetics
cited in JECFA 1982b), dominant lethal assay in rats (Newell et al., 1974), host-mediated assay in mice
(Newell et al., 1974) and mouse translocation test (Newell et al., 1974).
There is one reported study where the authors claimed that phosphoric acid (E 338) increased the
mean tail length and mean tail intensity in Comet assay in human lymphocytes in vitro (25, 50, 100,
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200 lg/mL) (Yilmaz et al., 2014). However, the relevance of the ﬁndings reported in this study for risk
assessment is questionable.
The Panel concluded that available data clearly show that phosphate is not genotoxic in standard
test systems.
3.5.7. Chronic toxicity and carcinogenicity
There are few chronic toxicity or carcinogenicity studies available for the phosphates under
evaluation. Only data on tetrasodium diphosphate, sodium triphosphate and sodium metaphosphate
(also referred as sodium hexametaphosphate or Graham’s salt) are available. Furthermore, the studies
are relatively old, of variable quality and not performed according to current guidelines.
Diphosphates
Rat
Tetrasodium diphosphate was administered to groups of rats (24–36 animals/group; strain, age and
numbers per sex not stated) in their diets at concentrations of 1.8%, 3% or 5% (approximately 810,
1,350 and 2,250 mg/kg bw per day) for 6 months (Hahn et al., 1958; Hahn and Seifen, 1959). Control
animals received basic control diet. Nephrocalcinosis was observed in animals administered 1,350 or
2,250 mg/kg bw per day tetrasodium diphosphate. In the group at 1,620 mg/kg bw per day, a slight,
but statistically signiﬁcant increase in kidney weights was recorded and microscopic examination
revealed renal calciﬁcation in some animals (number not stated). The study authors noted that slight
renal calciﬁcation was also observed in the control animals but as stated by JECFA (1982b) was much
less extensive than in the treated animals. No other adverse effects were reported. Therefore, the
NOAEL under the conditions of this study can be concluded to be less than 810 mg/kg bw per day
(corresponding to 189 mg/kg P bw per day) tetrasodium diphosphate in the diet. A lower
concentration of 1.1% (approximately 495 mg/kg bw per day) of tetrasodium diphosphate was later
tested under the same conditions for 6 months (Hahn, 1961; JECFA, 1982b). There was slight growth
retardation initially, but this did not persist throughout the exposure period. After 39 weeks, slight
kidney calciﬁcation was observed.
Triphosphates
Rat
Groups of weanling albino rats (50 animals/sex per group) were maintained on diets containing
0%, 0.05%, 0.5% and 5% (equivalent to 0, 25, 250 and 2,500 mg/kg bw per day) sodium
triphosphate (corresponding to pentasodium triphosphate) for 2 years (Hodge, 1959). Body weights of
the animals were recorded, blood samples taken, and urine analysis performed during the study. At
the end of the experimental period, surviving rats were terminated and the tissues and organs ﬁxed
and sectioned and studied for histopathology. Bone samples were collected at termination to detect
any abnormalities or calciﬁcation. At the 2,500 mg/kg dose, a clear growth depression was evident in
male rats, which was less pronounced in female rats during both the ﬁrst and second year. The
mortality was high but the majority of the deaths (8–28 rats per group) were due to respiratory
infection and pericarditis-peritonitis. The number of deaths from tumours was very small (≤ 2 animals
per group) and did not differ between the different dose levels and controls, presenting no evidence
for the carcinogenicity of sodium triphosphate. There was no indication of the treatment having an
effect percentage of sugar and protein in urine. Haematology data indicated that male rats at the
1-year time point receiving the 2,500 mg/kg diet may have been slightly anaemic. The red blood cell
count, haematocrit percentages and haemoglobin values were lower compared to other groups. A
similar trend was not established for female animals. No other changes in haematological values were
reported. In the high dose male rats, kidney weights, measured as the kidney to body ratio were
higher than in other groups. A similar effect was also noted in the liver, brain, testes, stomach and
heart weights. For female rats receiving the 2,500 mg/kg diet, an increase in liver and kidney weights
was also seen in the 2,500 mg/kg group. Bone analysis revealed shorter femur length in both sexes
receiving the 2,500 mg/kg diet, an indication that the rats had failed to grow as stated by study
authors. All calcium–phosphorus bone ratios were reported to be within normal range. At the end of
the 2-year study period, the surviving animals were sacriﬁced, and tissues gathered for histological
examination. The main ﬁnding was enlarged, granular kidneys in rats of both sexes receiving the
2,500 mg/kg diet. Convoluted renal tubules were found to be dilated, especially in the loop of Henle.
Hyaline casts were present in most cases. Associated changes were interstitial ﬁbrosis and hyalinised,
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ﬁbrotic glomeruli. The collective term to describe the condition was ‘chronic tubular nephropathy’,
which was present in all rats receiving the high dose. However, control rats, and rats receiving 25 mg/
kg bw per day and 250 mg/kg bw per day showed similar changes and therefore establishing deﬁnitive
treatment-related causality was not possible. Furthermore, chronic pyelonephritis is stated by the study
authors to be frequently present in older rats. However, the study authors conclude that the chronic
tubular nephropathy appears to be phosphate-speciﬁc in the high dose group due to scarcity of
inﬂammatory cell inﬁltrate, gross enlargement of the kidneys, extreme dilation of tubules of loop of
Henle and calciﬁcation. Tumour incidence in the control and treatment groups was comparable and not
considered to be treatment related. Based on the test article-speciﬁc kidney effects which were seen
only at the high dose. The panel concluded that 250 mg/kg bw per day (corresponding to 63 mg/kg P
bw per day) was the NOAEL in this study.
Polyphosphates
Rat
The carcinogenicity of sodium metaphosphate (corresponding to soluble sodium polyphosphate)
was investigated in F344 rats (50 animals/sex per dose; 6 weeks old) (Kitahori et al., 1998). Sodium
metaphosphate was administered in the diet at concentrations of 1.5% or 3.0%. (approximately 750
and 1,500 mg/kg bw per day) for 108 weeks. There was also a control group that received untreated
diet. Blood samples were taken from all surviving animals in week 108 for haematology and clinical
chemistry investigations. Urinalysis was also conducted. Macroscopic and microscopic examinations
were conducted on all animals in the study. There were no treatment-related effects on survival, body
weight gains, haematology, clinical chemistry or urinalysis. Many tumours developed in all groups,
including the controls. However, the organ distribution and histological characteristics were comparable
to those reported to occur spontaneously in this strain of rat. The authors of the study concluded that
sodium metaphosphate does not induce tumours in rats, when given orally in the diet for 108 weeks.
With regard to non-neoplastic effects, mineralisation (marked calcium deposition in the pars intermedia
of the kidney in the 3% group), cast formation and basophilic tubular cell proliferation was observed in
the kidneys of the treated female animals. The panel concluded that the NOAEL for carcinogenicity in
this study was 1,500 mg/kg bw per day (corresponding to 456 mg/kg P bw per day), the highest dose
tested whereas the NOAEL for microscopic effects observed in the kidneys was < 750 mg/kg bw per
day (corresponding to 229 mg/kg P bw per day).
Groups of albino Rochester rats (50 animals/sex per group; described as weanling) were
administered a diet containing 0.05%, 0.5% and 5% sodium hexametaphosphate (corresponding to
soluble sodium polyphosphate) (approximately 25, 250 and 2,500 mg/kg bw per day) for 2 years
(Hodge, 1960). Body weights were recorded weekly for the ﬁrst 3 months and then every 2 weeks
thereafter. Blood samples were taken from 5 animals/sex once before treatment began, monthly for
the ﬁrst 6 months, every 2 months for the rest of the ﬁrst year, and then every 3 months for the
second year. Haemoglobin values, red blood cell characteristics, red blood cell counts, white blood cell
counts and differential counts were recorded for all blood samples. Pooled urine samples were
collected three times per year to determine sugar and protein content. At termination, tissues and
organs from 10 animals/sex per group were collected and studied microscopically. Mortality rates were
high (64–78%) and were primarily due to respiratory infections. Tumour incidence increased with age
in almost all groups, but there was no dose relationship with sodium hexametaphosphate. Kidney
weights were increased in animals in the 5% group and microscopic examinations revealed increased
calciﬁcation in the tubules of the kidneys. The authors of the study stated that the calciﬁcation is
believed to be an intensiﬁcation of the severity of naturally occurring processes of infection and
degeneration. However, some of the rats in the 5% group had normal kidneys. Therefore, the NOAEL
in this study is approximately 250 mg/kg bw per day (corresponding to 76 mg/kg P bw per day)
hexametaphosphate based on treatment-related effects on the kidney and reduced body weight gain.
There was no evidence of increased tumour incidence in any group.
Graham’s salt (sodium hexametaphosphate) was administered to groups of rats (24–36 animals/
group; strain, age and numbers per sex not stated) in their diets at concentrations of 1.8%, 3% or
5% (approximately 1,620, 2,700 and 4,500 mg/kg bw per day) for 6 months (Hahn et al., 1958; Hahn
and Seifen, 1959). Control animals received untreated diets. In the 3% and 5% groups, body weight
gain was statistically signiﬁcantly reduced (p value not stated). In the 3% group, the reduction was
transient, whereas in the 5% group the reduction persisted through the 6-month exposure period. No
such effect on body weight gain was observed in the 1.8% group. Nephrocalcinosis was observed in
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animals administered 3% or 5% sodium hexametaphosphate. The renal calciﬁcation was less marked
in animals treated with Graham’s salt than with other phosphates, such as sodium tripolyphosphate.
No other adverse effects were reported.
In summary, there are three 2-year carcinogenicity studies in rats available, one with sodium
triphosphate and two with sodium polyphosphate. In none of the studies were there any relationship
between treatment with the phosphates and tumour development. The Panel thus concluded that
phosphates do not have any carcinogenic potential. The key adverse effects in these three life time
studies as well as in two chronic toxicity studies of 6 months duration were calciﬁcation in the kidneys
and tubular nephropathy. The lowest tested level of phosphate causing an effect in the kidney was
approximatively 750 mg/kg bw (corresponding to 229 mg P/kg bw per day) in a 2-year study with
sodium metaphosphate (Kitahori et al., 1998). Two reliable NOAELs could be identiﬁed, 250 mg/kg bw
per day (corresponding to 63 mg/kg P bw per day) and 250 mg/kg bw per day (corresponding to
76 mg/kg P bw per day) with sodium triphosphate and sodium hexametaphosphate, respectively
(Hodge, 1959, 1960).
In conclusion, the only signiﬁcant adverse effect of phosphates in standard short-term, subchronic
and chronic toxicity studies is calciﬁcation of the kidney and tubular nephropathy. These kidney effects
are observed in all species investigated and the onset of the effects are apparently quite rapid with
marked effects seen already after a few weeks of treatment.
3.5.8. Reproductive and developmental toxicity
Phosphoric acid, calcium and magnesium phosphate
Mouse
Female albino CD-1 outbred mice (23–26 mated animals/group) were administered monocalcium
phosphate monohydrate (corresponding to calcium dihydrogen phosphate) by gavage in doses of 0,
4.65, 21.6, 100 or 465 mg/kg bw per day through gestation days (GD) 6–15. All animals were
observed daily for appearance and behaviour, and body weights were recorded on GD 0, 6, 11, 15 and
17. On GD 17, all dams were subjected to caesarean section and the number of implantation sites,
resorption sites and live and dead fetuses were documented. The body weight of the live fetuses was
measured. All fetuses were examined for the presence of external congenital abnormalities.
Furthermore, one-third of the fetuses were examined for visceral abnormalities and the remaining two-
thirds for skeletal abnormalities. Treatment with monocalcium phosphate monophosphate induced no
maternal toxicity or developmental effects at dose levels up to 465 mg/kg bw per day in mice, the
highest dose tested (FDRL 1974, cited in (JECFA, 1982b)].
Rat
In a study with rats given 0.4% or 0.75% (equivalent to 200 or 375 mg/kg bw per day) dietary
phosphoric acid over the whole life span and with successive generations no adverse effect on the
growth of three successive generations was observed. The animals were mated when they were
32-week-old as well as 11 weeks later (only the 0.4% group); no adverse effects were noted as
evaluated by the body weight of the dams, the number of living pups and stillborn per litter, the
average pup weight at birth and the number of pups at weaning. No signiﬁcant differences were noted
in haematological parameters in comparison with control rats. The histological examination (liver,
spleen, adrenals, testes, skeletal muscle, femur and kidney) revealed no pathological changes. Teeth
were examined in a number of rats following dietary administration for 3–16 months (both 0.4% and
0.75% groups); no extensive lesions were observed except for dental attrition of the molars which was
slightly more marked in the treated group compared to the control group. According to the authors
the dental attrition was not to be regarded as a harmful effect (Bonting and Jansen, 1956).
Female albino rats (Wistar derived stock) (25–29 mated animals per group) were administered
monocalcium phosphate monohydrate by gavage (vehicle: water) at doses of 0, 4.1, 19.1, 88.5 or
410 mg/kg bw per day through GD 6–15. All animals were observed daily for appearance and
behaviour, and body weights were recorded on GD 0, 6, 11, 15 and 20. On GD 20, all dams were
subjected to caesarean section and the numbers of implantation sites, resorption sites, and live and
dead fetuses were recorded. The body weights of live pups were recorded and all fetuses were
examined grossly for the presence of external abnormalities. One-third of the fetuses of each litter
underwent detailed visceral examinations and the remaining two-thirds were examined for skeletal
defects. Treatment with monocalcium phosphate monophosphate induced no maternal toxicity or
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developmental effects at dose levels up to 415 mg/kg bw per day in rats, the highest dose tested
(FDRL 1974, cited in (JECFA, 1982b)).
Three groups (groups I–III) of pregnant Wistar rats (10 weeks old) were treated during GD 0–20
either with the standard diet (group I), corn oil vehicle on standard diet (group II) or on standard diet
supplemented with 175 mg/kg bw per day tricalcium phosphate (group III) (G€ung€orm€uș et al., 2010).
In a second study, the dose was 350 mg/kg bw per day (Kilic et al., 2012). Vehicle and tricalcium
phosphate were administered orally by gavage. Caesarean section was performed on GD 20. No signs
of illness or abnormal behaviour were observed in the dams during the treatment. There were no
statistically signiﬁcant effects on fetal mortality, fetal body lengths and weights. No resorptions, short
or absent tail, fore or hind limbs were observed in this study. The placental weights, but not placental
index (weight of placenta/weight of fetus), of the tricalcium phosphate group (Group III) were found
to be statistically decreased compared to group I (standard diet) (p ≤ 0.05). At skeletal examination,
there were no gross skeletal anomalies, incomplete ossiﬁcation, reduced sternebrae number,
misshaped sternebrae, rib or other bones. Moreover, the ossiﬁcation in fore- and hind-limbs, sacral and
caudal bones was complete, there were no extra or missing bones observed in any of the groups.
According to morphometric measurements of fetuses, the following parameters were signiﬁcantly
decreased; lengths of left ulna (28.3%, p ≤ 0.05), right femur (29.8%, p ≤ 0.05), left femur (34.9%,
p ≤ 0.05) and diameter of the skull of y-axis (12.3%, p ≤ 0.05) in the tricalcium phosphate treatment
groups when compared with control (group I). However, only ulna and left femur were statistically
signiﬁcant different from the vehicle control (group II, p ≤ 0.05). Fetal body lengths and weights were
not affected by treatment. Furthermore, there was an increase in transumbilical diameter in the
treatment group (group III) both compared to the control (group I) (p ≤ 0.05) and oil control groups
(Group II) (p ≤ 0.05) (G€ung€orm€uș et al., 2010).
The study from G€ung€orm€uș et al. (2010) has, however, several shortcomings and inconclusive
results. There were only ﬁve pregnant rats per group in the study which had two control groups, but
only one dose group. The number of fetuses is 11 in the untreated control group, 6.6 in the control
group fed with vehicle and 10.5 in the calcium phosphate groups indicating poor performance of the
study. Inconsistencies were observed between the results section where the authors conclude ‘no
gross structural anomalies or malformations’ and in the discussion where the sentence is found ‘We
observed several foetuses with malformations such as: reduced skull development and shorter forelimb
and hindlimb formation’. The ﬁndings of a reduction in length of left ulna and bilateral femurs are thus
most probably artefacts.
In the second study (Kilic et al., 2010), histopathological changes in maternal liver, kidney, heart,
brain, placenta and fetal liver and kidney were reported. In the fetuses, the absolute liver weight
increased whereas the relative liver weight decreased which is inconsistent.
Given the inconsistencies and the uncertainty about the causing agent, the Panel considered the
studies as inappropriate for risk assessment.
Rabbit
Virgin adult Dutch-belted female rabbits (15–27 artiﬁcially inseminated animals per group) were
administered with monocalcium phosphate monohydrate by gavage (vehicle: water) at doses of 0,
2.17, 10.10, 46.7 or 217.0 mg/kg bw per day through GD 6–18. All animals were observed daily for
appearance and behaviour, and body weights were recorded on GD 0, 6, 12, 18 and 29. On GD 29, all
dams were subjected to caesarean section and the numbers of corpora lutea, implantation sites,
resorption sites, and live and dead fetuses were recorded. The body weights of live fetuses were
recorded and all fetuses were examined grossly for the presence of external congenital abnormalities.
Live fetuses were then placed in an incubator for 24 h for an evaluation of neonatal survival. All pups
were then sacriﬁced and examined for visceral abnormalities and skeletal defects. Treatment with
monocalcium phosphate monophosphate induced no maternal toxicity or developmental effects at
dose levels up to 217 mg/kg bw per day in rabbits, the highest dose tested (FDRL 1974, cited in
(JECFA, 1982b)).
Sodium and potassium phosphate
Mouse
Female albino CD-1 outbred mice (19–22 pregnant animals per group) were administered with
monosodium phosphate by gavage at doses of 0, 3.7, 17.2, 79.7 or 370.0 mg/kg bw per day from GD
6 to 15. The vehicle used was water. Body weights were recorded on GD 0, 6, 11, 15 and 17. All
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animals were observed daily for appearance and behaviour. On GD 17, all dams were subjected to
caesarean section and the sex, numbers of corpora lutea, implantation sites, resorption sites, and live
and dead fetuses were recorded. The body weight of the live pups was also measured. All fetuses
were examined grossly for the presence of external congenital abnormalities. Furthermore, one-third of
the fetuses were examined for visceral abnormalities and the remaining two-thirds for skeletal defects.
No maternal toxicity or developmental effects were noted at dose levels up to 370 mg/kg bw, the
highest dose tested (FDRL 1975, cited in (JECFA, 1982b)).
Groups of pregnant albino CD-1 mice were dosed by gavage with monopotassium phosphate from
GD 6 through 16. Body weights were recorded on GD 0, 6, 11, 15 and 17 of gestation. On GD 17, all
dams were subjected to caesarean section and the number of implantation sites, resorption sites and
live and dead fetuses were recorded. The body weight of the live fetuses was also measured. All
fetuses were examined for the presence of external congenital abnormalities. Furthermore, one-third
of the foetuses were examined for visceral abnormalities and the remaining two-thirds for skeletal
abnormalities. No maternal toxicity or developmental effects were noted for monopotassium phosphate
at dose levels up to 320 mg/kg bw (FDRL 1975, cited in (JECFA, 1982b)).
Rat
Groups of 20 pregnant albino Wistar derived rats were dosed by gavage with monosodium
phosphate (anhydrous) at dose level of 0, 4.1, 19.0, 88.3 or 410.0 mg/kg bw per day from GD 6 to
15. The vehicle used was water. Body weights were recorded on days 0, 6, 11, 15 and 20 of gestation.
All animals were observed daily for appearance and behaviour. On GD 20, all dams were subjected to
caesarean section and the sex, numbers of corpora lutea, implantation sites, resorption sites, and live
and dead fetuses were recorded. The body weight of the live pups was also measured. The urogenital
tract of each dam was examined for anatomical normality. All fetuses were examined grossly for the
presence of external congenital abnormalities. Furthermore, one-third of the foetuses were examined
for visceral abnormalities and the remaining two-thirds for skeletal defects. No maternal toxicity or
developmental effects were noted at dose levels up to 410 mg/kg bw, the highest dose tested (FDRL
1975, cited in (JECFA, 1982b)).
Diphosphates
Mouse
Female albino CD-1 mice (25 mated animals/group) were administered from GD 6 to 15 with 0,
3.35, 15.6, 72.3 or 335 mg/kg bw per day disodium diphosphate by oral gavage (FDRL 1973, cited in
(JECFA, 1982b)). Maternal body weights were measured on GD 0, 6, 11, 15 and 17, and all animals
were observed for clinical signs of toxicity. Food consumption was also measured. On GD 17, a
caesarean section was conducted on all dams. The number of implantation sites, resorption sites, and
live and dead fetuses was recorded. All fetuses were examined macroscopically for external congenital
abnormalities. One-third of the fetuses were examined for visceral abnormalities and two-thirds for
skeletal abnormalities. No maternal toxicity or developmental effects were noted at dose levels up to
335 mg/kg bw, the highest dose tested.
Female albino CD-1 mice (25 mated animals/group) were with administered 0, 1.3, 6.0, 28 or
130 mg/kg bw per day tetrasodium diphosphate by gavage from GD 6 to 15 (FDRL 1975, cited in
(JECFA, 1982b)). Maternal body weights were measured on GD 0, 6, 11, 15 and 17, and all animals
were observed for clinical signs of toxicity. Food consumption was also measured. On gestation day 17
a caesarean section was conducted on all dams. The sex, numbers of corpora lutea, implantation sites,
resorption sites, and live and dead fetuses was recorded. The body weights of the live fetuses were
recorded. All fetuses were examined macroscopically for external congenital abnormalities. One-third of
the fetuses were examined for visceral abnormalities and two-thirds for skeletal abnormalities. No
maternal toxicity or developmental effects were noted at dose levels up to 130 mg/kg bw, the highest
dose tested.
Hamster
Female golden hamsters (25 mated animals/group) were administered with 0, 1.66, 7.71, 35.8 or
166 mg/kg bw per day disodium diphosphate by gavage from GD 6 to 10 (FDRL 1973, cited in (JECFA,
1982b)). Maternal body weights were measured on GD 0, 6, 8, 10 and 14, and all animals were
observed for clinical signs of toxicity. On GD 14 a caesarean section was conducted on all dams. The
number of implantation sites, resorption sites, and live and dead foetuses was recorded. The body
weights of the live fetuses were measured. All fetuses were examined macroscopically for external
Re-evaluation of the safety of phosphates (E 338–341, E 343, E 450–452)
www.efsa.europa.eu/efsajournal 65 EFSA Journal 2019;17(6):5674
congenital abnormalities. One-third of the fetuses were examined for visceral abnormalities and two-
thirds for skeletal abnormalities. No maternal toxicity or developmental effects were noted at dose
levels up to 166 mg/kg bw, the highest dose tested.
Rat
Female albino Wistar-derived rats (25 mated animals/group) were administered with 0, 1.69, 9.24,
42.95 or 169 mg/kg bw per day disodium diphosphate by gavage from GD 6 to 15 (FDRL 1973, cited
in (JECFA, 1982b)). Maternal body weights were measured on GD 0, 6, 11, 15 and 20, and all animals
were observed for clinical signs of toxicity. Food consumption was also measured. On GD 20 a
caesarean section was conducted on all dams. The number of implantation sites, resorption sites, and
live and dead fetuses recorded. The body weights of the live fetuses were measured. All fetuses were
examined macroscopically for external congenital abnormalities. One-third of the fetuses were
examined for visceral abnormalities and two-thirds for skeletal abnormalities. No maternal toxicity or
developmental effects were noted at dose levels up to 169 mg/kg bw, the highest dose tested.
Female albino Wistar-derived rats (25 mated animals/group) were administered with 0, 1.38, 6.41,
29.7 or 138 mg/kg bw per day tetrasodium diphosphate by gavage from GD 6 to 15 (FDRL 1975, cited
in (JECFA, 1982b)). Maternal body weights were measured on GD 0, 6, 11, 15 and 20, and all animals
were observed for clinical signs of toxicity. Food consumption was also measured. On GD 20 a
caesarean section was conducted on all dams. The sex, numbers of corpora lutea, implantation sites,
resorption sites, and live and dead fetuses were recorded. The body weights of the live fetuses were
measured. All fetuses were examined macroscopically for external congenital abnormalities. One-third
of the foetuses were examined for visceral abnormalities and two-thirds for skeletal abnormalities. No
maternal toxicity or developmental effects were noted at dose levels up to 138 mg/kg bw, the highest
dose tested.
Rabbit
Female Dutch-belted rabbits (15 artiﬁcially inseminated animals/group) were artiﬁcially inseminated
(were administered with 0, 1.28, 5.95, 27.6 or 128 mg/kg bw per day disodium diphosphate by
gavage from GD 6 to 18 (FDRL 1973, cited in (JECFA, 1982b)). Maternal body weights were measured
on GD 0, 6, 12, 18 and 29, and all animals were observed for clinical signs of toxicity. Food
consumption was also measured. On GD 29 a caesarean section was conducted on all dams. The
number of corpora lutea, implantation sites, resorption sites, and live and dead foetuses was recorded.
The body weights of the live fetuses were measured. All foetuses were examined macroscopically for
external congenital abnormalities. The live fetuses of each litter were then placed in an incubator for
24 h to evaluate neonatal survival. All surviving pups were sacriﬁced and examined for visceral and
skeletal abnormalities. No maternal toxicity or developmental effects were noted at dose levels up to
128 mg/kg bw, the highest dose tested.
Triphosphates
Rat
A study previously described by Hodge (1959) combined a chronic toxicity and a reproductive study
in rat. The reproductive study was carried out with the 250 mg/kg dose group and the control group.
Sixteen females and 8 males were mated. They were mated again at 10 days after weaning of the
ﬁrst litter. Thereafter, 16 females and 8 males were selected from the control and 250 mg/kg group at
weaning and continued on their respective diets. When the animals were 100 days old they were
mated and they were thereafter mated again 10 days after weaning the ﬁrst litter, and the whole
procedure was repeated with the rats to produce a second litter of the third generation. Parameters of
reproductive behaviour which were evaluated included number of females mated, number of
pregnancies, mortalities and number of live births, organ weights and pathology. When 21 days old,
10 males and 10 females from each group were necropsied, and the test material-related
abnormalities recorded. The initial mating (ﬁrst generation, ﬁrst litter) resulted in 14 pregnancies in the
control group and 15 pregnancies in the test group receiving 250 mg/kg sodium triphosphate. No
differences in performance were noted between the control and test animals. The second mating (ﬁrst
generation, second litter) resulted in 12 pregnancies in both test and control groups. No signiﬁcant
difference was reported between rats receiving the 250 mg/kg diet and the control rats. The ﬁrst
generation rats were raised to reach 100 days. They were then mated to produce the ﬁrst litter of the
second generation. By performance, the test and control rats were identical. The ﬁrst litter of the
second generation resulted in 12 pregnancies, with no difference in reproductive performance between
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test and control rats. Similarly, the second litter of the second generation was raised with no
complications or difference in survival, growth and fertility. The rats were raised to 100 days of age
and mated. The ﬁrst or second litter of the third generation were not affected in treatment-related
effects when test and control rats were compared. All animals investigated revealed no remarkable
pathological ﬁndings at necropsy, with no abnormalities in tissues of young animals. The authors of the
study concluded that there was no evidence of reproductive toxicity associated with administration of
250 mg/kg sodium triphosphate. The report is lacking in detail, but it adds weight of evidence to the
lack of reproductive and developmental effects of the triphosphates.
Rabbit
Dutch-belted rabbits (17 to 20 females artiﬁcially inseminated animals/group) were dosed by
gavage with 0, 2.5, 11.6, 54 or 250 mg/kg sodium triphosphate (corresponding to pentasodium
triphosphate) from GD 6 to 18 (FDRL 1973, cited in (JECFA, 1982b)). Between 13 and 16 mated
rabbits became pregnant out of the 17 to 20 animals per group. Body weights were recorded on GD 0,
6, 12, 18 and 29. Clinical signs, behaviour and food consumption were monitored throughout the
study. On GD 29, the animals were subjected to caesarean section and the numbers of corpora lutea,
implantation sites, resorption sites and live and dead fetuses were recorded. External abnormalities
assessed and body weights were recorded. The live fetuses were maintained in an incubator and
observed for neonatal survival for 24 h, after which surviving pups sacriﬁced and examined for visceral
abnormalities and skeletal defects. No maternal toxicity or developmental effects were noted at dose
levels up to 250 mg/kg bw, the highest dose tested.
Polyphosphates
Mouse
Female albino CD-1 mice (25 mated animals/group) were administered with 0 3.7, 17.2, 79.7 or
370 mg/kg bw per day sodium hexametaphosphate (corresponding to soluble sodium polyphosphate)
by gavage from GD 6 to 15 (FDRL, 1974). Maternal body weights were measured on GD 0, 6, 11, 15
and 17, and all animals were observed daily for clinical signs of toxicity. Food consumption was also
measured. On GD 17 a caesarean section was conducted on all dams. The sex, number of corpora
lutea, implantation sites, resorption sites, and live and dead fetuses were recorded. The body weights
of the live fetuses were recorded. All fetuses were examined macroscopically for external congenital
abnormalities. One-third of the fetuses were examined for visceral abnormalities and two-thirds for
skeletal abnormalities. No maternal toxicity or developmental effects were noted at dose levels up to
370 mg/kg bw, the highest dose tested.
Rat
Groups of albino Rochester rats (50 weanling animals/sex/group) were administered a diet
containing 0.05%, 0.5% and 5% (equal to 26, 260 and 2,600 mg/kg bw per day), sodium
hexametaphosphate for 2 years (Hodge, 1960). Animals (16 females and 8 males, 100 days old) from
the 0.5% hexametaphosphate group and the untreated control group were selected for a reproductive
toxicity study (P1 generation). These animals were bred to produce three F1 generations (F1a, F1b
and F1c). The F1a generation were sacriﬁced on postnatal day 30. Adults from the F1b generation
(P2) were mated at 100 days of age to produce the F2a generation, which was sacriﬁced on postnatal
day 30. A second mating of the P2 animals produced the F2b generation, which at 100 days of age
(P3) were mated to produce the F3a and F3b generations. The F3a animals were sacriﬁced on
postnatal day 30. The F3b animals were sacriﬁced on postnatal day 21 and a microscopic examination
conducted. Diet containing hexametaphosphate at a concentration of 0.5% and the control diet were
available to the animals throughout the study depending on the test group. The study authors
concluded that the average number of pups per litter was comparable between the control and treated
groups, as was pup mortality, and pup organ weights (F3b only). The microscopic examination did not
reveal any abnormal ﬁndings in treated animals. Therefore, there were no adverse effects observed
under the conditions of this non-standard study. Although this is a non-standard study conducted pre-
Good Laboratory Practice (GLP), in the absence of other more reliable studies it provides some
reassurance that sodium polyphosphate, and other polyphosphates, do not have an adverse effect on
reproduction up to a dose of approximately 260 mg/kg bw per day.
Female albino Wistar-derived rats (25 mated animals/group) were administered with 0, 2.4, 11.1,
51.7 or 240 mg/kg bw per day sodium hexametaphosphate by gavage from GD 6 to 15 (FDRL, 1974).
Maternal body weights were measured on GD 0, 6, 11, 15 and 20, and all animals were observed daily
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for clinical signs of toxicity. Food consumption was also measured. On GD 20 a caesarean section was
conducted on all dams. The sex, number of corpora lutea, implantation sites, resorption sites, and live
and dead fetuses were recorded. The body weights of the live pups were measured. The urogenital
tract of each dam was also examined. All fetuses were examined macroscopically for external
congenital abnormalities. One-third of the foetuses were examined for visceral abnormalities and two-
thirds for skeletal abnormalities. No maternal toxicity or developmental effects were noted at dose
levels up to 240 mg/kg bw, the highest dose tested.
Summary
In summary, there are a number of studies, although generally not conducted to current OECD
guidelines, evaluating reproductive and developmental toxicity of the phosphates under evaluation. In
studies performed in mice, rats, rabbits or hamsters, there are no signs of reproductive or
developmental toxicity at any dose tested. The Panel thus concluded that exposure to phosphates do
not present any risk for reproductive or developmental toxicity.
3.5.9. Other animal and in vitro studies
There are a large number of experimental in vivo and in vitro studies, many of which are quite
recent, investigating the association of phosphates at high concentrations with pathologies other than
kidney calciﬁcation and tubular nephropathy (Razzaque, 2012; Uribarri and Calvo, 2018).
Generally, in vitro systems, genetically modiﬁed animals and other animal models are used in these
studies. It was difﬁcult to establish underlining mechanisms and dose response for the observed
effects. Nevertheless, ﬁndings in some of the studies (e.g. activation of metabolic pathways that
promote cell transformation and cancer, regulation of osteopontin, induction of endothelial dysfunction,
alterations of FGF-23 levels and the Wnt pathway balance, etc.) may indicate potential adverse effects
of phosphates.
The Panel did not consider these sufﬁciently robust nor validated to be used in the risk assessment
of phosphate as food additives.
Bone
Several studies in animals report that high phosphorus intake causes bone reabsorption or
decreased bone formation.
Effect of high phosphorus intake on bone metabolism-related gene expression was demonstrated
young and aged mice measuring PTH and mediators of osteoclastic bone resorption. Young (12 week
old) and aged (80 week old) male mice (12 animals/group) were fed with control diet (0.3% P) or
high P content diet (1.2% P) for 4 weeks. The high P content diet increased serum PTH in both young
and aged mice and increased receptor activator of NF-kB ligand (RANK)/osteoprotegerin (OPG)mRNA
ratio in the femur of aged mice (Katsumata et al., 2014).
Male Wistar rats (20 animals/group) were fed with control diet (0.6% phosphate) or high
phosphate diet (1.2%) for 8 weeks. Bone mineral density (BMD) of femur and lumbar spine was
investigated and high-phosphate intake diet did not appear to negatively impact BMD value (Huttunen
et al., 2006).
Abnormal bone mineralisation occurred also when rats were given phosphoric-acid containing soft
drinks instead of water. Young adult (30 days) and immature (30 days) Sprague–Dawley male rats (14
animals/group) has access to tap water (control) or cola-containing drink ad libitum for one week. Both
adult and immature animals receiving cola-containing drink developed hypercalciuria and
hyperphosphaturia. Immature rats developed signiﬁcant reduction in calcium regulatory hormones such
as 1a,25(OH)2D3 and 25-OHD3 but only adult rats showed developed signiﬁcant hyperparathyroidism
(Amato et al., 1998).
Four groups (9 animals/group) of male Wistar rats (5 week old) were fed with semi-puriﬁed diet
non-supplemented or supplemented with 1%, 1.4%, or 2,2% calcium hydrogen phosphate (Hardwick
et al., 1987). Rats receiving diet supplemented with calcium hydrogen phosphate did not show effect
on whole blood or plasma ionised Ca, plasma, total Ca, or plasma inorganic P levels. Femur dry weight
and length was not affected by the different diets, nor did bone Ca content increase with
supplementation.
Anderson et al. (1977), investigated the effect of diets supplied by high phosphorus in monkeys.
Nineteen (male and female) juvenile cinnamon ringtail monkeys were fed diets with Ca:P ratio of 1:4,
1:2.1, 1:0.4, 1:0.5 (corresponding to 1.20%, 2%, 0.40% and 0.47% P) up to approximately 7 years.
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The results did not show any short or long-term effect in the skeleton in both young growing and
adult monkey. The authors reported that those results are in contrast to studies in other species
although the Ca:P tested were very similar.
The Panel concluded that effects observed on bone metabolism and bone mineralisation in animals
are not well characterised enough to derive an association with dietary high phosphate intake.
3.6. Epidemiology on cardiovascular diseases
3.6.1. Studies on dietary phosphorus and cardiovascular diseases-related
outcomes
Cardiovascular mortality
Chang et al. (2014) conducted a cohort study among healthy US subjects aged 20–80 years
(NHANES III; 1998–1994, n = 12,366) to investigate the association between phosphorus intake and
all-cause mortality and cardiovascular-speciﬁc mortality. Among those initially enrolled, 2,680 subjects
were excluded from the analysis because of the presence of diabetes, self-reported history of
myocardial infarction and/or congestive heart failure (HF) and/or stroke and/or cancer as well as
subjects with extreme energy intakes and with eGFR of 60 mL/min*1.73 m2 or lower. Out of the
12,366 initially enrolled individuals, 9,686 subjects were included in the analysis. Vital stats and cause of
death was obtained by using The NHANES III mortality ﬁle from the study participation to 31 December
2006 (median follow-up time: 14.7 years, Interquartile Range (IQR): 13.1–16.2 years). Dietary intake
data was assessed by a 24-h dietary recall. The median phosphorus intake was 1,166 mg/day (IQR:
823–1,610 mg/day); median phosphorus density was 0.58 mg/kcal (0.48–0.70 mg/kcal). Median values
of phosphorus consumption in the lowest to highest quartiles were 629, 993, 1,356 and 1,992 mg/day,
respectively. Estimated glomerular ﬁltration rate values (mL/min*1.73 m2) in the ﬁrst, second, third and
fourth quartile were as following: 102.6 SD = 0.7; 101.6, SD = 0.7; 102.1, SD = 0.6, 104.4, SD = 0.6.
In the multivariate analysis, adjusted for age, sex, race, ethnicity, poverty income ratio, BMI, blood
pressure (BP), smoking, physical activity, cholesterol, urine albumin/creatinine ratio, glomerular ﬁltration
rate and vitamin D, high absolute phosphorus intake (1,400 mg/day or more) was associated with high
overall mortality (HR: 1.89, 95% conﬁdence intervals (CI): (1.03–3.46) while phosphorus density was
not (HR: 1.05; 95% CI: 1.01–1.10). For cardiovascular mortality neither absolute intake of phosphorus
(HR: 1.02, 95% CI: 0.29–3.58) or phosphorus density (HR: 1.02, 95% CI: 0.93–1.12) were associated
with an increased risk. When serum phosphorus was introduced in the models, the risk estimates for
both absolute and density phosphorus intake and overall mortality did not change. Serum phosphorus
was associated with overall mortality (HR: 1.37, 95% CI: 1.13, 1.67) per each 1 mg/dL increase in
serum phosphorus (p = 0.002). The strength of the study was the long follow-up, the size of the study
and the good control of confounding factors. The main limitation of the study was the use of a single
24-h recall assessing dietary intake, in particular, phosphorus intake. A single day is unlikely to be
representative of usual individual intake, especially for phosphorus. The number of days necessary for
assessing nutrients and energy intake seems to be at least 5 days. Non-differential misclassiﬁcation
error leads to HR biases towards the null.
Blood pressure
Alonso et al. (2010) investigated in two US multicentre cohort studies the association between
phosphorus intake and hypertension. The study population consisted in 8,208 subjects (age range
45–65 years) from the Atherosclerosis Risk in Communities Study (ARIC) and 2,901 subjects (age
range 45–84 years) from the Multi-Ethnic study of Atherosclerosis (MESA). Subjects with hypertension
at baseline and with prevalent CVDs and diabetes were excluded from the analysis. Subjects with
missing data were also excluded. Demographic, clinical and dietary data were collected at baseline.
Dietary habits were assessed using a 66-item FFQ in the ARIC study and a 120-item FFQ in the MESA
study. Three measurements were averaged to estimate systolic and diastolic BP. After an average
follow-up of 7.1 years in the ARIC study and 3.8 years in the MESA study, 2,400 and 945 cases of
hypertension were identiﬁed. The average phosphorus intake was 1,084 mg daily in the ARIC study
and 1,103 mg daily in the MESA study. In the multivariate analysis, controlling for age, race, sex BMI,
waist circumference, eGFR, education, income, physical activity, cigarette smoking, study site, alcohol
intake, energy intake, calcium, vitamin D (only in ARIC), sodium, potassium, magnesium, fruits and
vegetables and whole grains intake, no increased risk was found for phosphorus intake and
hypertension in the pooled analysis of the two studies (HR: 1.01, 95% CI: 0.82–1.23). When the
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analysis was conducted separately, no increased risk was found for both ARIC study (Q5, 1,472 mg
phosphorus; HR: 0.97, 95% CI: 0.77–1.24) and MESA study (Q5, 1,526 mg phosphorus; HR: 1.10,
95% CI: 0.75; 1.61). The strength of the study was the pooled analysis of two cohort studies and the
good control for confounding factors. The limitation of the study was the high number of excluded
subjects mainly because of missing data, the lack of data comparing, for some important
characteristics the study base and the subjects included in the study (selection bias).
Mazidi et al. (2017) conducted a cross-sectional study in Iran to investigate the association
between diet, in particular phosphorus intake, and BP in individuals aged 35–64 years. Subjects with
history of unstable angina, myocardial infarction, stroke, HF, peripheral vascular disease including
transient ischaemic attack or amaurosis fugax, cardiovascular interventions or surgery, cancer,
autoimmune, infectious and inﬂammatory diseases were excluded from the analysis. Participants were
in total 5,670 subjects (2,179 males, mean age 50.1 years, SD = 8.1) and 3,491 females (mean age
48.2 years, SD = 7.8). Demographic information, clinical, anthropometric (weight, height, waist
circumference) and dietary data (24-h recall) were collected for all participants. Weight and height,
total cholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol were also measured. A
signiﬁcant inverse correlation between phosphorus intake and systolic BP (p = 0.04) and diastolic BP
(p = 0.03) was found. The limitation of the study was the cross-sectional design that impedes drawing
conclusions of a possible causality and the lack of a proper statistical method.
Left ventricular mass
Yamamoto et al. (2013), within the MESA, investigated, using a cross-sectional design, the
association between dietary phosphorus with left ventricular mass (LVM) in 4,494 subjects free of
known CVD (mean age 61.6 years) and with completed dietary data. Demographic, clinical and
lifestyle data were collected at baseline. Dietary phosphorus intake was assessed by a 120-item FFQ.
Mean dietary phosphorus intake was 1,167 mg/day in men and 1,017 mg/day in women. The mean
and standard deviation LVM for men and women were 168.6  36.8 g and 123.8  27.4 g,
respectively. In the multivariate analysis, after controlling for age, race, height and weight, total
dietary calories, dietary sodium, smoking, alcohol use, education, moderate-vigorous physical activity,
diabetes status, systolic BP, antihypertensive medication use, urinary albumin to creatinine ratio,
C-reactive protein and eGFR, each 20% greater estimated dietary phosphorus consumption was
associated with 1.06 g greater LVM (p < 0.001). The strength of the study was the good control for
confounding factors. The limitation of the study was the cross-sectional design.
Intima-media thickness
Itkonen et al. (2013) conducted a cross-sectional study to investigate the relationship between
dietary phosphorus intake, in particular food additive phosphate, and intima-media thickness (IMT). A
randomly sample of 1,920 subjects living in Helsinki, aged 37–47 years (females, n = 370; males,
n = 176) was derived from the Population Register Centre in Finland. Out of the 1,920 initially enrolled
subjects, 678 participated in the study. Subjects with renal dysfunction, post-menopausal females and
with subjects with missing data were excluded from the analysis. Data on smoking status, information
on dietary habits (3-day food records and FFQ) focusing on phosphorus, calcium and vitamin D, was
obtained for all participants. Fasting blood samples and spot urine samples, weight and height, BP, and
information on smoking habits and physical activity were also collected at the time of the visit.
Common carotid artery IMT was measured using high-resolution ultrasonography. Mean phosphorus
intake from diet (natural occurring phosphate) was 1 617 mg/day (SD = 428). Exposure estimate for
phosphates as food additives (FAP) were derived from maximum EU regulation FAP content from the
following foodstuffs: marinated meat, sausages, cold meat cuts, cola beverages and processed
cheeses. A FAP score (1–6) was created by dividing subjects into tertiles of intake for each FAP group
(meat products, cola beverages, processed cheeses), with score 0 indicating the lowest intake tertile,
score 1 the middle tertile and score 2 the highest tertile. Then, the scores from different FAP sources
were summed and each subject had a score of one to six. No signiﬁcant association was observed
between TP intake or FAP score and IMT after adjusting for sex, age, low-density/high-density
lipoprotein cholesterol ratio, smoking status and IMT sonographer class. The strength of the study was
the attempt to separate total phosphorus and FAP intake. The main limitation of the study was the
cross-sectional design that impedes drawing conclusions of a possible causality. Moreover, the FAP
score is not very easily interpreted.
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Coronary artery calciﬁcation
Kwak et al. (2014) conducted a cross-sectional study (n = 23,652) to study the relationship
between phosphorus intake and phosphorus serum levels and coronary artery calciﬁcation (CAC).
Eligible participants had no CKD (estimated glomerular ﬁltration rate ≥ 60 mL/min*1.73 m2) and/or
CVD. Participants (40.8  7.3 years) were mainly (males 83%), who underwent, as part of health
check-ups, cardiac computed tomographic estimation of CAC (scores, 1–100 and > 100). Dietary
habits, including alcohol intake was assessed by a FFQ. Clinical data and information on physical
activity and smoking were collected for all participants. In the multivariate analysis, adjusted for
adjusted for age, sex, smoking status, alcohol intake, physical activity, body mass index, educational
level, family history of CVD, medication for dyslipidaemia, diabetes mellitus, hypertension, glomerular
ﬁltration rate, albumin, ferritin, total calorie intake, calcium intake, phosphorus intake and calcium
supplements, high serum phosphorus (≥ 3.9 mg/dL) was associated with high CAC scores, (OR: 3.33,
95% CI: 2.55–4.35, p-trend < 0.001). No association was found for high intake of phosphorus
(≥ 965 mg/daily. The strength of the study is the large sample size and the good control of
confounding factors. The limitation of the study was the cross-sectional design that impedes drawing
conclusions of a possible causality.
Summary of the results of the studies on dietary phosphorus/phosphates and
cardiovascular-related outcomes
Two cohort studies (Alonso et al., 2010; Chang et al., 2014) and four cross-sectional studies;
(Itkonen et al., 2013; Yamamoto et al., 2013; Kwak et al., 2014; Mazidi et al., 2017) investigated the
relationship between dietary phosphorus and cardiovascular-related outcomes. Alonso et al. (2010)
pooled the data of two cohort studies (7.1-year and 3.2-year cohort studies, n = 8,208) and found no
association between phosphorus intake and hypertension. Chang et al. (2014) conducted a 3.4-year
cohort study (n = 7,705) and found no association between high phosphorus intake (> 1,400 mg/day)
estimated from a single 24-h recall, and cardiovascular speciﬁc mortality. The study of Yamamoto et al.
(2013) studied the association between dietary phosphorus with LVM in 4,494 subjects and showed
that each 20% greater estimated dietary phosphorus consumption was associated with 1.06 g greater
LVM and it was statistically signiﬁcant. Itkonen et al. (2013) studied the relationship between dietary
phosphorus intake, in particular food additive phosphate, and IMT and found no association. Kwak
et al. (2014) the relationship between phosphorus intake and coronary artery calciﬁcation and found
no association. Mazidi et al. (2017) investigated the association between phosphorus intake and BP
and found a statistically signiﬁcant inverse correlation between phosphorus intake and BP. In
conclusion, there is insufﬁcient data in the cohort studies to link dietary phosphates intake to
cardiovascular risk. Inconsistent results have been reported from cross-sectional studies.
One of the limitations of the epidemiological studies that assessed dietary phosphorus and CVDs
outcomes was the use of food composition databases which might not include data on all phosphates
used as food additives leading to underestimation of the total phosphate intake. Another limitation was
the use the 24-h recall assessing food intake. It is known that a single day is unlikely to be
representative of usual individual intake, especially for phosphorus. The number of days necessary for
assessing micronutrients and energy intake seems to be at least 5 days. Thus, this misclassiﬁcation
error may have led risk estimates towards null.
Overall, there is insufﬁcient evidence to link dietary phosphates intake to cardiovascular outcome.
3.6.2. Studies on serum phosphorus/phosphate and cardiovascular diseases-
related outcomes18
Cardiovascular disease incidence and cardiovascular mortality
Chang et al. (2014) investigated associations between serum phosphorous and all-cause and
cardiovascular mortality prospectively in 12,984 participants of NHANES III (mean age 44 years, 52%
women, after excluding 181 participants with more than 24 h fasting times or inconsistent venepuncture
times). Serum phosphorous was measured at baseline using the reaction of inorganic phosphorous with
ammonium molybdate, measured by spectrophotometry. Age, sex, race, ethnicity, cigarette smoking
(never, former or current), physical activity, and family income were self-reported, height, weight at
baseline were measured using standardised methods. Participants were stratiﬁed by fasting-duration
18 Due regard has been given to the convention in epidemiological studies for expression of the results as (serum/urine)
phosphorus rather than phosphate. In this section we regard serum phosphorus to mean phosphate.
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before venepuncture (≥ 12 h, 6,633 participants; < 12 h, 6,351 participants). Mortality data were
obtained from the NHANES III Mortality File, and cardiovascular mortality was deﬁned as International
Classiﬁcation of Diseases (ICD)-10 I00–178, and after a median follow-up of 14.3 years, 2,993 deaths
had occurred. After adjusting the multivariable model for examination session (morning vs afternoon/
evening), age, sex, African American race, Mexican ethnicity, poverty, inactivity, body mass index,
smoking status, systolic BP, diabetes, non-HDL cholesterol level, ACR, eGFR and vitamin D status, high
serum phosphorous was signiﬁcantly associated with all-cause [HR Q1 vs Q4: HR: 1.74 (95% CI: 1.38;
2.20)] and cardiovascular (HR: 2.00; 95% CI: 1.36; 2.96) mortality in those with 12 h or more fasting
before venepuncture, but not those with shorter fasting duration (HR: 1.08; 95% CI: 0.98, 1.32 and HR:
1.21; 95% CI: 0.88,1.67], respectively). A continuous analysis using linear splines shows a signiﬁcant
increase in all cause mortality (HR: 1.35; 95% CI: 1.05, 1.74) per mg/dL) and cardiovascular mortality
(HR: 1.45; 95% CI: 1.05, 2.00 per mg/dL). The strength of the study was the large sample size and the
long follow-up. The main limitation of the study was the lack of adjustment for diet.
Larsson et al. (2010) investigated associations between serum phosphorous and all-cause and
cardiovascular mortality in 2,176 men of the Uppsala Longitudinal Study of Adult Men [mean age
50 years, after excluding participants lacking data on creatinine, Ca or Pi measurements (n = 139), or
with eGFRCG of 60 mL/min* 1.73 m
2 or below (n = 7)]. Serum phosphorous (fasting blood samples,
fasting from midnight) was measured at baseline using the reaction of inorganic phosphorous with
ammonium molybdate, measured by spectrophotometry. Data on lifestyle, e.g. smoking habits and
medical history, were obtained by questionnaire at baseline. Cardiovascular death (ICD-8 and ICD-9,
codes 390–459; ICD-10 codes I00–I99) was established using the Swedish national cause-of-death
register, and after a median follow-up of 29.8 years, 1,009 participants had died, of which 466 were
due to CVDs. After adjusting for age, body mass index, smoking, high serum phosphorous (T3,
>2.8 mg/dL vs T1, <2.5 mg/dL) was associated with cardiovascular mortality (HR 1.31; 95% CI: 1.06,
1.63) but not all-cause mortality (HR: 1.16; 95% CI: 1.00, 1.35). In a continuous model, all cause (HR
1.06; 95% CI: 1.01, 1.12 and cardiovascular mortality (HR 1.10; 95% CI: 1.02, 1.18) per SD increase)
were both associated with serum phosphorus. This did not change materially by including only
participants with eGFRCG > 90 mL/min* 1.73 m
2 (n = 1,777). Strengths of the study was the long
follow-up time and the main limitation was the lack of adjustment for diet and physical activity.
Onufrak et al. (2009) investigated associations between serum phosphorous, all-cause mortality and
coronary artery disease (CAD) incidence in 13,998 participants (7,923 women, mean age 54 years, after
excluding those with missing serum phosphorous data (n = 150), self-reported history of stroke or CAD
(n = 1,010), and those with eGFR below 60 mL/min* 1.73 m2 (n = 392) or above 150 mL/min*
1.73 m2 (n = 182) of the ARIC who were free from CAD at baseline. Serum phosphorous was measured
in fasting blood samples using the DART method at baseline. Deaths were ascertained using a variety of
methods, including ofﬁcial records, obituaries, hospital records and interviews with next of kin, and
after a median of 13.2 years of follow-up, 1,546 participants had died. After adjusting for age, sex,
black race, body mass index, diabetes, hypertension, total cholesterol, HDL cholesterol, triglycerides,
current smoking, eGFR (by CKD-EPI formula), serum ﬁbrinogen, post-menopausal status and hormone
replace therapy (HRT), high serum phosphorous (> 3.8 mg/dL vs < 3.1 mg/dL) was associated with an
increased risk of CVDs (HR: 1.45; 95% CI: 1.04, 2.01) and all-cause mortality (HR. 1.45; 95% CI: 1.12,
1.88) was found for men but not for women. Strengths of the study were the long-term follow-up time
and the sample size; the limitations were the self-report assessment of the outcomes in some cases and
the lack of adjustment for diet and physical activity.
Dhingra et al. (2007) conducted a cohort study on 3,368 subjects within the Framingham Offspring
study (mean age, 44 years; 51% of women) to investigate the association between serum levels of
phosphorus and calcium and CVD incidence. All subjects with CKD and/or CVD were not included in
the study. Information on smoking habits and alcohol consumption was obtained from all participants.
Weight, height, BP, total cholesterol, HDL cholesterol, serum albumin, blood glucose, haemoglobin, C-
reactive protein and triglycerides were all measured at baseline and every 4 years. Subjects with eGFR
of less than 60 mL/min* 1.73 m2 were excluded from the study. After a follow-up of 16.1 years, 524
incident CVD cases (159 events in women) were identiﬁed through reviewing hospital records,
physician ofﬁce visit notes, and pathology reports. CVD was deﬁned as fatal or nonfatal myocardial
infarction, angina pectoris (stable or unstable), cerebrovascular events (stroke or transient ischaemic
attacks), peripheral vascular disease, or congestive HF. After adjusting in the multivariate model for
age, sex, BMI, diabetes, BP, hypertensive drug use, smoking, alcohol consumption, total high-density
cholesterol ratio, haemoglobin, serum albumin, eGFR, proteinuria and protein C-reactive protein, high
levels of serum phosphorus was associated with an increased CVD risk in a dose response manner
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(Q4 = 3.5–6.2 mg/dL; HR: 1.55, 95% CI: 1.16–2.07, p trend = 0.04). The increased risk remained
statistically signiﬁcant in the model in which up-dated CVD risk factors every 4 years were included
and in the model that excluded subjects with proteinuria and with an eGFR of 90 mL/min* 1.73 m2 or
lower. The strength of the study was the long follow-up time. The limitation of this study was the lack
of control for diet and physical activity.
Foley et al. (2008) conducted a US multicentre cohort study (Atherosclerosis Risk in Communities)
to investigate the relationship between calcium phosphate levels and coronary heart disease, stroke
and death. Out of 15,732 subjects (mean age 54.2 years, SD = 5.7) initially enrolled, a total of 13,816
subjects were included in the analysis. Demographic and clinical data was collected at baseline for all
participants. Information on smoking habits, alcohol consumption and dietary habits was obtained for
all participants. FFQ (61-item instrument) was used to assess dietary habits. Population phosphorus
and calcium intake was 14.2 mg/kg (SD = 6.2) and 8.7 mg/kg (SD = 5.3), respectively. Serum
phosphate and calcium was also measured at baseline. Mean serum levels of phosphate and calcium
was 3.4 (SD = 0.5) mg/dL and 9.8 (SD = 0.4) mg/dL, respectively. The mean level of eGFR was 93.1
(SD = 21.5) per mL/min* 1.73 m2. After 12.6 years of follow-up, 141 cases of coronary heart diseases
and 44 cases of stroke were identiﬁed. In this study, dietary intake of phosphorus was associated with
serum phosphate (p < 0.0001). In the multivariate analysis, adjusting for age, demographic
characteristics, comorbid conditions, serum albumin and eGFR, serum phosphorous (per 0.5 mg/dL)
was associated with both stroke (HR: 1.11, 95% CI: 1.02–1.21) and death (HR: 1.14, 95% CI: 1.09–
1.20). No association was found for serum phosphate and coronary heart disease (HR: 1.03, 95% CI:
0.98–1.08). For calcium-phosphate product (per 5.5 mg2/dL2) risk estimates for coronary heart
diseases, stroke and death were as following: HR: 1.03, 95% CI: 0.98–1.08; HR: 1.15, 95% CI: 1.05–
1.26; and HR: 1.15, 95% CI: 1.09–1.20. The strength of the study was the large sample size and the
good follow-up time. The limitation of the study was the lack of data on the number of people lost in
the follow-up, many missing values in the exposure variables; people with CVDs were not excluded
from the study; lack of adjustments for dietary variables, BMI, BP and physical activity.
Onufrak et al. (2009) investigated associations between serum phosphorous all-cause mortality and
CAD incidence in 13,998 participants [7,923 women, mean age 54 years, after excluding those with
missing serum phosphorous data (n = 150), self-reported history of stroke or CAD (n = 1,010), and
those with eGFR below 60 mL/min* 1.73 m2 (n = 392) or above 150 mL/min* 1.73 m2 (n = 182)] of
the ARIC who were free from CAD at baseline. Serum phosphorous was measured in fasting blood
samples using the DART method at baseline. Incident CAD was deﬁned as deﬁnite or probably
myocardial infarction (fatal or non-fatal) or death due to CAD. CAD events were detected through
annual interviews and surveys of hospital records, and after a median of 13.2 years of follow-up, 992
participants experienced incident CAD. After adjusting for age, sex, black race, body mass index,
diabetes, hypertension, total cholesterol, HDL cholesterol, triglycerides, current smoking, eGFR (by
CKD-EPI formula), serum ﬁbrinogen, post-menopausal status and HRT, high serum phosphorous
(> 3.8 mg/dL vs < 2.9 mg/dL) was associated with CAD incidence in men (HR: 1.45; 95% CI: 1.04;
2.01) but not in women (HR: 0.95; 95% 0.63; 1.41). Strengths of the study were the long-term
follow-up time and the sample size. The limitations were the self-report assessment of the outcomes
and the lack of adjustment for diet and physical activity.
Dhingra et al. (2010) investigated, within a cohort study (Framingham Offspring study), the
association between serum phosphorus and incidence of HF (n = 3,666). It was also studied, using a
cross-sectional design, the relationship between serum phosphorus and echocardiographic left
ventricular mass, dimensions and systolic function. Subjects with previous myocardial infarction and/or
atrial ﬁbrillation (AF) and/or eGFR < 60 mL/min* 1.73 m2 were excluded from the analysis. In total,
3,300 participants [1,616 men, mean age 44.7 years (SD = 10.3); 1,684 women, mean age 44.0 years
(SD = 9.9 years)] were included in the analysis. Clinical data and information on smoking and alcohol
were obtained for all participants. The mean eGFR (mL/min* 1.73 m2) was 106 (SD = 43) for men and
114 (SD = 76) for women. After a mean of 17.4 years of follow-up, 157 cases of HF were identiﬁed. After
pooling sex-speciﬁc quartiles and controlling for age, sex, BMI, diabetes mellitus, systolic BP, treatment
for hypertension, smoking, total cholesterol/HDL cholesterol ratio, valve disease, albumin, haemoglobin,
eGFR and proteinuria, subjects in the fourth quartile of serum phosphorus (mean: 3.8 mg/dL for women
and 3.6 mg/dL for men) had twice the risk of having a HF in comparison to subjects in the ﬁrst quartile
(HR: 2.09; 95% CI: 1.28–3.40, p-trend = 0.02). In a subgroup analysis that included 1,850 individuals
with eGFR > 90 mL/min* 1.73 m2 and no proteinuria and with phosphorus lower than 4.5 mg/dL, the
risk increased even more (HR: 3.11; 95% CI: 1.04–1.69, p-trend = 0.02). In the same model, using
serum phosphorus as a continuous variable the risk remained (HR: 2.40; 95% CI: 1.29–4.46). After
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adjusting for LVM, dimensions and left ventricular systolic function the risk associated with high
phosphorus levels and incidence of HF remained in all models. The strength of the study was the long
follow-up time. The limitation of the study was the lack of control for diet and physical activity.
McGovern et al. (2013) investigated the association between serum phosphate and cardiovascular
events within the ‘Quality Improvement in Chronic Kidney Disease’ (QICKD) cluster randomised trial.
Subjects with CKDs (n = 33,648, mean age 72.8 years, SD = 16.1 years) and subjects without CKDs
(n = 24.184, mean age 52.8 years, SD = 17 years) were included in the study and were followed over
a period of 2.5 years. Normal renal function was deﬁned as an eGFR of 90 mL/min* 1.73 m2 or more
and absence of signiﬁcant proteinuria. In the group with normal renal function, 133 strokes, 120 TIAs,
84 MIs, 110 coronary artery procedures, 45 other advanced CAD events, 77 new cases of HF and 521
deaths were identiﬁed during the 30 months of follow-up while in the group with CKD subjects, 291
strokes, 254 TIAs, 199 MIs, 222 coronary artery procedures, 77 other advanced coronary artery, 222
new cases of HF and 1,401 deaths were identiﬁed. After adjusting for sex, age, smoking,
hypertension, diabetes and cholesterol, subjects with normal renal function and high serum phosphate
(1.25–1.50 mmol/L) had an increased risk of cardiovascular events (OR: 1.36, 95% CI 1.06–1.74) in
comparison to subjects with normal renal function and serum phosphate levels from 0.75 to
1.00 mmol/L. The risk was even higher for subjects with phosphate levels of 1.50 mmol/L or more,
but it did not reach statistical signiﬁcance (OR: 1.80, 95% CI: 0.89–3.63). In people with CKD, a
statistically signiﬁcant increased risk for cardiovascular events was found for phosphate levels above
1.25 mmol/L. Limitations of the study was the short time of follow-up the broad deﬁnition of
cardiovascular events and the lack of control for dietary and physical activity.
Lutsey et al. (2014) within a US multicentre cohort study (ARIC) studied the relationship between
serum magnesium, phosphorus and calcium and incidence of HF. Subjects who had a previous HF and/or
missing information on the outcome and/or ethnic minorities were excluded from the analysis. A total of
14,709 (aged 45–64 years in the period from 1987 to 1989) were included in the analysis. Demographic
information, medical history and medication use, dietary habits including alcohol consumption and
lifestyle information such as smoking and physical activity were collected at baseline. After a median
follow-up of 20.6 years, 2,250 incident HF events (ICD-9 codes from 428.0 to 428.9) were identiﬁed
through calling by phone participants to ask information on hospitalisation, by reviewing local hospital
discharges and by retrieving death certiﬁcates. Mean phosphorus levels were 3.43 (SD = 0.49 mg/dL).
In the multivariate model, after adjusting for age, sex, race, centre, education, physical activity,
smoking status, BMI, diabetes, systolic BP, hypertension medication use, lipid-lowering medication use,
prevalent coronary heart disease (CHD), eGFR, low-density lipoprotein (LDL) cholesterol, HDL
cholesterol, triglycerides and albumin, subjects with high serum phosphorus (median 4.1 mg/dL) had
an increased risk for HF (median 4.1 mg/dL) (Q5 vs Q1, HR: 1.36; 95% CI: 1.18, 1.56, p-
trend = 0.0005). After including magnesium and calcium in the models, the risk estimates did not
change. The strength of the study was the large sample size. Limitations of the study were the inclusion
of subjects also with eGFR below 60 mL/min* 1.73 m2 and lack of control for dietary habits.
Hayward et al. (2017) conducted a retrospective cohort study within sentinel primary care
networks of the Royal College of General Practitioners Research and Surveillance Centre to investigate
if serum phosphate was a predictor of primary cardiac events. The study included 121,605 patients
(18–90 years) free from CVDs. The serum phosphate level was the mean of up to ﬁve phosphate
measurements before any cardiovascular event. The outcome was deﬁned as any primary cardiac
event of myocardial infarction, acute coronary syndrome or revascularisation procedures. After 5 and
9 years of follow-up (from the initial phosphate measurement), there were 1,595 and 2,268 events,
respectively. Demographic data, smoking habits and biochemical and clinical data such as systolic BP,
HDL cholesterol, LDL cholesterol, eGFR, diabetes status and blood markers HbA1c, corrected calcium,
sodium, potassium and albumin data was obtained for all patients. In the 9-year review, subjects with
phosphate levels of 0.75 mmol/L or less (OR: 1.89, 95% CI: 1.23–2.81) and subjects with phosphate
levels above 1.25 mmol/L (OR: 1.83, 95% CI: 1.44–2.31), in comparison to subjects with phosphate
levels between 1.0 and 1.25 mmol/L, had an increased risk of a cardiovascular event. The strength of
the study was the large sample size and the limitation of the study was the use of administrative
data, no clear indication of the confounding factors included in the models.
Lopez et al.(2013) investigated associations between serum phosphorous and AF in 14,998
participants [8,071 women, mean age 54 years, after excluding those who were of a racial group
other than white or black (n = 103), those with prevalent AF at visit 1 (n = 37), low-quality or missing
electrocardiograms (n = 242), missing phosphorus levels (n = 124), non-fasting blood samples
(n = 485), missing covariates (n = 108) and eGFR < 15 mL/min* 1.73 m2 (n = 18)] of the ARIC who
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were free from AF at baseline. Serum phosphorous was measured in frozen fasting blood samples
using a method based on ammonium molybdate at baseline. AF diagnoses were ascertained using
electrocardiograms performed at study visits, hospital discharge codes and death certiﬁcates. During a
median follow-up of 19.7 years, 1,656 incident AF occurred, and after adjusting for age, sex, race,
study site, education, height, smoking, alcohol drinking, body mass index, diabetes, serum calcium
(adjusted for albumin), systolic BP, diastolic BP, use of antihypertensive medications, eGFR (modelled
as a spline), prevalent stroke, prevalent HF and prevalent coronary heart disease, high serum
phosphorous (≥ 3.9 mg/dL vs ≤ 3.0 mg/dL) was not associated with increased risk of AF (HR: 1.15;
95% 0.98; 1.36). After stratiﬁcation by eGFR, a signiﬁcant association was only found in those
participants with eGFR ≥ 90 mL/min* 1.73 m2 (n = 10,149; 1,022 cases; (HR: 1.34; 95% CI: 1.09;
1.65), but not those with eGFR 60–90 mL/min* 1.73 m2 (n = 4297; 587 cases; HR 0.91 [0.68; 1.21])
or eGFR < 60 mL/min* 1.73 m2 (n = 243; 47 cases; HR 1.24; 95% CI: 0.44; 3.46). Strengths of this
study are the sample size and duration; the limitations were the lack of adjustment for diet and
physical activity.
Foley et al.(2009) investigated the association between serum phosphorous and coronary artery
calciﬁcation in 3,015 out of 5,115 participants of the Coronary Artery Risk Development in Young
Adults (CARDIA) study for whom data on serum phosphorous concentration at baseline and coronary
artery calcium level after 15 years of follow-up were available (mean age at baseline 25.2 years, 54%
women; 1,444 participants were lost at follow-up, 629 did not have data on coronary artery calcium
and a further 27 did not have data on serum phosphorous). Serum phosphorous was measured in
fasting (12 h) blood samples using a SMAC 12 continuous ﬂow analyser, coronary artery calciﬁcation
was assessed by different methods in different study centres, i.e. Imatron C-150 electron beam
scanner, GE Lightspeed multidetector scanner or Siemens (Berlin, Germany) VZ multidetector scanner
to calculate a calciﬁcation score. 9.6% of the study population had some artery calciﬁcation, but only
1.6% had moderate or severe calciﬁcation. After adjusting for age, sex, ethnicity, education, smoking
status, prevalent diabetes, family history of MI, BMI, blood lipids and glucose, BP, eGFR, exercise,
medication and diet (e.g. alcohol, calcium and phosphorous), serum phosphorous was signiﬁcantly
associated with calciﬁcation score category (0, 0–10, 10–100, 101–300 or 300 units, OR 1.17 (1.01;
1.34) per 0.5 mg/dL, and a calciﬁcation score above 10 (OR: 1.20; 95% CI: 1.01; 1.43). In categorical
analyses, using quantiles, high serum phosphorous (> 3.9 mg/dL vs ≤ 3.3 mg/dL) was signiﬁcantly
associated with a calciﬁcation score above 10 (OR 1.60; 95% CI: 1.01; 2.55). These associations did
not change materially after excluding participants with an eGFR below 60 mL/min* 1.73 m2. The
strength of the study was the long follow-up period and the limitations were the use of a logistic
model and the use of a single 24-h dietary recall.
In summary, nine cohort studies on CVD incidence (Dhingra et al., 2007, 2010; Foley et al., 2008;
Onufrak et al., 2009; Lopez et al., 2013; McGovern et al., 2013; Lutsey et al., 2014; Hayward et al.,
2017) and two cohort studies on cardiovascular mortality (Larsson et al., 2010; Chang et al., 2014)
were reviewed. Dhingra et al. (2007) conducted a cohort study on 3,368 subjects and observed that
high serum phosphorus was associated with an increased CVD risk in a dose response manner. Foley
et al. (2008) conducted a multicentre cohort study in 13,816 subjects and showed a positive
association between serum phosphates and stroke incidence but not for serum phosphorus and
coronary heart disease incidence. Onufrak et al. (2009) conducted a cohort study in 13,998
participants and showed that high serum phosphorous was associated with an increased risk for CAD
incidence among men but not among women. Dhingra et al. (2010) in cohort study of 3,666 subjects
showed that serum phosphorus was associated, in a dose-response manner, with an increased risk of
HF. McGovern et al. (2013) in a cohort study of 24,184 subjects showed that high phosphorus levels
were associated with an increased risk for cardiovascular events. Lutsey et al. (2014) within a US
multicentre cohort study (n = 14,709) showed that high serum phosphorus was associated with an
increased risk of HF. Hayward et al. (2017) conducted a retrospective cohort study on 121,605
subjects and showed an increased risk of cardiovascular events among subjects with both low
(0.75 mmol/L or less) and high serum phosphorus levels (1.25 mmol/L or more). Lopez et al. (2013) in
a cohort of 14,998 subjects showed that high serum phosphorous was not associated with the
incidence of AF. Foley et al. (2009) investigated in a cohort study of 3,015 subjects the association
between serum phosphorous and coronary artery calciﬁcation level and found a statistically signiﬁcant
association. Chang et al. (2014) in a cohort study of 12,984 subjects showed that high levels of
phosphorus was associated with an increased risk of cardiovascular mortality. Larsson et al. (2010) in
cohort study of 2,176 men showed an increased risk of cardiovascular mortality for those in the
highest category of phosphorus.
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Overall, there is evidence for a link between serum phosphorus and incidence of CVDs and some
evidence to link serum phosphorus and cardiovascular mortality.
Coronary artery calciﬁcation
Kwak et al. (2014) conducted a cross-sectional study (n = 23,652) to study the relationship
between phosphorus intake and phosphorus serum levels and CAC. Eligible participants had no CKD
(eGFRrate ≥ 60 mL/min* 1.73 m2) and/or CVD. Participants (40.8  7.3 years) were mainly (males
83%), who underwent, as part of health check-ups, cardiac computed tomographic (CT) estimation of
CAC (scores, 1–100 and > 100). Dietary habits, including alcohol intake was assessed by a FFQ.
Clinical data and information on physical activity and smoking were collected for all participants. In the
multivariate analysis, adjusted for adjusted for age, sex, smoking status, alcohol intake, physical
activity, body mass index, educational level, family history of CVD, medication for dyslipidaemia,
diabetes mellitus, hypertension, glomerular ﬁltration rate, albumin, ferritin, total calorie intake, calcium
intake, phosphorus intake and calcium supplements, high serum phosphorus (≥ 3.9 mg/dL) was
associated with high CAC scores, (OR: 3.33, 95% CI: 2.55–4.35, p-trend < 0.001). No association was
found for high intake of phosphorus (≥ 965 mg/daily). The strength of the study is the large sample
size and the good control of confounding factors. The limitation of the study was the cross-sectional
design that impedes drawing conclusions of a possible causality.
Linefsky et al. (2011) in a cross-sectional study investigated the association between serum
phosphorous and calciﬁc aortic valve disease (n = 1,938) (70% women, mean age 73 years)
participants of the cardiovascular health study (after excluding 1,428 participants with prevalent CVDs,
948 with insufﬁcient amounts of serum and 378 with missing echocardiogram). Serum phosphorous
was measured in fasting serum using time-rated colorimetric reaction with ammonium molybdate.
Outcomes were aortic annulus calcitication (AAC) and aortic valve calciﬁcation (AVC), and mitral
annular calciﬁcation (MAC). AVS was identiﬁed as aortic cusp thickening with normal aortic cusp, MAC
was deﬁned by an intense echocardiograph-producing structure located at the junction of the
atrioventricular groove and posterior mitral leaﬂet on the parasternal long-axis, short-axis or apical
four-chamber view. The presence of AAC was similarly deﬁned as increased echodensity of the aortic
root at the insertions of the aortic cusps. Following adjustment for age, sex, race, eGFR, hypertension,
diabetes, smoking, body mass index, LDL cholesterol, HDL cholesterol, statin use, serum calcium levels
and clinic site, high serum phosphorous (> 4.0 mg/dL vs < 3.0 mg/dL) was signiﬁcantly associated
with aortic valve sclerosis (OR: 1.64; 95% CI: 1.10, 2.43) and mitral annular calciﬁcation (OR: 1.62;
95% CI: 1.10; 2.38), but not aortic annual calciﬁcation (OR: 1.32; 95% 0.90; 1.92). Analyses using
serum phosphorous as a continuous variable showed a signiﬁcant association only for aortic valve
sclerosis (OR: 1.17; 95% CI: 1.04; 1.31) per 0.5 mg/dL increase). Strengths of this study is the
number of confounders included. The limitation of this study is the cross-sectional nature as well as
limited methodological information.
Park et al. (2016) investigated the association between serum phosphorous and coronary artery
calciﬁcation in 2,509 (37% women, mean age 54 years old) patients undergoing coronary CT
screening (after excluding those with eGFR below 60 mL/min* 1.73 m2, albuminuria and previous
history of overt vascular events. Serum phosphorous was measured using a clinical analyser, coronary
artery calciﬁcation was quantiﬁed as the Agatston Score on coronary CT. Following adjustment for age,
sex, diabetes, hypertension, body mass index, systolic BP, corrected serum calcium, albumin,
haemoglobin A1c, LDL cholesterol and HDL cholesterol, high serum phosphorous (> 4 mg/dL vs
< 3.2 mg/dL) was associated with a higher risk of an Agatston score above 100 [OR 2.11 (1.34;
3.32)]. The main limitation of the study was the cross-sectional design that impedes drawing
conclusions of a possible causality.
Criqui et al. (2010) investigated risk factors of artery calciﬁcation in 1,974 out of 6,814 participants
of the MESA (mean age 58 years old). Patients without complete CT scan and free of CVD at base-line
were excluded. Serum phosphorous was one risk factor and measured in 1,125 participants as part of
an ancillary study, but no information about analytical methods or collection date were available, nor
data on the composition of this subcohort, including calciﬁcation scores. Abdominal artery calciﬁcation
was determined by electron-beam CT scan, whereas coronary artery calciﬁcation was measured by
either electron-beam CT scan or multidetector CT, and the results used to calculate the Agatston score.
At follow-up, 552 participants had developed abdominal artery calciﬁcation, 813 coronary artery
calciﬁcation and 997 had both. After adjustment for age, sex, ethnicity, smoking status, blood-
pressure, antihypertensive drug use, glycaemic status, HDL, LDL, lipid-lowering drug use and calcium,
there were no statistically signiﬁcant associations between serum phosphorous and abdominal artery
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calciﬁcation (OR: 0.96; 95% CI: 0.79, 1.17] per SD [0.52 mg/mL] increase) or coronary artery
calciﬁcation (OR: 1.11; 95% CI: 0.95; 1.31), although there was a statistically signiﬁcant association
between serum phosphorous and coronary Agatston score in a continuous model (ln(CAC + 1),
b = 0.21; p < 0.01, per SD increase). The main limitation of this study was the lack of information on
follow-up time and the lack of information on the subcohort for whom serum phosphorous data were
available. Results were also not adjusted for diet or physical activity.
Linefsky et al. (2014) within the US Multi-Ethnic Study of Atherosclerosis (ARIC), a study was
conducted (n = 6,814) to examine the association between phosphate metabolism biomarkers (serum
phosphate, urine phosphate, PTH and FGF-23) and aortic valve calciﬁcation (AVC). Eligible criteria for
participating in the study was aged 45–84 years and being free from clinical CVD. Out of the 6,814
subjects initially enrolled, 5,145 subjects were free of AVC aortic valve calciﬁcation. Demographic data,
medical history, smoking status and medication history and fasting blood and urine samples were
collected from all subjects. BP, eGFR, total and HDL were also measured at baseline. Mean serum
phosphate levels was 3.67 (SD = 0.52 mg/dL) and median urine phosphate level was 44.1 mg/dL (IQR:
24.9–67.7 mg/dL). During the follow-up time (mean 2.4 years), 211 subjects developed AVC (4.1%).
The mean eGFR was 99.81 (SD = 25.8) mL/min* 1.73 m2 in subjects free from AVC (n = 5899) and
86.33 (SD = 24.5) mL/min* 1.73 m2 in subjects with AVC at baseline. AVC prevalence was 13.2% and
it was associated with higher phosphate levels (> 3.5 mg/dL). In the multivariate model, controlling for
age, gender, ethnicity, study site, scanner type, BMI, BP, diabetes, smoking, LDL-cholesterol, HDL-
cholesterol, 25-hydroxyvitamin D, eGFR, albumin to creatinine ratio and serum calcium, an increased
risk, although not statistically signiﬁcant, was found between high serum phosphate levels (> 4.0 mg/
dL) and incident of AVC (HR: 1.25; 95% CI: 0.90–1.72) and high urine phosphate levels (67.9 mg/dL)
and incident of AVC (HR: 1.18; 95% CI: 0.94–1.49). No association between PTH (HR: 1.10; 95% CI:
0.95–1.08) and serum FGF-23 pg/mL (HR: 1.10; 95% CI: 0.92–1.31, p-trend = 0.29) and incidence of
aortic valve calciﬁcation was found. The strength of the study was the prospective design and relatively
large sample size and the limitations were the short follow-up time, the inclusion of subjects not free of
AVC at baseline and the lack of control in the models for diet and physical activity.
Arterial stiffness
Ix et al. (2009) within the MESA (Multi-Ethnic Study of Atherosclerosis) study investigated the
association between serum phosphorus and ankle-brachial index in men and women (n = 1,370) In
order to maximise the range of kidney function in the study sample., they selected all participants
(n = 641) with an eGFR < 60 mL/min* 1.73 m2 and randomly selected 1,000 participants from the
remainder of the cohort with higher GFR. Serum phosphorous was measured in morning serum
obtained after an overnight fast using reﬂectance spectrophotometry. Arterial stiffness was assessed
using ankle brachial index (ABI, calculated as ratio of leg and arm systolic BP), pulse pressure and
large and small artery elasticity (using pulse wave analysis). After adjusting for age, sex, race/ethnicity,
diabetes, smoking (ever), BMI, LDL, HDL, log triglycerides, eGFR, log CRP and log albuminuria, high
serum phosphorous (> 4.0 mg/dL vs < 3.0 mg/dL) was signiﬁcantly associated with high ABI
(ABI > 1.3; OR: 4.6, 95% CI: 1.6; 13.2), but no statistically signiﬁcant associations were found for
other measured of arterial stiffness. The limitation of the study was the cross-sectional design that
impedes drawing conclusions of a possible causality.
Carotid artery intima-media thickness
Onufrak et al. (2008) investigated the association between serum phosphorous and carotid IMT
(cIMT) in 13,340 participants (57% women) of the community-based ARIC. Participants were without
known coronary heart disease, stroke or renal disease. Participants with eGFR above 150 mL/min*
1.73 m2 (n = 165) or below 45 mL/min* 1.73 m2 (n = 47) were excluded from the analysis. Dietary
data (FFQ) were available for 10,688 participants. Serum phosphorous was measured in fasting blood
samples. cIMT was determined by measuring the far wall of the common carotid artery, the bulb and
the internal carotid artery bilaterally. Following adjustment for age, sex, race, diabetes, hypertension,
total cholesterol, HDL and smoking status and eGFR, cIMT was signiﬁcantly associated with serum
phosphorous in a dose-response manner (p-trend = 0.003). The limitation of the study was the cross-
sectional design that impedes drawing conclusions of a possible causality.
Summary of the results of studies on serum phosphorus and other related outcomes
Kwak et al. (2014) conducted a cross-sectional study (n = 23,652) to study the relationship
between phosphorus intake and phosphorus serum levels and CAC and found that high serum
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phosphorus was associated with high CAC scores. Linefsky et al. (2011), in a cross-sectional study
investigated the association between serum phosphorous and calciﬁc aortic valve disease and found
that high serum phosphorous was signiﬁcantly associated with aortic valve sclerosis and mitral anular
calciﬁcation but not aortic anular calciﬁcation. Park et al. (2016) in a cross-sectional study investigated
the association between serum phosphorous and coronary artery calciﬁcation in 2,509 and found a
higher risk of an Agatston score above 100 for those with high serum phosphorus levels. Criqui et al.
(2010) in a cross-sectional study investigated risk factors of artery calciﬁcation in 1,974 and found no
statistically signiﬁcant associations between serum phosphorous and abdominal artery calciﬁcation or
coronary artery calciﬁcation, although there was a statistically signiﬁcant association between serum
phosphorous and coronary Agatston score. Linefsky et al. (2014) in a cross-sectional study (n = 6,814)
examined the association between phosphate biomarkers (serum phosphate, urine phosphate, PTH
and serum FGF-23 and AVC and found no statistically signiﬁcant association between high serum
phosphate and urine phosphate levels and incident of AVC. Arterial stiffness was assessed using ABI,
calculated as ratio of leg and arm systolic BP), pulse pressure and large and small artery elasticity
(using pulse wave analysis and found that high serum phosphorous was signiﬁcantly associated with
high ABI-IX 2009 (Onufrak et al., 2008) investigated in a cross-sectional study the association between
serum phosphorous and cIMT and found a statistically signiﬁcant association, with a dose–response,
between serum phosphorus and cIMT, with a dose-response.
Overall, because of the cross-sectional nature of all studies, the results ﬁnding an association
between phosphorus serum levels and vascular calciﬁcation are uncertain and ﬁrm conclusion cannot
be drawn.
3.6.3. Studies on urinary phosphorus/phosphate and cardiovascular-related
outcomes19
Cardiovascular diseases and mortality
In 880 patients with stable CVD and normal kidney functions, serum phosphorus excretion were
measured and the participants were followed for 7.4 years. Cardiovascular events and all-cause
mortality were recorded (Palomino et al., 2013).
Urinary phosphorous excretion has been investigated as surrogate marker of phosphorous intake
(Trautvetter et al., 2018), and it has been suggested that it can be used to estimate actual intake
(Morimoto et al., 2014), but the data available are very limited. Human intervention studies (see
below) suggest that urinary phosphorous excretion mainly reﬂects acute changes in intake and not
long term, habitual intake.
The results of the study by Palomino are therefore not suitable to assess the risk of phosphorous
intake.
3.6.4. Overall conclusion
• there is insufﬁcient evidence to link dietary phosphates intake to cardiovascular outcome.
• there is some evidence to link serum phosphorus and CVDs incidence and some evidence to
link serum phosphorus and cardiovascular mortality. However, serum phosphorus cannot serve
as surrogate for phosphorus intake and studies did not control for important confounding
factors.
• the link between phosphorus serum levels and vascular calciﬁcation seen in cross sectional
studies does not allow drawing conclusions of a possible causality due the limitation of the
study design.
3.7. Epidemiology studies on bone health
Few epidemiological studies investigated the role of phosphate on bone health in the general
healthy population. Cross-sectional studies were not included in the evaluation.
Tucker et al. (2006) within the Framingham Osteoporosis study (1,413 women and 1,125 men)
showed that cola-ﬂavoured carbonated beverages containing phosphate were associated, in a dose
response manner, with BMD in women but not in men. BMD was measured using dual-energy X-ray
absorptiometry (DXA) at the right hip and the lumbar spine. After controlling for confounders such as
19 Due regard has been given to the convention in epidemiological studies for expression of the results as (serum/urine)
phosphorus rather than phosphate. In this section, we regard serum phosphorus to mean phosphate.
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BMI, smoking, alcohol use, age, physical activity, calcium, vitamin D, caffeine intake from other
sources other than cola and oestrogen use, negative linear associations were seen for cola consumption
and BMD at each hip site femoral neck, ward’s area trochanter, but not the spine, in women (p < 0.001).
After stratifying the consumption of colas by caffeine content (caffeinated/decaffeinated), the effect
remained only for ward’s area but not for other hip. No association was seen between non cola-ﬂavoured
carbonated beverage consumption and BMD. In this study, total dietary phosphorus intake was not
different from daily cola-ﬂavoured carbonated beverage consumers and no cola-ﬂavoured carbonated
beverage consumers but the calcium-to-phosphorus ratio was lower.
Campos-Obando et al. (2017) combined data (n = 23,412) from two cohorts studies (Dutch
Rotterdam study and the US Osteoporotic Fractures in Men study) to investigate the relation between
serum phosphorus and incidence of fractures (self-reported in the US study and measured by X-ray in
the Dutch Rotterdam study). In the pool analysis, serum phosphate was inversely associated with
lumbar BMD measured by DXA in men (b = 0.06; 95% CI: 0.11 to 0.02) but not in women, after
controlling for age, BMI, smoking and race. In the combined data analysis, after 6.6 years of follow-up
a total of 1,825 fractures were recorded. In the multivariate analysis, adjusting for age, body mass
index, smoking, serum levels of calcium, potassium, 25-hydroxyvitamin D, eGFR, phosphate intake,
PTH, FGF-23 levels and phosphate levels (1 mg/dL increase), an elevated risk of fractures was
observed for both women and men (HR: 1.47; 1.31–1.65) When the analysis was conducted using
phosphate in quintiles (Q5 = 3.8 mg/dL), a dose–response was observed between serum phosphate
and all types of fractures. Limitations of the studies were the outcome variable used in the US study
(self-report) and the lack of control in both studies for physical activity and other potential
confounders.
In summary, in the study of Tucker et al. (2006) the effect of phosphate on BMD was seen only in
women, but not in man, consuming cola-ﬂavoured carbonated beverages containing phosphate, while
in the study of Campos-Obando et al. (2017) the effect of serum phosphorus on BMD was observed
only in men and for lumbar spine BMD but not femoral neck BMD. In the study of Campos-Obano that
investigated also the effect of serum phosphorus on the incidence of fractures, an increased risk of
fractures was observed for both sex in a dose-response manner.
It is important to note that phosphate serum level is not considered to be appropriate to estimates
phosphates intake. Therefore, more data on actual intake to assess the impact of phosphate intake on
bone density and fractures are needed, in agreement with Vorland et al. (2017).
In conclusion, despite the effect of a high phosphorus intake on the activity of calcium-phosphate
metabolism regulating hormones, there is insufﬁcient evidence for an association between dietary
phosphate intake and pathologically reduced BMD which is in accordance with evaluation from the
NDA Panel (EFSA NDA Panel, 2005). There is also insufﬁcient evidence for an association between
serum phosphate and incidence of fractures.
3.8. Human studies
The Panel noted that in all human case reports and interventional studies the customary dietary
phosphate intake was not reported and therefore the dose estimate only relates to supplementary
phosphates intake observed in case reports or given in the clinical interventional studies.
3.8.1. Effects on kidney
Case series and case reports after acute administration
Publications were identiﬁed by a systematic literature search in which nineteen case of acutely
severely impaired renal function are described after administration of phosphate as a treatment for
bowel cleansing in preparation for colonoscopy (Fine and Patterson, 1997; Vukasin et al., 1997; Orias
et al., 1999; Markowitz et al., 2004; Gonlusen et al., 2006; Santos et al., 2010; Cakar et al., 2012;
Arikan et al., 2013).
For 15 of the patients, the dose was reported and the lowest dose which was causally related to an
impairment of renal function was reported as 11,600 mg/day, in most cases consisting of two
5,800 mg doses taken 12–24 h apart (see Appendix P). In some of the cases, the patients recovered
but, in several cases, renal impairment persisted and leading to CKD. One patient died. It is to be
noted that many patients had an advanced age and pre-existing pathological conditions, e.g.
hypertension. However, when baseline creatinine values have been measured, they resulted in the
normal range (Aasebø et al., 2007).
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The Panel noted that acute doses of phosphorus of 11,600 mg (165.7 mg/kg bw) given within
12–24 h can have deleterious effects on the kidney in some patients, in particular in the elderly
(Study n. 2 in Appendix F; all but one patient were older than 55 years).
Histopathological evaluations of kidney specimens were published from patients with acute phosphate
nephropathy after intake of phosphate salts as a treatment for bowel cleansing. The histological ﬁndings
clearly showed calcium-phosphate crystals deposits within the cytoplasm of tubular epithelial cells and
within tubular lumina (Aasebø et al., 2007; Vervaet et al., 2009; Markowitz and Perazella, 2009).
Interventional studies with short–term exposure
In seven clinical intervention studies with short-term exposure towards phosphorus, no impaired
renal function was mentioned (see Appendix Q). The doses varied between 660 mg phosphorus and
2,500 mg phosphorus daily (11–40 mg P/kg bw/day) and the duration of the treatment was between
1 day and 14 days. The number of study participants encompassed 6–20 subjects.
Interventional studies with long-term exposure
Fifteen clinical studies were identiﬁed by a literature search in which subjects were exposed at least
1 month up to 2 years to phosphate (see Appendix R). The number of included subjects was small
(between 5 and 13 subjects) with the exception of two studies in which 25 subjects (Ettinger, 1976)
and 47 subjects (Miller et al., 1991) were treated. Doses between 350 and 7,200 mg/day phosphorus
were given, mostly by the oral route with the exception of two studies where phosphorus was given
by the intravenous route. The doses were an add-on to the phosphorus intake by the normal diet. In
14 of the 16 studies, the daily dose was at or below 2,000 mg phosphorus/day (28.6 mg/kg bw per
day) and no inﬂuence on the renal function was described. The number of patients from all studies
was 200.
In the clinical interventional trial of Dudley and Blackburn (1970), nine patients, age 35–71 years,
were studied in a variety of conditions [hyperparathyroidism (4 patients); multiple myeloma
(1 patient); renal calculi (4 patients)]. The patients received daily doses between 2,250 (32.1 mg/kg
per day) and 4,500 mg daily (64.2 mg/kg per day) (one patient 2,250 mg/day, 7 patients 3,375 mg/
day and 1 patient 4,500 mg/day) over a period of 9–87 months. In this study, creatinine clearance
decreased in 2 patients (dose 4,500 mg/day for 78 months and 3,375 mg/day for 42 months). In all,
but two patients (dose 2,250 mg daily for 16 months and 87 months, respectively) calciﬁcation in
tissues were noted.
In the clinical interventional trial of Bernstein and Newton (1966), 10 patients, 16–69 years old,
received phosphorus for studying its effect on kidney stone formation. 4 patients received 2,400 mg,
5 patients 4,800 mg and 1 patient 7,200 mg phosphorus daily for 4–24 weeks. At the end of the
treatment period, in the dose group of 2,400 mg phosphorus daily, one patient had slightly reduced
renal function; in the dose group of 4,800 mg phosphorus daily two patients had a reduced renal
function and in the highest dose individual (7,200 mg phosphorus daily) creatinine clearance reduced
to 50% of the pre-treatment value.
The Panel noted that in clinical trials daily doses up to 2,000 mg phosphorus (28.6 mg/kg bw per
day) given over several months up to 2 years were tolerated without impairment of the renal function,
whereas doses of 4,800 mg/day (68.6 mg/kg bw per day) and higher elicited renal impairment.
A meta-analysis of the studies with the aim to construct a dose–response relationship is hampered
by the differing design, the differing duration, the low number of subjects per dose group and the
insufﬁcient reporting of study details. Nevertheless, these studies can give valuable information on the
tolerability of phosphate doses in humans.
3.8.2. Effects on the gastrointestinal tract
In several of the clinical studies, it was noted that the subjects had soft stools or diarrhoea. In the
study of Brixen et al. (1992) which was a short-term study of 7 days duration, 2 of 19 patients
receiving 750 mg/day (10.7 mg/kg bw per day), 3 of 19 patients receiving 1,500 mg/day (21.4 mg/kg
bw per day) and 7 of 20 patients receiving 2,250 mg/day (32.1 mg/kg bw per day) complained of
gastrointestinal side effects. The Panel noted that the described effect is not to be seen as adverse but
is classiﬁed as discomfort. However, when higher doses are given, such as the doses for bowel
cleansing in preparation for colonoscopy (11,600 mg/day or 165.7 mg/kg bw) these doses acted as a
cathartic agent and this effect has to be clearly seen as adverse.
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3.8.3. Effects on PTH
Studies showing that phosphates intake induce PTH elevation are available (Reiss et al., 1970; Bell
et al., 1977; Silverberg et al., 1986; Calvo and Heat, 1988; Calvo, et al. 1988; Calvo et al., 1990; Brixen
et al., 1992; K€arkk€ainen and Lamberg-Allardt, 1996). The studies were of short duration, mainly in
young adults, and long-term studies measuring fractures incidence or bone density changes are lacking.
3.8.4. Effects on blood pressure
In an experimental interventional study in healthy subjects, Mohammad et al. (2018) investigated
the inﬂuence of 6 weeks phosphorus intake in a dose of 17.15 mg/kg bw per day on top of the normal
diet compared to a control group without additional phosphorus intake on a plethora of endpoints.
Further treatment of 5 weeks was administered after a single intramuscular injection of vitamin D3
(600,000 U). An increase in P in serum was observed from 1.1 mmol/L to 1.3 mmol/L (week 6) and
1.4 mmol/L (week 11) in the group loaded with phosphorus with a corresponding elevation of urinary
excretion of P. From further endpoints studied, FGF-23, Klotho and PTH were increased at week 6 as
was urinary Klotho the values returning to normal within the next 5 weeks under treatment. Related to
the administration of vitamin D3 serum 25(OH)D and serum 1,25(OH)D were elevated in both groups.
Mean 24-h systolic and diastolic BP as well as heart rate were increased in the phosphorus exposed
group. The mean increase was 4 mm Hg (systolic) and 3 mm Hg (diastolic) and the pulse rate
increased from 68 to 72 beats/min. Metanephrine and normetanephrine excretion in the urine was
increased but within the reference range.
Further 41 parameters were measured and only the sodium excretion in both groups in urine was
elevated due to the administration of phosphorus as sodium salt and of sodium in the control group. It
is to be noted that none of the three parameters of endothelial function and arterial elasticity were
changed by the phosphorus treatment.
The authors claim that the elevations of BP and pulse rate are caused by an elevated adrenergic
activity. However, there is no physiological explanation and basis by which mechanism phosphorus
intake may act on BP and pulse rate. Unfortunately, the authors did investigate only one single dose
level of phosphorus which precludes drawing conclusions on the inﬂuence of higher and lower doses of
phosphorus on the BP. A further shortcoming of the study is that the intake of phosphorus by the diet
was not controlled by a dietary questionnaire and although some information can be drawn from the
urinary concentration of phosphorus the amount of phosphorus excreted is not given in the
publication. Although this publication is of interest, further conﬁrmation of the ﬁndings is necessary
and further dose levels have to be investigated.
3.9. Special populations – Infants below the age of 16 weeks
Sometimes in addition to natural phosphate content phosphates are added to infant formulas food for
special medical purposes (FSMP) either for technological reasons and/or for its nutritional role (see
Section 1.2). Special physiology and relevant toxicological and clinical studies are reviewed in the SNE
publication (https://www.specialisednutritioneurope.eu/sne-literature-review-on-phosphates). A summary
based on this document is given here.
Several clinical studies in infants consuming infant formula or FSMP with added phosphate have
been performed. The outcomes investigated in these studies are generally effects on growth and/or on
serum inorganic phosphate levels.
Most of these studies have investigated the effect of added phosphate (phosphoric acid, sodium
phosphate, potassium phosphate or calcium phosphate) on growth parameters (including body weight,
length and head circumference). These studies involved more than 2,600 infants and ranged in
duration between 16 weeks and 1 year. In all studies, there were no statistical differences in the
growth of the infant cohorts fed the various formulae from those of breast-fed infants and their growth
matched the WHO growth standards.
There are a limited number of studies that assess the effect of formulas with or without added
phosphate on serum inorganic phosphate concentration. Most of the studies have investigated the
effects of formula not containing any added phosphate but where the phosphorus comes from natural
presence in the milk ingredients. These studies indicate that infants fed formula have somewhat higher
serum inorganic phosphate concentration than breastfed infants. However, the average serum
inorganic phosphate concentration in formula-fed infants is within the normal reference range for
serum inorganic phosphate laboratory values for infants.
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Few studies have been performed where the effect on serum inorganic phosphate concentrations of
infant formula with added phosphate has been investigated. Despite high phosphorus concentration in
the supplemented formula the infants receiving this formula did not have higher serum inorganic
phosphate concentrations
In conclusion, clinical studies in infants who consume either standard infant formula or FSMP with
added phosphates demonstrate that the important clinical outcome, growth, is similar to WHO growth
standard. This observation demonstrates that the addition of phosphates within the regulatory limits is
of no concern. Furthermore, any adverse effect contributed to added phosphates would be through
increased serum inorganic phosphate concentration. As demonstrated in a clinical study with high
phosphorus, content in infant formula did not result in any signiﬁcant increase of serum inorganic
phosphate, which still fell within the normal range.
3.10. Mode of action, derivation of a phosphate-speciﬁc adjustment
factor and derivation of ADI
3.10.1. Mode of action
Since nephrocalcinosis and/or tubular-interstitial nephropathy were identiﬁed as common endpoints
in human and animal studies whereas bone and cardiovascular endpoints could not be conﬁrmed as
relevant for healthy human population in epidemiology studies, the only mode of action of interest
concerns the effects on kidney.
Key events: In the process of renal excretion, phosphate is freely ultraﬁltrated through glomerular
barrier and reabsorbed in the proximal tubule by sodium-dependent transporters. When phosphate
ultraﬁltrate load exceeds the reabsorption capacity of the proximal tubule, the delivery of phosphate to
the distal renal tubule increases disproportionately. As a consequence, calcium-phosphate
concentration increases within the distal tubular lumen, up to formation of Ca-P crystals. It is
important to note that this can occur in the distal tubule and in the collecting ducts, and that calcium-
phosphate solubility is also a function of luminal ﬂuid pH. In normal conditions, the pH values changes
from 7.4 in the Bowman capsule to 6.6 in the distal tubule, a difference which does not strongly
inﬂuence the solubility of calcium phosphate (see Section 3.1.1). Concerning the tubular ﬂuid volume,
another factor inﬂuencing phosphate solubility, it reduces along the tubular transit. When we compare
the processes in man and rat, it can be assumed that the production of the urine is guided by the
same principles. However, quantitative differences are evident. The estimated median volume of
primary urine is 4.4 L /kg bw per day in the rat (Pestel et al., 2007) and 2.16 L/kg bw per day in man
(range 1.60–2.8 L/kg bw per day; 5th to 95th percentile) (Poggio et al., 2009). The volume of urine
excreted from the bladder is 67.8  16 mL/kg bw per day in rats (Shevock et al., 1993) and 33.5 mL/
kg bw per day in man (ICRP, 2002). According to these data, the rat produces twice the volume of the
primary urine than a human and excretion of the urine volume from the bladder is similarly twice in rat
compared to man. Hence, it can be assumed that along the lumen in the tubule and in the collecting
duct of the kidney the volume in rat is twice of that in man. The volume of urine plays a deciding role
as the concentration of calcium phosphate and its solubility depends on its volume. At the rat NOAEL
for added phosphate with a daily dose of 76 mg/kg bw, the concentration in the primary urine and
along the renal tubules is twice in humans compared to rat because the volume of the urine in
humans is a factor 2 lower than the urine volume in rats.
Concordance of the key events in man and animal: In several short-term and subchronic rat
studies, the endpoint calciﬁcation in the kidney has been observed in a dose-dependent manner with
different phosphates (Chow et al., 1980; Mars et al., 1988; Ritskes-Hoitinga et al., 1989; Seo et al.,
2011). The effect has also been observed in dogs (Schneider et al., 1981). The most reliable NOAEL
from the short-term and subchronic studies was 500 mg/kg bw per day, corresponding to 116 mg/kg
bw per day phosphorus in a 90-day study (Seo et al., 2011). In chronic rat studies, calciﬁcations in the
kidneys and tubular nephropathy was observed with NOAELs of 250 mg/kg bw per day with sodium
triphosphate, corresponding to 63 mg/kg bw per day phosphorus and 250 mg/kg be per day sodium
hexametaphosphate, corresponding to 76 mg/kg bw per day phosphorus (Hodge, 1959, 1960). The
human interventional studies indicate that a dose of 2,000 mg/day (corresponding to 28.5 mg/kg bw
per day) may be without an effect on the kidney function (references see Appendix Q). The
mechanism and its key events are conﬁrmed to be also relevant for humans by comparison of the
histopathological changes described in the animal studies and in some publications describing
the histopathology in human renal specimens. In these specimens, calcium phosphate crystals
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precipitate predominantly in the distal tubule and collecting duct in patients with renal damage due to
high intake of phosphate (Aasebø et al., 2007; Markowitz and Perazella, 2009; Vervaet et al., 2009). In
addition, following high acute phosphate exposure renal tissue histology shows tubular atrophy and
interstitial ﬁbrosis that are signs of an irreversible chronic damage. It is likely that the persistence of
crystal deposition within tubules prevents recovery of the acute damage leading to ﬁbrosis (Markowitz
et al., 2004). Vervaet et al. (2009) have investigated the fate of the crystal deposits in the renal tubule
and observed overgrowth of the crystal deposits in the tubule, translocation into the interstitium and
followed by inﬂammation and ﬁbrosis. These histopathological changes are described in the
Section 3.10.2 (derivation of ADI).
Temporal association: The key events, calcium-phosphate crystal formations in the distal tubules in
the kidneys and impaired kidney function, are observed in humans with a temporal relationship to the
intake of phosphate which depends on the dose. There are case reports indicating that acute renal
failure was elicited with a single extremely high dose (160 mg/kg bw and more) whereas up to
2,500 mg/day (35.7 mg/kg bw per day) phosphorus (short-term exposure of up to 2 weeks) had no
effect and calciﬁcations were noted with a dose of 32.1 mg/kg bw per day in a long-term administration.
As pointed out in Section 3.8, the dose of phosphorus is in addition to that found in the normal diet.
Strength, consistency and speciﬁcity of association of toxicological response with key events: There
are no alternative mechanisms explaining the observed calciﬁcations in the kidney and kidney
impairment after phosphate exposure.
Biological plausibility and coherence: The observed effect is the consequence of the exposure of the
kidney as it is the only excretory organ for phosphate with a salt that will deposit in the event of
saturation. The effect is plausible and explained by physicochemical properties and the biology of the
urine production in mammalia.
Uncertainties, inconsistencies and data gaps: The induction of precipitates in the kidney following
exposure to calcium phosphate is well established. Clear dose responses have been reported in rats
exposed to phosphates and in some human studies. In all the studies the dose of phosphorus is in
addition to that found in the normal diet. Solid information on the phosphorus content of the feed
could be retrieved for one of the rat studies (personal communication, Purina Korea, January 2019).
Uncertainty and inconsistencies are very low concerning mode of action.
3.10.2. Derivation of a chemical-speciﬁc adjustment factor for phosphate
The evidence from epidemiological and human interventional studies is not suited to derive an ADI.
In the epidemiological studies in which effects were seen concentrations of phosphorus in plasma/
blood were related to the effects. However, plasma/blood phosphorus levels cannot be converted into
dietary phosphorus exposure rendering the information on concentration–effect relationship unsuitable
for the derivation of an ADI. The human interventional studies had major deﬁciencies as explained in
Section 3.8.1. Therefore, evidence provided in the animal models has to be the basis for derivation of
the ADI.
In this respect, it is important to note that the effects on kidney are consistent between humans
and animals. The Panel considered which uncertainties factor would be appropriate and the
Panel decided that the data are sufﬁcient to derive and apply a chemical-speciﬁc adjustment factor for
phosphate instead of the default factor of 100. Whereas the term uncertainty factor is used when the
default value of 100 is used to convert the NOAEL into an ADI value, the term ‘adjustment factor’ is
appropriate in cases where a substance speciﬁc factor (here: phosphate speciﬁc factor) is derived and
used.
The default uncertainty factor of 100 is composed of a factor of 10 accounting for the interspecies
differences between test species and humans and a second factor of 10 accounting for the
interindividual differences in the human population. The two factors allow for interspecies differences
and human variability in TK differences and toxicodynamics (TD). For the TK component of the
interspecies factor, a value of 4 is then used when the extrapolation is made from the rat to the
human (EFSA SC 2012 guidance on default value reference). This factor of 4 is based on allometric
scaling from rat to humans. The remaining factor of 2.5 is attributed to the interspecies differences in
TD. The uncertainty factor for interindividual differences has been further subdivided into two factors
of 3.2 to allow to account for TK and TD differences. Whereas the factor of 10 describes the variability
in the human population well as can be taken from an analysis of variability of doses of drugs, the
subdivision into the two factors of 3.2 is not well supported by data.
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In 2005, the IPCS/WHO proposed a framework indicating how chemical-speciﬁc TK and/or TD data
can be used to replace the default factors or its subfactors. In line with the suggestions and following
the extended approach as described in the IPCS/WHO document (2014), the quantitative analysis of
the mode of action can aid to develop chemical-speciﬁc adjustment factors allowing for (interspecies
and interindividual differences in TK and TD processes and their applications in chemical risk
assessment has been recently reviewed (Bhat et al., 2017). The adverse effect of phosphate is due to
the physico-chemical properties of calcium phosphate, the solubility, which is a substance property and
is not species-speciﬁc. Hence, the TD part of the interspecies factor can be reduced to 1. With regard
to the ‘kinetic’ part of the interspecies factor the renal handling of phosphate has to be considered.
Phosphate is excreted by glomerular ﬁltration and tubular reabsorption occurs, in both rats and
humans. The solubility depends on the concentration of calcium phosphate which depends on the
phosphate dose and the volume of the urine.
A chemical-speciﬁc adjustment factor for phosphate for interspecies differences in TK: the
difference of the volume of the primary urine is the main determinant for the volume of urine in the
tubule where calcium phosphate precipitation occurs and can be calculated for rat and humans. The
estimated median primary volume is 4.4 L/kg bw per day  0.88 in the rat (Pestel et al., 2007) and
2.16 L/kg bw per day in man with a range of 1.60–2.8 L/kg bw per day (5th–95th percentile) in
healthy kidney donors (Poggio et al., 2009). The ratio of the median glomerular ﬁltration rate between
rat and human (4.4 L/kg per day divided by 2.16 L/kg bw per day) equals 2. A ratio of 2 between rat
and man results also from the volume of urine excreted from the bladder which is 67.8  16 mL/kg
bw per day in rats (Shevock et al., 1993) and 33.5 mL/kg bw per day in man (International
Commission on Radiological Protection (ICRP), 2002).
From these data, we derived a phosphate-speciﬁc adjustment factor allowing for interspecies
differences in TK of 2 giving phosphate-speciﬁc adjustment factors for interspecies differences of 2 (2
(TK) 9 1(TD)) (see Figure 2).
A chemical-speciﬁc adjustment factor for phosphate for interindividual differences in TK: the same
argument as for the TD interspecies subfactor is applicable for TD subfactor in humans which therefore
is 1. For TK processes, creatinine clearance reﬂects the physiology of renal ﬁltration of endogenous
substances and xenobiotics and the normal range of healthy clinical values for adults and elderly are
between 60 and 120 mL/min, with 90 mL/min often considered as the reference for creatinine
clearance. Taking the ratio between the mean creatinine clearance (90 mL/min) and the lower end of
the range (60 mL/min) gives a value of 1.5 (giving a ratio of 1.5 The Panel decided to increase this
factor allowing for interindividual differences in TK to a value of 2 to provide a conservative estimate
particularly to further take into consideration the healthy elderly population Hence, the phosphate
speciﬁc adjustment factor for interindividual differences in TK was set a value of 2.
The composite phosphate speciﬁc adjustment factor accounting for interspecies and interindividual
differences in TK and TD is then 2 9 2 = 4.
Figure 2: Comparison between default uncertainty factors and the chemical speciﬁc adjustment
factors for phosphate
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3.10.3. Minimum and maximum levels of phosphorus for infant formula (infants
below the age of 16 weeks) and for infant formula for special medical
purposes
For the age group of the infants below the age of 16 weeks, the special physiology of phosphate
has to be considered. As pointed out in the introduction part of Section 3.5 the plasma levels of
phosphate are twofold higher in the ﬁrst 6 months of life compared with the adult plasma level
indicating that the regulation of the plasma level is different in this age group compared to the adult
man.
By regulation, the minimum and maximum total levels of phosphorus for infant formula are set at
25 mg/100 kcal and 90 mg/100 kcal, in the case of infant formula based on soy the maximum level is
100 mg/100 kcal. The minimum and maximum levels for infant formula for special medical purposes
are set at 25 and 100 mg/100 kcal (Commission Delegated Regulation (EU) 2016/127 and Commission
Delegated Regulation (EU) 2016/128, as well as Commission Directive 2006/141/EC and Commission
Directive 1999/21/EC). These limits mean that at the high level consumption of 260 mL/kg bw per day
by infant formula and by FSMP for infants (as calculated by EFSA, 2017) the exposure would be
approximately between 44 and 175 mg/kg bw per day for phosphorus irrespective of whether
phosphorus is delivered from the formula as nutrient or as food additive.
4. Discussion
Phosphates are normal constituents in the body and are regular components of the diet; however,
no Tolerable Upper Intake Level (UL) (EFSA NDA Panel, 2005) has been established but in 2015 the
NDA Panel set Adequate Intakes (AIs) values for various age groups.
In the context of this opinion, the Panel was in the special situation to derive an ADI for a
substance which at the same time is a nutrient and a food additive. The ADI is the acceptable daily
intake of a substance by exposure to phosphates from all sources including those naturally occurring in
the diet, food additives and water.
4.1. Technical data
According to Commission Regulation (EU) No 231/2012, calcium dihydrogen phosphate (E 341(i)),
calcium hydrogen phosphate (E 341(ii)), tricalcium phosphate (E 341(iii)), dimagnesium phosphate
(E 343(ii)) and dicalcium dihydrogen diphosphate (E 450(vii)) are described as ‘insoluble in water’ or
‘sparingly soluble’. However, information from other sources indicates that tricalcium phosphate (E 341
(iii)) is soluble in water at 25C (2.5 mg/100 g H2O), and calcium dihydrogen phosphate (E 341(i)) is
soluble in dilute hydrochloric acid (US National Library of Medicine, https://pubchem.ncbi.nim.nih.gov).
Their solubilities in the gastrointestinal tract are not known especially given the presence of other
dissolved ions and differences in pH that may be encountered. Thus, insoluble particles of these
phosphate salts could theoretically be present within the gastrointestinal tract. It is conceivable that a
small proportion of these particles may be in the nanorange. Based on the information received on the
particle size of these phosphates, the Panel cannot exclude that particles in the nanorange can be
present in phosphates when used as a food additive and, therefore, identiﬁed the need for additional
information.
There are few validated ofﬁcial methods available for the determination of phosphates in foodstuffs
permitted to contain phosphate additives in the EU. Those identiﬁed to date are summarised with
standard methods listed by BVL (BVL, 2018) in Table 2. The scope of these methods covers ortho-,
condensed and polyphosphate analytes, and most foodstuffs and beverages apart from those for infants
(e.g. infant formula). The analytical techniques described in these methods are essentially limited to TLC
and/or spectrophotometry, except for IC which is speciﬁed for the analysis of soft drinks. Data provided
by CEFIC-PAPA provide evidence for the accuracy and precision requirements of standard methods for
phosphate determination. For example, the total phosphorus is calculated as g/100 g reported to two
signiﬁcant ﬁgures (Documentation provided to EFSA n. 11). The Panel therefore identiﬁed the need for
the development of analytical methods for phosphates in the range of foods permitted to contain them.
When considering the information submitted by the industry on the actual aluminium content in
infant formula (ﬁnal food), the Panel noted that the amount of aluminium may result in an exceedance
of the respective TWI.
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The Panel noted that the use of calcium phosphate (E 341), for which maximum limits for
aluminium have been set in the EU speciﬁcations, can contribute to the total aluminium content in
infant formula.
4.2. Kinetics
In humans, phosphorus deriving from food additives is mainly absorbed as free orthophosphate.
The amount of orthophosphate absorbed from food additives is about 80–90%. No metabolism takes
place and excretion is via the kidney through glomerular ﬁltration and tubular handling. Data are
available on the kinetics of disodium diphosphate, trisodium diphosphate, tetrasodium diphosphate and
tetrapotassium diphosphate but not on dicalcium diphosphate and calcium dihydrogen diphosphate.
In animal models, the kinetics of phosphate are generally the same as in humans.
4.3. Animal toxicity data
There is a large number of toxicity studies on phosphates primarily in rats and mice but also in
other species such as dogs, guinea pigs and hamsters
Data were not always available for all the authorised phosphates for all endpoints but the
Panel considered possible to perform read-across between different phosphate additives.
Most studies are not performed according to the current guidelines and standard (OECD). The
available data is however robust enough to be used to assess the safety of phosphates in animals and
for NOAEL estimation.
For certain phosphate species added to feed, the number of water molecules were not speciﬁed. In
these cases, the calculation of P content has been based on the anhydrous form.
It is clear from the available data that none of the phosphates are genotoxic in vitro or in vivo and
that they are not carcinogenic. Furthermore, they do not present any risk for reproductive or
developmental toxicity.
The only signiﬁcant adverse effect observed with phosphates in standard toxicity studies is related to
calciﬁcation of the kidneys and tubular nephropathy. These adverse effects are observed in acute, short-
term, subchronic and chronic toxicity studies and in all species tested. The underlying mechanism behind
these effects has been described in the mode of action (Section 3.9). As the renal effects are due
to excess phosphate load and not to a direct effect of the cation and since all phosphate additives
(E 338–341, E 343, E 450–542) are converted to orthophosphate, it is expected that all classes and
structures of the phosphate additives would produce the same critical effects at high doses. Therefore, a
single NOAEL can be established for all phosphates used as food additives. The NOAELs varied between
the studies and phosphates tested but the reason for this variation is probably primarily due to doses of
phosphates chosen and to spacing of the doses. Dietary factors, such as calcium and phosphate levels in
the diet, may also contribute to the variability. Information regarding phosphate and calcium levels in the
diets used are lacking in a most studies.
NOAELs and lowest-observed-adverse-effect-levels (LOAELs) could be identiﬁed from short-term,
subchronic and chronic toxicity studies in rats. In subchronic studies, the highest reliable NOAEL
relating to effects in the kidney was 500 mg/kg bw per day (corresponding to 116 mg P/kg bw per
day), derived from a 90-day rat study with tetrasodium diphosphates performed according to OECD
guidelines. The lowest phosphate level leading to effects on the kidney can be estimated to be
approximately 1,000 mg/kg bw per day (corresponding to 233 mg P/kg bw per day) in the same
study. In chronic toxicity studies, reliable NOAELs could be identiﬁed from two 2-year studies, 250 mg/
kg bw per day (corresponding to 63 mg P/kg bw per day) and 250 mg/kg bw per day (corresponding
to 76 mg P/kg bw per day) with sodium triphosphate (corresponding to pentasodium triphosphate)
and sodium hexametaphosphate (corresponding to soluble sodium polyphosphate), respectively. The
lowest level of phosphate causing an effect in the kidney was approximatively 750 mg/kg bw per day
(corresponding to 229 mg P/kg bw per day) in a 2-year study with sodium metaphosphate.
In conclusion, the only signiﬁcant adverse effect of phosphates in animals is nephrocalcinosis and
tubule-interstitial nephropathy. The onset and progression of these effects appears quite rapid and the
NOAELs and LOAELs for derived from subchronic and chronic studies are in the same range.
Although studies in animals report that high phosphorus intake causes bone reabsorption or
decreased bone formation, the Panel considered that effects observed on bone metabolism and bone
mineralisation in animals are not well characterised enough to derive an association with dietary high
phosphate intake.
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4.4. Epidemiology
The epidemiological studies reviewed here did not ﬁnd consistent associations between dietary
phosphorous intake and cardiovascular-related outcomes; all studies had important limitations such as
the lack of control for important confounding factors (e.g. diet and physical activity). In addition, the
use of food composition databases which might not include data on all phosphates used as food
additives might lead to underestimation of the total phosphate intake. A further limitation is the
considerable variability of phosphorus content in many foods depending on a number of factors such
as food seasonality (Poulsen et al., 2015) and bioavailability of phosphorous from different sources
(Karp et al., 2012). These factors make an accurate assessment of internal exposure from dietary
sources unreliable.
Moreover, a single-day dietary record is unlikely to be representative of usual individual intake,
especially for phosphorus. Multiple dietary records are necessary for assessing micronutrients. The
misclassiﬁcation of food intake can attenuate observed associations between intake and disease risk,
and therefore risk estimates are biased towards the null.
Most studies reviewed using serum phosphorus concentration as a measure for exposure found an
increase in risk for CVDs with high serum phosphorous concentrations (3.4–4.5 mg/dL). However, the
concentrations observed were generally within the reference range (2.7–4.5 mg/dL). It is however
important to be aware of the fact that serum phosphorus levels are inﬂuenced not only by diet but
also by various metabolic factors. Although Moore et al. (2015) suggested that serum phosphorous
concentrations are more sensitive to phosphate additives, the association between dietary intake and
serum phosphorous is weak (R2=0.03 in multivariable model including kidney function, BMI and
albumin-to-creatinine ratio). In contrast, serum phosphorous concentrations change considerably
throughout the day and follow a circadian rhythm (Ix et al., 2014), and these changes are affected by
diet in a non-dose-response way. For example, phosphorous supplementation can affect the 24-h
mean phosphorous concentration but it does not affect the serum concentration after an overnight fast
(Portale et al., 1987). Moreover, serum phosphorous cannot be used to distinguish between different
dietary phosphorous sources. Serum phosphorous concentration is therefore not a suitable surrogate
marker of phosphorous intake, but rather a marker of other physiological processes. In summary, the
results from epidemiological studies reviewed do not provide reliable information to assess the impact
of phosphorous on CVDs.
Only two epidemiological studies investigated the role of phosphate on bone health in the general
healthy population.
In the study of Tucker et al. (2006) the effect of phosphate on BMD was seen only in women, but
not in man, consuming cola-ﬂavoured carbonated beverages containing phosphate while in the study
of Campos-Obando et al. (2017) the effect of serum phosphorus on BMD was observed only in men
and for lumbar spine BMD but not femoral neck BMD. In the study of Campos-Obano that investigated
also the effect of serum phosphorus and incidence of fractures, an increased risk of fractures was
observed for both sexes, in a dose-response manner.
In summary, the results of these two studies do not provide sufﬁcient and reliable data to assess
the role of phosphate on bone health. More data on actual intake to assess the impact of phosphate
intake on bone density and fractures are needed.
Studies showing that high phosphates intake induces PTH elevation are available (see Vorland
et al., 2017). The studies were of short duration, mainly in young adults, and long-term studies
measuring fractures incidence or bone density changes are lacking.
4.5. Case reports and clinical data in humans
Several case reports indicate that a high acute single dose of phosphate (160 mg/kg bw and more)
can induce renal impairment.
Clinical interventional trials in which the doses were given on top of the normal diet were
performed over several months. No impairment of the renal function was reported with daily doses up
to 2,000 mg phosphorus (28.6 mg/kg per day) whereas doses of 4,800 mg/day (68.6 mg/kg per day)
elicited renal impairment. Histopathological examinations of human kidney specimens from exposed
patients showed similar ﬁndings as seen in animals. In several of the studies using phosphorus doses
up to 2,000 mg/day, the subjects had soft stools or diarrhoea which is not to be seen as adverse but
is classiﬁed as discomfort. However, when higher doses are given, such as the doses for bowel
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cleansing in preparation for colonoscopy (e.g. 11,600 mg per person or 165.7 mg/kg bw) these doses
acted as a cathartic agent and this effect has to be clearly seen as adverse.
In conclusion, in a chronic exposure setting the clinical data indicate that adverse effects on the
kidney have been reported in human at added phosphates doses threefold lower than that causing
adverse renal effects in animals.
4.6. Mode of action and discussion of uncertainty
The mode of action for the kidney impairment is precipitation of calcium phosphate which occurs in
the kidney, the only organ for phosphate excretion, when the solubility is exceeded. Thus, the
mechanism of action is related to a physicochemical property of calcium phosphate. From the
identiﬁed mechanism of action which is species independent and independent from individual factors,
the Panel derived a TD inter- and intraspecies factor of 1.
The maximum limit of solubility depends on the volume in which a certain amount of calcium
phosphate is dissolved. Concerning the solubility of calcium phosphate in the primary urine, the urinary
volume is relevant. The interspecies difference (rat vs man) in the volume of primary urine is 4.4 L/kg
bw per day in rat vs 2.16 L/kg bw per day in man (see Section 3.10.2) resulting in a factor of 2. In
other words, when a certain amount of phosphorus/kg bw per day would not exceed the solubility in
rat with a urine volume of twice that in humans, the daily dose in humans not exceeding the solubility
would be half of that amount.
For the variability of the urinary volume in humans, the Panel used information on the variability of
the glomerular ﬁltration rate in healthy subjects (between 60 and 120 mL/min). In order to account
for the potentially lower glomerular ﬁltration in subjects of the general population with a higher age
and slightly impaired renal function, the Panel decided to consider the lower level of glomerular
ﬁltration rate resulting in an intraspecies factor for TK to 2. In other words, when a certain amount of
phosphorus/kg bw per day which would not exceed the solubility in humans with a normal urine
volume, the daily dose in humans with slight to moderate renal impairment not exceeding the solubility
would be half of that amount.
Uncertainty:
(1) The ﬁrst aspect is the application of the read across approach. Phosphates have been
studied for all relevant endpoints required to assess the safety of a food additive. However,
toxicological studies do not exist for all salts of phosphates authorised as food additives
and the Panel applied a read across approach. Whereas no arguments point to the fact
that the endpoints for toxicity of the various phosphates would differ it has to be assumed
that the bioavailability and hence the dose for eliciting toxicity would differ with the
solubility of the salts. In this respect as the calcium salts are only sparingly soluble or even
insoluble in water, their bioavailability may be lower than that of other salts. Experimental
data directly comparing the bioavailability of the various phosphate salts are lacking.
However, the lowest phosphate dose leading to effects in the kidney in short-term studies with
monosodium phosphate dehydrate, the phosphorus dose is 123.8 mg/kg bw per day (Mars et al.,
1988). The corresponding dose of the mixture of calcium dihydrogen phosphate and monosodium
phosphate is 149.1 mg/kg bw per day. The comparison the two dose levels leading to effects on the
kidney shows that the dose of the water-soluble and hence highly bioavailable monosodium phosphate
dehydrate is only slightly lower (20%) than the dose of the sparingly soluble calcium dihydrogen
phosphate and the water-soluble monosodium phosphate as a mixture. This indicates that phosphate
is also available from calcium dihydrogen phosphate. The study from which the reference point is
derived was a study with sodium metaphosphate which is water-soluble. Hence, the selected reference
point overestimates the toxicity of the sparingly water-soluble and -insoluble calcium salts of
phosphate, the extent might be around 20%.
(2) The second aspect is the selection of the key toxicity endpoint. Calciﬁcations in the kidney
have been identiﬁed as the most relevant endpoint for phosphorus which is observed in
several species and also in man. Based on available data the selection of the key toxicity is
unlikely to contribute to the uncertainty.
(3) The third aspect is the selection of the NOAEL. The highest reliable NOAEL from the short-
term and subchronic studies was 500 mg/kg bw per day, corresponding to 116 mg/kg bw
per day phosphorus in a 90-day study (Seo et al., 2011). In chronic rat studies
Re-evaluation of the safety of phosphates (E 338–341, E 343, E 450–452)
www.efsa.europa.eu/efsajournal 88 EFSA Journal 2019;17(6):5674
calciﬁcations in the kidneys and tubular nephropathy was observed and the NOAELs of
250 mg/kg bw per day with sodium triphosphate (corresponding to pentasodium
triphosphate) (63 mg/kg be per day phosphorus) and 250 mg/kg bw per day sodium
hexametaphosphate (corresponding to soluble sodium polyphosphate) (76 mg/kg bw per
day phosphorus) were identiﬁed (Hodge, 1959, 1960).
(4) The forth aspect is the derivation of the chemical speciﬁc adjustment factor for phosphorus.
The derivation of the TD factor is based on the physicochemical property of the causing
agent, calcium phosphate and this is applicable to the situation in rat and in humans as
demonstrated by comparison of histopathology in both species. The TK interspecies factor of
2 is based on the species-speciﬁc different volumes of urine (see Section 3.10.2) and the TK
intraspecies factor was set at 2 (see Section 3.10.2). For the interspecies TK factor of 2, the
uncertainty could be estimated from the standard deviation of the measurements which
would result in values between 1.44 and 2.85 indicating a relatively low uncertainty in the
estimate of 2. The intraspecies TK factor was estimated from a study in healthy subjects and
resulted in a factor of 1.5. The Panel decided to enlarge this factor to 2 to reduce the
uncertainty in the extrapolation from the healthy subjects to the general population. The
resulting total compound speciﬁc adjustment factor is then 4.
Considering all aspects which have to be discussed to characterise the uncertainty surrounding the
ADI it can be stated that the uncertainty is low although a ﬁrm numerical number for the magnitude of
the uncertainties cannot be given.
An ADI did not exist until now, and in 1982, JECFA concluded that the allocation of an ADI was not
appropriate for phosphates ‘as phosphorus is an essential nutrient and unavoidable constituent of food’
(JECFA, 1982a). Therefore, JECFA assigned a ‘maximum tolerable daily intake’ (MTDI) of 70 mg/kg bw
per day (expressed as phosphorus) for the sum of phosphates and polyphosphates, both naturally
present in food and ingested as food additives. The rationale for the MTDI was that ‘The lowest level of
phosphate that produced nephrocalcinosis in rat (1% P in the diet) is used as the basis for the evaluation
and, by extrapolation based on the daily food intake of 2,800 calories, gives a dose level of 6,600 mg P
per day as the best estimate of the lowest level that might conceivably cause nephrocalcinosis in man’. In
the evaluation, JECFA justiﬁed not to apply a safety factor with the argument that phosphorous was also
a nutrient.
The solubility of calcium phosphate was identiﬁed as the relevant mechanism of action causing
nephrocalcinosis in animals and man. In contrast to JECFA the Panel identiﬁed the urinary volume as
relevant biological difference between rat and humans which inﬂuences the solubility of calcium
phosphate. Taking also into account the variability of the urinary volume expressed as glomerular
ﬁltration rate in the human population the Panel derived a chemical speciﬁc adjustment factor of 4 for
phosphorus.
4.7. Derivation of the ADI
In the context of this opinion, the Panel was in the special situation to derive an ADI for a
substance which at the same time is a nutrient and a food additive. The ADI is the acceptable daily
intake of a substance and includes exposure by food additives in addition to the exposure to the
substance naturally occurring in the diet.
As explained in the discussion above the derivation of the ADI for phosphorus has to be based on
the results of studies in animals. Three studies, one subchronic study and two chronic studies are
available from which NOAELs could be derived. In the two chronic studies, the NOAELs were 63 mg/kg
P bw per day and 76 mg/kg P bw per day (Hodge, 1959, 1960). However, the content of phosphorus
in the background diet could not be identiﬁed. In the subchronic 90-day rat study performed according
to OECD guidelines the NOAEL was 116 mg/kg bw per day phosphorus (Seo et al., 2011). The content
of phosphorus in the diet could be retrieved (personal communication, Cargill Agri Purina Korea, 29
January 2019) and was calculated to result in a daily intake of 91 mg P/kg bw per day.
The Panel noted that the most appropriate reference point for derivation the ADI would be a
NOAEL from a chronic study. Among the present two chronic studies, the higher NOAEL of 76 mg P/kg
bw per day has been selected. Considering that ADI includes exposure by food additives in addition to
the substance naturally occurring in the diet, the content of the phosphorus in the animal diet has to
be taken into account. The Panel considered the content of phosphorus retrieved for Seo et al. study
as an appropriate estimate of a standard animal diet which is also in conformity with phosphorus
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content in laboratory animal diets from different sources (Ritskes-Hoitinga et al., 1991; Nutrient
Requirements of Laboratory Animals, 1995).
Adding the dietary P of 91 mg/kg bw per day to the NOAEL of 76 mg P/kg bw per day gives a value
of 167 mg P/kg bw per day. To this value, the chemical-speciﬁc adjustment factor for phosphate of 4 is
to be applied resulting in an ADI value of 42 mg/kg bw per day, rounded to 40 mg/kg bw per day.
The Panel noted that this ADI would be the same if derived from the 90-day study. Since this is a
subchronic study an adjustment factor of 2 should be applied (EFSA guidance 2012) resulting in a
NOAEL of 58 mg P/kg bw per day. Adding the dietary P of 91 mg/kg bw per day to the adjusted
NOAEL of 58 mg P/kg bw per day gives a value of 149 mg P/kg bw per day. Following the application
of the phosphorus-speciﬁc adjustment factor of 4, this would result in an ADI of 37 mg/kg bw per day.
The Panel noted that the ADI of 40 mg P/bw per day does not apply to humans with moderate to
severe reduction in renal function since the adjustment factor for intraspecies variability covers only
individual with slight renal impairment.
The EFSA NDA Panel has not set an upper level for phosphorus but a ‘safety’ level of intake. The
ADI of 40 mg/kg bw per day would result in an intake level of 2,800 mg P per person per day for a
70 kg adult person which is within the limits of the safety intake level of 3,000 mg P/person per day
set by the EFSA NDA Panel (2005).
The newly derived ADI value for P compares well with consumption data from epidemiological
studies. The mean dietary consumption was 1,373 mg phosphorus per day in adult subjects in the
NHANES studies 2001 to 2014, the mean intake of phosphorus in adults from the diet alone was
1,725 mg/day with a P95 intake of 2,855 mg/day in a recent Norwegian survey (VKM Report 2017:
18) and the highest phosphorus dietary intake in the epidemiological studies reviewed (see
Appendix S) was 3,600 mg/day. In contrast, the MTDI of JECFA (1982a) of 70 mg phosphorus/kg bw
per day (equally to 4,900 mg phosphorus per adult person per day, assuming 70 kg body weight) is
higher that the exposure reported in the cited epidemiological studies.
4.8. Exposure assessment
Phosphates (E 338–341, E 343, E 450–452) are authorised for 108 different uses (corresponding to
65 different food categories) according to Annex II to Regulation (EC) No 1333/2008 and data were
received for most of the uses in which the food additives are authorised to be added.
To assess the dietary exposure to phosphates (E 338–341, E 343, E 450–452) from their uses as
food additives, the exposure was calculated based on two different sets of concentration data: (1)
MPLs as set down in the EU legislation (deﬁned as the regulatory maximum level exposure assessment
scenario); and (2) reported use levels (deﬁned as the reﬁned exposure assessment scenario).
While analytical data were used to consider the exposure to phosphorus from all dietary sources.
As mentioned above, in the context of this opinion, the Panel was in the special situation to assess
the safety of food additives, phosphate salts, which are also nutrients. The Panel based its assessment
on the toxicity of phosphorus (phosphate moiety). Since the ADI encompasses the phosphorus intake
from natural sources and from food additives sources, the usual exposure assessment using the
reported use levels of the food additives was not appropriate to characterise the risk linked to the
exposure to phosphorus and the exposure assessment was based on analytical data of the total
phosphorus content of foods. In other contexts, the evaluation of the adverse effects of nutrients
serve as a basis to set ULs (EFSA NDA Panel, 2006). The Panel noted the lack of a harmonised
procedure to assess the safety and set HBGVs for substances that are at the same time food additives
and nutrients. The Panel considered that there is a need for developing a general approach to be
followed in the case a food additive is also a nutrient.
Based on the reported use levels, the Panel calculated two reﬁned exposure estimates based on
different assumptions as described in Section 3.4.1: a brand-loyal consumer scenario and a non-brand-
loyal scenario. The Panel considered that the reﬁned exposure assessment approach resulted in more
realistic long-term exposure estimates compared to the regulatory maximum level exposure
assessment scenario.
The exposure estimates in the regulatory maximum level exposure assessment scenario were
between 12 and 113 mg P/kg bw per day at the mean and between 21 and 196 mg P/kg bw per day
at the 95th percentile for all population groups (Table 5b). The Panel noted that the estimated long-
term exposures based on this scenario are very likely conservative, as this scenario assumes that all
foods and beverages listed under the Annex II to Regulation No 1333/2008 contain phosphates
(E 338–341, E 343, E 450–452) as food additives at the MPL.
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Considering the reﬁned brand-loyal exposure assessment scenario, estimated exposure to
phosphates (E 338–341, E 343, E 450–452) was between 2 and 53 mg P/kg bw per day at the mean
and between 9 and 69 mg P/kg bw per day at the 95th percentile for all population groups.
For the reﬁned non-brand-loyal exposure assessment scenario, estimated exposure to phosphates
(E 338–341, E 343, E 450–452) ranged between 1 and 48 mg P/kg bw per day at the mean and
between 3 and 62 mg P/kg bw per day at the 95th percentile for all population groups (Table 5b).
The Panel considered that for the main food category (bread and rolls) contributing to the exposure
estimates, brand-loyalty would not be expected and therefore selected the reﬁned non-brand loyal
scenario as the most relevant exposure scenario for the safety evaluation of phosphates (E 338–341,
E 343, E 450–452) for toddlers, children, adolescents, adults and the elderly. Dietary exposure to
phosphates (E 338–341, E 343, E 450–452) according to this exposure scenario was maximally 11 mg/kg
bw per day at the mean level and 26 mg/kg bw per day at the high (P95) level. For infants, infant formulae
were the main contributing food category, and the brand-loyal scenario should be considered.
For the food supplements consumers only, mean exposure to phosphates (E 338–341, E 343, E
450–452) from their uses as food additives ranged from 275 mg P/person per day for children to
1,541 mg P/person per day for the elderly. The 95th percentile of exposure to phosphates (E 338–341,
E 343, E 450–452) ranged from 753 mg P/person per day for adolescents to 7,292 mg P/person per
day for adults. The Panel noted the high levels for food supplements compared to therapeutic use (see
Section 3.8.1). According to data providers, in a number of cases, the phosphates are added
principally as nutrient substance and not as additives. However, in other cases, the addition of
phosphates (e.g. higher reported use levels) is due to their technical requirements as food additives
rather than an intended use as nutrient sources. The Panel noted the high intakes resulting from such
levels and the potential risk for people who might consume food supplements regularly.
The Panel calculated that out of the foods authorised to contain phosphates (E 338–341, E 343,
E 450–452) according to Annex II to Regulation (EC) No 1333/2008, a minimum of 30 (for children) to
a maximum of 93% (for infants) of the amount of food consumed (by weight) per population group
was reported to potentially contain phosphates (E 338–341, E 343, E 450–452) as food additives.
The exposure assessments were inﬂuenced by several uncertainties (Table 9). The Panel noted that
most of Mintel subcategories were included in the current exposure assessment (missing food
categories are alcoholic beverages, some vegetables, see Section 3.3.2). The percentage of foods per
subcategory labelled to contain phosphates (E 338–341, E 343, E 450–452) was on average of 9.6%
whereas in the assessment, it was assumed that 100% of the foods belonging to an authorised food
category contained the additive. The Panel noted that an exposure assessment based on the premise
that all of the foods contain phosphates would probably lead to an overestimation of the dietary
exposure which represents the largest uncertainty.
Overall, the Panel considered that the uncertainties identiﬁed would, in general, result in an
overestimation of the exposure to phosphates (E 338–341, E 343, E 450–452) from their use as food
additives according to Annex II in European countries considered in the EFSA European database for the
regulatory maximum level exposure scenario. For the reﬁned estimated exposure scenario, uncertainties
would also lead to an overestimation of exposure to phosphates (E 338–341, E 343, E 450–452).
The Panel also noted that the reﬁned exposure estimates are based on information provided on the
reported level of use of phosphates (E 338–341, E 343, E 450–452). If actual practice changes, these
reﬁned estimates may no longer be representative and should be updated.
Scenarios based on uses and use levels estimating exposure including the proposed extension of
use were performed. The proposed extension of use did not show any change in the total estimated
exposure probably because the proposed change in the authorised use of the FC 05.2 does not add a
large number of foods compared to the current authorisation.
Exposure to phosphates from the whole diet was estimated using mainly analytical data (estimated
exposure scenario based on analytical data). Not all available data could be included in the assessment
but most of the foods consumed were taken into account in this estimate.
In this scenario, the exposure exceeds the ADI of 40 mg/kg bw per day in infants from 12 weeks
to 11 months, toddlers and children both at the mean and high level. In adolescents, the high level is
also exceeding the ADI of 40 mg/kg bw per day.
Both estimates using reported use levels and analytical data are limited by several uncertainties
described in exposure section. Although caveats related to these estimates, exposure from food
additives for all population groups except infants would indicatively contribute between 6 and 21% of
the total mean intakes. For infants from 12 weeks to 11 months, the percentages would range
between 12 and 30%.
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To compare the estimated exposure scenario based on analytical data, with the exposure published
in other opinions and surveys the mean exposure to phosphorus was calculated as the exposure per
person per day and compared to exposure data from surveys. The values ranged from 254 mg P/
person per day in infants to 1,625 mg P/person per day for adults, and the high exposure (95th
percentile) from 331 mg P/person per day in infants to 2,728 mg P/person per day for adults.
Exposure estimates of phosphorus using the same methodology (consumption data from national
dietary surveys and levels of phosphorus in food from analytical measurement) was also performed in
the NDA Panel opinion (EFSA NDA Panel, 2015). Intake estimates from the 2015 opinion and the
current estimates are very much similar per population groups. Foods in both opinion are not classiﬁed
under the same categories but food categories contributing the most to the mean exposure are also
the same: milk and dairy products, grains and grain-based products and meat and meat products in
EFSA, 2015; unﬂavoured pasteurised and sterilised (including UHT) milk, bread and rolls and meat
products for EFSA, 2018 (this opinion).
The high level of exposure to phosphorus coming from food supplements is reﬂected also in the
dietary exposure in the food supplements consumers only scenario using analytical data.
Direct comparison of exposure based on analytical data with exposure reported in the
epidemiological studies is not readily achieved due to differences in methodologies applied. Whereas
comparison between such data is indicative only, the exposure levels are reasonably similar.
4.9. Infants and young children
By regulation, the minimum and maximum total levels of phosphorus for infant formula are set at
25 and 90 mg/100 kcal, in the case of infant formula based on soy the maximum level is 100 mg/
100 kcal. The minimum and maximum levels for infant formula for special medical purposes are set at
25 and 100 mg/100 kcal (Commission Delegated Regulation (EU) 2016/127 and Commission
Delegated Regulation (EU) 2016/128, as well as Commission Directive 2006/141/EC and Commission
Directive 1999/21/EC). These limits mean that at the high level consumption of 260 mL/kg bw per day
by infant formula and by FSMP for infants (as calculated by EFSA, 2017), the exposure would be
approximately between 44 and 175 mg/kg bw per day for phosphorus irrespective of whether
phosphorus is delivered from the formula as nutrient or as food additive. Given the limits set by
existing regulation, it seems not appropriate to use the ADI set for food additives only for infants
formulae, nor is necessary to derive a numerical ADI applicable for this age group.
5. Conclusions
Considering the overall database relevant for phosphoric acid–phosphates – di-, tri- and
polyphosphates, the Panel derived a group ADI for phosphates expressed as phosphorus of 40 mg/kg
bw per day from a chronic study. This ADI corresponds to an acceptable intake of phosphorus of
2,800 mg/day for an adult of 70 kg. This is within the level of 3,000 mg/day indicated by the EFSA
NDA Panel (2005) as being tolerated by healthy individuals.
The Panel considers that the group ADI of 40 mg/kg bw per day, expressed as phosphorus, is
protective for healthy adults because it is below the doses at which clinically relevant adverse effects
were reported in short-term and long-term studies in humans. However, this ADI does not apply to
humans with moderate to severe reduction in renal function. Ten per cent of general population might
have CKD with reduced renal function and they may not tolerate the amount of P per day which is at
the level of ADI. The total phosphorus content of foods (naturally occurring and added as additives) is
not mandatory to be reported on food labels.
The Panel noted that the exposure estimates based on analytical data exceeded the proposed ADI
for infants, toddlers and children at the mean level and for infants, toddlers, children and adolescents
at the 95th percentile. The Panel also noted that P exposure from food supplements exceeds the
proposed ADI.
The Panel concluded that the available data did not give rise to safety concerns in infants below
16 weeks of age consuming formula and food for medical purposes. When receiving data on the
content of contaminants in formula, the Panel noted that the high aluminium content may exceed the
TWI.
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6. Recommendations
The Panel recommends that:
• The EC considers setting numerical Maximum Permitted Level for phosphates as food additives
in food supplements.
• The European Commission considers revising the current limits for toxic elements (Pb, Cd, As
and Hg) in the EU speciﬁcations for phosphates (E 338–341, E 343, E 450–452) in order to
ensure that phosphates (E 338–341, E 343, E 450–452) as a food additive will not be a
signiﬁcant source of exposure to those toxic elements in food.
• The European Commission considers revising the current limit for aluminium in the EU
speciﬁcations for the use of calcium phosphate (E 341).
• The European Commission to consider revising the current EU speciﬁcations for calcium
dihydrogen phosphate (E 341(i)), calcium hydrogen phosphate (E 341(ii)), tricalcium phosphate
(E 341(iii)), dimagnesium phosphate (E 343(ii)) and calcium dihydrogen diphosphate
(E 450(vii)) to include characterisation of particle size distribution using appropriate statistical
descriptors (e.g. range, median, quartiles) as well as the percentage (in number and by mass)
of particles in the nanoscale (with at least one dimension < 100 nm) present in calcium
dihydrogen phosphate (E 341(i)), calcium hydrogen phosphate (E 341(ii)), tricalcium phosphate
(E 341(iii)), dimagnesium phosphate (E 343(ii)) and calcium dihydrogen diphosphate
(E 450(vii)) used as a food additive. The measuring methodology applied should comply with
the EFSA Guidance document (EFSA Scientiﬁc Committee, 2018).
• The development of analytical methods for the determination of phosphate additives in the
range of foods and beverages permitted to contain them should be considered.
• The EFSA Scientiﬁc Committee reviews current approaches to the setting of HBGVs for
regulated substances which are also nutrients to assess if a coherent harmonised strategy for
such risk assessments should be devised.
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AAC aortic annulus calciﬁcation
ABI ankle brachial index
ACR Albumin-to-creatinine ratio
ADEPALE Association des Entreprises Produits Alimentaires Elabores
ADI acceptable daily intake
AF atrial ﬁbrillation
AI adequate intake
AIPCE-CEP European Fish Processors and Traders Association & European Federation of
National Organisations of Importers and Exporters of Fish
ALP alkaline phosphatase
ALT alanine aminotransferase
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AMP adenosine monophosphate
ANS EFSA Panel on Food Additives and Nutrient Sources
AOAC Association of Ofﬁcial Analytical Chemists
ARIC Atherosclerosis Risk in Communities study
AST aspartate aminotransferase
ATP adenosine triphosphate
AVC aortic valve calciﬁcation
BMD bone mineral density
BMI body mass index
BP blood pressure
BVL German Federal Ofﬁce for Consumer Protection and Safety
bw body weight
CAC coronary artery calciﬁcation
CAD coronary artery disease
cAMP adenosine monophosphate
CARDIA Coronary Artery Risk Development in Young Adults
CAS Chemical Abstract Service
CE capillary electrophoresis
CEFIC European Chemical Industry Council
CEFS Comite Europeen des Fabricants de Sucre
cGMP cyclic guanine monophosphate
CHD coronary heart disease
CI conﬁdence interval
CIR Cosmetic Ingredient Review Expert Panel
cITP capillary isotachophoresis
CKD chronic kidney disease
CRF corticotropin-releasing factor
CTP cytidine triphosphate
CVD cardiovascular disease
CZE capillary zone electrophoresis
DCP direct current plasma spectrometry
DLS dynamic light scattering
Dn number-based
DRV Dietary Reference Value
Dv volume-based
DXA dual X-ray absorptiometry
ECF extracellular ﬂuid
ECHA European Chemicals Agency
EDA European Dairy Association
eGFR estimated glomerular ﬁltration rate
EINECS European Inventory of Existing Commercial chemical Substances
EUPPA European Potato Processors’ Association
EVM Expert Group on Vitamins and Minerals
F1 ﬁrst-generation pups
F2 second-generation pups
FAF Food Additives and Flavourings
FAP phosphates as food additives
FC food category
FCS food categorisation system
FDA US Food and Drug Administration
FDE Food Drink Europe
FDRL Food and Drink Research Laboratories
FGF-23 ﬁbroblast growth factor 23
FFQ food frequency questionnaires
FSE Food Supplement Europe
FSMP food for special medical purposes
GD gestation days
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GLP Good Laboratory Practice
GNPD Global New Products Database
GTP guanosine-5’-triphosphate
HBGV health-based guidance value
HCT hychlorothiazide
HDL high-density lipoprotein
HF heart failure
HPLC high-performance liquid chromatography
HR hazard ratio
HRT hormone replace therapy
HTA Hypertonia arterialis
IC ion chromatography
ICD International Classiﬁcation of Diseases
ICGA International Chewing Gum Association
IMT intima-media thickness
IPCS International Program on Chemical Safety
IQR Interquartile Range
IUCLID International Uniform Chemical Information Database
JECFA Joint FAO/WHO Expert Committee on Food Additives
KCl Potassium chloride
LC left-censored
LD50 lethal dose, 50%, i.e. dose that causes death among 50 % of treated animals
LDL low-density lipoprotein
LOAEL lowest-observed-adverse-effect-level
LOD limit of detection
LOQ limit of quantiﬁcation
LVM left ventricular mass
MB middle-bound
MESA Multi-Ethnic study of Atherosclerosis
MI myocardial infarction
MPL maximum permitted level
MTDI maximum tolerable daily intake
NDA Nutrition, Novel Food and Food Allergens
NHANES III Third National Health and Nutrition Examination Survey
NMR nuclear magnetic resonance
NOAEL no-observable-adverse-effect level
NOEL no-observed-effect level
NOS Newcastle–Ottawa Scale
OECD Organisation for Economic Co-operation and Development
OPG osteoprotegerin
P phosphorus
Pi inorganic phosphorus
P1 ﬁrst-generation adults
P2 second-generation adults
P3 third-generation adults
PAPA Phosphoric Acid and Phosphates Producers Association
PTH parathyroid hormone
QICKD Quality Improvement in Chronic Kidney Disease
QS quantum satis
RANK receptor activator of NF-kB ligand
REACH Registration, Evaluation, Authorisation and restriction of CHemicals
RNA ribonucleic acid
SCF Scientiﬁc Committee for Food
SDP plasma spectrometry
SEM scanning electron microscopy
sFRP-4 secreted frizzled-related protein 4
SNE Specialised Nutrition Europe
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TCA trichloroacetic acid
TD toxicodynamics
TEM transmission electron microscopy
TemaNord Nordic Council of Ministers
TIA Transient Ischemic Attack
TK toxicokinetics
TLC thin-layer chromatography
TmP tubular maximum for P
TWI tolerable weekly intake
UHT Ultra High Temperature
UL upper level
UTP uridine-5’-triphosphate
UV ultraviolet
VKM Norwegian Scientiﬁc Committee for Food Safety
WHO World Health Organization
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Appendix A – Summary of range of phosphates functional classes according to JECFA
E No. Phosphate name Acidulant Sequestrant
Synergist
antioxidant
Emulsiﬁer
Emulsion
stabiliser
Texturiser Buffer(1)
Neutralising
agent
Raising
agent(2)
Firming
agent
Anti
caking
agent
338 Phosphoric acid + + +
339(i) Monosodium + +
339(ii) Disodium + + +
339(iii) Trisodium + + +
340(i) Monopotassium + + + +
340(ii) Dipotassium + + +
340(iii) Tripotassium + + +
341(i) Monocalcium + + + +
341(ii) Dicalcium + + +
341(iii) Tricalcium +
343(i) Monomagnesium +
343(ii) Dimagnesium
450(i) Disodium di + + +
450(ii) Trisodium di + + +
450(iii) Tetrasodium di + + +
450(v) Tetrapotassium di + +
450(vi) Dicalcium di + + +
450(vii) Calcium dihydrogen + + +
450(ix) Magnesium
dihydrogen
+ + +
451(i) Pentasodium tri + +
451(ii) Pentapotassium tri +
452(i) Sodium poly + + +
452(ii) Potassium poly + + +
452(iii) Sodium calcium poly + + +
452(iv) Calcium poly + + +
(1): Including acidity regulator.
(2): Including leavening agent/dough conditioner/yeast food.
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Appendix B – Table for converting phosphates into phosphorus pentoxide (P2O5) and phosphorus (P)
E number Formula MW 1 g substance = g P2O5 1 g P2O5 = g P
E 338 H3PO4 98.00 0.724 0.315
E 339(i) NaH2PO4 119.98 0.592 0.258
“ NaH2PO4, H2O 138.00 0.514 0.224
“ NaH2PO4, 2H2O 156.01 0.455 0.198
E 339(ii) Na2HPO4 141.96 0.500 0.218
“ Na2HPO4, 2H2O 177.99 0.399 0.174
“ Na2HPO4, 7H2O 268.06 0.265 0.115
“ Na2HPO4, 12H2O 358.14 0.198 0.086
E 339(iii) Na3PO4 163.94 0.433 0.188
“ Na3PO4, 2H2O 181.96 0.390 0.170
“ Na3PO4, 12H2O 380.12 0.187 0.081
E 340(i) KH2PO4 136.09 0.522 0.227
E 340(ii) K2H2PO4 174.17 0.407 0.177
E 340(iii) K3PO4 212.28 0.334 0.145
E 341(i) Ca(H2PO4)2 234.05 0.606 0.264
E 341(ii) CaH2PO4, 2H2O 172.09 0.412 0.179
E 341(iii) 10CaO, 3P2O5, H2O 1,004.67 0.424 0.185
E 343(i) Mg(H2PO4)2, 4H2O 290.34 0.489 0.213
E 343(ii) MgHPO4, n H2O (n = 0–3) 120.28* 0.590 0.257
E450(i) Na2H2P2O7 221.94 0.640 0.279
E450(ii) Na3HP2O7 243.92 0.582 0.253
“ Na3HP2O7, H2O 261.94 0.542 0.236
E 450(iii) Na4P2O7 265.90 0.534 0.233
“ Na4P2O7, 10H2O 446.05 0.318 0.138
E 450(v) K4P2O7 330.34 0.430 0.187
“ K4P2O7, 3H2O 383.39 0.369 0.161
E 450(vi) Ca2P2O7 254.10 0.559 0.243
E 450(vii) CaH2P2O7 216.04 0.657 0.286
E 451(i) Na5P3O10 367.86 0.579 0.252
“ Na5P3O10, 6H2O 475.95 0.447 0.195
E 451(ii) K5P3O10 448.41 0.475 0.207
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E number Formula MW 1 g substance = g P2O5 1 g P2O5 = g P
E 452(i) (NaPO3)n (n > 3) 102*n 0.696*n 0.303*n
E 452(ii) (KPO3)n 118*n 0.601*n 0.262*n
E 452(iv) (CaP2O6)n (n ≥ 2) 198*n 0.717*n 0.312*n
*: Anhydrous form.
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Appendix C – The link between phosphates and cardiovascular diseases:
epidemiology search protocol
Objective
To assess, if any, the association between phosphates/phosphorus intake and cardiovascular
diseases and serum phosphorus level and cardiovascular diseases, including cardiovascular speciﬁc
mortality.
To assess, if any, the association between phosphates/phosphorus intake and stroke and serum
phosphorus level and stroke, including stroke speciﬁc mortality.
To assess, if any, the association between phosphates intake and serum phosphorus levels and
intermediate outcomes of cardiovascular events, such as coronary artery calciﬁcation.
To assess, if any, the association between phosphate-responsive hormones (ﬁbroblast growth
factor-23, parathyroid hormone) and cardiovascular diseases and/or stroke.
Methods
Types of studies and participants
Observational studies (cohort, case–control and cross-sectional studies) will be included, that
investigated the association between: phosphates in diet and/or serum phosphorus and cardiovascular
diseases; phosphates in diet and/or serum phosphorus and stroke; phosphates in diet and/or serum
phosphorus and cardiovascular speciﬁc mortality; phosphates in diet and/or serum phosphorus and
stroke speciﬁc mortality; phosphates in diet and serum phosphorus levels and intermediate outcomes
of cardiovascular events such as coronary artery calciﬁcation; phosphate-responsive hormones
(ﬁbroblast growth factor-23, parathyroid hormone) and cardiovascular events.
Study participants will be adults of either sex or age. Studies that evaluated phosphates/
phosphorus from other sources other than diet (medicine, environmental/occupational exposure) will
be excluded. Studies that were included in the EFSA report (2013) that are considered informative will
be also included in the report.
Types of outcome measures to be included
Primary outcome:
Incidence of cardiovascular diseases and incidence of stroke.
Secondary outcome:
(i) Intermediate outcomes for cardiovascular diseases and cardiovascular mortality.
(ii) Phosphate-responsive hormones (ﬁbroblast growth factor-23, parathyroid hormone and
calcitriol) and cardiovascular events.
Search Strategy and Data Extraction
Electronic searches
Relevant studies were located by searching PubMed. PRISMA ﬂow diagram (Moher et al., 2009)
helped managing search strategy and data extraction.
((“phosphates”[MeSH Terms] OR “phosphates”[All Fields] OR “phosphate”[All Fields]) AND intake
[All Fields]) AND (“cardiovascular system”[MeSH Terms] OR (“cardiovascular”[All Fields] AND
“system”[All Fields]) OR “cardiovascular system”[All Fields] OR “cardiovascular”[All Fields]) AND
(“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR “epidemiology”[MeSH Terms])
AND
((“phosphorus”[MeSH Terms] OR “phosphorus”[All Fields] OR “phosphorus”[All Fields]) AND intake
[All Fields]) AND (“cardiovascular system”[MeSH Terms] OR (“cardiovascular”[All Fields] AND
“system”[All Fields]) OR “cardiovascular system”[All Fields] OR “cardiovascular”[All Fields]) AND
(“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR “epidemiology”[MeSH Terms])
AND
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND (“atherosclerosis”[MeSH Terms] OR
“atherosclerosis”[All Fields] OR “atherogenesis”[All Fields]) AND (“cohort studies”[MeSH Terms] OR
(“cohort”[All Fields] AND “studies”[All Fields]) OR “cohort studies”[All Fields] OR “cohort”[All Fields])
AND
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(“phosphorus, dietary”[MeSH Terms] OR (“phosphorus”[All Fields] AND “dietary”[All Fields]) OR
“dietary phosphorus”[All Fields] OR “phosphorus”[All Fields] OR “phosphorus”[MeSH Terms]) AND
(“atherosclerosis”[MeSH Terms] OR “atherosclerosis”[All Fields] OR “atherogenesis”[All Fields]) AND
(“cohort studies”[MeSH Terms] OR (“cohort”[All Fields] AND “studies”[All Fields]) OR “cohort
studies”[All Fields] OR “cohort”[All Fields])
AND
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND (“atherosclerosis”[MeSH Terms] OR
“atherosclerosis”[All Fields] OR “atherogenesis”[All Fields]) AND (“case-control studies”[MeSH Terms]
OR (“case-control”[All Fields] AND “studies”[All Fields]) OR “case-control studies”[All Fields] OR
(“case”[All Fields] AND “control”[All Fields]) OR “case control”[All Fields])
AND
(“phosphorus, dietary”[MeSH Terms] OR (“phosphorus”[All Fields] AND “dietary”[All Fields]) OR
“dietary phosphorus”[All Fields] OR “phosphorus”[All Fields] OR “phosphorus”[MeSH Terms]) AND
(“atherosclerosis”[MeSH Terms] OR “atherosclerosis”[All Fields] OR “atherogenesis”[All Fields]) AND
(“case-control studies”[MeSH Terms] OR (“case-control”[All Fields] AND “studies”[All Fields]) OR “case-
control studies”[All Fields] OR (“case”[All Fields] AND “control”[All Fields]) OR “case control”[All Fields])
AND
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND (“cardiovascular system”[MeSH
Terms] OR (“cardiovascular”[All Fields] AND “system”[All Fields]) OR “cardiovascular system”[All Fields]
OR “cardiovascular”[All Fields]) AND (“case-control studies”[MeSH Terms] OR (“case-control”[All Fields]
AND “studies”[All Fields]) OR “case-control studies”[All Fields] OR (“case”[All Fields] AND “control”[All
Fields] AND “studies”[All Fields]) OR “case control studies”[All Fields])
AND
(“parathyroid hormone”[MeSH Terms] OR (“parathyroid”[All Fields] AND “hormone”[All Fields]) OR
“parathyroid hormone”[All Fields]) AND (“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND
(“cardiovascular system”[MeSH Terms] OR (“cardiovascular”[All Fields] AND “system”[All Fields]) OR
“cardiovascular system”[All Fields] OR “cardiovascular”[All Fields]) AND (“cohort studies”[MeSH Terms]
OR (“cohort”[All Fields] AND “studies”[All Fields]) OR “cohort studies”[All Fields] OR “cohort”[All
Fields])
AND
(“parathyroid hormone”[MeSH Terms] OR (“parathyroid”[All Fields] AND “hormone”[All Fields]) OR
“parathyroid hormone”[All Fields]) AND (“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND
(“cardiovascular system”[MeSH Terms] OR (“cardiovascular”[All Fields] AND “system”[All Fields]) OR
“cardiovascular system”[All Fields] OR “cardiovascular”[All Fields]) AND (“case-control studies”[MeSH
Terms] OR (“case-control”[All Fields] AND “studies”[All Fields]) OR “case-control studies”[All Fields] OR
(“case”[All Fields] AND “control”[All Fields]) OR “case control”[All Fields])
AND
(“ﬁbroblast growth factors”[MeSH Terms] OR (“ﬁbroblast”[All Fields] AND “growth”[All Fields] AND
“factors”[All Fields]) OR “ﬁbroblast growth factors”[All Fields] OR (“ﬁbroblast”[All Fields] AND
“growth”[All Fields] AND “factor”[All Fields]) OR “ﬁbroblast growth factor”[All Fields]) AND
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND (“cardiovascular system”[MeSH Terms]
OR (“cardiovascular”[All Fields] AND “system”[All Fields]) OR “cardiovascular system”[All Fields] OR
“cardiovascular”[All Fields]) AND (“cohort studies”[MeSH Terms] OR (“cohort”[All Fields] AND
“studies”[All Fields]) OR “cohort studies”[All Fields] OR “cohort”[All Fields])
AND
(“ﬁbroblast growth factors”[MeSH Terms] OR (“ﬁbroblast”[All Fields] AND “growth”[All Fields] AND
“factors”[All Fields]) OR “ﬁbroblast growth factors”[All Fields] OR (“ﬁbroblast”[All Fields] AND
“growth”[All Fields] AND “factor”[All Fields]) OR “ﬁbroblast growth factor”[All Fields]) AND
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND (“cardiovascular system”[MeSH Terms]
OR (“cardiovascular”[All Fields] AND “system”[All Fields]) OR “cardiovascular system”[All Fields] OR
“cardiovascular”[All Fields]) AND (“case-control studies”[MeSH Terms] OR (“case-control”[All Fields]
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AND “studies”[All Fields]) OR “case-control studies”[All Fields] OR (“case”[All Fields] AND “control”[All
Fields]) OR “case control”[All Fields])
No language restriction was applied. Previous review articles will be hand searched for other
relevant studies.
Study selection, data extraction and assessment of methodology quality (bias)
Working Group experts in epidemiology will identify potential studies to be added in the draft
review provided by EFSA. These experts will screen the full-texts and identify studies for inclusion and
identify and record reasons for exclusion of the ineligible studies. Disagreement will be solved through
discussion or, if required, the working group will be consulted. Duplicate records will be identiﬁed and
excluded and multiple reports that relate to the same study will collated so that each study rather than
each report is the unit of interest in the evaluation.
Sources of bias in observational studies can be due to the study design and analytic methods.
Using statistical adjustments in the models or matching procedures, may decrease the risk of bias,
which can increase conﬁdence in the results. The Newcastle–Ottawa Scale (NOS) will be used as a
guideline for describing and interpreting studies. The latter scale for judging the quality of the studies
will be used if a meta-analysis is envisaged, as recommended by the Cochrane Collaboration (Higgins
et al., 2008). This scale uses a star system to assess the quality of a study in three domains: selection,
comparability and outcome (cohort studies) or exposure (case–control studies). The NOS assigns a
maximum of four stars for selection, two stars for comparability and three stars for exposure/outcome.
Therefore, nine stars reﬂect the highest quality. Any discrepancies will be addressed by a joint re-
evaluation of the original article by the epidemiology group. Studies in which mortality/and
intermediate outcomes are the outcome will be given a different weight. Cross-sectional studies are of
limited value in assessing whether there is a true exposure-outcome relationship, nonetheless they will
be described in the opinion for completeness.
The following items will be included while describing each study:
1) Type of study (case–control/cohort/cross-sectional)
2) Characteristics of the population and setting (e.g. age, sex, sample size, sources and
methods of selection of participants, eligibility criteria, methods of case ascertainment and
control selection, matching criteria and the number of controls per case)
3) Objective of the study
4) Exposure (e.g. type of dietary questionnaire and mode of assessment)
5) Type of outcome (incidence/mortality/intermediate outcomes)
6) Number of cases identiﬁed during the follow-up (cohort)
7) Time of follow-up and number of lost to follow-up
8) Results of the main ﬁndings:
8.1) ORs or hazard ratios, with their 95% conﬁdence intervals and p for trend if present
and cut-off values associated with the risk of cardiovascular diseases and/or stroke
and/or intermediate outcomes and/or cardiovascular and/or stroke mortality
8.2) Confounding factors considered by the authors (main risk factors for the speciﬁc
outcomes) and included in the multivariate analysis (e.g. age, sex, socioeconomic
status and/or education, smoking, BMI, calcium, alcohol, vitamin D, total energy
intake)
9) Subgroup analysis if conducted (e.g. sex and factors that may potentially affect
phosphorus’ metabolism such as renal dysfunction)
10) Strength and limitation of each study.
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Appendix D – The link between phosphates, bone metabolism and
osteoporosis: epidemiology search protocol
Search 1
Database Coverage Access
Embase Inception-present www.embase.com
Pubmed Inception-present www.ncbi.nlm.nih.gov/pubmed
Search strategies
Embase
No. Query
#13 #11 NOT #12
#12 ‘osteoporosis’/exp OR osteoporosis:ti,ab
#11 #10 AND ([english]/lim OR [german]/lim)
#10 #8 NOT #9
#9 (‘animal’/exp OR ‘nonhuman’/exp) NOT ‘human’/exp
#8 #1 AND #7
#7 #2 OR #3 OR #4 OR #5 OR #6
#6 (broken NEAR/5 bone*):ti,ab
#5 fracture*:ti,ab OR bmc:ti,ab OR bmd:ti,ab
#4 bone*:ti,ab AND mineral:ti,ab AND concentration:ti,ab
#3 (bone* NEAR/5 (content OR densit* OR health OR mass OR volume OR loss* OR metabolism OR
mineral* OR disease*)):ti,ab
#2 ‘bone health’/exp OR ‘bone density’/exp OR ‘bone disease’/de OR ‘bone mass’/exp OR ‘bone mineral’/
exp OR ‘fracture’/exp OR ‘bone metabolism’/exp
#1 ‘phosphate’/exp AND ‘dietary intake’/de OR (((phosphate OR phosphates) NEAR/15 intak*):ti,ab)
PubMed
No. Query
#13 #11 NOT #12
#12 ‘osteoporosis’/exp OR osteoporosis:ti,ab
#11 #10 AND ([english]/lim OR [german]/lim)
#10 #8 NOT #9
#9 (‘animal’/exp OR ‘nonhuman’/exp) NOT ‘human’/exp
#8 #1 AND #7
#7 #2 OR #3 OR #4 OR #5 OR #6
#6 (broken NEAR/5 bone*):ti,ab
#5 fracture*:ti,ab OR bmc:ti,ab OR bmd:ti,ab
#4 bone*:ti,ab AND mineral:ti,ab AND concentration:ti,ab
#3 (bone* NEAR/5 (content OR densit* OR health OR mass OR volume OR loss* OR metabolism OR
mineral* OR disease*)):ti,ab
#2 ‘bone health’/exp OR ‘bone density’/exp OR ‘bone disease’/de OR ‘bone mass’/exp OR ‘bone mineral’/
exp OR ‘fracture’/exp OR ‘bone metabolism’/exp
#1 ‘phosphate’/exp AND ‘dietary intake’/de OR (((phosphate OR phosphates) NEAR/15 intak*):ti,ab)
Search 2
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND ((“fractures, bone”[MeSH Terms] OR
(“fractures”[All Fields] AND “bone”[All Fields]) OR “bone fractures”[All Fields] OR “fractures”[All Fields])
AND (“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR “epidemiology”[MeSH Terms]))
(“phosphates”[MeSH Terms] OR “phosphates”[All Fields]) AND ((“fractures, bone”[MeSH Terms] OR
(“fractures”[All Fields] AND “bone”[All Fields]) OR “bone fractures”[All Fields] OR “fracture”[All Fields])
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AND (“cohort studies”[MeSH Terms] OR (“cohort”[All Fields] AND “studies”[All Fields]) OR “cohort
studies”[All Fields] OR “cohort”[All Fields]))
((“phosphorus, dietary”[MeSH Terms] OR (“phosphorus”[All Fields] AND “dietary”[All Fields]) OR
“dietary phosphorus”[All Fields] OR “phosphorus”[All Fields] OR “phosphorus”[MeSH Terms]) AND
intake[All Fields]) AND ((“fractures, bone”[MeSH Terms] OR (“fractures”[All Fields] AND “bone”[All
Fields]) OR “bone fractures”[All Fields] OR “fracture”[All Fields]) AND (“cohort studies”[MeSH Terms]
OR (“cohort”[All Fields] AND “studies”[All Fields]) OR “cohort studies”[All Fields] OR “cohort”[All
Fields]))
(“phosphorus, dietary”[MeSH Terms] OR (“phosphorus”[All Fields] AND “dietary”[All Fields]) OR
“dietary phosphorus”[All Fields] OR “phosphorus”[All Fields] OR “phosphorus”[MeSH Terms]) AND
(“fractures, bone”[MeSH Terms] OR (“fractures”[All Fields] AND “bone”[All Fields]) OR “bone
fractures”[All Fields] OR “fractures”[All Fields]) AND (“case-control studies”[MeSH Terms] OR (“case-
control”[All Fields] AND “studies”[All Fields]) OR “case-control studies”[All Fields] OR (“case”[All Fields]
AND “control”[All Fields] AND “study”[All Fields]) OR “case control study”[All Fields])
Phosphate [All Fields] AND (“fractures, bone”[MeSH Terms] OR (“fractures”[All Fields] AND
“bone”[All Fields]) OR “bone fractures”[All Fields] OR “fractures”[All Fields]) AND (“case-control
studies”[MeSH Terms] OR (“case-control”[All Fields] AND “studies”[All Fields]) OR “case-control
studies”[All Fields] OR (“case”[All Fields] AND “control”[All Fields] AND “study”[All Fields]) OR “case
control study”[All Fields])
(“phosphoric acid”[Supplementary Concept] OR “phosphoric acid”[All Fields] OR “phosphoric
acids”[MeSH Terms] OR (“phosphoric”[All Fields] AND “acids”[All Fields]) OR “phosphoric acids”[All
Fields] OR (“phosphoric”[All Fields] AND “acid”[All Fields])) AND (“fractures, bone”[MeSH Terms] OR
(“fractures”[All Fields] AND “bone”[All Fields]) OR “bone fractures”[All Fields] OR “fractures”[All Fields])
AND (“cohort studies”[MeSH Terms] OR (“cohort”[All Fields] AND “studies”[All Fields]) OR “cohort
studies”[All Fields] OR “cohort”[All Fields])
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Appendix E – Identity of the substances and speciﬁcations
Phosphoric acid
According to Commission Regulation (EU) No 231/2012, the food additive E 338 is identiﬁed as
Chemical name: Phosphoric acid
EINECS Number: 231-633-2
Chemical formula: H3PO4
Molecular weight: 98.00
Physical description: Clear, colourless, odourless, viscous liquid
CAS number: 7664-38-20
Solubility: Miscible with water and with ethanol
Phosphoric acid has a melting point of 42.4°C and a boiling point of 407°C (CRC, 2012a). Regarding
acidity, the dissociation constants are pKa1 2.12, pKa2 7.21 and pKa3 12.67 (EFSA-FEEDAP-Panel,
2013). The partition coefﬁcient (log p value) is 1.644  0.350 (at a temperature of 25°C) (Calculated
using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994–2013 ACD/Labs)
(SciFinder, 2013a).
Synonyms include: Orthophosphoric acid and monophosphoric acid.
Monosodium phosphate
According to Commission Regulation (EU) No 231/201220), the food additive E 339(i) is identiﬁed as
Chemical name: Sodium dihydrogen monophosphate
EINECS Number: 231-449-2
Chemical formula: NaH2PO4 (anhydrous form), NaH2PO4 ∙ H2O (monohydrate form) or NaH2PO4 ∙ 2H2O
(dehydrate form)
Molecular weight: 119.98 (anhydrous form), 138.00 (monohydrate form) or 156.01 (dehydrate form)
Physical description: White odourless, slightly deliquescent powder, crystals or granules
CAS number: 7558-80-7
Solubility: Freely soluble in water and insoluble in ethanol or ether
Monosodium phosphate (anhydrous) has a melting point of 200°C, at which temperature it
decomposes (CRC, 2012a).
No information on log p value has been retrieved.
Synonyms include: Monosodium monophosphate; acid monosodium monophosphate; monosodium
orthophosphate; monobasic sodium phosphate and sodium dihydrogen monophosphate.
Disodium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 339(ii) is identiﬁed as
Chemical name: Disodium hydrogen monophosphate and disodium hydrogen orthophosphate
EINECS Number: 231-448-7
Chemical formula: Na2H2PO4 (anhydrous form), Na2H2PO4 ∙ nH2O (n = 2,7 or 12) (hydrates form)
Molecular weight: 141.98 (anhydrous form)
Physical description: Anhydrous disodium phosphate occurs as a white, hygroscopic, odourless
powder. The dihydrate occurs as a white crystalline, odourless solid. The heptahydrate occurs as white,
odourless, efﬂorescent crystals or granular powder. The dodecahydrate occurs as a white, efﬂorescent,
odourless powder or crystals
CAS number: 7558-79-4
Solubility: Disodium phosphate is freely soluble in water and insoluble in ethanol
No information on melting point or log p value has been retrieved.
Synonyms include: Disodiummonophosphate; secondary sodium phosphate; disodium orthophosphate;
dibasic sodium phosphate and disodium acid phosphate.
Trisodium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 339(iii) is identiﬁed as
Chemical name: Trisodium monophosphate, trisodium phosphate and trisodium orthophosphate
EINECS Number: 231-509-8
20 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down speciﬁcations for food additives listed in Annexes II
and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p. 1–295.
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Chemical formula: Na3PO4 (anhydrous form), Na3PO4 ∙ nH2O (n = 1/2,1,6,8 or 12) (hydrates form)
Molecular weight: 163.94 (anhydrous form)
Physical description: White odourless crystals, granules or a crystalline powder
CAS number: 7601-54-9
Solubility|: Freely soluble in water and insoluble in ethanol
Trisodium phosphate (anhydrous) has a melting point of 1,583°C (CRC, 2012b).
No information on log p value has been retrieved.
Synonyms include: Tribasic sodium phosphate and sodium phosphate.
Monopotassium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 340(i) is identiﬁed as
Chemical name: Potassium dihydrogen phosphate, monopotassium dihydrogen orthophosphate and
monopotassium dihydrogen monophosphate
EINECS Number: 231-913-4
Chemical formula: KH2PO4
Molecular weight: 136.09
Physical description: Odourless, colourless crystals or a white granular or crystalline powder
CAS number: 7778-77-0
Solubility: Freely soluble in water and insoluble in ethanol
Monopotassium phosphate has a melting point of 253°C (CRC, 2012e; SciFinder, 2013c).
No information on log p value has been retrieved.
Synonyms include: Monobasic potassium phosphate; monopotassium monophosphate and mono
potassium orthophosphate.
Dipotassium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 340(ii) is identiﬁed as
Chemical name: Dipotassium hydrogen monophosphate, dipotassium hydrogen phosphate and
dipotassium hydrogen orthophosphate
EINECS Number: 231-834-5
Chemical formula: K2HPO4
Molecular weight: 174.18
Physical description: Colourless or white granular powder, crystals or masses and is a deliquescent
and hygroscopic substance
CAS number: 7758-11-4
Solubility: Freely soluble in water and insoluble in ethanol
Dipotassium phosphate has a melting point of 151.5–154.0°C where it decomposes (CRC, 2012c).
No information on log p value has been retrieved.
Synonyms include: Dipotassium monophosphate; secondary potassium phosphate; dipotassium
orthophospahte and dibasic potassium phosphate.
Tripotassium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 340(i) is identiﬁed as
Chemical name: Tripotassiummonophosphate, tripotassium phosphate and tripotassium orthophosphate
EINECS Number: 231-907-1
Chemical formula: K3PO4 (anhydrous form), K3PO4 ∙ nH2O (n = 1 or 3) (hydrates form)
Molecular weight: 212.27 (anhydrous form)
Physical description: Colourless or white, odourless hygroscopic crystals or granules
CAS number: 7778-53-2
Solubility: Freely soluble in water and insoluble in ethanol
Tripotassium phosphate (anhydrous) has a melting point of 1,340°C (CRC, 2012d).
No information on log p value has been retrieved.
Synonyms include: Tribasic potassium phosphate; potassium phosphate and tripotassium
orthophosphate.
Calcium dihydrogen phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 341 (i) is identiﬁed as
Chemical name: Calcium dihydrogen phosphate
EINECS Number: 231-837-1
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Chemical formula: Ca(H2PO4)2 anhydrous or Ca(H2PO4)2 ∙ H2O monohydrate
Molecular weight: Anhydrous 234.05; monohydrate 252.07
Physical description: Hygroscopic white crystals or granules or granular powder
CAS number: anhydrous 7758-23-8; monohydrate 10031-30-8
Solubility: Sparingly soluble in water, insoluble in ethanol
Calcium dihydrogen phosphate monohydrate has a melting point of 100°C where it decomposes
(CRC, 2012d).
No information on log p value has been retrieved.
Synonyms include: Monobasic calcium phosphate; monocalcium orthophosphate; monocalcium
phosphate; calcium biphosphate and acid calcium phosphate.
Calcium hydrogen phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 341(ii) is identiﬁed as
Chemical name: Calcium monohydrogen phosphate, calcium hydrogen orthophosphate and
secondary calcium phosphate
EINECS Number: 231-826-1
Chemical formula: CaHPO4 anhydrous or Ca(HPO4) ∙ 2H2O dihydrate
Molecular weight: anhydrous 136.06; dihydrate 172.09
Physical description: Hygroscopic white crystals or granules or granular powder
CAS number: anhydrous 7757-9309
Solubility: Sparingly soluble in water, insoluble in ethanol
No information on melting point or log p value has been retrieved.
Synonyms include: Dibasic calcium phosphate and dicalcium phosphate
Tricalcium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 341(iii) is identiﬁed as
Chemical name: Pentacalcium hydroxy monophosphate and tricalcium monophosphate
EINECS Number: 235-330-6
Chemical formula: Ca5(PO4)3 ∙ OH or Ca3(PO4)2
Molecular weight: 502 Ca5(PO4)3; 310 Ca3(PO4)2
Physical description: White, odourless powder which is stable in air
CAS number: 7758-87-4
Solubility: Practically insoluble in water; insoluble in ethanol, soluble in dilute hydrochloric and nitric acid
Tricalcium phosphate has a melting point of 1,670°C (CRC, 2012c; SciFinder, 2013b).
No information on log p value has been retrieved.
Synonyms include: Calcium phosphate, tribasic; calcium orthophosphate; pentacalcium hydroxy
monophosphate and calcium hydroxyapatite.
Monomagnesium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 343(i) is identiﬁed as
Chemical name: Monomagnesium dihydrogen monophosphate
EINECS Number: 236-004-6
Chemical formula: Mg(H2PO4)2 ∙ nH2O (n = 0–4)
Molecular weight: 218.3 (anhydrous), 254.3 (dihydrate), 290.3 (tetrahydrate)
Physical description: White, odourless, crystalline powder
CAS number: 13092-66-5 (anhydrous),15609-87-7 (dehydrate)
Solubility: Slightly soluble in water
No information on melting point or log p value has been retrieved.
Synonyms include: Magnesium dihydrogen phosphate; magnesium phosphate, monobasic;
monomagnesium orthophosphate.
Dimagnesium phosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 343(ii) is identiﬁed as
Chemical name: dimagnesium monohydrogen monophosphate
EINECS Number: 231-823-5
Chemical formula: MgHPO4 ∙ nH2O (n = 0–3)
Molecular weight: 120.30 (anhydrous)
Physical description: white, odourless, crystalline powder
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CAS number: 7757-86-0
Solubility: Slightly soluble in water, soluble in dilute acids, but insoluble in ethanol
Dimagnesium phosphate has a melting point of 550°C where it decomposes (CRC, 2012b).
No information on log p value has been retrieved.
Synonyms include: Magnesium hydrogen phosphate; magnesium phosphate, dibasic; dimagnesium
orthophosphate and secondary magnesium phosphate.
Disodium diphosphate
According to Commission Regulation (EU) No 231/201220), the food additive E 450(i) is identiﬁed as
Chemical name: Disodium dihydrogen diphosphate
EINECS Number: 231-972-6
Chemical formula: Na2H2P2O7
Molecular weight: 221.94
Physical description: White powder or grains
CAS number: 7758-16-9
Solubility: Soluble in water
The melting point is reported as > 450°C (Haynes, 2010).
Synonyms include: disodium dihydrogen diphosphate, disodium pyrophosphate, disodium
dihydrogen pyrophosphate and acid sodium pyrophosphate.
Trisodium diphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 450(ii) is identiﬁed as
Chemical name:
EINECS Number: 238-735-6
Chemical formula: Na3HP2O7 (anhydrous form) or Na3HP2O7 ∙ H2O (monohydrate form)
Molecular weight: 243.93 (anhydrous form), 261.95 (monohydrate form)
Physical description: White powder or grains
CAS number: 14691-80-6 (anhydrous form), 26573-04-6 (monohydrate form)
Solubility: Soluble in water
Synonyms include: trisodium monohydrogen diphosphate, trisodium monohydrogen pyrophosphate,
trisodium hydrogen phosphate, trisodium pyrophosphate and acid trisodium pyrophosphate.
Tetrasodium diphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 450(iii) is identiﬁed as
Chemical name: Tetrasodium phosphate
EINECS Number: 231-767-1
Chemical formula: Na4P2O7 (anhydrous form) or Na4P2O7 ∙ 10H2O (decahydrate form)
Molecular weight: 265.94 (anhydrous form), 446.09 (decahydrate form)
Physical description: Colourless or white crystals or a white crystalline or granular powder
CAS number: 7722-88-5
Solubility: Soluble in water
The melting point is reported as 988°C (Haynes, 2010).
Synonyms include: include tetrasodium pyrophosphate, tetrasodium disphosphate, tetrasodium
phosphate and sodium pyrophosphate.
Tetrapotassium diphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 450(v) is identiﬁed as
Chemical name: Tetrapotassium diphosphate
EINECS Number: 230-785-7
Chemical formula: K4P2O7
Molecular weight: 330.34 (anhydrous form)
Physical description: Colourless crystals or a white, very hygroscopic powder
CAS number: 7320-34-5
Solubility: Soluble in water
The substance is reported to decompose at 1,300°C (Haynes, 2010).
Synonyms include: Tetrapotassium pyrophosphate, potassium pyrophosphate and tetrapotassium
salt of diphosphoric acid.
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Dicalcium diphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 450(vi) is identiﬁed as
Chemical name: Dicalcium diphosphate, dicalcium pyrophosphate
EINECS Number: 232-221-5
Chemical formula: Ca2P2O7
Molecular weight: 254.12
Physical description: Fine, white, odourless powder
CAS number: 7790-76-3
Solubility: Insoluble in water
Synonyms include: Calcium pyrophosphate and dicalcium pyrophosphate.
Calcium dihydrogen diphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 450(vii) is identiﬁed as
Chemical name: Calcium dihydrogen diphosphate
EINECS Number: 238-933-3
Chemical formula: CaH2P2O7
Molecular weight: 215.97
Physical description: White crystals or powder
CAS number: 14866-19-4
Solubility: Not speciﬁed in Commission Regulation (EU) No 231/2012
Synonyms include: Acid calcium pyrophosphate, monocalcium dihydrogen pyrophosphate, calcium
dihydrogen pyrophosphate andmonocalcium dihydrogen diphosphate.
Magnesium dihydrogen diphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 450(ix) is identiﬁed as
Chemical name: Monomagnesium dihydrogen diphosphate
EINECS Number: 244-016-8
Chemical formula: MgH2P2O7
Molecular weight: 200.25
Physical description: White crystals or powder
CAS number: 13446-24-7
Solubility: Slightly soluble in water, practically insoluble in ethanol
Synonyms include: Acid magnesium pyrophosphate, monomagnesium dihydrogen pyrophosphate;
magnesium diphosphate, magnesium pyrophosphate.
Pentasodium triphosphate
According to Commission Regulation (EU) No 231/201220), the food additive E 451(i) is identiﬁed as
Chemical name: Pentasodium triphosphate
EINECS Number: 231-838-7
Chemical formula: Na5P3O10 ∙ nH2O (n = 0 or 6)
Molecular weight: 367.86 (anhydrous form), 475.94 (hexahydrate form)
Physical description: White, slightly hygroscopic granules or powder
CAS number: 7758-29-4
Solubility: Freely soluble in water and insoluble in ethanol
The melting point is reported as 622°C (Haynes, 2010).
Synonyms include: pentasodium tripolyphosphate and sodium tripolyphosphate.
Pentapotassium triphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 451(ii) is identiﬁed as
Chemical name: Pentapotassium triphosphate, pentapotassium tripolyphosphate
EINECS Number: 237-574-9
Chemical formula: K5P3O10
Molecular weight: 448.82
Physical description: White, very hygroscopic powder or granules
CAS number: 13845-36-8
Solubility: Very soluble in water
Synonyms include: potassium triphosphate and potassium tripolyphosphate.
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Sodium polyphosphate
According to Commission Regulation (EU) No 231/201220), the food additive E 452(i) is identiﬁed as
Chemical name: Sodium polyphosphate
Commission Regulation (EU) No 231/2012 is laying down speciﬁcations for E 452(i), in two forms.
Soluble sodium polyphosphate
EINECS Number: 272-808-3
Chemical formula: H(n+2)PnO(3n+1) where ‘n’ is not less than 2
Molecular weight: (102)n
Physical description: Colourless or white, transparent platelets, granules or powders
CAS number: 68915-31-1, 10124-56-8 and 10362-03-2
Solubility: Very soluble in water
Synonyms include: sodium hexametaphosphate; sodium tetrapolyphosphate; Graham’s salt; sodium
polyphosphates, glassy; sodium polymetaphosphate; sodium metaphosphate.
Soluble sodium polyphosphate is described in Commission Regulation (EU) No 231/2012 as follows:
‘Soluble sodium polyphosphates are obtained by fusion and subsequent chilling of sodium
orthophosphates. These compounds are a class consisting of several amorphous, water-soluble
polyphosphates composed of linear chains of metaphosphate units, (NaPO3)x where x ≥ 2, terminated
by Na2PO4 groups. These substances are usually identiﬁed by their Na2O/P2O5 ratio or their P2O5
content. The Na2O/P2O5 ratios vary from about 1.3 for sodium tetrapolyphosphate, where
x = approximately 4; to about 1.1 for Graham’s salt, commonly called sodium hexametaphosphate,
where x = 13 to 18; and to about 1.0 for the higher molecular weight sodium polyphosphates, where
x = 20 to 100 or more. The pH of their solutions varies from 3.0 to 9.0’.
JECFA speciﬁcation describes the chain structure as ‘metaphosphate units, (NaPO3)x where x = 2’;
this is at odds with this point in the deﬁnition above and also with the comments in JECFA on the
composition of various forms, which are the same as those in the deﬁnition above.
The REACH Registration Dossier on sodium metaphosphate (REACH Registration Dossier, online)
submitted to the European Chemicals Agency (ECHA) includes a melting point of > 723 K, and a
solubility of 54.8–59.7% (w/w).
Insoluble sodium polyphosphate
EINECS Number: 272-808-3
Chemical formula: H(n+2)PnO(3n+1) where ‘n’ is not less than 2
Molecular weight: (102)n
Physical description: A white crystalline powder
CAS number: No CAS registry number is included in Commission Regulation (EU) No 231/2012 for
this form
Solubility: Insoluble in water, soluble in mineral acids and in solutions of potassium and ammonium
(but not sodium) chlorides
Synonyms include: Insoluble sodium metaphosphate; Maddrell’s salt; insoluble sodium polyphosphate;
IMP
This form of sodium polyphosphate is not included in the JECFA speciﬁcations.
Potassium polyphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 452 (ii) is identiﬁed as
Chemical name: Potassium polyphosphate
EINECS Number: 232-212-6
Chemical formula: (KPO3)n
Molecular weight: (102)n
Physical description: Fine white powder or crystals or colourless glassy platelets
CAS number: 7790-53-6
Synonyms include: One gram dissolves in 100 mL of a 1 in 25 solution of sodium acetate
Synonyms include: Include potassium metaphosphate, potassium polymetaphosphate and Kurrol
salt.
Re-evaluation of the safety of phosphates (E 338–341, E 343, E 450–452)
www.efsa.europa.eu/efsajournal 123 EFSA Journal 2019;17(6):5674
Sodium calcium polyphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 452 (iii) is identiﬁed as
Chemical name: sodium calcium polyphosphate
EINECS Number: 233-782-921
Chemical formula: (NaPO3)n CaO where n is typically 5
Molecular weight: No molecular weight is included in Commission Regulation (EU) No 231/2012 and
in JECFA speciﬁcations
Physical description: White glassy crystals or spheres
CAS number: No CAS registry number is included in either Commission Regulation (EU) No 231/2012
or the JECFA speciﬁcations for this substance.
Solubility: Not included in either Commission Regulation (EU) No 231/2012 or the JECFA
speciﬁcations for this substance
Synonyms include: Sodium calcium polyphosphate, glassy.
Calcium polyphosphate
According to Commission Regulation (EU) No 231/2012, the food additive E 452 (iv) is identiﬁed as
Chemical name: calcium polyphosphate
EINECS Number: 236-769-6
Chemical formula: (CaP2O6)n
Molecular weight: (198)n
Physical description: Odourless, colourless crystals or white powder
CAS number: No CAS registry number is included in either Commission Regulation (EU) No 231/2012
or the JECFA speciﬁcations for this substance, entering the EINECS number in the ESIS database and
the ECHA public database gives a CAS registry number of 13477-39-9
Solubility: Usually sparingly soluble in water, soluble in acid medium
Synonyms include: Calcium metaphosphate and calcium polymetaphosphate.
The speciﬁcations for phosphoric acid (E 338), monocalcium phosphate (E 341(i)), dicalcium phosphate
(E 341(ii)), tricalcium phosphate (E 341(iii)), monomagnesium phosphate (E 343(i)), dimagnesium
phosphate (E 343(ii)) monosodium phosphate (E 339(i)), disodium phosphate (E 339(ii)), trisodium
phosphate (E 339(iii)), monopotassium phosphate (E 340(i)), dipotassium phosphate (E 340(ii)),
tripotassium phosphate (E 340(iii)), disodium diphosphate (E 450(i)), trisodium diphosphate (E 450(ii)),
tetrasodium diphosphate (E 450(iii)), tetrapotassium diphosphate (E 450(v)), dicalcium diphosphate
(E 450(vi)), calcium dihydrogen diphosphate (E 450(vii)), pentasodium triphosphate (E 451(i)),
pentapotassium triphosphate (E 451(ii)), sodium polyphosphate (E 452(i)), potassium polyphosphate
(E 452(ii)), sodium calcium polyphosphate (E 452(iii)) and calcium polyphosphate (E 452(iv)) as deﬁned in
the Commission Regulation (EU) No 231/2012 and by JECFA are listed in Tables E.1–E.26.
21 There is a lack of clarity in relation to the EINECS number. Entering 233-782-9 into the ESIS database or the ECHA public
database returns the substance sodium metaphosphate with a CAS registry number 10361-03-2; this name and number are
included under sodium polyphosphate I: soluble polyphosphate in Commission Regulation (EU) No 231/2012 and the number
is included in the JECFA speciﬁcation for INS No. 452(i). The same name and/or CAS registry number are associated with
EINECS number 233-782-9 on some chemical supplier web-sites, for example Guidechem (http://www.guidechem.com/products/
10361-03-2.html), Carlo Erba (http://www.carloerbareagenti.com/Repository/DIR199/CH1213_GB.pdf).
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Table E.1: Speciﬁcations for phosphoric acid (E 338) according to Commission Regulation (EU)
No 231/2012 and JECFA (2002)
Commission Regulation (EU) No 231/2012 JECFA (2002)
Deﬁnition Phosphoric acid Phosphoric acid, orthophosphoric acid
Assay Content not less than 67.0% and not more than
85.7%. Phosphoric acid is commercially
available as an aqueous solution at variable
concentrations
Not less than 75% and not less than the
minimum or within the range of percent
claimed by the vendor
Description Clear, colourless, viscous liquid Clear, colourless, odourless, viscous liquid
Identiﬁcation Test for acid: Passes test
Test for phosphate: Passes test
Solubility: Miscible with water and with ethanol
Test for acid: Strongly acid, even at high
dilution
Test for phosphate: Neutralise a few millilitres
of phosphoric acid and add dilute nitric acid
TS. Then, add an equal volume of ammonium
molybdate TS and warm. A bright canary-
yellow precipitate is obtained which is soluble
in dilute ammonia TS
Purity(a) Volatile acids: not more than 10 mg/kg (as
acetic acid)
Chlorides: not more than 200 mg/kg (expressed
as chlorine)
Nitrates: not more than 5 mg/kg (as NaNO3)
Sulfates: not more than 1,500 mg/kg (as
CaSO4)
Fluoride: not more than 10 mg/kg (expressed
as ﬂuorine)
Arsenic: not more than 1 mg/kg
Cadmium: not more than 1 mg/kg
Lead: not more than 1 mg/kg
Mercury: not more than 1 mg/kg
Nitrates: not more than 5 mg/kg
Volatile acids: not more than 10 mg/kg as
acetic acid
Chlorides (Vol. 4): not more than 200 mg/kg
as chlorine
Sulfates (Vol. 4): not more than 0.15%
Fluoride (Vol. 4): not more than 10 mg/kg
Arsenic (Vol. 4): not more than 3 mg/kg
Lead (Vol. 4): not more than 4 mg/kg
(a): This speciﬁcation refers to a 75% aqueous solution.
Table E.2: Speciﬁcations for monosodium phosphate (E 339(i)) according to Commission Regulation
(EU) No 231/2012 and JECFA (2006b,c,d,e,f)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay After drying at 60°C for 1 h and then at
105°C for 4 h, contains not less than 97%
of NaH2PO4
P2O5 content between 58.0% and 60.0%
on the anhydrous basis
Not less than 97% after drying
Description A white odourless, slightly deliquescent
powder, crystals or granules
White odourless, slightly deliquescent powder,
crystals, or granules
Identiﬁcation
Test for sodium Passes test Passes test
Test for
phosphate
Passes test Passes test
Solubility Freely soluble in water. Insoluble in
ethanol or ether
Freely soluble in water; insoluble in ethanol,
ether or chloroform
pH Between 4.1 and 5.0 (1% solution) 4.2–4.6 (1 in 100 solution)
Test for
orthophosphate
– To a 1% solution of the sample add silver
nitrate TS; the yellow precipitate formed is
soluble in dilute nitric acid TS
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Table E.3: Speciﬁcations established for disodium phosphate (E 339(ii)) according to Commission
Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay After drying at 40°C for 3 h and
subsequently at 105°C for 5 h, contains not
less than 98% of Na2HPO4
P2O5 content between 49% and 51% on
the anhydrous basis
Not less than 98.0% after drying
Description Anhydrous disodium hydrogen phosphate is
a white, hygroscopic, odourless powder.
Hydrated forms available include the
dihydrate: a white crystalline, odourless
solid; the heptahydrate: white, odourless,
efﬂorescent crystals or granular powder;
and the dodecahydrate: white, efﬂorescent,
odourless powder or crystals
Anhydrous: White, hygroscopic, odourless
powder
Dihydrate: White crystalline, odourless solid
Heptahydrate: White, odourless, efﬂorescent
crystals or granular powder
Dodecahydrate: White, efﬂorescent,
odourless powder or crystals
Identiﬁcation
Test for sodium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Freely soluble in water. Insoluble in ethanol Freely soluble in water; insoluble in ethanol
pH Between 8.4 and 9.6 (1% solution) 9.0–9.6 (1 in 100 solution)
Test for
orthophosphate
– Dissolve 0.1 g of the sample in 10 mL water,
acidify slightly with dilute acetic acid TS and
add 1 mL of silver nitrate TS. A yellow
precipitate is formed
Purity
Loss on drying The anhydrous salt loses not more than
5.0%, the dihydrate not more than 22.0%,
the heptahydrate not more than 50.0%, the
dodecahydrate not more than 61.0% (40°C,
3 h then 105°C, 5 h)
Anhydrous: Not more than 5.0% (40°C, 3 h,
then 105°C, 5 h). Dihydrate: Not more than
22.0% (40°C, 3 h, then 105°C, 5 h)
Heptahydrate: Not more than 50.0% (40°C,
3 h, then 105°C, 5 h)
Dodecahydrate: Not more than 61.0% (40°C,
3 h, then 105°C, 5 h)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Purity
Loss on drying The anhydrous salt loses not more than
2.0%, the monohydrate not more than
15.0%, the dihydrate not more than 25%
(60°C, 1 h then 105°C, 4 h)
Anhydrous: Not more than 2% (60°C, 1 h,
then 105°C, 4 h)
Monohydrate: Not more than 15% (60°C, 1 h,
then 105°C, 4 h)
Dihydrate: Not more than 25% (60°C, 1 h,
then 105°C, 4 h)
Water-insoluble
matter
Not more than 0.2% on the anhydrous
basis
–
Free acid and
disodium
phosphate
– 2.00 g of the sample dissolved in 40 mL of
water require for neutralisation not more than
0.3 mL of either N sodium hydroxide or N
sulfuric acid, using methyl orange TS as
indicator
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Cadmium Not more than 1 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Table E.4: Speciﬁcations established for trisodium phosphate (E 339(iii)) according to Commission
Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Sodium phosphate anhydrous and the
hydrated forms, with the exception of the
dodecahydrate, contain not less than 97.0%
of Na3PO4 calculated on the dried basis
Sodium phosphate dodecahydrate contains
not less than 92.0% of Na3PO4 calculated
on the ignited basis
P2O5 content between 40.5% and 43.5%
on the anhydrous basis
Anhydrous, hemihydrate and monohydrate:
Not less than 97.0% calculated on the dried
basis
Dodecahydrate: Not less than 92.0%
calculated on the ignited basis
Description White odourless crystals, granules or
crystalline powder
White odourless crystals, granules or a
crystalline powder; hydrated forms available
include hemi- and monohydrates,
hexahydrate, octahydrate, decahydrate and
dodecahydrate; the dodecahydrate contains
1/4 mol of sodium hydroxide
Identiﬁcation
Test for sodium Passes test To 5 mL of a 1 in 20 solution of the sample
add 1 mL of acetic acid TS and 1 mL of
uranyl zinc acetate TS. A yellow crystalline
precipitate is formed within a few min
Test for phosphate Passes test To 5 mL of a 1 in 100 solution of the sample
add 1 mL of concentrated nitric acid and
5 mL of ammonium molybdate TS and warm.
A bright canary-yellow precipitate is obtained
Solubility Freely soluble in water. Insoluble in ethanol Freely soluble in water; insoluble in ethanol
pH Between 11.5 and 12.5 (1% solution) 11.5–12.5 (1 in 100 solution)
Test for
orthophosphate
– Dissolve 0.1 g of the sample in 10 mL water,
acidify slightly with dilute acetic acid TS and
add 1 mL of silver nitrate TS. A yellow
precipitate is formed
Purity
Loss on ignition When dried at 120°C for 2 h and then
ignited at about 800°C for 30 min, the
losses in weight are as follows: anhydrous
not more than 2.0%, monohydrate not
more than 11.0%, dodecahydrate: between
45.0% and 58.0%
Anhydrous: Not more than 2% (120°C, 2 h,
then 800°C, 30 min)
Monohydrate: Not more than 11% (120°C,
2 h, then 800°C, 30 min)
Dodecahydrate: 45–58% (120°C, 2 h, then
800°C, 30 min)
Water-insoluble
matter/substances
Not more than 0.2% on the anhydrous
basis
Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 50 mg/kg (Method I or III)
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Water-insoluble
matter/substances
Not more than 0.2% on the anhydrous
basis
Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 50 mg/kg (Method I or III)
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Cadmium Not more than 1 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Table E.6: Speciﬁcations established for dipotassium phosphate (E 340(ii)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Content not less than 98% after drying at
105°C for 4 h
P2O5 content between 40.3% and 41.5%
on the anhydrous basis
Not less than 98.0% after drying
Description Colourless or white granular powder,
crystals or masses; deliquescent substance,
hygroscopic
Colourless or white granular powder, crystals
or masses; deliquescent
Identiﬁcation
Test for potassium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Freely soluble in water. Insoluble in ethanol Freely soluble in water, insoluble in ethanol
pH Between 8.7 and 9.4 (1% solution) 8.7–9.3 (1 in 100 solution)
Test for
orthophosphate
Dissolve 0.1 g of the sample in 10 mL water,
acidify slightly with dilute acetic acid TS and
add 1 mL of silver nitrate TS. A yellow
precipitate is formed
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Cadmium Not more than 1 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Table E.5: Speciﬁcations established for monopotassium phosphate (E 340(i)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Content not less than 98.0% after drying at
105°C for 4 h
P2O5 content between 51.0% and 53.0%
on the anhydrous basis
Not less than 98.0% after drying
Description Odourless, colourless crystals or white
granular or crystalline powder
Odourless, colourless crystals or white
granular or crystalline powder
Identiﬁcation
Test for potassium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Freely soluble in water. Insoluble in ethanol Freely soluble in water; insoluble in ethanol
pH Between 4.2 and 4.8 (1% solution) 4.2–4.7 (1 in 100 solution)
Test for
orthophosphate
– To 5 mL of a 1 in 100 solution of the sample,
add silver nitrate TS. A yellow precipitate is
obtained
Purity
Loss on drying Not more than 2.0% (105°C, 4 h) Not more than 2% (105°C, 4 h)
Water-insoluble
matter/substances
Not more than 0.2% on the anhydrous
basis
Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
See description under TESTS
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Purity
Loss on drying Not more than 2.0% (105°C, 4 h) Not more than 5% (105°C, 4 h)
Water-insoluble
matter/substances
Not more than 0.2% (on the anhydrous
basis)
Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
See description under TESTS
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Table E.7: Speciﬁcations established for tripotassium phosphate (E 340(iii)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation 231/2012 JECFA (2006b,c,d,e,f)
Assay Content not less than 97% calculated on
the ignited basis
P2O5 content between 30.5% and 34.0%
on the ignited basis
Not less than 97.0% of K3PO4, calculated on
the ignited basis
Description Colourless or white, odourless hygroscopic
crystals or granules. Hydrated forms
available include the monohydrate and
trihydrate
Colourless or white, odourless hygroscopic
crystals or granules; hydrated forms available
include the monohydrate and trihydrate
Identiﬁcation
Test for potassium Passes test To a 1 in 100 solution of the sample add 1
volume of saturated sodium hydrogen
tartrate solution and 1 volume of ethanol and
shake. A white crystalline precipitate is
formed
Test for phosphate Passes test To 5 mL of a 1 in 100 solution of the sample
add 1 mL of concentrated nitric acid and
5 mL of ammonium molybdate TS and warm.
A bright canary-yellow precipitate is obtained
Solubility Freely soluble in water. Insoluble in ethanol Freely soluble in water; insoluble in ethanol
pH Between 11.5 and 12.3 (1% solution) 11.5–12.5 (1 in 100 solution)
Test for
orthophosphate
– Dissolve 0.1 g of the sample in 10 mL water,
acidify slightly with dilute acetic acid TS and
add 1 mL of silver nitrate TS. A yellow
precipitate is formed
Purity
Loss on ignition Anhydrous: not more than 3.0%; hydrated:
not more than 23.0% (determined by
drying at 105°C for 1 h and then ignite at
about 800  25°C for 30 min)
Anhydrous: Not more than 3% (120°C, 2 h,
then 800°C, 30 min)
Hydrated: Not more than 23% (120°C, 2 h,
then 800°C, 30 min)
Water-insoluble
matter/substances
Not more than 0.2% (on the anhydrous
basis)
Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
See description under TESTS
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Table E.8: Speciﬁcations established for calcium dihydrogen phosphate (E 341 (i)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Content not less than 95% on the dried
basis
P2O5 content between 55.5% and 61.1%
on the anhydrous basis
Anhydrous: Not less than 16.8% and not
more than 18.3% of Ca Monohydrate: Not
less than 15.9% and not more than 17.7%
of Ca
Description Granular powder or white, deliquescent
crystals or granules
Hygroscopic white crystals or granules, or
granular powder
Identiﬁcation
Solubility – Sparingly soluble in water, insoluble in
ethanol
Test for calcium Passes test Passes test
Test for phosphate Passes test Passes test
CaO content Between 23.0% and 27.5% (anhydrous)
Between 19.0% and 24.8% (monohydrate)
Purity
Loss on drying Anhydrous: not more than 14% (105°C,
4 h)
Monohydrate: not more than 17.5% (105°C,
4 h)
Monohydrate: Not more than 1% (60°C,
3 h)
Loss on ignition Anhydrous: not more than 17.5% (after
ignition at 800  25°C for 30 min)
Monohydrate: not more than 25.0%
(determined by drying at 105°C for 1 h,
then ignite at 800  25°C for 30 min)
Anhydrous: Between 14.0% and 15.5%
(800°C, 30 min)
Fluoride Not more than 30 mg/kg (expressed as
ﬂuorine)
Not more than 50 mg/kg
Anhydrous: Determine as directed in
Method II
Monohydrate: Proceed as directed under
Method IV
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Cadmium Not more than 1 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Aluminium Not more than 70 mg/kg (only if added to
food for infants and young children)
Not more than 200 mg/kg (for all uses
except food for infants and young children)
–
Table E.9: Speciﬁcations established for calcium hydrogen phosphate (E 341(ii)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Dicalcium phosphate, after drying at 200°C
for 3 h, contains not less than 98% and not
more than the equivalent of 102% of
CaHPO4
P2O5 content between 50.0% and 52.5%
on the anhydrous basis
Not less than 98.0% and not more than the
equivalent of 102.0% after drying
Description White crystals or granules, granular powder
or powder
White crystals or granules, granular powder
or powder
Identiﬁcation
Solubility Sparingly soluble in water. Insoluble in
ethanol
Sparingly soluble in water; insoluble in
ethanol
Test for calcium Passes test Passes test
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Table E.10: Speciﬁcations established for tricalcium phosphate (E 341(iii)) according to Commission
Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Content not less than 90% calculated on
the ignited basis
P2O5 content between 38.5% and 48.0%
on the anhydrous basis
Not less than the equivalent of 90% of
Ca3(PO4)2, calculated on the ignited basis
Description A white, odourless powder which is stable
in air
White, odourless powder which is stable in
air
Identiﬁcation
Solubility Practically insoluble in water; insoluble in
ethanol, soluble in dilute hydrochloric and
nitric acid
Practically insoluble in water; insoluble in
ethanol, soluble in dilute hydrochloric and
nitric acid
Test for calcium Passes test Dissolve about 100 mg of the sample by
warming with 5 mL of dilute hydrochloric acid
TS and 5 mL of water. Add 1 mL of ammonia
TS, dropwise, with shaking and then add
5 mL of ammonium oxalate TS. A white
precipitate forms
Test for phosphate Passes test To a warm solution of the sample in a slight
excess of nitric acid add ammonium
molybdate TS. A yellow precipitate forms
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Test for phosphate Passes test Passes test
Purity
Loss on drying – Anhydrous: Not more than 2% (200°C, 3 h)
Dihydrate: Not less than 18% and not more
than 22% (200°C, 3 h)
Loss on ignition Not more than 8.5% (anhydrous), or 26.5%
(dihydrate) after ignition at 800  25°C for
30 min
–
Fluoride Not more than 50 mg/kg (expressed as
ﬂuorine)
Not more than 50 mg/kg (Method I or III)
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg (Method II)
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Cadmium Not more than 1 mg/kg –
Mercury Not more than 1 mg/kg –
Aluminium Not more than 100 mg/kg for the anhydrous
form and not more than 80 mg/kg for the
dihydrated form (only if added to food for
infants and young children)
Not more than 600 mg/kg for the anhydrous
form and not more than 500 mg/kg for the
dihydrated form (for all uses except food for
infants and young children). This applies
until 31 March 2015
Not more than 200 mg/kg for the anhydrous
form and the dihydrated form (for all uses
except food for infants and young children).
This applies from 1 April 2015
–
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Table E.11: Speciﬁcations established for monomagnesium phosphate (E 343(i)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2008)
Commission Regulation No 231/2012 JECFA (2008)
Assay Not less than 51.0% after ignition
calculated as P2O5 at the ignited basis
(800  25°C for 30 min)
Not less than 96% and not more than 102%
as Mg2P2O7 on the ignited basis
Description White, odourless, crystalline powder White, odourless, crystalline powder
Identiﬁcation
Solubility Slightly soluble in water Slightly soluble in water
Test for
magnesium
Passes test Passes test
Test for phosphate Passes test Passes test
Purity
Loss on drying Anhydrous: Not more than 1.5% (105°C,
4 h)
Loss on ignition Anhydrous: Not more than 18.5%
Dihydrate: Not more than 33%
Tetrahydrate: Not more than 43%
MgO content Not less than 21.5% after ignition or at an
anhydrous basis (105°C, 4 h)
–
Fluoride Not more than 10 mg/kg (as ﬂuorine) Not more than 10 mg/kg
See description under TESTS
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Cadmium Not more than 1 mg/kg –
Mercury Not more than 1 mg/kg –
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Purity
Loss on ignition Not more than 8% after ignition at
800  25°C for 0.5 h
Not more than 10% after ignition at 825°C to
constant weight
Fluoride Not more than 50 mg/kg (expressed as
ﬂuorine)
Not more than 50 mg/kg (Method I or III)
Arsenic Not more than 1 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Cadmium Not more than 1 mg/kg –
Mercury Not more than 1 mg/kg –
Aluminium Not more than 150 mg/kg (only if added to
food for infants and young children)
Not more than 500 mg/kg (for all uses
except food for infants and young children).
This applies until 31 March 2015
Not more than 200 mg/kg (for all uses
except food for infants and young children).
This applies from 1 April 2015
–
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Table E.13: Speciﬁcations for disodium diphosphate (E 450(i)) according to Commission Regulation
(EU) No 231/2012 and as INS 450(i) according to JECFA (2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 95% of disodium
diphosphate. P2O5 content not less than 63.0%
and not more than 64.5%
Not less than 95.0%
Description White powder or grains White, crystalline powder
or granules
Identiﬁcation
Test for sodium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Soluble in water Soluble in water
pH Between 3.7 and 5.0 (1% solution) 3.7–5.0 (1 in 100 solution)
Purity
Loss on drying Not more than 0.5% (105°C, 4 h) Not more than 0.5%
(105°, 4 h)
Water-insoluble
matter
Not more than 1% Not more than 1%
Fluoride Not more than 10 mg/kg
(expressed as ﬂuorine)
Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Aluminium No more than 200 mg/kg –
Table E.12: Speciﬁcations established for dimagnesium phosphate (E 343(ii)) according to
Commission Regulation (EU) No 231/2012 and JECFA (2006a)
Commission Regulation No 231/2012 JECFA (2006b,c,d,e,f)
Assay Not less than 96% after ignition
(800  25°C for 30 min)
Not less than 96.0% on the ignited basis
Description White, odourless, crystalline powder Odourless white crystalline powder
Identiﬁcation
Solubility Slightly soluble in water Slightly soluble in water, soluble in dilute
acids, but insoluble in ethanol
Test for
magnesium
Passes test Dissolve 100 mg in 0.5 mL of diluted acetic
acid TS and 20 mL of water. Add 1 mL of
ferric chloride TS, let stand for 5 min and
ﬁlter. The ﬁltrate gives a positive test for
magnesium
Test for phosphate Passes test Passes test
Purity
Loss on ignition Not less than 29% and not more than 36%
(800  25°C to constant weight)
MgO content Not less than 21.5% after ignition or at an
anhydrous basis (105°C, 4 h)
–
Fluoride Not more than 10 mg/kg (as ﬂuorine) Not more than 10 mg/kg (Method III)
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Cadmium Not more than 1 mg/kg –
Mercury Not more than 1 mg/kg –
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Table E.15: Speciﬁcations for tetrasodium diphosphate (E 450(iii)) according to Commission
Regulation (EU) No 231/2012 and as INS 450(iii) according to JECFA (2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 95% of Na4P2O7 on the
ignited basis. P2O5 content not less than 52.5% and
not more than 54.0%
Not less than 95.0% on the ignited
basis
Description Colourless or white crystals, or a white crystalline or
granular powder. The decahydrate efﬂoresces
slightly in dry air
Colourless or white crystals, or a
white crystalline or granular powder;
the decahydrate efﬂoresces slightly
in dry air
Identiﬁcation
Test for sodium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Soluble in water. Insoluble in ethanol Soluble in water. Insoluble in
ethanol
pH Between 9.8 and 10.8 (1% solution) 9.9–10.8 (1 in 100 solution)
Purity
Loss on ignition Not more than 0.5% for the anhydrous salt, not less
than 38% and not more than 42% for the
decahydrate (105°C, 4 h then 550°C, 30 min
Not more than 0.5% for anhydrous,
38–42% for decahydrate
(105°, 4 h then 550°, 30 min)
Water-insoluble
matter
Not more than 0.2% Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as ﬂuorine) Not more than 10 mg/kg
Table E.14: Speciﬁcations for trisodium diphosphate (E 450(ii)) according to Commission
Regulation (EU) No 231/2012 and as INS 450(ii) according to JECFA (2012a,b).
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 95% on the dried basis. P2O5
content not less than 57% and not more than 59%
Not less than 57% and not more
than 59% expressed as P2O5 on the
dried basis
Description White powder or grains, occurs anhydrous or as a
monohydrate
White powder or grains
Identiﬁcation
Test for sodium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Soluble in water Soluble in water
pH Between 6.7 and 7.5 (1% solution) –
Purity
Loss on ignition Not more than 4.5% on the anhydrous compound
(450–550°C). Not more than 11.5% on the
monohydrate basis
Anhydrous: not more than 4.5
Monohydrate: not more than 11.5%
Loss on drying Not more than 0.5% (105°C, 4 h) for anhydrous
Not more than 1.0% (105°C, 4 h) for monohydrate
Anhydrous: not more than 0.5%
(105°, 4 h)
Monohydrate: not more than 1.0%
(105°, 4 h)
Water-insoluble
matter
Not more than 0.2% Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as ﬂuorine) Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Table E.16: Speciﬁcations for tetrapotassium diphosphate (E 450(v)) according to Commission
Regulation (EU) No 231/2012 and as INS 450(v) according to JECFA (2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 95% (800°C for 0.5 h). P2O5
content not less than 42.0% and not more than
43.7%
Not less than 95% on the ignited
basis
Description Colourless crystals or white, very hygroscopic
powder
Colourless or white crystals, or a
white crystalline or granular powder,
powder of granular solid;
hygroscopic
Identiﬁcation
Test for potassium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Soluble in water
Insoluble in ethanol
Soluble in water
Insoluble in ethanol
pH Between 10.0 and 10.8 (1% solution) 10.0–10.7 (1 in 100 solution)
Purity
Loss on ignition Not more than 2% (105°C, 4 h then 550°C, 30 min Not more than 2% (105°, 4 h; then
550°, 30 min)
Water-insoluble
matter
Not more than 0.2% Not more than 0.2%
Fluoride Not more than 10 mg/kg (expressed as ﬂuorine) Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Table E.17: Speciﬁcations for dicalcium diphosphate (E 450(vi)) according to Commission
Regulation (EU) No 231/2012 and as INS 450(vi) according to JECFA (2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 96%. P2O5 content not less than
55% and not more than 56%
Not less than 96%
Description A ﬁne, white, odourless powder Fine, white, odourless powder
Identiﬁcation
Test for calcium Passes test Passes test
Test for
phosphate
Passes test Passes test
Solubility Insoluble in water
Soluble in dilute hydrochloric and nitric acids
Insoluble in water
Soluble in dilute hydrochloric and
nitric acids
pH Between 5.5 and 7.0 (10% suspension in water) 5.5–7.0 (1 in 10 slurry)
Purity
Loss on ignition Not more than 1.5% (800  25 °C, 30 min) Not more than 1.5%
Fluoride Not more than 50 mg/kg (expressed as ﬂuorine) Not more than 50 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
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Table E.18: Speciﬁcations for calcium dihydrogen diphosphate (E 450(vii)) according to Commission
Regulation (EU) No 231/2012 and as INS 450(vii) according to JECFA (2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 90% on the anhydrous basis.
P2O5 content not less than 61% and not more than
66%
Not more than 64% expressed as
P2O5 on dried basis
Description White crystals or powder White crystals or powder
Identiﬁcation
Test for calcium Passes test Passes test
Test for phosphate Passes test Passes test
Purity
Loss on drying – Anhydrous: not more than 1%
(105°, 4 h)
Acid-insoluble matter Not more than 0.4% Not more than 0.4%
Fluoride Not more than 30 mg/kg (expressed as ﬂuorine) Not more than 30 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Aluminium Not more than 800 mg/kg
This applies until 31 March 2015
Not more than 200 mg/kg
This applies from 1 April 2015
–
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Table E.19: Speciﬁcations for magnesium dihydrogen diphosphate (E 450(ix)) according to
Commission Regulation (EU) No 231/2012 and as INS 450(ix) according to JECFA
(2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay P2O5 content not less than 68.0% and not more
than 70.5% expressed as P2O5MgO content not less
than 18.0% and not more than 20.5% expressed as
MgO
Description White crystals or powder
Identiﬁcation
Solubility Slightly soluble in water, practically insoluble in
ethanol
Particle size The average particle size will deviate between 10
and 50 lm
Test for magnesium Passes test
Purity
Loss on ignition Not more than 12% (800°C, 0.5 h) Not more than 12% (800°C, 0.5 h)
Orthophosphate Not more than 4% as (PO4)
3
Calcium Not more than 4%
Fluoride Not more than 20 mg/kg (expressed as ﬂuorine) Not more than 20 mg/kg
Arsenic Not more than 1 mg/kg Not more than 1 mg/kg
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Table E.20: Speciﬁcations for pentasodium triphosphate (E 451(i)) according to Commission
Regulation (EU) No 231/2012 and as INS 451(i) according to JECFA (2012a,b)
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Assay Content not less than 85.0% (anhydrous) or 65.0%
(hexahydrate)
P2O5 content not less than 56% and not more than
59% (anhydrous) or not less than 43% and not
more than 45% (hexahydrate)
Anhydrous: not less than 85.0% of
Na5O10P3 and not less than 56.0%
and not more than 58.0% of P2O5
Hexahydrate: not less than 65.0% of
Na5O10P3 and not less than 43.0%
and not more than 45.0% of P2O5
Description White, slightly hygroscopic granules or powder White, slightly hygroscopic granules
or powder
Identiﬁcation
Test for sodium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Freely soluble in water. Insoluble in ethanol Freely soluble in water. Insoluble in
ethanol
pH Between 9.1 and 10.2 (1% solution) Between 9.1 and 10.1 (1% solution)
Purity
Loss on drying Anhydrous: not more than 0.7% (105°C, 1 h)
Hexahydrate: not more than 23.5% (60°C, 1 h, then
105°C, 4 h)
Anhydrous: not more than 0.7%
(105°, 1 h)
Hexahydrate: not more than 23.5%
(60°, 1 h, followed by 105°, 4 h)
Water-insoluble
matter
Not more than 0.1% Not more than 0.1%
Higher
polyphosphates
Not more than 1% Not detectable
Fluoride Not more than 10 mg/kg (expressed as ﬂuorine) Not more than 50 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Commission Regulation (EU) No 231/2012 JECFA (2012a,b)
Cadmium Not more than 1 mg/kg Not more than 1 mg/kg
Lead Not more than 1 mg/kg Not more than 1 mg/kg
Aluminium Not more than 50 mg/kg Not more than 50 mg/kg
Table E.21: Table 2 Speciﬁcations for pentapotassium triphosphate (E 451(ii)) according to
Commission Regulation (EU) No 231/2012 and as INS 451(i) according to JECFA
(2012a,b)
Commission Regulation (EU)
No 231/2012
JECFA (2012a,b)
Assay Content not less than 85% on the
anhydrous basis
Not less than 85% of K5O10P3 on the dried
basis, the remainder being principally other
potassium phosphates
Description White, very hygroscopic powder or
granules
Hygroscopic white granules or powder
Identiﬁcation
Test for potassium Passes test Passes test
Test for phosphate Passes test Passes test
Solubility Very soluble in water Very soluble in water
pH Between 9.2 and 10.5 (1% solution) Between 9.2 and 10.1 (1% solution)
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Table E.22: Speciﬁcations for sodium polyphosphate (E 452(i) I. Soluble polyphosphate) according
to Commission Regulation (EU) No 231/2012 and as INS 452(i) according to JECFA
(2012a,b)
Commission Regulation (EU)
No 231/2012
JECFA (2012a,b)
Assay P2O5 content not less than 60% and not
more than 71% on the ignited basis
Not less than 60.0% and not more than
71.0% of P2O5
Description Colourless or white, transparent platelets,
granules or powders
Colourless or white, transparent platelets,
granules or powders
Identiﬁcation
Test for sodium Passes test A 1 in 20 solution passes test
Test for phosphate Passes test Dissolve 0.1 g of the sample in 5 mL of hot
dilute nitric acid TS. Warm on a steam bath for
10 min and cool. Neutralise to litmus with
sodium hydroxide TS, and add silver nitrate TS.
A yellow precipitate is formed which is soluble
in dilute nitric acid TS
Solubility Very soluble in water Very soluble in water
pH Between 3.0 and 9.0 (1% solution) –
Purity
Loss on ignition Not more than 1% Not more than 1.0%
Water-insoluble
matter
Not more than 0.1% Not more than 0.1%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Commission Regulation (EU)
No 231/2012
JECFA (2012a,b)
Purity
Loss on ignition Not more than 0.4% (105°C, 4 h, then
550°C, 30 min)
Not more than 0.4% after drying (105°, 4 h)
followed by ignition at 550° for 30 min)
Water-insoluble
matter
Not more than 2% Not more than 2%
P2O5 content P2O5 content not less than 46.5% and not
more than 48%
Not less than 46.5% and not more than
48.0%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Table E.24: Speciﬁcations for potassium polyphosphate (E 452(ii)) according to Commission
Regulation (EU) No 231/2012 and as INS 452(ii) according to JECFA (2012a,b)
Commission Regulation (EU)
No 231/2012
JECFA (2012a,b)
Assay P2O5 content not less than 53.5% and not
more than 61.5% on the ignited basis
Not less than 53.5% and not more than
61.5% of P2O5 on the ignited basis
Description Fine white powder or crystals or colourless
glassy platelets
Odourless, colourless or white glassy masses,
fragments, crystals or powder
Identiﬁcation
Test for potassium Passes test Mix 0.5 g of the sample with 10 mL of nitric acid
and 50 mL of water, boil for about 30 min and
cool. The resulting solution is used for the test
Test for phosphate Passes test Mix 0.5 g of the sample with 10 mL of nitric acid
and 50 mL of water, boil for about 30 min and
cool. The resulting solution is used for the test
Solubility 1 g dissolves in 100 mL of a 1 in 25
solution of sodium acetate
1 g dissolves in 100 mL of a 1 in 25 solution of
sodium acetate
pH Not more than 7.8 (1% suspension) –
Purity
Loss on ignition Not more than 2% (105°C, 4 h then
550°C, 30 min)
Not more than 2% after drying (105°, 4 h)
followed by ignition at 550°C for 30 min
Cyclic phosphate Not more than 8% on P2O5 content Not more than 8.0%
Fluoride Not more than 10 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Table E.23: Speciﬁcations for sodium polyphosphate (E 452(i) II. insoluble polyphosphate)
according to Commission Regulation (EU) No 231/2012 and as INS 452(i) according to
JECFA (2012a,b)
Commission Regulation (EU) No 231/2012
Assay P2O5 content not less than 68.7% and not more than 70.0%
Description White crystalline powder
Identiﬁcation
Test for sodium Passes test
Test for phosphate Passes test
Solubility Insoluble in water, soluble in mineral acids and in solutions of potassium and
ammonium (but not sodium) chlorides
pH About 6.5 (1 in 3 suspension in water)
Purity
Fluoride Not more than 10 mg/kg (expressed as ﬂuorine)
Arsenic Not more than 1 mg/kg
Cadmium Not more than 1 mg/kg
Lead Not more than 1 mg/kg
Mercury Not more than 1 mg/kg
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Table E.25: Speciﬁcations for sodium calcium polyphosphate (E 452(iii)) according to Commission
Regulation (EU) No 231/2012 and as INS 452(iii) according to JECFA (2012a,b)
Commission Regulation (EU)
No 231/2012
JECFA (2012a,b)
Assay P2O5 content not less than 61% and not
more than 69% on the ignited basis
Not less than 61% and not more than 69%
expressed as P2O5 on dried basis
Description White glassy crystals, spheres White glassy crystals, spheres
Identiﬁcation
Test for sodium – Passes test
Test for calcium – Passes test
Test for phosphate – Passes test
pH Approximately 5–7 (1% m/m slurry) –
CaO content 7–15% m/m –
Purity
Fluoride Not more than 10 mg/kg Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
Table E.26: Speciﬁcations for calcium polyphosphate (E 452(iv)) according to Commission
Regulation (EU) No 231/2012 and as INS 452(iv) according to JECFA (2012a,b)
Commission Regulation (EU)
No 231/2012
JECFA (2012a,b)
Assay P2O5 content not less than 71% and not
more than 73% on the ignited basis
Not less than 50.0 and not more than 71.0%
of P2O5 on the ignited basis
Description Odourless, colourless crystals or white
powder
Odourless, colourless crystals or powder
Identiﬁcation
Test for calcium Passes test The solution of the test for phosphate gives
positive tests for calcium
Test for phosphate Passes test Mix 0.5 g of the sample with 10 mL of nitric acid
and 50 mL of water, boil for about 30 min and
cool. The resulting solution is used for the test
Solubility Usually sparingly soluble in water. Soluble
in acid medium
Usually incompletely soluble in water; soluble
in acid medium
CaO content 27–29.5% –
Purity
Loss on ignition Not more than 2% (105°C, 4 h than
550°C, 30 min)
Not more than 2% after drying (105°C, 4 h)
followed by ignition (550°C, 30 min)
Cyclic phosphate Not more than 8% (on P2O5 content) Not more than 8% calculated on P2O5 content
Fluoride Not more than 30 mg/kg (expressed as
ﬂuorine)
Not more than 10 mg/kg
Arsenic Not more than 1 mg/kg Not more than 3 mg/kg
Cadmium Not more than 1 mg/kg –
Lead Not more than 1 mg/kg Not more than 4 mg/kg
Mercury Not more than 1 mg/kg –
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Appendix F – Summary of the reported use levels (mg/kg or mg/L as
appropriate) of phosphates (E 338–341, E 343, E 450–452) provided by
industry
Appendix G – Summary of analytical results (mg P/kg or mg P/L as
appropriate) of phosphorus provided by Member States
Appendix H – Number and percentage of food products labelled with
phosphates (E 338-341, E 343, E 450-452) out of the total number of food
products present in the Mintel GNPD per food subcategory between 2014
and 2019
Appendix I – Concentration levels of phosphates (E 338–341, E 343,
E 450–452) used in the regulatory maximum level exposure assessment
scenario and in the reﬁned exposure assessment scenarios (mg/kg or
mL/kg as appropriate)
Appendix J – Summary of total estimated exposure of phosphates
(E 338–341, E 343, E 450–452) from their use as food additives for the
regulatory maximum level exposure assessment scenario and the reﬁned
exposure assessment scenarios, in seven population groups (min-max
across the dietary surveys in mg P2O5/kg bw per day and in mg P2O5/
person per day)
Appendix K – Total estimated exposure of phosphates (E 338–341, E 343,
E 450–452) from their use as food additives for the regulatory maximum
level exposure assessment scenario and the reﬁned exposure assessment
scenarios per population group and survey: mean and 95th percentile
(mg P2O5/kg bw per day)
Appendix L – Main food categories contributing to exposure to phosphates
(E 338–341, E 343, E 450–452) using the regulatory maximum level
exposure assessment scenario and the reﬁned exposure assessment
scenarios, based on the results expressed in mg P2O5/kg bw per day
(> 5% to the total mean exposure)
Appendix M
M1: Summary of total estimated exposure of phosphates (E 338–341, E 343,
E 450–452) from their use as food additives and the proposed extension of
uses for the regulatory maximum level exposure assessment scenario and
the reﬁned exposure assessment scenarios (min–max across the dietary
surveys in mg P2O5/kg bw per day and in mg P2O5/person per day)
M2: Total estimated exposure of phosphates (E 338–341, E 343, E 450–
452) from their use as food additives and the proposed extension of use
for the regulatory maximum level exposure assessment scenario and the
reﬁned exposure assessment scenarios per population group and survey:
mean and 95th percentile (mg P2O5/kg bw per day)
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Appendix N
N1: Summary of exposure to total phosphorus via the diet (using
analytical data) per population group and survey: mean and 95th
percentile (mg P/kg bw per day)
N2: Summary of exposure to total phosphorus via the diet (using
analytical data) per population group and survey: mean and 95th
percentile (mg P/person per day)
Appendix O – Main food categories contributing to exposure to total
phosphorus via the diet (using analytical data, based on exposure in
mg P/kg bw per day) (> 5% to the total mean exposure)
Appendices F–O can be found in the online version of this output (‘Supporting information’ section):
https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2019.5674
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Appendix P – Case series and case reports after acute administration
Case series and case reports after acute administration
No. Author
Age/
sex
History
Dose given in
mg of
phosphorus
Oral Solution
Outcome
Serum
creatinine
levels
(mg/dL)
Clinical/
pathological
observation
1 Aasebø
et al.
(2007)
69/F Breast cancer.
Hypertension
11,600
(2 9 5,800
within 12 h)
Remission Baseline: 0.79
Onset:
4.32–5.97
Follow-up:
1.60
Baseline: diagnosis
of membranous
glomerulonephritis
(?) after the
increase of
creatinine > 5.97,
in a second biopsy
calcium phosphate
deposits
2 Arikan
et al.
(2013)
18/F Ileus 11,600
(2 9 5,800
within 12 h)
Haemodialysis
remission
Baseline:
0.41
Onset:
0.87–1.08
Follow-up:
0.60
3 Cakar
et al.
(2012)
65/M Hypertension 11,600
(2 9 5,800
within 12 h)
CKD. Patient
started
haemodialysis
treatment
Baseline:
1.14
Onset: 1.82
Follow-up:
3.14
Kidney biopsy
showed mild focal
tubulointerstitial
inﬂammation,
tubular atrophy,
sclerosis
4 Fine and
Patterson
(1997)
84/F Hypertension, mild
cardiac insufﬁciency.
34,800
(6 9 5,800)
over 4 days
Death Baseline: 0.7
Onset: 2.5
–
5 Gonlusen
et al.
(2006)
56/F Gastroesophageal
reﬂux, mild Crohn’s
disease
11,600
(2 9 5,800
within 12 h)
Remission Baseline: 0.8
Onset: 3.8
Follow-up:
1.6
Renal biopsy (44
days after
colonoscopy)
nephrocalcinosis
6 Markowitz
et al.
(2004)
69/M HTA (losartan),
carcinoma, mild
hyperparathyroidism.
Folic acid
11,600
(2 9 5,800
within 12 h)
Unknown Baseline: 1.2
Onset:
6.7–8.5
Follow-up: –
After the
colonoscopy, the
patient presented
with an episode of
gross haematuria
7 Markowitz
et al.
(2004)
82/M Hypertension.
Surgical intervention
with hemicolectomy
15,500
(2 9 5,800 =
11,600 within
12 h) + 3,900
Unknown Baseline: 0.9
Onset:
5.2–4.9
Follow-up:
4.3
8 Markowitz
et al.
(2004)
55/F Diabetes mellitus,
Hypertension,
coronary heart
disease
11,600
(2 9 5,800
within 12 h)
Unknown Baseline: 0.6
Onset: 4.5
Follow-up:
3.5
9 Markowitz
et al.
(2004)
64/F hypertonia arterialis
(enalapril, HCT,
aspirin) diabetes
mellitus (glipizide,
rosiglitazone),
obesity. Use of KCL.
Adenomatous rectal
polyp
11,600
(2 9 5,800
within 12 h)
Unknown Baseline: 0.9
Onset: 2.3
Follow-up:
3.3
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Case series and case reports after acute administration
No. Author
Age/
sex
History
Dose given in
mg of
phosphorus
Oral Solution
Outcome
Serum
creatinine
levels
(mg/dL)
Clinical/
pathological
observation
10 Markowitz
et al.
(2004)
76/F Hypertension), 11,600
(2 9 5,800
within 12 h)
Unknown Baseline: 0.9
Onset:
6.0–8.0
Follow-up:
3.7
Patient needed
haemodialysis
11 Orias
et al.
(1999)
76/M Hypertension 29,000
(5 9 5,800
within 2 days)
Remission,
without further
haemodialysis
Baseline: 1.1
Onset:
2.5–3.7
Follow-up:
1.3
Haemodialysis was
initiated
12 Santos
et al.
(2010)
84/M History of stage 3
obstructive CRF
11,600
(2 9 5,800
10–12 h apart)
Regular
haemodialysis
Baseline: –
Onset: 9.2
Follow-up: –
Kidney biopsy
showed tubules
were mildly
dilated and
nephrocalcinosis
13 Santos
et al.
(2010)
88/M B-cell lymphoma IV-
B stage
11,600
(2 9 5,800
10–12 h apart)
Phosphate
nephropathy.
No clinical
improvement
Death
Baseline: –
Onset: 3.45
–
Renal ultrasound
showed kidneys
with enhanced
echogenicity
14 Slee et al.
(2008)
62/F Hypertension 11,600
(2 9 5,800
within 12 h)
CKD stage 4 Baseline:
0.83
Onset:
1.97–4.95
Follow-up:
1.8
Kidney biopsy (on
day 10)
nephrocalcinosis
with diffuse non-
polarising tubular
deposits in the
tubulointerstitium
15 Vukasin
et al.
(1997)
69/F Unknown 23,200
(2 9 5,800
12 h apart) +
5,800 9 2 (5 h
apart)
Remission Baseline: –
Onset:
1.7–2.3
Follow-up:
Normal
CKD: chronic kidney disease.; HTA: Hypertonia arterialis; HCT: hychlorothiazide; KCl: Potassium chloride; CRF: corticotropin-
releasing factor.
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Appendix Q – Interventional studies – short-term exposure
Interventional studies – short–term exposure
Authors
(publication
year)
Title
Number
of
patients
Phosphorus
dose
(mg/day)
Duration of
exposure
(days)
Renal function
Bowel
complaints
1 Brixen et al.
(1992)
Effects of a Short
Course of Oral
Phosphate Treatment
on Serum
Parathyroid Hormone
(I-84) and
Biochemical Markers
of Bone Turnover: A
Dose-Response
Study
19
19
20
750
1,500
2,250
7
7
7
No change in
serum creatinine
mentioned
2 patients
3 patients
7 patients
2 Ittner et al.
(1986)
Reduced parathyroid
hormone response to
peroral phosphate in
osteoporotic patients
7 1,500 1 No change in
serum creatinine
Not
mentioned
3 Portale et al.
(1987)
Dietary intake of
phosphorus
modulates the
circadian rhythm in
serum concentration
of phosphorus.
Implications for renal
production of 1,25-
dihydroxyvitamin D
6 1,000
2,500
9
10
No change in
serum creatinine
Not
mentioned
4 Silverberg
et al. (1986)
The effect of oral
phosphate
administration on
major indices of
skeletal metabolism
in normal subjects
13 660 5 Not mentioned Not
mentioned
5 Smith and
Nordin (1964)
The effect of a high
phosphorus intake
on total and
ultraﬁltrable plasma
calcium and
phosphate clearance.
8 1,500 7–10 Not mentioned Not
mentioned
6 Van Den Berg
et al. (1980)
Orthophosphate
therapy decreases
urinary calcium
excretion and 1,25
(OH)2D
concentration in
idiopathic
hypercalciuria
11 2,000 14 Not mentioned Not
mentioned
7 Yamaoka
et al. (1989)
Effect of single oral
phosphate loading
on vitamin D
metabolites in
normal subjects and
in X-linked
hypophosphatemic
rickets
7 2,000 1 No change in
serum creatinine
Not
mentioned
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Appendix R – Interventional studies – long-term exposure
Interventional studies – long-term exposure
Authors
(publication
year)
Title
Number of
patients
Phosphorus
dose
(mg/day)
Duration
of
exposure
(months)
Renal
function
Bowel
complaints
1 Alexandre
et al. (1988)
Effects of a one-
year administration
of phosphate and
intermittent
calcitonin on bone-
forming and bone-
resorbing cells in
involutional
osteoporosis: a
histomorphometric
study
15 500 12 Not
mentioned as
reduced
Not
mentioned
2 Bernstein and
Newton
(1966)
The effect of oral
sodium phosphate
on the formation of
renal calculi and on
idiopathic
hypercalcuria
10 2,400
(4 patients)
4,800
(5 patients)
7,200
(1 patient)
6–24
4–24
24
Slightly
reduced
(1 patient)
reduced
(2 patients)
50%
reduction
Not
mentioned
3 Calvo et al.
(1990)
Persistently
Elevated
Parathyroid
Hormone Secretion
and Action in Young
Women after Four
Weeks of Ingesting
High Phosphorus,
Low Calcium Diets.
10 807 (1,723
(phosphate-
rich diet)–
916 (basal
diet))
1 Not
mentioned
Not
mentioned
4 Dudley and
Blackburn
(1970)
Extraskeletal
calciﬁcation
complicating oral
neutral phosphate
therapy
9 2,250 (1)
3,375 (7)
4,500 (1)
9–87 Renal
function
decreased
(2 patients:
3,375 and
4,500)
Not
mentioned
5 Ettinger
(1976)
Recurrent
Nephrolithiasis:
Natural History and
Effect of Phosphate
Therapy.
25 1,400 36 No changes
in renal
function, or
creatinine
mentioned
Stool
softness
6 Goldsmith
et al. (1968)
Phosphate
supplementation as
an adjunct in the
therapy of multiple
myeloma.
10 Nine patients
1,000
one patient
2,000
0.75–9 No
deterioration
of renal
function
Not
mentioned
7 Goldsmith
et al. (1976)
Hormone and bone
morphology in
osteoporosis effects
of phosphorus
supplementation on
serum parathyroid
7 1,000 3–20 Inulin
clearance and
PAH
clearance not
changed
Not
mentioned
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Interventional studies – long-term exposure
Authors
(publication
year)
Title
Number of
patients
Phosphorus
dose
(mg/day)
Duration
of
exposure
(months)
Renal
function
Bowel
complaints
8 Hulley et al.
(1971)
The effect of
supplemental oral
phosphate on the
bone mineral
changes during
prolonged bed rest
5 1,327 4 No changes
of creatinine
clearance
Not
mentioned
9 Kuntz et al.
(1986)
Treatment of post-
menopausal
osteoporosis with
phosphate and
intermittent
calcitonin
10 535
(1,500 mg/
day for
5 days every
third week for
6 months)
6 No changes
in renal
function, or
creatinine
mentioned
Not
mentioned
10 Miller et al.
(1991)
Effect of cyclical
therapy with
phosphorus and
etidronate on axial
bone mineral
density in
postmenopausal
osteoporotic
women
47 65.75 (for
3 days a dose
of 2,000 mg,
8 times over
2 years)
24 No changes
in renal
function, or
creatinine
mentioned
Not
mentioned
12 Popovtzer
et al. (1976)
Effects of
alternating
phosphorus and
calcium infusions
on osteoporosis
5 150–300
(5–10 mg/kg
bw per day:
3 days per
week)
10–12 No change in
creatinine
clearance
(pre vs. post)
Not
mentioned
13 Bell et al.
(1977)
Physiological
responses of
human adults to
foods containing
phosphate additives
8 1,100 1 Not
mentioned
Not
mentioned
14 Shapiro et al.
(1975)
Osteoporosis 10 2,200 12–24 No changes
in serum
creatinine
mentioned
Not
mentioned
15 Ulmann et al.
(1984)
Frequence des
recifdives
lithiasiques apres
une curre de
diurese simple ou
assiciee a un
traitement par un
duiretique
thiazidique ou le
phophore
13 1,500 24 (median) No change
in serum
creatinine
mentioned
Not
mentioned
16 Whybro et al.
(1998)
Phosphate
supplementation in
young men: lack of
effect on calcium
homeostasis and
bone turnover
12 1,000, 1,500
and 2,000
(escalating)
3 No change
in serum
creatinine
Not
mentioned
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Appendix S – Phosphorus intake, middle and high intakes (mg/day),
reported in human studies referenced in the present opinion
Author (year)
Middle phosphate
intake (mg/day)
Highest expressed
phosphate intake
(mg/day)
Country
Dietary
assessment
method
Alonso et al. (2010) 1,084 (ARIC-study)
mean
2,856 (highest) USA FFQ (66 items)
1,103 (MESA-study) 3,570 (highest) USA FFQ (120 items)
Yamamoto et al.
(2013)
1,167 (men)
1,017 (women)
5,032 (men)
4,069 (women)
maximum intake
USA FFQ (120 items)
Kwak et al. (2014) 759
median
976
75th percentile
Korea FFQ (103 items)
Mazidi et al. (2017) 1,222
median
1,641
highest 75th percentile
Iran Single 24-h recall
Chang et al. (2014) 1,166
median
2,355 (75th percentile
in highest quartile)
USA Single 24-h recall
Itkonen et al. (2013) 1,617 1,795  469 (SD)
males
Finland 3 day food record +
FFQ
Tucker et al. (2006) 1,198–1,206
(categorised by cola
consumption)
adjusted for age and
energy intake
1,206  10
mean  SD
adjusted for age and
energy intake
USA FFQ (126 items)
FFQ: food frequency questionnaires.
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Annex 1 – Newcastle–Ottawa quality assessment scale case control studies
NEWCASTLE – OTTAWA QUALITY ASSESSMENT SCALE
CASE–CONTROL STUDIES
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability.
Selection
1) Is the case definition adequate?
a) yes, with independent validation 
b) yes, eg record linkage or based on self reports
c) no description
2) Representativeness of the cases
a) consecutive or obviously representative series of cases
b) potential for selection biases or not stated
3) Selection of Controls
a) community controls 
b) hospital controls
c) no description
4) Definition of Controls
a) no history of disease (endpoint) 
b) no description of source
Comparability
1) Comparability of cases and controls on the basis of the design or analysis
a) study controls for _______________  (Select the most important factor.)
b) study controls for any additional factor   (This criteria could be modified to indicate specific
      control for a second important factor.)
Exposure
1) Ascertainment of exposure
a) secure record (eg surgical records) 
b) structured interview where blind to case/control status 
c) interview not blinded to case/control status
d) written self report or medical record only
e) no description
2) Same method of ascertainment for cases and controls
a) yes 
b) no
3) Non-Response rate
a) same rate for both groups 
b) non respondents described
c) rate different and no designation
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NEWCASTLE – OTTAWA QUALITY ASSESSMENT SCALE
COHORT STUDIES
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and
Outcome categories. A maximum of two stars can be given for Comparability
Selection
1) Representativeness of the exposed cohort
a) truly representative of the average _______________ (describe) in the community 
b) somewhat representative of the average ______________ in the community 
c) selected group of users eg nurses, volunteers
d) no description of the derivation of the cohort
2) Selection of the non exposed cohort
a) drawn from the same community as the exposed cohort 
b) drawn from a different source
c) no description of the derivation of the non exposed cohort
3) Ascertainment of exposure
a) secure record (eg surgical records) 
b) structured interview 
c) written self report
d) no description
4) Demonstration that outcome of interest was not present at start of study
a) yes 
b) no
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) study controls for _____________ (select the most important factor) 
b) study controls for any additional factor   (This criteria could be modified to indicate specific
control for a second important factor.)
Outcome
1) Assessment of outcome
a) independent blind assessment 
b) record linkage 
c) self report
d) no description
2) Was follow-up long enough for outcomes to occur
a) yes (select an adequate follow up period for outcome of interest) 
b) no
3) Adequacy of follow up of cohorts
a) complete follow up - all subjects accounted for 
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an
      adequate %) follow up, or description provided of those lost) 
c) follow up rate < ____% (select an adequate %) and no description of those lost
d) no statement
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Annex 2 – Coding manual for case control and cohort studies
CODING MANUAL FOR CASE-CONTROL STUDIES
SELECTION
1) Is the Case Definition Adequate?
a) Requires some independent validation (e.g. >1 person/record/time/process to 
extract information, or reference to primary record source such as x-rays or 
medical/hospital records)
b) Record linkage (e.g. ICD codes in database) or self-report with no reference to 
primary record 
c) No description
2) Representativeness of the Cases
a) All eligible cases with outcome of interest over a defined period of time, all cases 
in a defined catchment area, all cases in a defined hospital or clinic, group of 
hospitals, health maintenance organisation, or an appropriate sample of those 
cases (e.g. random sample)
b) Not satisfying requirements in part (a), or not stated.
3) Selection of Controls
This item assesses whether the control series used in the study is derived from the 
same population as the cases and essentially would have been cases had the outcome 
been present.
a) Community controls (i.e. same community as cases and would be cases if had 
outcome)
b) Hospital controls, within same community as cases (i.e. not another city) but 
derived from a hospitalised population 
c) No description
4) Definition of Controls
a) If cases are first occurrence of outcome, then it must explicitly state that controls 
have no history of this outcome.  If cases have new (not necessarily first) 
occurrence of outcome, then controls with previous occurrences of outcome of 
interest should not be excluded.
b) No mention of history of outcome
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COMPARABILITY
1) Comparability of Cases and Controls on the Basis of the Design or Analysis
A maximum of 2 stars can be allotted in this category
Either cases and controls must be matched in the design and/or confounders must be
adjusted for in the analysis.  Statements of no differences between groups or that 
differences were not statistically significant are not sufficient for establishing 
comparability.  Note: If the odds ratio for the exposure of interest is adjusted for the
confounders listed, then the groups will be considered to be comparable on each 
variable used in the adjustment.
There may be multiple ratings for this item for different categories of exposure (e.g. 
ever vs. never, current vs. previous or never)
 Age =     , Other controlled factors = 
EXPOSURE
1) Ascertainment of Exposure
Allocation of stars as per rating sheet
2) Non-Response Rate
Allocation of stars as per rating sheet
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CODING MANUAL FOR COHORT STUDIES
SELECTION
1) Representativeness of the Exposed Cohort
Item is assessing the representativeness of exposed individuals in the community, not 
the representativeness of the sample of women from some general population.  For 
example, subjects derived from groups likely to contain middle class, better educated,
health oriented women are likely to be representative of postmenopausal estrogen 
users while they are not representative of all women (e.g. members of a health 
maintenance organisation (HMO) will be a representative sample of estrogen users.
While the HMO may have an under-representation of ethnic groups, the poor, and 
poorly educated, these excluded groups are not the predominant users users of 
estrogen).
Allocation of stars as per rating sheet
2) Selection of the Non-Exposed Cohort
Allocation of stars as per rating sheet
3) Ascertainment of Exposure
Allocation of stars as per rating sheet
4) Demonstration That Outcome of Interest Was Not Present at Start of Study
In the case of mortality studies, outcome of interest is still the presence of a disease/ 
incident, rather than death.  That is to say that a statement of no history of disease or 
incident earns a star.
COMPARABILITY
1) Comparability of Cohorts on the Basis of the Design or Analysis
A maximum of 2 stars can be allotted in this category 
Either exposed and non-exposed individuals must be matched in the design and/or
confounders must be adjusted for in the analysis.  Statements of no differences 
between groups or that differences were not statistically significant are not sufficient 
for establishing comparability.  Note: If the relative risk for the exposure of interest is
adjusted for the confounders listed, then the groups will be considered to be 
comparable on each variable used in the adjustment.
There may be multiple ratings for this item for different categories of exposure (e.g. 
ever vs. never, current vs. previous or never)
 Age =     , Other controlled factors =
Re-evaluation of the safety of phosphates (E 338–341, E 343, E 450–452)
www.efsa.europa.eu/efsajournal 153 EFSA Journal 2019;17(6):5674
OUTCOME
1) Assessment of Outcome
For some outcomes (e.g. fractured hip), reference to the medical record is sufficient to
satisfy the requirement for confirmation of the fracture.  This would not be adequate
for vertebral fracture outcomes where reference to x-rays would be required.
a) Independent or blind assessment stated in the paper, or confirmation of the 
outcome by reference to secure records (x-rays, medical records, etc.)
b) Record linkage (e.g. identified through ICD codes on database records)
c) Self-report (i.e. no reference to original medical records or x-rays to confirm the 
outcome)
d) No description.
2) Was Follow-Up Long Enough for Outcomes to Occur
An acceptable length of time should be decided before quality assessment begins (e.g.
5 yrs. for exposure to breast implants)
3) Adequacy of Follow Up of Cohorts
This item assesses the follow-up of the exposed and non-exposed cohorts to ensure 
that losses are not related to either the exposure or the outcome.
Allocation of stars as per rating sheet
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Annex 3 – STROBE Statement—Checklist of items that should be included
in reports of cross-sectional studies
STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies
Item
noitadnemmoceRoN
(a) Indicate the study’s design with a commonly used term in the title or the abstract Title and abstract 1
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8* For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
(a) Describe all statistical methods, including those used to control for confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) If applicable, describe analytical methods taking account of sampling strategy 
Statistical methods 12 
(e) Describe any sensitivity analyses 
Results
(a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
Participants 13* 
(c) Consider use of a flow diagram 
(a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
Descriptive data 14* 
(b) Indicate number of participants with missing data for each variable of interest 
Outcome data 15* Report numbers of outcome events or summary measures 
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
Main results 16 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
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Discussion
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
*Give information separately for exposed and unexposed groups. 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org. 
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